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Abstract 
The clinical classification of inherited nucleotide sequence variants identified in disease-related 
genes has a direct impact on the clinical management of patients and their families. Lynch 
syndrome is an autosomal dominant cancer predisposition syndrome caused by germline mutations 
in the mismatch repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2).  However, ~30% of MMR 
gene variants identified in suspected Lynch cases are of uncertain clinical significance, which 
constitutes a challenge for genetic counselling and clinical management of families.  In the past 
there has been no uniform system to tackle these variants, and mainly ad hoc methods have been 
utilized to determine if they are disease causing. 
  
In collaboration with the multi-disciplinary International Society for Gastrointestinal Hereditary 
Tumours Variant Interpretation Committee (InSiGHT VIC), we have developed a standardized 
five-tiered classification scheme to classify variants in the MMR genes, which is linked to clinical 
recommendations for patient management. The rules incorporate validated interpretations of clinical 
and functional qualitative data and quantitative measures of pathogenicity. 
  
The multifactorial likelihood model approach was initially developed for the evaluation of sequence 
variants in the BRCA1/2 cancer predisposition genes. It was adapted for MMR gene variants to 
provide a quantitative measure of risk in the form of probability of pathogenicity. Estimates of prior 
probability of pathogenicity based on evolutionary sequence conservation and physicochemical 
characteristics of predicted alterations were combined with variant segregation information and 
tumour features. Microsatellite instability (MSI) and somatic BRAF V600E tumour data for 
unselected colorectal cancer probands of known pathogenic variant status were used to derive 
likelihood ratios (LR) for tumour characteristics using the Colon Cancer Family Registry resource. 
The LR in favour of pathogenicity was estimated to be ~12-fold for a MSI and BRAF V600E 
mutation-negative colorectal tumour. Our findings provide a working multifactorial likelihood 
model for classifications that carefully considers mode of ascertainment for gene testing. 
  
Using both published and unpublished qualitative and quantitative evidence we led efforts by the 
VIC to apply the refined scheme to 2,360 unique sequence alterations and disseminated online 
through the publically accessible InSiGHT database. Clinical recommendations based on 
transparent evaluation are now possible for 1,370 variants that were not obviously protein 
truncating from nomenclature. Furthermore, a framework that can be transferred to variant 
classification in other disease/cancer predisposition genes has been developed. 
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Chapter 1: Introduction 
Identification of cancer-causing germline mutations in high-risk cancer genes in cancer cases, 
directs the clinical management of not only the individual, but also the whole family. These 
measures include presymptomatic surveillance, prophylactic surgery and chemotherapy regimens1. 
Thus it is very important to identify carriers of damaging (functionally compromised) or pathogenic 
(disease causing) mutations in these cancer genes.  
 
Inactivating mutations in the mismatch repair genes (MLH1, MSH2, MSH6, and PMS2) cause the 
cancer susceptibility disorder, Lynch Syndrome2. In the clinical setting family history and/or 
tumour features are used to prioritise cases with an increased chance of having Lynch syndrome for 
mutation testing3,4. For a significant proportion of cases, sequence variants of uncertain clinical 
significance are identified. The effect on protein function of these variants is difficult to interpret 
and pose a major problem for clinicians, researchers and families that are suspected to have Lynch 
syndrome. The main aim of this thesis is to describe quantitative (statistical) and qualitative 
approaches to interpreting the clinical significance of sequence variants identified in the mismatch 
repair genes. 
  
1.1 Lynch Syndrome 
Lynch syndrome (LS), formerly known as hereditary non-polyposis colon cancer (HNPCC), is an 
autosomal dominantly inherited disorder of cancer predisposition. Dr Aldred Warthin first 
identified the multi-cancer syndrome in mid-western USA in 1895. A seamstress who was a 
member of “family G” reported a preponderance of gynaecological and gastrointestinal cancers in 
her family5. It was rediscovered by Dr Henry T Lynch in 1966, who reported an inherited 
predisposition to colon, endometrial and gastric cancers in two families from mid-west USA6. 
Lynch initially called the disease entity “family cancer syndrome”, and then coined the term 
HNPCC, since associated polyposis is rare7. It was not until 1984 that the moniker Lynch Syndrome 
was used8. Lynch Syndrome (LS) is now favoured over HNPCC to describe the syndrome, because 
endometrial cancer is often the sentinel cancer in affected women9 and because of the prevalence of 
other extra-colonic cancers among carriers. 
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Lynch Syndrome is caused by defects in DNA mismatch repair due to inherited germline mutations 
in one of four mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS210,11. Affected 
families often present clinically with multiple cases of early onset colorectal and endometrial 
cancers across several generations12,13. It is the most common form of hereditary colorectal and 
endometrial cancer, accounting for about 1-3% of these cancers14-17. Carriers of a MMR gene 
mutation have been reported to have an estimated lifetime risk up to 90% of developing CRC18. 
However, evidence suggests that there is an over prediction of cancer risk in studies that do not 
correct for ascertainment bias19,20. In studies taking into account ascertainment bias combining 
MLH1, MSH2 and MSH6 mutation carriers, the cumulative risk to age 70 for CRC ranges between 
30-75% for men and 25-50% for women, and between 30-45% for women with endometrial 
cancer19-25. Overall there is an increased risk of CRC in males, compared to females. Other factors 
that may influence penetrance include potential modifiers of cancer risk (e.g. alleles in 8q23.3 and 
11q23.1) and environmental factors26,27. A recent study has also reported that a parent of origin 
effect can also influence CRC risk28. 
 
The associated lifetime risk of CRC and endometrial cancer varies between the four MMR genes. 
The estimated colorectal cancer risks for age 70 years reported for MLH1 and MSH2 mutation 
carriers tend to vary, ranging from 28-74% for males and 23-61% in females, and 18-54% for 
endometrial cancer20,29. MSH6 and PMS2 display a reduced penetrance compared to MLH1 and 
MSH2 mutations. The corresponding CRC risks reported for a mutation in MSH6 are 22-36% and 
10-18% for males and females respectively30,31, and for PMS2 mutation carriers the risks are 20% 
and 15%32. For MSH6 mutation carriers there is about a 10 year later age of onset and a higher 
association with endometrial cancer than MLH1/MSH2 mutation carriers18,30,33-37. The estimated 
risk of endometrial cancer by age 70 reported for different studies is between 16 and 49%19,25,30,38.  
 
Several other cancers are included in the Lynch spectrum, and are associated with a more modest 
penetrance. The increased lifetime risk for these other well-recognized LS cancers are: gastric (0.7-
20%), small bowel (0.6-7%), ovarian (6-14%), pancreatic (0.4-3.7%), hepatobiliary tract (0.6-
2.1%), urothelial (including renal pelvis, ureter and bladder – 1.2-11.2%), and brain (1.2-
3.7%)7,20,29,39. The standardized incidence ratios (SIRs) for mutation carriers compared to the 
general population, are shown for most of these cancers in Figure 1.1.  
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Figure 1.1: Standardized incidence rates of cancers in MMR gene mutation carriers. Derived from a prospective 
cohort study published by Win et al40 (including 95% confidence intervals). 
 
A moderate increase in risk of breast and prostate cancer has been associated with MMR gene 
mutation carriers, however inclusion of these cancers in the syndrome is a controversial issue. An 
MMR deficient phenotype (see section 1.2 for a description of the phenotype) is infrequent in non-
carriers41-44, however only demonstrated in 51% of breast cancers45 and 73% of prostate cancers46 
from mutation carriers. Current studies demonstrate a modest increase in risk of these cancers in 
mutation carriers40,45-48. Muir-Torre syndrome and Turcot’s syndrome are also considered variants 
of LS. Muir-Torre is characterised by the presence of multiple benign/malignant sebaceous 
carcinomas or keratoacanthomas and other LS-associated tumours2,49. While Turcot’s syndrome, 
which can also be included in constitutional mismatch repair deficiency syndrome (CMMR-D), is 
typified by presentation of brain tumours, such as glioblastoma/astrocytoma, and CRC50,51. CMMR-
D is caused by bi-allelic MMR gene germline mutations and is detailed in section 1.6.4. Brain 
tumours are less common in heterozygote mutation carriers and predominantly occur in MSH2 
mutation carriers29,52. It has even been suggested that the original Turcot’s syndrome cases (two 
siblings with CRC and brain tumours in their teens) could have been cases of CMMR-D50,53. Other 
rare tumours with an apparent association with LS in some cases include leiomyosarcoma, 
adrenocortical carcinoma and malignant fibrous histiocytoma54-56. 
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1.2 Phenotypes of Lynch spectrum tumours  
Phenotypic tumour features associated with MMR deficiency have been identified in many of the 
Lynch-associated tumours. Consistent with mutations in genes integral to DNA mismatch repair 
(see section 1.3), the tumours develop through a mutator phenotype pathway, where elevated 
mutation of simple repeats produces the defining molecular signature of widespread somatic 
microsatellite instability (MSI)57-59. The MSI phenotype of tumours was an integral factor in the 
discovery of the MMR genes. MSI and other tumour features are described below. 
 
1.2.1 Microsatellite instability 
Mismatch repair deficiency causes microsatellite instability, which is characterized by clonal global 
expansion or contraction of genomic short repetitive elements known as microsatellites. These 
replication errors are frequently observed in repetitive mononucleotide and dinucleotide (tri- and 
tetranucleotide repeat instability is not associated with Lynch syndrome) microsatellite DNA 
markers and thus high levels of microsatellite instability (MSI-H) are frequently observed when 
several of these microsatellite markers are assessed using a microdissection and PCR-based 
strategy3,60-62. Examples of MSI and the process of measurement of instability at a microsatellite 
marker is shown in Figure 1.2. The MSI-H phenotype occurs in about ~15% of colorectal tumours 
without a MMR gene germline mutation, commonly referred to as sporadic MSI-H CRC86,87. These 
sporadic colorectal cancers generally have a good prognosis compared to microsatellite stable 
tumours that develop through the conventional adenoma-carcinoma pathway63.  
 
 
Figure 1.2: Examples of microsatellite instability. (A) Effects of DNA strand slippage with intact (microsatellite 
stable – MSS) and defective MMR (MSI - contraction of a mononucleotide repeat and expansion of a dinucleotide 
repeat). (B) A schematic of PCR-based detection of somatic MSI at a microsatellite marker demonstrating the allelic 
shift in the unstable tumour DNA. 
B 
Normal 
Molecular weight 
Tumour 
A 
A A A A A A 
T T T T T T 
T 
5’ 
3’ 
3’ 
5’ 
C A C A C A C A 
G T G T G T G T 
C A 
5’ 
3’ 
3’ 
5’ 
Mononucleotide 
Dinucleotide 
A A A A A A A 
T T T T T T T 
5’ 
3’ 
3’ 
5’ 
7 repeats 
Template Strand 
Template Strand 
A A A A A A 
T T T T T T 
5’ 
3’ 
3’ 
5’ 
6 repeats 
C A C A C A C A 
G T G T G T G T 
5’ 
3’ 
3’ 
5’ 
4 repeats 
C A C A C A C A C A 
G T G T G T G T G T 
5’ 
3’ 
3’ 
5’ 
5 repeats 
Intact 
MMR 
Intact
 MMR
 
Deficient MMR 
Deficient MMR 
MSS 
MSS 
MSI 
MSI 
Allelic Shift 
 5!
MSI-H LS-associated colorectal tumours arise through the conventional adenoma-carcinoma 
pathway, which constitutes the major pathway of colorectal carcinogenesis64. The distinction 
between LS-related MSI-H CRC and sporadic MSI-H CRC is underpinned by a difference in 
tumourigenic pathways, the latter developing through the serrated pathway rather than the 
traditional adenoma-carcinoma pathway65. MMR deficiency in the sporadic tumours is frequently 
caused by methylation of CpG islands in the MLH1 gene promoter through the CpG island 
methylator phenotype (CIMP – acquired epimutation of both alleles), leading to transcriptional 
silencing of the MLH1 gene66-69. Acquired MLH1 promoter hypermethylation is also frequent in 
MMR gene mutation negative MSI-H endometrial70,71, ovarian72,73, gastric74 and urothelial 
tumours75. A single somatic mutation in the oncogene BRAF (BRAF c.1799T>A p.Val600Glu – a 
mutation hotspot, referred to from herein as BRAF V600E) is frequently present with MLH1 
methylation in CRCs76,77, but infrequent in MLH1 methylated endometrial tumours71. BRAF V600E 
is almost completely absent from Lynch-associated MSI-H cancers78-82. Moreover, there is 
supporting evidence for a role of the miRNA miR-155 in modulating expression of the MMR 
genes, causing MSI is sporadic colorectal tumours83. 
 
A distinct gene mutation profile is produced by MSI in tumours. Specific coding microsatellites are 
targeted. In MSI-H colorectal, gastric and urothelial tumours frameshift mutations in coding 
microsatellites are common in TGFBR2 and ACVR2A, but not in KRAS and TP5384-87. While JAK1 
coding microsatellites are specifically targeted in MSI-H endometrial tumours rather than TGFBR2, 
but the tumours also do not contain frameshift mutations in KRAS and TP5386,88.  
 
1.2.2 Tumour location and morphology 
The LS-associated colorectal tumours typically originate in the proximal colon (right-side), and 
follow the conventional adenoma to carcinoma pathway. CRC tumours are thought to develop 
within five years from the earliest detectable polyp, compared to over ten years in sporadic 
colorectal cancer89-91. Histopathologic markers of MSI-H colorectal tumours in general, include 
mucinous or signet ring cell features, tumour-infiltrating lymphocytes, poor differentiation with a 
medullary growth pattern, and a Crohn-like lymphocytic reaction92,93. MMR deficient Biliary, small 
bowel, and pancreatic tumours have demonstrated similar morphological features94-97. 
 
Both LS-associated and sporadic MMR-deficient endometrial cancers have some similar 
pathological features to the CRCs. These include, poor differentiation, presence of Crohn-like 
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lymphoid reaction and tumour-infiltrating lymphocytes98-100. Tumours tend to be higher grade, have 
an endometrioid histology, originate from the lower uterine segment, and demonstrate changes in 
myometrial and vascular invasion98,101,102. However, when distinguishing tumour morphological 
features in MMR gene mutation carriers the association with location in the uterine segment and 
tumour heterogeneity was no longer significant9. High tumour-infiltrating lymphocyte counts and 
the presence of peritumoural lymphocytes were still effective at distinguishing LS-associated 
endometrial tumours9,103. 
 
Other Lynch spectrum tumours have distinct tumour morphological features compared to MMR 
proficient and in some cases MMR deficient sporadic tumours. Compared to sporadic or BRCA1/2-
associated ovarian cancers, LS-associated ovarian tumours are reported to have a non-serous 
histology (endometrioid or clear cell)104,105. Furthermore, unlike endometrial cancer, tumour-
infiltrating lymphocytes and peritumoural lymphocytes are not associated with MSI in sporadic 
ovarian tumours106, and are yet to be assessed in LS-associated ovarian tumours. The majority of 
MSI-H gastric tumours (both LS-associated and sporadic) are intestinal type, preferentially located 
in the antrum and not associated with tumour-infiltrating lymphocytes74,107,108. Furthermore, LS-
associated gastric cancers demonstrate a significantly lower methylation index74. Whether MMR 
deficient tumours of the urinary tract and central nervous system have a distinct histology still needs 
to be determined. 
 
1.3 DNA Mismatch Repair 
Lynch syndrome is caused by mutations inactivating the DNA MMR genes (MLH1, MSH2, MSH6 
and PMS2) and deletions in EPCAM. Sequence alterations in mutL homolog 1 (MLH1) on 
chromosome 3p21 and mutS homolog 2 (MSH2) on chromosome 2p16 account for nearly 80-90% 
of the cancer causing mutations in Lynch syndrome4,14. The genes were initially linked to 
susceptibility loci on chromosomes 2 and 3 through linkage analysis in large LS kindreds64,109-113. 
Several founder mutations have been identified in these genes, including the Ashkenazi Jewish 
missense mutation MSH2 c.1906G>C p.Ala636Pro114; MLH1 deletion of exon 16, which accounts 
for >50% of all LS cases in Finland115, and the Dutch founder mutation MLH1 c.112A>C 
p.Asn38His116. Additionally, the splicing mutation MSH2 c.942+3A>T in intron 5 may account for 
5-10% of all LS cases7. 
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Germline alterations of mutS homolog 6 (MSH6), epithelial cell adhesion molecule (EPCAM – both 
on chromosome 2p16), and postmeiotic segregation 2 (PMS2) on chromosome 7p22 make up the 
remaining causal mutations4,35,51. MSH6 (initially known as GTBP for G/T binding protein) was 
linked to MMR deficiency through the discovery of truncating mutations in genetically unstable 
tumour cell lines and was found to form a heterodimer with MSH2117,118. Between 8-13% of causal 
mutations in families ascertained from CRC registries are found in MSH64,14, which is likely to 
increase taking into account endometrial cancer families17,70. PMS2 (known as Pms1 in yeast) is 
another homologue of the prokaryotic mutL, which account for 2-9% of mutations in LS4,14. It was 
discovered through examination of expression sequence tagged (EST) databases64 and mutations 
found to segregate in LS families119. Mutation testing of PMS2 is complicated by presence of 16 
paralogous pseudocopies on the same chromosome120,121. Deletion of the 3’ end of EPCAM 
(formerly TACSTD1), the gene adjacent to MSH2, causes ~1% of LS4. The deletions at the end of 
the gene lead to epigenetic inactivation of the cis MSH2 allele122,123. 
 
Mismatch repair gene germline mutations readily recognised to be disease causing are generally 
single nucleotide alterations, small insertions/deletions (indels) or large genomic rearrangements 
(LGRs – usually deletions). LGRs have been reported to make up nearly a third of MLH1 and 
MSH2 deleterious mutations and include many Alu-mediated deletions115,124-127. Additionally, a rare 
constitutional MLH1 epimutation that leads to promoter hypermethylation (which is usually 
associated with sporadic CRC cases) has been reported128,129. MMR deficiency in tumour tissue 
manifests after inactivation of both alleles. The second allele can be inactivated by a variety of 
mechanisms including, whole gene deletion, gene conversion, and point mutation (the least likely 
mechanism)130. In the colon bile-induced endogenous mutagens and food-derived exogenous 
mutagens greatly increase the likelihood of losing the wild-type allele of the mutated MMR gene, 
either by somatic mutation or loss of heterozygosity (LOH)131-135. The risk of malignant 
transformation in MMR gene mutation carriers is relatively high in the gastrointestinal epithelium 
and endometrium, due to the high proliferation rate of these cells136. 
 
Other mismatch repair genes have been investigated for associations with Lynch syndrome by 
screening index cases with suspected genetic predisposition and/or confirmed LS families. PMS1 
was proposed as a susceptibility gene in the initial study identifying PMS2119, however it was later 
revealed that a large deletion in MSH2 was the causative mutation in that family137. Subsequently, 
no other mutations in PMS1 have been associated with LS. The involvement of MLH3 has been 
suggested138,139, but the absence of germline mutations in MSI-H tumours suggests that it is not 
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involved in the MSI pathway of tumourigenesis139,140. Furthermore, functional assays have 
demonstrated that MLH3 dysfunction alone cannot interrupt mismatch repair activity141,142. A 
possible LS association with EXO1 has been reported143, but not proven in subsequent studies144-146. 
There is currently no evidence implicating any other mismatch repair genes in the cause of Lynch 
syndrome tumours. However, in some cases biallelic mutations in the base excision repair gene 
MUTYH, which usually cause MUTYH-associated polyposis (MAP), have been shown to mimic 
the LS phenotype (i.e. histopathological tumour features and family history)147,148. 
 
1.3.1 The DNA mismatch repair system 
The mismatch repair complex corrects errors in newly synthesized DNA made by DNA polymerase 
during replication. Its major role is to protect cells from spontaneous mutations, like MSI149,150. The 
MMR system originated in prokaryotes and is well conserved through eukaryotes151. The process is 
initiated by the recognition of a DNA base-base mispairing or insertion/deletion loop (IDL – caused 
by polymerase slippage during replication) by MutSα, which is made up of a heterodimer of MSH2 
and MSH6, or MutSβ consisting of a MSH2 and MSH3 heterodimer. MutSα is more abundant and 
recognizes single base mismatches and small IDLs (in mono-tetranucleotide repeats), while MutSβ 
preferentially recognizes dinucleotide and larger IDLs149,150. The function of the two MutS 
heterodimers is overlapping, and therefore partly redundant. The histone mark H3K36me3 has 
recently been shown to regulate the recruitment of MutSα to chromatin, through direct interaction 
with the PWWP DNA binding domain in MSH6 (see Figure 1.3)152. Upon recognition of the 
mismatch, MutSα (or MutSβ) recruits MutLα (MLH1 and PMS2 heterodimer) in an ATP 
dependent reaction153. The prokaryotic homologues MutS and MutL form homodimers rather than 
heterodimers154. MutLα interacts with and modulates the activity of several MMR proteins. PMS2 
introduces a nick in the daughter strand at the 5’ end of the mismatch using its endonuclease 
activity. This serves as an entry point for the exonuclease EXO1 to excise the mismatch-containing 
strand of DNA in a 5’ to 3’ direction. The excision intermediate is protected from nuclease 
degradation by replication protein A (RPA). The excised DNA strand is then resynthesized by DNA 
polymerase (Polδ or ε) and DNA ligase in the presence of RPA, proliferating cell nuclear antigen 
(PCNA) and the clamp loader replication factor C (RFC)149,155,156. A summary of the process 
involved is shown in Figure 1.4. 
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Figure 1.3: Linear schematic of mismatch repair gene structure and functional domains. The nucleotide (nt) and amino acid (αα) positions are numbered for the exon 
boundaries of MLH1 (A), PMS2 (B), MSH2 (C), and MSH6 (D). Position numbering is based on Human Genome Variation Society (HGVS) nomenclature157. The proteins include 
the following functional domains: ATPase domain – MLH1158-163, PMS2164, MSH2165,166, and MSH6166-168; MutSα interaction in MLH1162,169; EXO1 interaction and/or stabilisation 
domain – MLH1 and MSH2170; nuclear localisation signal (NLS) and/or nuclear export signal (NES) – MLH1171, PMS2172, and MSH6173; MLH1/MLH3/PMS1/PMS2 interaction 
domain – MLH1 and PMS2174,175; DNA binding domain – MSH2165,176 and MSH6177; connector and lever domains – MSH2165,176 and MSH6167; MutLα interaction domains in 
MSH2178; clamp domain – MSH2165,176 and MSH6179; helix-turn-helix domain in MSH2165,176; MSH2/MSH3/MSH6 interaction domains – MSH2 and MSH6180; PCNA interaction 
domain in MSH6181; PWWP domain in MSH6 binds double-stranded DNA non-specifically182. 
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Figure 1.4: Schematic representation of the mismatch repair process. This schematic shows a summary of the 
proteins and steps involved in 5’ nick directed repair. There are additional steps involved in the repair process when the 
complex binds 3’ of the mismatch on the daughter strand, due to the inability of EXO1 to degrade the strand in the 3’ to 
5’ direction. The 3’ nick directed repair process is shown in detail in Jiricny et al183.  
 
Schematic representations of MLH1, MSH2, MSH6 and PMS2, including the functional domains 
encoded by the proteins, are shown in Figure 1.3. The MutSα clamp and lever domains are 
involved in the recognition and binding of mismatches176, while the connector domains contain the 
interface for binding with MutLα178. The MSH2 ATPase domain mediates the proofreading activity 
of MutSα by the exchange of adenosine diphosphate (ADP) for ATP149,150. ATP binding induces a 
conformational change in the proteins. MSH6 and MSH3 are unstable in the absence of functional 
MSH2184, nor is PMS2 in the absence of MLH1174. MutLα also has an ATPase domain and an 
ADP-ATP cycle174,175,185. In its ATP-bound state, the heterodimer coordinates downstream events, 
like EXO1 binding and endonucleolysis150,186. 
 
The MMR complex also functions in cell cycle transition. As expected, the activity of the complex 
is most abundant in S-phase, when DNA replication occurs187. Intact MMR function is required for 
activation of cell cycle checkpoints188. Consequently, it has been demonstrated that MMR deficient 
cells are more resistant to apoptosis and more tolerant to DNA damaging agents189. Furthermore, 
MutSα and MutLα have been shown to interact with other proteins/complexes involved in repair of 
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DNA damage, including BRIP1 (formerly FANCJ)190, the BRCA1-associated genome surveillance 
complex (BASC)182,191,192, p53193, and CAF-1 (chromatin assembly factor-1)167. 
 
1.4 Lynch syndrome identification and molecular diagnostic testing 
Identification of Lynch syndrome cases is very important, because these individuals have an 
increased risk of developing multiple metachronous and synchronous tumours194,195. Once an at-risk 
individual is identified for diagnostic testing an algorithmic approach is generally used to detect 
MMR mutations. MSI testing and/or MMR protein immunohistochemistry (IHC) are used to 
identify MMR deficiency in tumours196-199, and then MLH1 promoter methylation and BRAF 
V600E (for CRC only) testing are used to exclude individuals with somatic alterations200-203. The 
remaining cases are prioritised for genetic testing. 
 
1.4.1 Clinical criteria 
Criteria based on family history and histopathological features of tumours have been developed to 
prioritise cases for Lynch syndrome diagnostic testing. In 1990 a standard set of criteria called the 
Amsterdam Criteria (AC-I) was established by a panel of experts (the International Collaborative 
Group on Hereditary Non-polyposis Colorectal Cancer – ICG-HNPCC) to be used in the diagnosis 
of Lynch syndrome and recruitment of these cases to studies204. The initial criteria were based on 
common characteristics of LS-associated CRCs (i.e. young age of onset and family history), and 
then revised (AC-II) to incorporate extra-colonic cancers205. The original and revised criteria that 
need to be fulfilled to reach a diagnosis of LS are shown in Table 1.1. While the Amsterdam 
criteria are the most internationally recognised, other criteria have been developed to identify LS 
families. These include: CRC-centric – modified Amsterdam Criteria206, Mount Sinai Hospital 
Criteria207, Japanese Criteria208, Korean Criteria209, and Chinese Criteria210; and endometrial cancer 
centric criteria – Society of Gynecologic Oncology (SGO) guidelines211 and the Australian National 
Endometrial Cancer Study (ANECS) criteria212. Fulfilment of the clinical criteria is recommended 
to direct referral to diagnostic testing for an affected family. However, MMR mutation carriers are 
not identified in all Amsterdam families. Familial CRC type X cases are those from AC-1 families, 
but whose tumours are MMR proficient213,214. 
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Table 1.1: Clinical and clinicopathological diagnostic criteria for identifying MMR gene mutation carriers 
Amsterdam Criteria I204 (est. 1990) 
Individuals must meet ALL the following criteria: 
1. At least three relatives with colorectal cancer 
2. At least two successive generations should be affected 
3. At least one colorectal cancer should be diagnosed <50 years of age 
4. One of the individuals should be a first-degree relative to the other two 
5. Familial adenomatous polyposis should be excluded 
6. The tumours should be verified by pathological examination 
Amsterdam Criteria II205 (est. 1998) 
Individuals must meet ALL the following criteria: 
1. At least three relatives with a Lynch-associated cancer (colorectal, endometrial, small bowel, 
ureter/renal pelvis) 
2. At least two successive generations should be affected 
3. At least one tumour should be diagnosed <50 years of age 
4. One of the individuals should be a first-degree relative to the other two 
5. Familial adenomatous polyposis should be excluded in the colorectal cancer case(s), if any 
6. The tumours should be verified by pathological examination 
Bethesda Guidelines for testing colorectal tumours for MSI215 (est. 1997) 
Tumours should be tested for MSI in any of the following situations: 
1. Cancer in a family that meets Amsterdam Criteria I 
2. Two Lynch-associated cancers, including synchronous and metachronous colorectal cancers 
or extracolonic cancers (endometrial, ovarian, gastric, hepatobilliary, small bowel cancer, 
transitional cell carcinoma of the renal pelvis/ureter) 
3. Colorectal cancer and a first-degree relative with colorectal cancer and/or Lynch-associated 
extracolonic cancer and/or a colorectal adenoma; one of the cancers diagnosed <45 years of 
age, and the adenoma diagnosed <40 years of age 
4. Colorectal cancer or endometrial cancer diagnosed <45 years of age 
5. Right-sided colorectal cancer with an undifferentiated (solid/cribriform) tumour histology, 
diagnosed <45 years of age 
6. Signet-ring-cell-type colorectal cancer diagnosed <45 years of age  
7. Adenomas diagnosed <40 years of age 
Revised Bethesda Guidelines for testing colorectal tumours for MSI3 (est. 2004) 
Tumours should be tested for MSI in any of the following situations: 
1. Colorectal cancer diagnosed <50 years of age 
2. Presence of synchronous/metachronous colorectal, or other Lynch-associated tumours 
(colorectal, endometrial, gastric, ovarian, pancreas, small bowel, ureter and renal pelvis, 
hepatobiliary tract, glioblastoma in Turcot syndrome, sebaceous adenomas and 
keratoacnthomas in Muir-Torre syndrome) regardless of age 
3. Colorectal cancer with the MSI-H histology diagnosed <60 years of age 
4. Colorectal cancer diagnosed in one or more first-degree relatives with a Lynch-associated 
tumour, with one of the cancers diagnosed <50 years of age 
5. Colorectal cancer diagnosed in two or more first- or second-degree relatives with Lynch-
associated tumours, regardless of age 
 
1.4.2 Clinicopathological criteria 
The Bethesda Guidelines were developed to aid in the identification of LS in cases not identified by 
the Amsterdam Criteria. The criteria are based on the clinicopathologic aspects of LS and were 
established to direct MSI testing in potential Lynch-associated colorectal tumours, to aid in early 
diagnosis215. In 2004 the Bethesda guidelines were revised in order to broaden the criteria and 
improve LS detection3,216. These clinicopathological guidelines are detailed in Table 1.1. Compared 
to AC-II, the revised Bethesda guidelines result in a significantly increased sensitivity (27.2% to 
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88.1%) and reduced specificity (97.9% to 54.4%)14. Nevertheless, selective screening based on the 
revised Bethesda Guidelines misses approximately a quarter of cases200,217-219. Therefore, there have 
been recommendations of molecular testing of early onset CRC probands for features of tumour 
MMR deficiency irrespective of family history (i.e. Melbourne220 and Perth221 criteria, and 
Jerusalem recommendations222), or universal testing for MMR deficiency of all CRC and 
endometrial tumours from probands70,200. 
 
1.4.3 MMR gene risk prediction models 
As an alternative to the clinical and clinicopathological criteria detailed above, prediction models 
have been developed to predict MMR mutation carrier status and cancer risk in potential Lynch 
syndrome cases. The models use CRC and endometrial cancer family history and in some cases 
MSI and/or IHC tumour testing results to estimate the probability of carrying a MLH1, MSH2 or 
MSH6 mutation. The existing risk prediction models include: Leiden223, Amsterdam-plus224, 
Amsterdam-alternative224, AIFEG225, MMRpro226, MMRpredict227, PREMM228,229, and Myriad230. 
The probabilities are derived based on a number of different statistical methods, including: 
multivariate logistic regression analysis, Bayes theorem, and Mendelian models of autosomal 
dominant inheritance. Recent meta-analyses evaluating PREMM, MMRpro, MMRpredict, and the 
Leiden risk prediction models demonstrated that all models predict with reasonable accuracy, and 
the study was unable to discriminate which model performed the best out of the four tested230. 
 
1.4.4 Microsatellite instability analysis 
Since microsatellite instability (MSI) is an identifying feature of Lynch syndrome colorectal 
tumours, it is used to prioritise potential at-risk individuals for MMR mutation testing. To 
standardize MSI testing a consensus panel of five markers was proposed. The Bethesda or National 
Cancer Institute (NCI) panel includes the mononucleotide repeats BAT25 and BAT26, and the 
dinucleotide microsatellites D2S123, D5S346 and D17S250231. If ≥2 microsatellite markers are 
unstable the tumour is classified as MSI-high (MSI-H). If <2 of the microsatellite markers are 
unstable the tumour is MSI-low (MSI-L). Lastly, if all the markers are stable the tumour is termed 
microsatellite stable (MSS)232. Further evaluation of additional markers is recommended if only 
dinucleotide repeats are mutated (since they are less sensitive for detecting MSI-H) or to exclude an 
MSI-L phenotype3,233. MSI-L is not a useful marker for identifying LS colorectal tumours, 
particularly since there is evidence that all CRCs have some degree of inherent instability61,234. As 
an alternative to the Bethesda panel a penta-panel of quasimonomorphic mononucleotide repeats 
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has been suggested due to the high predictive value of these markers, with the advantage of not 
requiring normal matching DNA for interpreting MSI status in a tumour235-240. 
 
The Bethesda panel has subsequently been used to test for MSI in extracolonic tumours87,105,241. 
MSI analysis is slightly less informative in endometrial tumours due to the increased prevalence of 
MSH6 mutations70,242. MSH6 as part of the MutSα heterodimer is primarily involved in the repair 
of mismatches and single nucleotide IDLs243. Accordingly, MSI analysis using a mononucleotide 
microsatellite marker panel has been shown to be more effective at identifying MSH6 mutation 
carriers244. 
 
The MSI phenotype develops late in LS tumour development, therefore only around half of LS-
associated adenomas are MSI-H. Thus, lack of MSI in adenomas is not a good exclusion 
criterion245,246. In addition, some sporadic adenomas may show an MSI-H phenotype, particularly in 
cases under the age of 40 years247. Nevertheless, testing adenomas using MSI in combination with 
IHC to detect LS has been suggested in cases where tumour is unavailable248. 
 
1.4.5 Tumour immunohistochemistry analysis 
Loss of tumour MMR protein expression assessed by immunohistochemistry (IHC) is reported to 
be evident in >90% of cases with clearly pathogenic MMR gene mutations and shows greater than 
90-95% correlation with the MSI-H phenotype140. MMR IHC testing provides additional 
information to prioritise specific MMR genes for mutation testing, with the caveat that tumours 
with protein stable missense alterations that have reduced MMR function are not identified by IHC 
testing116,197,249,250. There have been some studies suggesting that IHC by itself should be used to 
triage at-risk cases200,201,203, particularly for identifying MSH6 and PMS2 mutation carriers70,220. 
Compared to IHC, the detection rate for MSH6 mutation carriers is reduced using MSI (as 
mentioned above)251. However, when used alone (as with MSI only testing) not all LS cases are 
identified. 
 
A four-antibody panel including MLH1, MSH2, MSH6, and PMS2 is used to test for abnormal 
protein expression. MMR IHC interpretation is based on the in vivo heterodimerization 
relationships of the MMR proteins. When MLH1 is defective there is loss of MLH1 and PMS2, 
because PMS2 stability depends on MLH1. Similarly there is MSH2 & MSH6 loss when MSH2 is 
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defective. When MSH6 and PMS2 are non-functional, isolated loss of MSH6 and PMS2 is seen, 
respectively. Since, both of their binding partners are stably expressed unbound216,243,252,253. The 
staining patterns associated with inactivation of each gene are shown in Figure 1.5. Based on the 
concomitant expression of these proteins, use of a two-antibody panel of MSH6 and PMS2 has been 
suggested254.  
 
 
Figure 1.5: A schematic of the expected pattern of loss in tumour IHC analysis given inactivation of a MMR 
gene. The images are courtesy of Michael Walsh. 
 
1.4.6 MLH1 promoter methylation and BRAF V600E 
MLH1 promoter methylation causes MMR deficiency in ~15% of sporadic colorectal and 
endometrial tumours1786,87. The somatic BRAF V600E (c.1799T>A mutation hotspot) mutation is 
highly associated with MLH1 promoter methylation in colorectal tumours (not endometrial), but not 
all methylated tumours have the BRAF mutation71,78,255,256. It has been suggested that colorectal 
tumours with MLH1 promoter methylation and/or the BRAF V600E mutation should not be 
screened for MMR mutations256-258. Furthermore, testing for MLH1 methylation and the BRAF 
V600E mutation appears to have become increasingly utilised in molecular and genetic testing 
algorithms in clinical practice to discriminate sporadic MSI-H CRC from MSI-H CRC in LS. 
MLH1 promoter methylation analysis has also been suggested as an effective tool for triaging 
endometrial tumours with loss of MLH1 expression17. 
 
Current data confirm that somatic BRAF mutations are most commonly found in mutation-negative 
cases with MSI-H colorectal tumours demonstrating MLH1 expression loss. Thus, it has been 
suggested that using BRAF status as a selection criteria for referring patients to germline genetic 
testing could be a strategy for reducing costs and effort258,259. However, four studies have identified 
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the BRAF V600E mutation and a germline MMR gene mutation in MLH1, MSH2 and PMS2 
32,82,260,261. Therefore the presence of a BRAF V600E mutation in a CRC, while a strong negative 
predictor of carrying a MMR mutation should not be assumed to exclude positive mutation status 
for any of the four MMR genes, particularly in the context of a family history suggestive of LS. 
 
Testing CpG islands in the proximal MLH1 promoter in colorectal and endometrial tumours 
demonstrates the best correlation with somatic changes in MLH1 protein expression; other regions 
do not correlate11,71,262,263. Akin to BRAF V600E, mutation carriers demonstrating MLH1 
methylation have been identified rarely. In these carriers, MLH1 promoter methylation is likely the 
“second hit”128,264. Further, there is increasing evidence for a role of constitutional epimutations in 
LS129,139,265.  
 
1.4.7 Genetic testing 
The gold standard for MMR gene mutation detection involves sequence analysis, usually by direct 
germline DNA sequencing, and MLPA (Multiplex Ligase-dependent Probe Amplification) to 
identify large genomic rearrangements. Detection of PMS2 mutations is problematic due to the 
presence of PMS2 pseudogenes; therefore special RNA-based and long-range genomic DNA based 
techniques have been developed to ensure targeted screening of the gene266-268. Additionally, 
screening for EPCAM deletions has been implemented in clinical MLPA testing since the discovery 
in 2009 of the role of these deletions in MSH2 transcriptional silencing269.  
 
There are several examples in the literature of hereditary mutations that would escape detection 
using “standard” screening methods. These include variants resulting in constitutional epigenetic 
silencing as mentioned above129,139,265, a deep intronic mutation in MSH2270,271, and a MSH2 
inversion that was detected in a large number of unexplained LS cases272. If no MMR gene 
mutation is identified in a proband with a Lynch syndrome phenotype it is recommended that the 
patient and at-risk relatives undergo surveillance regardless3. 
 
1.5 Lynch syndrome family management 
Once Lynch syndrome is diagnosed, surveillance and medical management based on the natural 
history of the disease is initiated in at-risk individuals. The US-based National Comprehensive 
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Cancer Network (NCCN – http://www.nccn.org) and the European-based Mallorca group1 have 
compiled an effective set of guidelines for Lynch syndrome patient management. The general 
recommendations for colorectal cancer surveillance and management include, colonoscopy 
beginning at age 20-25 every 1-2 years and prophylactic surgery in the form of colorectal resection 
only if cancer is diagnosed and removal of carcinoma/polyp is not possible during 
colonoscopy1,90,197,273. Aspirin usage can also reduce the risk of CRC in MMR gene mutations 
carriers274. 
 
For the gynaecological cancers (endometrial and ovarian), gynaecological examination, aspiration 
biopsy, and transvaginal ultrasound are the recommended screening strategies every 1-2 years 
beginning at age 35-401. However, it is currently unknown whether the surveillance is effective in 
identifying these cancers. There is evidence that prophylactic bilateral salpingo-oophorectomy and 
hysterectomy reduces risk and can even prevent the development of endometrial and ovarian 
cancer275. Prophylactic surgery is recommended around 40 years of age or after childbearing is 
completed in women with Lynch syndrome1,276,277. Use of the oral contraceptive pill in female 
mutation carriers wanting to delay hysterectomy/oophorectomy, has also been recommended due to 
its effectiveness as a chemopreventative agent for endometrial and ovarian cancer278.  
 
Surveillance recommendations for other LS-associated cancers (gastric, urinary tract, and 
pancreatic) have also been suggested. For gastric cancer, surveillance by upper gastrointestinal 
endoscopy every 1-2 years starting at age 30-35 is recommended in LS families from countries with 
high incidence of gastric cancer, in addition to screening for Helicobacter Pylori infection in all 
carriers >25 years of age1,279. The Mallorca group has recommended annual surveillance from age 
30-35 of MSH2 carriers only (in a research LS registry setting) by urine cytology and ultrasound for 
urinary tract cancers1. Screening at risk individuals with a family history of pancreatic cancer using 
radiographic and endoscopic imaging has been suggested39. However, the benefits and effectiveness 
for early detection of pancreatic tumours is currently unknown, thus screening in a research setting 
only is recommended1. Due to the unknown benefit of surveillance, no specific screening 
recommendations have been made for the other LS-associated cancers. 
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1.6 Mechanisms underlying MMR deficiency in germline mutation carriers 
Germline sequence alterations found in the MMR genes may affect a number of biochemical 
processes. Such mutations can cause aberrant mRNA splicing or amino acid changes leading to 
defective MMR through; (i) inactivation of enzymatic activity (ATP binding/hydrolysis); (ii) 
defective protein-protein interaction (complex formation); (iii) defective protein-DNA binding 
(mismatch recognition); (iv) defective subcellular localization; (v) altered protein expression 
(stoichiometry of MMR complexes); and (vi) altered protein stability136 (see Figure 1.6). A 
multitude of functional assays in a number of experimental systems have been developed to assay 
the effect of sequence alterations on the function of the MMR complex. Many of these assays have 
been used to define the function and interactions of these mismatch repair proteins. Some of these 
assays are described in more detail in Chapter 4. 
 
 
Figure 1.6: Schematic of MMR functions that can be tested using functional assays. Repair function as a whole 
process can be tested, in addition to assaying specific biological or biochemical functions of the MMR proteins. 
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1.6.1 mRNA splicing assays 
The exon/intron boundaries of a gene are defined by conserved intronic cis-elements. The 5’ donor 
splice site is characterized by a GU dinucleotide, while the 3’ consensus splice site is defined by 
three elements: the branch site, the polypyrimidine tract and the 3’ acceptor splice site dinucleotide 
AG280,281. Additional regulatory elements in introns (intronic splicing enhancers (ISE)) and exons 
(exonic splicing enhancers (ESE)) can work to enhance exon recognition and inclusion, while other 
elements (exonic and intronic splicing silencers (ESS and ISS)) can cause exon exclusion282,283 or 
suppress splicing at sequences that resemble splice junction consensus sequences. 
 
There are several types of splicing aberrations284, which are represented in the MMR genes. These 
include sequence alterations that disrupt the canonical dinucleotides or other splicing elements, 
leading to complete exon skipping285-287, intron retention288, and use of cryptic splice sites in an 
exon/intron287. Alternatively, nucleotide substitutions may introduce a new splice site (de novo)287 
or in rare cases activate a pseudoexon266,271. The most common experimental methods used to assay 
splicing are reverse transcriptase-PCR (RT-PCR) and minigene assays. In RT-PCR, RNA usually 
derived from lymphocytes or lymphoblastoid cell lines (LCL) is converted into single-stranded 
cDNA and then amplified289,290. A minigene is a simplified version of a natural gene inserted into a 
vector, which lacks one or more (or portions of) exons and introns. In the minigene-splicing assay, a 
small sequence fragment containing the exon/intron to be interrogated is inserted into the vector and 
then transfected into a mammalian cell line285,291.  
 
1.6.2 In vitro or in vivo functional assays 
The canonical MMR process as a whole can be studied in vitro. The repair efficiency is measured in 
a DNA heteroduplex assay by the proficiency of a mutated protein to repair a mismatch in an 
artificial substrate. These assays can be cell-free or cell-based. Cell-free assays measure the repair 
efficiency of cellular extracts containing the mutated MMR protein165,292-294. Whereas, cell-based 
assays may measure spontaneous mutation rates or response to methylating agents using human 
expression systems in mammalian cell lines295,296. Recently a rapid next-generation in vitro assay 
for testing the integral activity of missense substitutions encoded by sequence variants in MLH1, 
MSH2, MSH6, and PMS2 has been developed for use in a clinical setting297-299. In the assays 
variant proteins derived using a mutagenic PCR procedure are expressed in an in vitro expression 
kit (under development for commercial use), and repair efficiency is quantified fluorescently in a 
complementation assay.  
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In vivo assays exploit the functional conservation of MMR through different species, enabling 
investigation of the functional consequences of variants in autologous and heterologous systems. 
The yeast Saccharomyces cerevisiae is particularly amenable for assessing the activity of human 
MMR variants300,301. Multiple different strategies have been used: expression of mutant yeast MMR 
gene in a haploid yeast strain deficient for the same MMR gene302,303; expression of human MMR 
genes in wild-type haploid yeast to assay the dominant-negative effect that wild-type human MMR 
proteins have in these cells 301,304,305; and expression of a mutant yeast MMR gene in a diploid yeast 
strain containing only one functional allele of the same gene306. Additionally, several methods have 
been used to evaluate spontaneous mutation rates in yeast strains (expressing mutant MMR 
proteins) using reporter genes (e.g. LYS2, canavanine). When mutated the reporter genes lose or 
regain their function and can be used to measure the MMR capacity of the introduced mutant MMR 
protein300,301,303,305,307. A major limitation to yeast-based assays is that only conserved residues can 
be assayed.  
 
Additional assays can test other specific biological or biochemical functions of the MMR proteins. 
The assays focus on individual aspects of protein function, such as mismatch binding and ADP-
ATP cycle308, protein stability163,309, protein-protein interaction310-313, and subcellular 
localization165,294,312. A benefit of these assays is that they provide a more specific description of 
how a variant is disrupting MMR function. However, they are technically difficult to perform and 
therefore not suitable for application to routine screening. It has been proposed that these more 
specific assays be utilised when a variant is tested in an in vitro MMR assay demonstrates equivocal 
or normal MMR activity, to further evaluate a missense variant in the research setting314,315. 
 
1.6.3 In silico assays 
Besides experimental methods, the effect of amino acid changes on the MMR proteins, and 
sequence alterations on mRNA splicing can be predicted using computational analyses. Some of the 
in silico programs that predict the effects of amino acid substitutions include: PolyPhen-2316, 
SIFT317,318, Align-GVGD319,320, MutPred321, Mutation assessor (Xvar)322, MAPP-MMR323, PON-
MMR324, and the more recent CADD325. All of these programs employ differing algorithms, 
combining evolutionary conservation as a measure of residue importance, with a measurement of 
changes in physicochemical properties between wild-type and variant proteins319. CADD also 
integrates other features to measure the effect of a sequence alteration325.  
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Web-based bioinformatic programs can be used to predict the likelihood of a sequence alteration 
disrupting normal splicing. There are two main classes of in silico programs; those that analyse the 
effects of sequence alterations on the splicing consensus sites or the creation of de novo/cryptic 
splice sites326,327, and programs that predict possible ESE/ISE and ESS/ISS328,329. The effects of 
disrupting the canonical donor and acceptor dinucleotides are well predicted330. However, the 
introduction of cryptic or de novo splice sites is not as well predicted by all programs. 
Computational algorithms accommodating nucleotide dependencies and using the maximum 
entropy model (e.g. MaxEntScan) are best at discriminating these sites in the donor and acceptor 
sites331,332. Position weight matrices tools are the best at predicting the effect of mutations327. 
However, no one single program is the best at predicting all the effects of mutations. Furthermore, 
there is not yet any statistical evidence that ESE detection software can identify nucleotide 
substitutions with clearly elevated probability to damage splicing330. 
 
1.6.4 Constitutional mismatch repair deficiency 
CMMR-D (introduced in section 1.1) represents the clinical phenotype for “in vivo” functional 
abrogation of the MMR genes. It is a very rare syndrome, which is caused by two different types of 
co-occurrence of mismatch repair mutations: bi-allelic (homozygous mutations) and compound 
heterozygote (different mutations on each allele in the same gene, i.e. in trans). The syndrome is 
highly penetrant and the clinical phenotype commonly includes very early onset haematological 
malignancies, brain tumours, Lynch spectrum cancers, and neurofibromatosis type-1 (NF1) like 
features333. Due to the types of malignancies that present and the very early age of onset, CMMR-D 
cases have a worse prognosis than LS cases. As of June 2013, there are 146 known cases of 
CMMR-D (with mutation status) in 91 families worldwide. Consanguinity is reported in just over 
50% (46/91) of families333. There are also multiple potential CMMR-D cases reported in the 
literature that predate the discovery of the MMR genes (and thus have not had any molecular 
testing), which could be potential CMMR-D cases334. Cases demonstrate protein expression loss 
and in some cases MSI in both tumour and normal tissues. The evidence in the literature suggests 
that IHC is a better diagnostic tool for identifying CMMR-D cases than MSI testing288. In all cases, 
except one family335, where tumour material was tested the dysfunctional gene could be identified 
using IHC336, but not all the tumours were MSI-H, particularly the glioblastomas288,337-343.  
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The distribution of mutation carriers in the four MMR genes contrasts that of LS. The majority of 
families (60%) carry bi-allelic PMS2 mutations, followed by MSH6 (17%) and MLH1/MSH2 
(19%)333. Many of the families with bi-allelic MSH6 and PMS2 mutations did not report a family 
history or cancers at a later age of onset (<50 years old). These results are consistent with the fact 
that mutations in these two genes are less penetrant in a dominant mode of inheritance, and thus 
CMMR-D phenotypes are recessively inherited. There were also compound heterozygotes that do 
not present with the classical CMMR-D phenotype, namely age of onset later than other CMMR-D 
cases (late teens, early twenties), but earlier than LS cases. These include cases of co-occurrence 
involving the variants PMS2 c.1A>G and a PMS2 splice site variant or large deletion32, and MSH6 
c.3226C>T p.Arg1076Cys and MSH6 nonsense or truncating mutations344-347. 
 
Animal models of CMMR-D share some similarities with the human phenotype. In MMR mouse 
knockouts there is frequent lymphoma development and a high abundance of gastrointestinal 
tumours, in Mlh1 and Msh2 knockouts in particular348-354. However, brain tumours are rare and the 
NF1 phenotype of neurofibromas and café au lait spots is absent348-359. Unlike mice, Zebrafish 
knockouts do have an NF1 phenotype, but otherwise a different tumour spectrum360. 
 
1.7 MMR gene sequence variant interpretation 
As indicated above (section 1.4), identification of a high-risk disease-causing MMR gene mutation 
in Lynch syndrome cases defines the clinical management of that patient and also their family 
members. However, between 20-50% of MMR gene sequence variants found by germline genetic 
testing in suspected Lynch syndrome patients are reported to be of uncertain clinical 
significance361,362. These variants, also termed unclassified variants, are not predicted to lead to 
premature termination of translation. Such unclassified sequence variants include nucleotide 
changes predicted to cause missense substitutions, small in-frame insertions/deletions, or 
intragenic/intergenic sequence changes that may alter splicing or gene regulation.  
 
Between 20-30% of genetic variants identified are missense variants, many of which are considered 
of unknown clinical significance362. Only a subset of missense variants that cause a single amino 
acid substitution in a protein sequence are predicted by bioinformatics methods to alter protein 
function363. They have unclear functional and medical consequences and cannot be easily classified 
as either pathogenic or neutral before they have been subjected to a detailed analysis. Accurately 
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placing them in a spectrum from neutral to clearly pathogenic through the development of 
classification systems will require a lot of work, but would allow resources for screening, 
prevention, and treatment to be focused on individuals truly at elevated genetic risk and provide 
reassurance to those who are not at risk363-365. 
 
1.7.1 Classification systems for sequence variants 
Establishing the clinical significance of unclassified variants has direct clinical relevance, since 
positive mutation status for a high-risk gene defines clinical management - with respect to genetic 
counselling approaches, presymptomatic screening, and choice/timing of prophylactic surgery for 
individuals in families276. Until recently there have been no standardized variant classification 
guidelines specific for MMR genes, and many clinicians and genetic counsellors classified variants 
based on an “experience-based” approach. Four groups have proposed generic guidelines for 
interpretation and reporting of unclassified variants (see Table 1.2). Use of several types of 
evidence is recommended in the interpretation of sequence variants. Of these, only the IARC 5-
tiered system defines clinical management recommendations for each category366. 
 
Table 1.2: Classification/interpretation systems for sequence variants 
UK Clinical Molecular Genetics Society & Dutch Society of Clinical Genetic Laboratory Specialists (est. 2007)367 
Class 1: Certainly not pathogenic 
Class 2: Unlikely to be pathogenic but cannot be formally proven 
Class 3: Likely to be pathogenic but cannot be formally proven 
Class 4: Certainly pathogenic 
American College of Medical Genetics (est. 2007)368 
Class 1: Sequence variation is previously reported and is a recognized cause of the disorder 
Class 2: Sequence variation is previously unreported and is expected to cause the disorder 
Class 3: Sequence variation is previously unreported and may or may not be causative of the disorder 
Class 4: Sequence variation is previously unreported and is probably not causative of disease 
Class 5: Sequence variation is previously reported and is a recognized neutral variant 
IARC Unclassified Genetic Variants Working Group (est. 2008)366 
Class 1: Not pathogenic or of no clinical significance (PP <0.001) 
Class 2: Likely not pathogenic or of little clinical significance (PP 0.001-0.049) 
Class 3: Uncertain (PP 0.05-0.949) 
Class 4: Likely pathogenic (PP 0.95-0.99) 
Class 5: Definitely pathogenic (PP >0.99) 
Myriad Genetics Inc. (est. unknown)369 
Class 1: Polymorphism 
Class 2: Genetic variant, favour polymorphism 
Class 3: Variant of uncertain clinical significance 
Class 4: Suspected deleterious 
Class 5: Deleterious 
Abbreviations: IARC – International Agency for Research on Cancer; PP – probability of being pathogenic. 
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For MMR there are several criteria that can be assessed to qualitatively classify variants of 
unknown clinical significance, none of which should be used alone. These include analysis of 
tumour characteristics, such as IHC (loss of expression of the appropriate protein/s) and 
MSI136,370,371, which could demonstrate an association of the variant with Lynch syndrome. 
Furthermore, as specified in section 1.4.6 the presence of MLH1 promoter hypermethylation and/or 
BRAF V600E (for colorectal only) in a tumour can indicate unlikely pathogenicity of a sequence 
variant17,136,263. Non-tumour characteristics associated with pathogenic mutations include, 
segregation with disease, absence in control individuals, evolutionary conservation and changes in 
the physicochemical properties of an amino acid, and a deleterious effect in functional assays 
(protein function or splicing) or in an animal model136,315,319,363,370-372. Co-occurrence in trans with a 
pathogenic mutation, without an abnormal phenotype (i.e. CMMR-D) also suggests that a variant is 
likely not pathogenic.  
 
1.7.2 Locus-specific databases 
Locus-specific databases (LSDBs) are an important source of information for both clinicians and 
researchers to assess opinion on clinical relevance of sequence variants in known disease genes. 
However, consistent data curation is critical to the value of such databases for categorizing the 
relationship between genetic variation and disease373. The International Society for Gastrointestinal 
Hereditary Tumours (InSiGHT, www.insight-group.org) formed the InSiGHT Colon Cancer Gene 
Variant Databases as part of a pilot program with the Human Variome Project (HVP) to collect all 
inherited variation affecting CRC susceptibility genes374. Eleven gene mutation/variant repositories 
were merged or linked to form the database, including the MMR genes. The three main MMR gene 
variant databases merged were: the original ICG-HNPCC variant database361,375, the Memorial 
University of Newfoundland literature database362, and the University Medical Center Groningen 
functional database376. The InSiGHT database is the primary store of public information for the 
MMR gene sequence variants, and as of May 2012 there were 12,538 entries for 3,072 apparently 
unique variants377. 
 
To circumvent the problems leading to and arising from discordant classifications on LSDBs, it has 
been previously recommended that all LSDBs have a level of curation between submission of 
information and publically accessible display, and specifically that a panel that covers a range of 
expertise in variant classification provides consensus opinion on pathogenicity of variants373. 
Moreover, it has been recognised that an important component of the classifications provided by 
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LSDBs is transparency regarding the classification criteria and supporting information used for 
classification, so that LSDB users can consider the information for their own application in the 
research and clinical setting. The InSiGHT Variant Interpretation Committee (VIC, formerly termed 
the Mutation Interpretation Committee) was formed in 2011 to tackle the issue of classifying 
submissions to the InSiGHT database378.  
 
1.7.3 Multifactorial likelihood analysis 
Multifactorial likelihood analysis (also termed Bayesian integrated evaluation) was established to 
tackle the issue of unclassified variants in the familial breast cancer genes BRCA1 and BRCA2379,380. 
It has since been proposed as the method of choice to assess cancer risk associated with rare 
variants of uncertain clinical significance for other cancer gene syndromes363,380, particularly since 
it provides a quantitative measure of probability in favour of pathogenicity tied to qualitative 
translation into the five class scheme (mentioned above) that is linked to clinical 
recommendations366.  
 
Strategies to integrate these methods have been a topic of significant activity for researchers and 
clinicians working with MMR and the melanoma susceptibility gene CDKNA2136,314,365,381-383. The 
model integrates different lines of genetic evidence using Bayesian analysis379,384. Each variant 
starts with a “prior probability” of pathogenicity, which can be based on in silico analyses. One 
approach to measuring the prior probabilities for missense substitutions using the integrative model 
is to calibrate in silico algorithm outputs predicting the effects based on conservation and 
physicochemical properties of the residues319,363, against a reference set of variants that have been 
classified with confidence using other types of data.  
 
A “posterior probability” of pathogenicity is derived by updating the prior probability with 
likelihood ratios (LR) or odds ratios (OR) for pathogenicity determined from statistical analyses of 
observational data such as segregation of the variant in families, pathological characteristics, and in 
vitro studies. An outline of the model is shown in Figure 1.7. The posterior probability is used to 
classify a sequence variant based on the cut-offs for the classes in the five class scheme366. 
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Figure 1.7: Outline of the MMR multifactorial likelihood model. 
 
Approaches to integrate Lynch syndrome tumour characteristics (in particular colorectal and 
endometrial) into the multifactorial likelihood model are discussed in Hofstra et al136. The review 
highlights the pathology features that could be incorporated to evaluate variant pathogenicity. Since 
there is a definitive link between MMR defects and Lynch syndrome, functional assays would also 
have a high predictive value if properly validated314. A methodology to estimate a likelihood of 
pathogenicity based on variant segregation with disease in families using cancer risk estimates from 
MLH1 and MSH2 mutation carriers has already been derived381, and can be transferred to the other 
MMR genes.  
 
1.8 Rationale and aims 
Pathogenic mutations in the MMR genes are the most common cause of hereditary colorectal and 
endometrial cancer, accounting for 2-5% of cancers. With various phases of population-level 
MSI/IHC testing implemented for colorectal and endometrial tumours, these genes are routinely 
screened for mutations in the clinical setting14,17,385-388. Variants of uncertain clinical significance 
are often identified and present a large problem for clinicians, genetic counsellors and researchers. 
Furthermore, with the advent of high-throughput sequencing techniques, the identification of rare 
variants is sure to increase389. It is extremely important to determine whether a sequence variant 
identified in diagnostic genetic screening is disease-causing (i.e. pathogenic), because it determines 
implementation of cancer management strategies for the patient and at-risk relatives. Traditionally, 
an ad-hoc “experience-based” approach has been used to classify variants of uncertain significance, 
and no standardized “international” criteria existed. Hence, I aimed to develop, test and implement 
standardized MMR gene sequence variant classification criteria in collaboration with relevant 
international resources. 
 
MMR gene 
sequence 
variant 
Prior Probability 
of Pathogenicity: 
bioinformatics 
Likelihood Ratios (LR) 
or Odds Ratios (OR): 
clinical/molecular/
functional data 
Posterior Probability of 
Pathogenicity: 
quantitative classification 
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1.8.1 Project aims 
The main objective of this project was to develop standardized methods to interpret the clinical 
significance of germline sequence variants in the mismatch repair genes, using the following 
approaches: 
 
Aim 1: Develop a MMR multifactorial model for use in quantitative classification of variants of 
unknown clinical significance. 
1.1 Derive prior probabilities based on amino acid conservation and physicochemical properties 
for all amino acid substitutions in the MMR proteins. 
1.2 Estimate LRs for pathogenicity through statistical analysis of observational data to 
incorporate into the multifactorial model. 
 
Aim 2: Develop standardized criteria for classification of sequence variants in the MMR genes for 
international use. 
2.1 Develop qualitative criteria based on an evidence-based approach, in collaboration with 
international multi-disciplinary experts (InSiGHT VIC).  
2.2 Construct a catalogue of all known naturally occurring MMR gene alternatively spliced 
mRNA transcripts, to help inform the qualitative classification criteria. 
2.3 Use the standardized criteria to classify all variants on the InSiGHT MMR gene databases. 
 
1.9 Thesis overview 
This thesis is comprised of publications. Each chapter includes tables, figures, appendices in the 
form of supporting/supplementary information, and references relevant to its content. Chapters 2 
and 3, which are published as complementary articles, focus on the development of a working 
multifactorial likelihood model for the MMR genes (aim 1). Together chapters 4 and 5 address aim 
2 of the project. The research article in chapter 4 presents the standardized variant classification 
system (aims 2.1 and 2.3), also incorporating use of the multifactorial model (aim 1) and qualitative 
criteria developed during the course of this project. The final chapter of the thesis provide a 
discussion of the significant overall findings and future directions for the project. 
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Chapter 2: Calibration of Multiple In Silico Tools for Predicting Pathogenicity 
of Mismatch Repair Gene Missense Substitutions 
Human Mutation 2013 Jan;34(1):255-65. 
 
In this publication, curated classified MMR gene variants were used to calibrate in silico tools to 
derive a probability of pathogenicity for all possible amino acid substitutions in MLH1, MSH2, 
MSH6, and PMS2, based on amino acid conservation and physicochemical properties. We tested 
various combinations of six prediction programs, and found that a combined tool using customised 
forms of MAPP and PolyPhen2 was the best at predicting the effect of a missense substitution on 
protein function. The output probability of pathogenicity was implemented in the multifactorial 
likelihood model in the complementary study that is presented in Chapter 3. I also curate a 
publically accessible database (hci-lovd.utah.edu) that contains scores for all possible amino acid 
substitutions for the MMR genes, so that they are easily accessible to clinicians and researchers for 
future application in missense variant classification. 
METHODS
OFFICIAL JOURNAL
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ABSTRACT: Classification of rare missense substitutions
observed during genetic testing for patient management is
a considerable problem in clinical genetics. The Bayesian
integrated evaluation of unclassified variants is a solu-
tion originally developed for BRCA1/2. Here, we take a
step toward an analogous system for the mismatch repair
(MMR) genes (MLH1, MSH2, MSH6, and PMS2) that
confer colon cancer susceptibility in Lynch syndrome by
calibrating in silico tools to estimate prior probabilities of
pathogenicity for MMR gene missense substitutions. A
qualitative five-class classification system was developed
and applied to 143MMRmissense variants. This identified
74 missense substitutions suitable for calibration. These
substitutions were scored using six different in silico tools
(Align-Grantham Variation Grantham Deviation, multi-
variate analysis of protein polymorphisms [MAPP], Mut-
Pred, PolyPhen-2.1, Sorting Intolerant From Tolerant,
and Xvar), using curated MMR multiple sequence align-
ments where possible. The output from each tool was cal-
ibrated by regression against the classifications of the 74
missense substitutions; these calibrated outputs are inter-
pretable as prior probabilities of pathogenicity. MAPP was
the most accurate tool and MAPP + PolyPhen-2.1 pro-
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vided the best-combined model (R2 = 0.62 and area under
receiver operating characteristic = 0.93). The MAPP +
PolyPhen-2.1 output is sufficiently predictive to feed as
a continuous variable into the quantitative Bayesian inte-
grated evaluation for clinical classification of MMR gene
missense substitutions.
Hum Mutat 34:255–265, 2013. C© 2012 Wiley Periodicals, Inc.
KEY WORDS: mismatch repair; in silico; missense substi-
tutions; probability of pathogenicity
Introduction
Missense variants that cause a single amino acid substitution in
a protein sequence may or may not lead to altered protein func-
tion [Tavtigian et al., 2008c]. Many germline missense variants have
unclear functional and medical consequences and cannot be eas-
ily classified as either pathogenic or neutral before they have been
subjected to a detailed analysis. These variants of unknown clinical
significance cannot be used to guide patient management, and are a
source of anxiety for families [O’Neill et al., 2009]. Accurately plac-
ing them in a spectrum from neutral to clearly pathogenic through
the development of robust classification systems would allow re-
sources for screening, prevention, and treatment to be focused on
individuals truly at elevated genetic risk and provide reassurance
to those who are not at risk [Hicks et al., 2011; Miller et al., 2011;
Tavtigian et al., 2008c].
The most common form of hereditary colorectal cancer (CRC)
is Lynch syndrome (LS), which accounts for about 3% of all CRC
[Lynch et al., 2009]. LS results from defects in DNA mismatch
repair due to the inherited mutations in one of four mismatch
C© 2012 WILEY PERIODICALS, INC.
repair (MMR) genes MLH1 (MIM# 120436), MSH2 (MIM#
609389), MSH6 (MIM# 600678), and PMS2 (MIM# 600259) [Viel
et al., 1998; Wang et al., 1999]. Genetic testing for these four genes
is routinely performed. Between 20% and 30% of genetic variants
identified are missense variants, almost all of which are considered
of unknown clinical significance [Woods et al., 2007].
A five-tiered classification system, with recommendations for
clinical management of variants, was proposed by the IARC Work-
ing Group onUnclassified Genetic Variants, and is now under study
in several areas of clinical cancer genetics. When possible, each class
is associated with a probability that a variant is pathogenic derived
from statistical studies [Plon et al., 2008] that incorporate data from
various independent sources important to disease pathology. These
include clinicopathologic and epidemiological studies, but also in
vivo or in vitro functional assays, and computational (in silico)
analyses [Couch et al., 2008; Tavtigian et al., 2008b].
Strategies to integrate these methods have been a topic of sig-
nificant activity for researchers and clinicians working with MMR
and other cancer susceptibility genes [Arnold et al., 2009; Barnetson
et al., 2008; Easton et al., 2007;Goldgar et al., 2004;Miller et al., 2011;
Pastrello et al., 2011]. An increasingly well-developed method for
classifying variants (initially BRCA1 [MIM# 113705] and BRCA2
[MIM# 600185] variants) integrates different lines of genetic ev-
idence using Bayesian analysis [Easton et al., 2007; Goldgar et al.,
2004]: each variant starts with a “prior probability” of pathogenicity
based on in silico algorithm outputs, ultimately calibrated against a
reference set of variants that have been classifiedwith confidence us-
ing other types of data [Easton et al., 2007; Tavtigian et al., 2008a];
a “posterior probability” of pathogenicity is derived by updating
the prior probability with likelihood ratios (LR) or odds ratios for
pathogenicity determined from statistical analyses of observational
data such as segregation of the variant in families, pathological char-
acteristics, and in vitro studies.
A wide variety of in silico tools using various implementations
and combinations of features have now been developed [Tavtigian
et al., 2008c; Thusberg et al., 2011]. These in silico tools are gener-
ally based on: (1) analyses of sequence conservation at the position
of a missense substitution, which is measured from a protein mul-
tiple sequence alignment, (2) severity of a missense substitution
with respect to the observed range of variation at its position in
an alignment, and/or (3) structural features of the wild-type and
variant proteins. This study focuses on comparing the accuracies
and calibrating the outputs of in silico tools forMMRmissense sub-
stitution analysis. We report (1) a list of 74 qualitatively classified
MMR variants used in the calibration, (2) the creation of curated
protein multiple sequence alignments for the four MMR genes as-
sociated with LS, (3) comparison of six in silico tools for predicting
the pathogenicity of the list of variants, (4) comparison of pair-
wise combinations of these in silico tools, and (5) calibration of the
output, expressed as a continuous variable, of the best paired com-
bination in describing probability in favor of pathogenicity. This
output variable can be used now as a tool for classification, feeding
into the quantitative integrated evaluation of MMR gene missense
substitutions (see the accompanying paper [Thompson et al., in
press]).
Methods and Materials
Development of the Qualitative Classifier
An existing qualitative missense classifier originally developed
for research classification of Colon Cancer Family Registry (CCFR)
MMR gene variants [Thompson et al., 2012] was further devel-
oped with the coauthors, following suggestions from the InSiGHT
Mutation Interpretation Committee. The classifier presents a five-
class system as described for quantitative assessment of variant
pathogenicity in [Plon et al., 2008]. However, instead of mathe-
matically derived probabilities of pathogenicity, the classes reflect
consensus opinion that a set of qualitative data correspond to a
≥99%, ≥95%, ≤5%, or ≤0.1% probability of pathogenicity. Two
general types of data were combined: (1) association of the variant
with clinical cases of LS cancers, such as segregation with disease
in families, microsatellite instability-high (MSI-H) or loss of the
appropriate protein by immunohistochemistry (IHC) in tumors of
variant carriers; and (2) association of the variant with decreased
function in an in vitro assay. The criteria used to classify the vari-
ants are shown in Table 1. Importantly, the standardized qualitative
classifier excluded data from in silico tools.
Generation of the List of Qualitatively Classified Missense
Substitutions
An initial list of 143 MMR missense variants considered (likely)
pathogenic or neutral was compiled from five sources for stan-
dardized classification using the qualitative criteria (Table 1). These
sources were: a population-based study by Barnetson et al. (2008),
two studies of in silicomethods by Chan et al. (2007) and Chao et al.
(2008), variants identified by the Australasian CCFR population
and clinic-based recruitment arms [Arnold et al., 2009], common
missense substitutions drawn from dbSNP, (http://www.ncbi.nlm
.nih.gov/sites/entrez?db=snp). All the MMR variants assessed
(classes 1–5) have been submitted to the InSiGHT locus-specific
database (www.insight-group.org). Standardized classification used
mostly information from the literature/databases, supplemented
with someunpublished data on tumor characteristics collected from
the clinicians listed in the acknowledgments. None of these sources
reported using tumor prescreening criteria; overall only 56% of
these variants were associated with MSI-H tumors and only 41%
showed loss of IHC staining.
The 143 missense substitutions were classified independently by
two investigators (BAT and MSG), and discrepancies resolved by
consensus among four investigators (BAT, MSG, ABS, and SVT).
Variants with reported evidence of a splice defect were excluded
from further analysis to prevent the possibility of pathogenicity
actually attributable to splice effects from confounding analyses
of pathogenicity attributable to missense dysfunction. Calibration
used all truemissense variants that were ultimately classified as class
1, 2, 4, or 5 (but not class 3 variants).
Preparation of Protein Multiple Sequence Alignments
We constructed MLH1, MSH2, MSH6, and PMS2 protein mul-
tiple sequence alignments over a fixed phylogeny of species: hu-
man, Cercopithecidae (Macaca mulatta or Chlorocebus aethiops),
Glires (Mus musculus), Laurasiatheria (Bos taurus or Canis lupus),
Marsupialia (Monodelphis domestica), Aves (Gallus gallus), Am-
phibia (Xenopus laevis or Xenopus tropicalis), Teleostei (Danio re-
rio), Agnatha (Petromyzon marinus), Urochordata (Ciona intesti-
nalis), Cephalochordata (Branchiostoma floridae), Echinodermata
(Strongylocentrotus purpuratus), Cnidaria (Nematostella vectensis),
and Placozoa (Trichoplax adhearens). Individual sequences were
curated by hand, and in areas where exon predictions or splice
junction predictions were unclear, peptide sequences were re-
placed with “X,” rather than “-” to allow distinction between
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Table 1. Missense Classification Criteria
Class Criteria used for qualitative classification
Class 5—Pathogenic All of the following characteristics:
– deficient protein function in in vitro/ex vivo functional assays in mammalian system (cannot be in yeast only)
– cosegregation with disease in at least one AMS family with ≥4 affected carriers, or ≥2 familiesa with ≥3 affected nonproband carriers
– not present in the general population (>160 individuals = 320 alleles)
– MSI-H in ≥2 independent tumors with no contradictory IHC results or immunoloss of MMR protein(s) consistent with the variant
location in ≥2 independent tumors for MLH1 or ≥1 tumor for MSH2, MSH6, and PMS2
Class 4—Likely pathogenic Deficient protein function in one or more in vitro/ex vivo assays in any eukaryote, plus one of the following:
– cosegregation with disease in at least one AMS family with ≥3 affected carriers
– MSI-H in ≥2 independent tumors with no contradictory IHC results or immunoloss of MMR protein(s) consistent with the variant
location in ≥2 independent tumors for MLH1 or ≥1 tumor for MSH2, MSH6, and PMS2
Class 3—Uncertain Insufficient evidence to classify, that is, not class 1, 2, 4, or 5
Class 2—Likely not pathogenic Variants reported to occur in a specific ethnic group at frequency ≥1%, and that have not yet been excluded as known founder mutations
Or variants reported to occur in the general population at a frequency <1%, with normal protein function in in vitro/ex vivo functional
assays in any eukaryote and no aberrant splicing
Class 1—Not pathogenic Variants reported to occur in the general population at frequency ≥1%
Or present in the general population at frequency 0.1%– 1% and determined by large case-control studies to be associated with estimated
risk <1.5, with upper bound 95% CI <4
Note: These classification guidelines (froze in October 2011) are similar to criteria currently being developed and tested by the InSiGHT Mutation Interpretation Committee.
aThe families used in variant classification fulfilled the Amsterdam Criteria.
AMS, revised Amsterdam criteria [Vasen et al., 1999]; MSI-H, microsatellite instability-high.
ambiguous amino acids and true alignment gaps [Tavtigian et al.,
2008c]. Sequences were aligned using M-Coffee [Wallace et al.,
2006], followed by minor hand editing. The sequences and align-
ments satisfied three criteria: (1) the individual sequences are essen-
tially full-length and encode clear orthologs of the relevant human
protein, (2) the individual sequences are substantially free of cDNA
(or gene model) structural errors, and (3) the concatenated align-
ment of all four genes contains an average of at least three amino
acid substitutions per position and meets the missense substitution
analysis program Sorting Intolerant From Tolerant (SIFT) “me-
dian sequence conservation” criterion for confident prediction of
substitutions that should “affect protein function,” thus meeting
criteria of sufficient sequence diversity to grade missense substitu-
tions [Greenblatt et al., 2003;Ng andHenikoff, 2002; Tavtigian et al.,
2008c]. These alignments, or updated versions thereof, are available
at http://agvgd.iarc.fr/alignments.php.
Missense Substitution Scoring and Output Manipulation for
Regression Analyses
Missense substitutions were scored using six distinct in silico
tools.
(1) Align Grantham Variation Grantham Deviation (Align-
GVGD—http://agvgd.iarc.fr/) [Tavtigian et al., 2006, 2008a]
was run at three depths of sequence alignment: through
Strongylocentrotus (the shallowest alignment to reach the se-
quence diversity target of an average of three substitutions per
position), through Nematostella, and through Trichoplax. For
regressions, the standard output of seven grades was coded as 0
(for C0, the least likely functionally deleterious grade) through
6 (for C65, the most likely functionally deleterious grade). For
some regressions, C0 was split into two grades: GD = 0 (least
likely to be functionally deleterious) and GD > 0 (slightly more
likely to be functionally deleterious).
(2) Multivariate analysis of protein polymorphisms (MAPP—
http://mendel.stanford.edu/SidowLab/downloads/MAPP/)
[Stone and Sidow, 2005] was run at three depths of sequence
alignment: through Strongylocentrotus, through Nematostella,
and through Trichoplax. For regressions, we used the
MAPP score as a continuous variable and also used
ln(MAPP Score) as a continuous variable. MAPP-MMR
(http://mappmmr.blueankh.com/), which is a modification of
MAPP that focuses on the MMR genesMLH1 andMSH2, was
also run [Chao et al., 2008].
(3) PolyPhen-2.1 (http://genetics.bwh.harvard.edu/pph2/) [Adzh-
ubei et al., 2010] was used in two modes: (1) default mode
with native alignments, which is equivalent to the online
version, and (2) a custom mode in which the program was
retrained without MMR gene data. In the latter case, the na-
tive PolyPhen-2.1 MMR gene alignments were lightly edited to
remove 5′ or 3′ protein sequence segments that bore little or
no resemblance to the corresponding human gene, and internal
insertions that were likely to be consequences of exon boundary
prediction errors. From both modes, “HumVar” outputs were
used for statistical analyses. For regressions, “Class” (deleteri-
ous/neutral) was used as a binary predictor. “Benign/possible
damaging/probably damaging” was used as a trinary predictor
with benign set to 0, “probably damaging” set to 2, and the
value for “possible damaging” optimized; on this scale, the op-
timum value usually came out between 0.9 and 1.1. The output
variable “pph2_prob” was used as a continuous variable.
(4) MutPred (http://mutpred.mutdb.org/) [Li et al., 2009]was used
in two modes: (1) default mode with native alignments, which
is equivalent to the online version, and (2) a custom mode in
which the program was retrained without MMR gene data. For
regressions, we used the MutPred “RF score” with a threshold
of 0.5 as a binary variable, MutPred “RF score” as a continuous
variable, and ln(RF score) as a continuous variable.
(5) SIFT (http://sift.jcvi.org/) [Kumar et al., 2009;Ng andHenikoff,
2002] was used in two modes: (1) SIFT BLINK, which uses na-
tive SIFT alignments, and (2) with our curated alignments. In
the latter case, we checked the SIFT “median sequence con-
servation” score and found that only the complete alignments
(through Trichoplax) were diverse enough for confident pre-
diction of substitutions that should “affect protein function.”
Consequently, these are the alignments that we used with SIFT.
For regressions, we used the SIFT predictions of tolerated/affect
protein function as a binary predictor. We also used the SIFT
score and –log(SIFT + 0.01) as continuous variables.
HUMANMUTATION, Vol. 34, No. 1, 255–265, 2013 257
(6) Mutation Assessor (Xvar; http://mutationassessor.org/) [Reva
et al., 2011] was used in default online mode. Qualitative func-
tional impact (low/medium/high) was used as a trinary predic-
torwith low set to 0, “high” set to 2, and the value for “medium”
optimized; on this scale, the optimum value came out be-
tween 1.0 and 1.1. We used the output variable “Functional
Impact Score” and ln(Functional Impact Score) as continuous
variables.
Regression and Related Analyses
We performed three types of regression and related analyses: least
squares regression, ordinal logistic regression, and receiver oper-
ating characteristic (ROC) area analysis. Statistical analyses were
performed in STATA 11.0 (StataCorp, College Station, Texas, USA).
For least squares regressions, the qualitative class of each sequence
variant (pathogenic, likely pathogenic, likely not pathogenic, or not
pathogenic) was treated as the dependent variable and assigned the
minimumvalue for the threshold probability in favor of pathogenic-
ity from the corresponding quantitative classification system (0.99,
0.95, 0.05, or 0.001, respectively) [Plon et al., 2008]. The scores gen-
erated by the in silico tools for each sequence variant were treated as
independent variables. For analyses of the performance of individ-
ual in silico tools, we then performed least squares regressions on
logit(probability in favor of pathogenicity) (logit[Pr]) versus pro-
gram scores. For analyses of combined outputs from two in silico
tools, we performed bivariate least squares regressions on logit(Pr)
versus pairs of program scores. We note that using logit(Pr) as the
dependent variable constrains the resulting regression equations to
produce probabilities between 0.00 and 1.00, a feature normally
associated with logistic regression. For ordinal logistic regressions,
the qualitative class of each sequence variant was treated as the
dependent variable and assigned the ordering pathogenic > likely
pathogenic > likely not pathogenic > not pathogenic. Program scores
generated were treated as independent variables. For analyses of the
performance of individual in silico tools, we then performed ordinal
logistic regressions of qualitative class versus program scores. For
analyses of combined outputs from two in silico tools, we performed
bivariate ordinal logistic regressions on qualitative class versus pairs
of program scores. For ROC area under the curve (AUC) analyses,
we collapsed the qualitative classifications “pathogenic” and “likely
pathogenic” into“pathogenic” andcollapsed“likelynotpathogenic”
and “not pathogenic” into “not pathogenic.” For analyses of the per-
formance of individual in silico tools, this binary classification was
used as the reference variable and program scores were used as the
classification variable. For ROC area analyses of combined outputs
from two in silico tools, we used the regression intercept and co-
efficients calculated for a given pair of tools from the least squares
regression to calculate their combined score. The binary classifi-
cation was then used as the reference variable and the combined
program score was used as the classification variable.
A 10-fold cross-validation approach was used to estimate the
goodness of fit of the combined models, reported as adjusted R2
from bivariate least squares regressions. In each cross-validation
cycle, the 74 missense substitutions were randomly split into 10
approximately equal partitions, and each partition was then used
for testing the estimated linear regression equation learned from
the remaining nine partitions. After all 10 partitions were tested,
an adjusted R2 between the predicted and observed probabilities of
pathogenicity was calculated. This process was repeated indepen-
dently 1,000 times to obtain the adjusted R2 point estimates and
95% confidence intervals (CIs).
Results
Classification of 143 MMR Missense Variants Using a
Qualitative Classifier
Of the 143 variants analyzed, 12 were excluded because of the
evidence of aberrant splicing. Seventy-four (56.5%) of the remain-
ing missense substitutions could be classified as class 1, 2, 4, or 5,
which are clinically actionable. Of these, approximately 85% were
easily classified by consensus, and approximately 15% were con-
sidered potentially ambiguous, usually because of the existence of
discordant data combinations that were not explicitly included in
the criteria. The distribution of classifications was: class 1 (n = 20),
class 2 (n = 9), class 4 (n = 37), and class 5 (n = 8) (Table 2; Supp.
Table S1). The remaining 57 variants remained class 3, uncertain.
In silico Tools
In silico tools were applied as described in the section “Materials
and Methods.” In our initial analysis, MutPred, PolyPhen-2, and
Xvar were used as trained in their standard online form. These pro-
grams plus SIFT were used with their internally generated protein
alignments and all six programs were used under essentially default
conditions. All single programs performed fairly well. Most pro-
duced least squares regression adjusted R2 values >0.45 and P values
<10–10 (Table 3). The AUC of the ROC for all methods was >0.80
(data not shown). In these initial analyses, the two best performing
in silico tools from this analysis were MutPred and PolyPhen-2. We
explored whether evaluating output as a continuous rather than
a binary or trinary function would affect results. The continuous
variable approach yielded better correlation and lower P values for
the three programs where it was possible to compare continuous
output using least squares regression (Table 3) to binary output
using ordinal logistic regression (data not shown). The correlation
and P values differed little between continuous and trinary output
(likelydeleterious, intermediate, likelyneutral) for the twoprograms
where it was possible to compare least squares regression (Table 3)
to trinary output using ordinal logistic regression (data not shown).
Because the MutPred and PolyPhen-2.1 training data included
MMR gene missense substitutions that overlapped with our quali-
tatively classified set of substitutions, we conducted a second round
of analyses in whichMutPred and PolyPhen-2.1 were retrained with
datasets that excluded all MMR gene missense substitutions. The
multiple sequence alignments produced by PolyPhen-2.1 were also
lightly curated, and SIFT was rerun using the same set of highly cu-
rated alignments that were used with Align-GVGD and MAPP. All
six in silico tools output a continuous variable that was appropriate
for our analyses, so this second round of analyses focused on con-
tinuous variable outputs. Results, which we consider to have been
produced under analytically appropriate conditions for each of the
in silico tools tested, are summarized in Table 4. The performance
of SIFT improved using the curated alignments (least squares re-
gression R2 increased from 0.420 to 0.541), there was a very slight
degradation in the performance of PolyPhen-2.1 (R2 decreased from
0.591 to 0.575) and there was a more notable decrease in MutPred’s
performance (R2 decreased from 0.600 to 0.396). In this analysis,
the program rankings obtained after least squares regression and
after ordinal logistic regression were identical, and there was only
one difference in the ordering obtained from the ROC area anal-
ysis. The best result was obtained for MAPP, with R2 > 0.58 and
AUC > 0.92; these results were only very slightly stronger than those
obtained for PolyPhen-2.1 (Table 4). The distributions of the set
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Table 2. Qualitative Classification of 143 Missense Substitutions Evaluated for Use in Calibration of In Silico Tools
Class 1—not pathogenic (n = 20) Class 3—uncertain (cont.) Class 3—uncertain (cont.) Class 4—likely pathogenic (cont.)
MLH1 p.(Ile32Val) MLH1 p.(Glu89Gln) MSH2 p.(Pro349Arg) MLH1 p.(Leu749Pro)
MLH1 p.(Val213Met) MLH1 p.(Ser93Gly) MSH2 p.(Phe447Val) MLH1 p.(Arg755Ser)
MLH1 p.(Ile219Val) MLH1 p.(Thr117Arg) MSH2 p.(Gly548Asp) MSH2 p.(Val161Asp)
MLH1 p.(Ile219Leu) MLH1 p.(Lys134Asn) MSH2 p.(Asn596Ser) MSH2 p.(Gly162Arg)
MLH1 p.(Gln689Arg) MLH1 p.(Arg217Cys) MSH2 p.(His639Leu) MSH2 p.(Gly164Arg)
MLH1 p.(Val716Met) MLH1 p.(Asp304Gly) MSH2 p.(Ile704Val) MSH2 p.(Leu173Pro)
MLH1 p.(His718Tyr) MLH1 p.(Arg325Gln) MSH2 p.(Ala834Thr) MSH2 p.(Leu187Pro)
MSH2 p.(Asn127Ser) MLH1 p.(Lys443Gln) MSH2 p.(Asn835His) MSH2 p.(Cys333Tyr)
MSH2 p.(Gly322Asp) MLH1 p.(Thr452Ser) MSH2 p.(Leu911Arg) MSH2 p.(Asp603Asn)
MSH2 p.(Leu390Phe) MLH1 p.(Val506Ala) MSH2 p.(Val923Glu) MSH2 p.(Gly692Arg)
MSH2 p.(Ile735Val) MLH1 p.(Gly532Val) MSH6 p.(Pro623Ala) MSH2 p.(Cys697Arg)
MSH6 p.(Gly39Glu) MLH1 p.(Trp538Gly) MSH6 p.(Glu983Gln) MSH2 p.(Cys697Phe)
MSH6 p.(Leu396Val) MLH1 p.(Leu549Pro) PMS2 p.(Arg20Gln) MSH2 p.(Glu749Lys)
MSH6 p.(Val878Ala) MLH1 p.(Pro581Leu) PMS2 p.(Asn775Ser) MSH2 p.(Gly751Arg)
MSH6 p.(Ile886Val) MLH1 p.(Asp601Gly) PMS2 p.(Ser46Ile)Class 4—Likely pathogenic (n = 37)
PMS2 p.(Thr277Lys) MLH1 p.(Leu607His) Class 5—Pathogenic (n = 8)
PMS2 p.(Pro470Ser) MLH1 p.(Lys618Ala) MLH1 p.(Pro28Leu)
PMS2 p.(Thr485Lys) MLH1 p.(Lys618Thr) MLH1 p.(Asp63Glu) MLH1 p.(Met35Arg)
PMS2 p.(Thr597Ser) MLH1 p.(Tyr646Cys) MLH1 p.(Gly67Trp) MLH1 p.(Asn38His)
PMS2 p.(Met622Ile) MLH1 p.(Arg659Gln) MLH1 p.(Gly67Glu) MLH1 p.(Ser44Phe)
Class 2—Likely not pathogenic (n = 9) MLH1 p.(Leu729Val) MLH1 p.(Cys77Arg) MLH1 p.(Gly67Arg)
MLH1 p.(Asp737Val) MLH1 p.(Cys77Tyr) MLH1 p.(Thr117Met)
MLH1 p.(Val326Ala) MSH2 p.(Ala2Thr) MLH1 p.(Phe80Val) MLH1 p.(Leu622His)
MLH1 p.(Val384Asp) MSH2 p.(Val3Leu) MLH1 p.(Lys84Glu) MSH2 p.(Pro622Leu)
MLH1 p.(Ser406Asn) MSH2 p.(Phe19Leu) MLH1 p.(Ile107Arg) MSH2 p.(Ala636Pro)
MLH1 p.(Ile655Val) MSH2 p.(Thr33Pro) MLH1 p.(Leu155Arg) Splicing Defects (n = 12)
MLH1 p.(Lys751Arg) MSH2 p.(Leu93Phe) MLH1 p.(Val185Gly)
MLH1 p.(Asp41Gly)MSH2 p.(Asp167His) MSH2 p.(Arg96His) MLH1 p.(Gly244Asp)
MLH1 p.(Arg100Pro)MSH2 p.(Gln629Arg) MSH2 p.(Tyr103Cys) MLH1 p.(Ser247Pro)
MLH1 p.(Arg182Gly)MSH2 p.(Met688Ile) MSH2 p.(Arg106Lys) MLH1 p.(Leu550Pro)
MLH1 p.(Arg265Cys)MSH6 p.(Val509Ala) MSH2 p.(Val163Asp) MLH1 p.(Asn551Thr)
MSH2 p.(Leu175Pro) MLH1 p.(Leu559Arg) MLH1 p.(Ser295Asn)
Class 3—Uncertain (n = 57) MSH2 p.(Glu188Gln) MLH1 p.(Leu582Phe) MLH1 p.(His329Pro)
MLH1 p.(Arg18Cys) MSH2 p.(Lys246Gln) MLH1 p.(Ala589Asp) MLH1 p.(Arg659Leu)
MLH1 p.(Gly22Ala) MSH2 p.(Lys248Glu) MLH1 p.(Pro648Ser) MLH1 p.(Arg659Pro)
MLH1 p.(Glu23Lys) MSH2 p.(Leu330Pro) MLH1 p.(Pro648Leu) MLH1 p.(Glu663Asp)
MLH1 p.(Ala29Ser) MSH2 p.(Leu341Pro) MLH1 p.(Pro654Leu) MSH2 p.(Ala272Val)
MLH1 p.(Asn38Ser) MSH2 p.(Val342Ile) MLH1 p.(Arg687Trp) MSH2 p.(Ser554Gly)
MSH2 p.(Ser554Asn)
Note: Variant nomenclature was derived from the GenBank reference sequences NM_000249.3 forMLH1, NM_000251.1 forMSH2, NM_000179.2 forMSH6, and NM_000535.5
for PMS2. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, with the initiation
codon as codon 1.
Table 3. Least Squares Regression Results from Individual Analysis Programs Run under Essentially Default Conditions
Binary classification Trinary classification Continuous variable
Analysis program Adjusted R2 P value Adjusted R2 P value Adjusted R2 P value
MutPreda 0.550 2.39× 10–14 N/A N/A 0.600 3.41× 10–16
PolyPhen2.1a 0.464 1.45× 10–11 0.577 2.60× 10–15 0.591 7.60× 10–16
MAPPb N/A N/A N/A N/A 0.586 1.15× 10–15
Align-GVGDc N/A N/A N/A N/A 0.452 3.35× 10–11
Xvara N/A N/A 0.465 1.39× 10–11 0.449 4.01× 10–11
SIFTa 0.356 1.19× 10–8 N/A N/A 0.420 2.53× 10–10
aOnline, default running conditions.
bHand-curated alignment through star anemone, using ln(MAPP score) as a continuous variable.
cHand-curated alignment through sea urchin, using the default 7 grades.
N/A, not applicable.
of 74 missense variants on the sigmoid curves generated from the
least squares regression equations for MAPP and PolyPhen-2.1 are
shown in Figure 1A and B.
Under the conditions used to compare these six in silico tools,
their outputs were highly correlated (Table 5). The strongest cor-
relation was between PolyPhen-2.1 and SIFT (R2 = 0.92). Seven of
15 pairs had R2 ≥ 0.80. The weakest correlation was between Align-
GVGDandMutPred (R2 = 0.61).Usingbivariate regressions,we then
explored the consequence of combining the output from each of the
three better performing in silico tools with the output of each of the
other tools. By the criterion that both programs make a significant
contribution to the least squares regression bivariate model, five
pairs of programs gave stronger results than either member of the
pair alone. In order of adjusted R2, these were: MAPP + PolyPhen-
2.1, Polyphen-2.1 + Align-GVGD, PolyPhen-2.1 + MutPred, SIFT +
Align-GVGD, and SIFT + MutPred (Table 6). With the addition of
the criteria that both programs also make a significant contribution
to the bivariate ordinal logistic regression and increase the ROC area
over that achieved by either program alone, only the combination
MAPP + PolyPhen-2.1 outperformed its individual components.
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Table 4. Results from Individual Analysis Programs Run Under Analytically Appropriate Conditions
Logit regression Ordered logistic regression
Analysis program Adjusted R2 P value Pseudo R2 P value ROC area
MAPPa 0.586 1.15× 10–15 0.253 2.26× 10–11 0.928
PolyPhen-2.1b 0.575 3.15× 10–15 0.250 2.83× 10–11 0.925
SIFTc 0.541 5.07× 10–14 0.250 2.76× 10–11 0.878
Align-GVGDd 0.505 7.73× 10–13 0.222 2.61× 10–10 0.912
Xvare 0.449 4.01× 10–11 0.191 5.83× 10–9 0.872
MutPredf 0.396 1.12× 10–9 0.163 7.78× 10–8 0.867
aHand-curated alignment through star anemone, using ln(MAPP score) as a continuous variable.
bTrained excluding MMR genes, with lightly curated PolyPhen-generated alignments, using “probability pph2” as a continuous variable.
cHand-curated alignment through Trichoplax, using –log(SIFT score +0.01) as a continuous variable.
dHand-curated alignment through sea urchin, using 8 grades.
eRun under default conditions using “Functional Impact Score” as a continuous variable.
fTrained excluding MMR genes, using the “probability of a deleterious substitution” as a continuous variable.
Backward selection arrived at the same result. Starting with all six
in silico tools in a single model, removing the tool that made the
weakest contribution to the combined model, and then repeating
the process with five-tool, four-tool, and three-tool models, the or-
der in which tools dropped out was: SIFT, Xvar, Align-GVGD, and
MutPred. There were no models combining three or more in silico
tools in which all of the tools made a significant contribution. The
order in which the in silico tools dropped out was the same under
least squares regression and ordinal logistic regression. Therefore,
MAPP + PolyPhen-2.1 appears to be the best combination. This pair
achieved an adjusted least squares regression R2 of 0.62 (bootstrap
95% CI 0.46–0.80) and an ordinal logistic regression pseudo R2 of
0.28 (bootstrap 95% CI 0.16–0.41). The ROC AUC (Fig. 1C) was
0.933 (95% CI 0.87–0.99). The lower bound of the 95% CIs for
adjusted R2, pseudo R2, and AUC includes the performance point
estimates from four of the individual algorithms and all of the pairs
tested, but provides evidence against the argument that the two
weaker in silico tools are actually equivalently effective predictors
under the conditions used. To assess whether we have overestimated
model performance, we used a cross-validation approach to reesti-
mate adjusted R2 for the bivariate least squares regression models.
The cross-validationR2 were only slightly decreased, by 0.03 to 0.04,
from the directly estimated R2 (Table 6).
The least squares regression equation determined for the combi-
nationMAPP +PolyPhen-2.1was: logit(Pr) = –9.20 + 2.27(ln[MAPP
score]) + 4.26(“pph2_prob” output from retrained PolyPhen-2.1).
The 95% CIs on the intercept, MAPP coefficient, and PolyPhen-
2.1 coefficient were (–11.61 to –6.79), (0.80–3.75), and (1.11–7.41),
respectively. Figure 1D shows the scatter plot of results compar-
ing qualitatively assigned probability in favor of pathogenicity ver-
sus probability of pathogenicity as a continuous variable calculated
from the MAPP + PolyPhen-2.1 output. Of the set of 74 variants,
there were six class 4/5 variants with <50% prior probability of
pathogenicity, and five class 1/2 variants with >50% probability of
pathogenicity. No major patterns were noted among the 11 dis-
cordant predictions; however, two of the MLH1 pathogenic vari-
ants that were predicted to have <50% likelihood of pathogenicity
were in adjacent codons within the interaction domain. In addition,
there was existing in vitro evidence suggesting partial loss of MMR
function or protein binding for three of the five variants considered
“likely not pathogenic” (see Fig. 1D and Supp. Table S1). These three
variants were classified on the basis of allele frequency in a control
population, overriding functional assay results as per criteria stated
in Table 1.
Results from the MAPP + PolyPhen-2.1 prior probability
database/calculator are available through: http://hci-lovd.hci.utah
.edu/. For the 57 variants that were assigned Class 3, 25% had in
silico scores predicting >90% probability of pathogenicity, and 30%
predicting >10% probability of pathogenicity (see Supp. Table S2).
Discussion
In several areas in cancer genetics, multiple data types are com-
bined to assess the effects of genetic variants. Quantifying data types
and applying integrated Bayesian analysis appears to be a robust ap-
proach to classifying variants [Arnold et al., 2009; Easton et al.,
2007; Goldgar et al., 2004; Miller et al., 2011]. An important princi-
ple of classification, using this method, is that at least two different
sources of data should be used for variant classification [Plon et al.,
2008]. One approach to calibration of the individual components
of the integrated evaluation of MMR gene unclassified missense
substitutions would be to begin from a large series of securely classi-
fied missense substitutions. Ideally, these would be classified on the
combined basis of segregation data (to show that the allele is asso-
ciated with the syndrome) and functional assay data (to show that
the identified variant, rather than a linked but unobserved variant,
damages protein function) as a gold standard. However, because
extensive segregation data on individual missense substitutions are
scarce and functional assay data are often conflicting, very fewMMR
missense substitutions can actually be classified on this basis.
As an alternative first step, in silico tools can provide prelimi-
nary evidence on the effects of all missense variants. To develop this
approach for clinical use in statistical variant classification mod-
els, we have qualitatively classified a set of MMR gene missense
substitutions that were not preselected for IHC, MSI, or other clin-
icopathologic features, and then used class 1, 2, 4, and 5 variants
to calibrate the output from a number of in silico missense substi-
tution analysis tools as a probability in favor of pathogenicity. The
performance of all classifiers that we tested was generally good, with
95% CIs overlapping considerably for many of them. Although we
rank our preferences for the various methods, our study solidifies
the concept that properly applied in silico methods carry sufficient
power to be used clinically inmodels for variant classification. As an
indication of the internal consistency of our study, it is encouraging
that MAPP performed best in all regression and AUC of the ROC
analyses, and that PolyPhen-2.1 functioned almost as well.
Three noteworthy factors emerged from our analyses of the indi-
vidual in silico tools:
(1) The importance of excluding MMR gene variants from a train-
ing set used to train the in silico tool. The generally accessible
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Figure 1. A: Distribution of the set of 74 class 1–2–4–5 missense variants on a sigmoid curve for MAPP outputs derived using the logit regression
calibration equation—Logit(Pr) = −10.84 + 3.99(ln[MAPP score]), where Pr is the probability in favor of pathogenicity. The classifications of the
variants are identified by colored symbols (defined in the legend). B: Sigmoid curve showing the outputs of the 74 missense variants from PolyPhen-
2.1 using the logit regression calibration equation—Logit(Pr) = −6.04 + 8.45(pph2_prob). The missense variants with the largest differences (!)
in probability of pathogenicity derived from MAPP versus PolyPhen-2.1 are identified in (A) and (B): MLH1 V185G (! = 0.528), MLH1 V326A (! =
0.733),MLH1 L582F (! = 0.748),MLH1 H718Y (! = 0.719), andMSH6 V509A (! = 0.553). C: Receiver operating characteristic (ROC) curves for MAPP
and combined MAPP + PolyPhen-2.1 accuracy, using probabilities and scores associated with each program. D: Scatter diagram comparing the
qualitatively assigned probability in favor of pathogenicity (class 1—not pathogenic, class 2—likely not pathogenic, class 4—likely pathogenic,
and class 5—pathogenic) with the probability of pathogenicity as a continuous variable calculated from the MAPP + PolyPhen-2.1 outputs. The
pie graphs are proportional representations of overlapping variants in the four mismatch repair genes (MLH1—blue,MSH2—red,MSH6—green,
and PMS2—black). The variants with in silico scores predicting <0.40 probability of pathogenicity that were qualitatively classified as class 4 and
class 5 are identified, as were variants that had in silico scores predicting >0.60 probability of pathogenicity with qualitative classifications of class
1 and class 2.
Table 5. Pairwise Correlation Matrix
PP2.1a SIFT A-GVGDb Xvar MutPred
MAPP 0.86 0.89 0.82 0.78 0.69
PolyPhen-2.1 0.92 0.80 0.86 0.67
SIFT 0.79 0.84 0.67
Align-GVGD 0.73 0.61
Xvar 0.75
Computational tool use conditions are as in Table 4.
aPP2.1 is PolyPhen-2.1.
bA-GVGD is Align-GVGD.
online versions ofMutPred, PolyPhen-2, and Xvar were trained
using data sets that includedMMR variants. To eliminate over-
lap between training and calibration sets and thereby reduce
the possibility of overfitting during our calibration exercise, the
twomore promising methods (MutPred and PolyPhen-2) were
retrained by omitting all MMR variants from their training
set. This resulted in significant degradation of performance for
MutPred, but only a very small decrease for PolyPhen-2.1. This
result calls into question a number of missense substitution
in silico tool performance studies (e.g., Thusberg et al., 2011)
reported over the last several years, in which variants in the
gene of interest were part of the training set. Therefore, it is
very important that this process is repeated for genes included
in previous studies to investigate whether there is a similar
degradation in program performance.
(2) The performance of the in silico tools is sometimes influenced
by themultiple sequence alignmentwithwhich they are run. All
of the in silico tools except for Align-GVGDandMAPPhave in-
ternally generated libraries of alignments. SIFT is unique in that
it also gives users the option to supply their own alignment. In
agreement with previous observations [Chan et al., 2007; Hicks
et al., 2011], we found that SIFT performed markedly better
with our hand-curated alignments than with its native align-
ments. PolyPhen-2.1 was run using two sets of alignments:
native PolyPhen-2, and lightly hand-curated versions omit-
ting grossly discordant sequences in conserved areas that were
probably artifacts of either gene model assembly from genomic
sequence or the automated alignment generating programs.
Modest curation of the PolyPhen-2 alignment led to only mod-
est changes in the results. Align-GVGD and MAPP were run
with hand-curated alignments prepared at three different phy-
logenetic depths. Modest changes in depth of alignment pro-
duced only modest changes in performance.
(3) Using in silico tool output as a continuous variable. Although,
many methods generate data on a continuous scale, most al-
gorithms apply a binary “cutoff point” and report results as
likely pathogenic or likely not. The continuous output from
our analysis showed that the predictive value for many vari-
ants was well over 90% and for other variants was between
25% and 75%. This degree of variation would be diluted if the
output were categorized. We showed that considering data as a
continuous variable provides better correlation with classifica-
tion than does the binary output. There was no evidence for a
Table 6. Results from Regressions Using Pairs of Programs
Program combination Least squares regression Ordered logistic regression
First programa Second programa
Adjusted
R2(b)
Adjusted
R2(c)
First
program
P value
Second
program
P value Model P value Pseudo R2
First
program
P value
Second
program
P value Model P value ROC aread
MAPP PolyPhen-2.1 0.620 0.585 0.003 0.009 4.67× 10–16 0.2753 0.038 0.048 2.57× 10–11 0.933
MAPP SIFT 0.595 0.553 0.002 0.116 4.30× 10–15 0.2679 0.080 0.108 4.95× 10–11
MAPP Align-GVGD 0.603 0.570 <0.001 0.051 2.23× 10–15 0.2665 0.009 0.119 5.63× 10–11
MAPP Xvar 0.595 0.562 <0.001 0.112 4.20× 10–15 0.2622 0.001 0.194 8.19× 10–11
MAPP MutPred 0.602 0.566 <0.001 0.056 2.37× 10–15 0.2656 <0.001 0.122 6.07× 10–11
PolyPhen-2.1 SIFT 0.578 0.537 0.009 0.226 1.91× 10–14 0.2635 0.123 0.132 7.34× 10–11
PolyPhen-2.1 Align-GVGD 0.599 0.561 <0.001 0.024 3.07× 10–15 0.2686 0.006 0.073 4.66× 10–11 0.922
PolyPhen-2.1 Xvar 0.571 0.534 <0.001 0.598 3.47× 10–14 0.2515 0.002 0.610 2.12× 10–10
PolyPhen-2.1 MutPred 0.598 0.564 <0.001 0.026 3.31× 10–15 0.2674 <0.001 0.078 5.17× 10–11 0.923
SIFT Align-GVGD 0.580 0.541 <0.001 0.007 1.53× 10–14 0.2692 0.007 0.072 4.43× 10–11 0.912
SIFT Xvar 0.544 0.505 <0.001 0.238 3.00× 10–13 0.2529 0.002 0.496 1.87× 10–10
SIFT MutPred 0.570 0.531 <0.001 0.018 3.62× 10–14 0.2649 <0.001 0.103 6.45× 10–11 0.914
aComputational tool operating conditions were as defined in Table 4.
bAdjusted R2 directly from least squares regression.
cAdjusted R2 directly from cross-validation.
dROC area calculated after application of the equation defined by the logit regression. Note that ROC area was only calculated for the combined computational tools where both
tools contributed P < 0.05 to the least squares regression (in bold).
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difference in the utility of using the output as a trinary variable,
but fitting trinary variables for each of the in silico tools would
involve considerable multiple testing and increase risk of over-
fitting.We encourage the use of continuous variable outputs for
all results included in classification tools, to avoid the artificial
dichotomy of binary categorization that may disregard useful
subtleties in data, particularly for variants that are difficult to
categorize using any individual tool. In the overall flow of the
Bayesian integrated evaluation, the only point where we abso-
lutely need to collapse from continuous variables to a limited
set of qualitative classes is at the very end, when the output
(posterior probability in favor of pathogenicity) is interpreted
through the clinical five-class system described by Plon et al.
(2008).
Many studies report the predicted effect of MMR gene missense
substitutions on protein function determined from in silico tools,
most commonly SIFT and PolyPhen. Those relevant to this study
are discussed below. Chao et al. (2008) classified a set of MMR
gene missense variants based on less rigorous clinical criteria than
those incorporated in our qualitative classifier, and then used these
classified variants to compare the accuracy of three in silico tools:
MAPP, PolyPhen, and SIFT. As in this study, MAPP was the best
performing in silico tool [for Chao et al., 2008]; however, it should
be noted that use of the multiple sequence alignments with MAPP
in the Chao et al. (2008) study was manipulated by varying the gap
weight threshold across the alignments. Nonetheless, we note that
the MAPP-MMR AUC of the ROC value reported by Chao et al.
(2008) (0.945) was very near our point estimate and well within
the 95% CI for our MAPP ROC value. Thus in a research area
not noted for between-study consistency, the close correspondence
between results obtained withMAPP in these two studies stands out
as a welcome exception. On the contrary, both SIFT and PolyPhen
performed somewhat better in our study than they had in Chao
et al. (2008). For SIFT, we attribute the difference to our use of
hand-curated alignments and use of the SIFT score as a continuous
variable rather than as a binary classifier. For PolyPhen, there have
been notable algorithm improvements in the intervening years, and
these may account for the difference.
Ali et al. (2012) have recently published on a consensus-based
predictor called PON-MMR that combines five in silico programs
to derive a probability that a missense substitution will show loss of
function in a functional assay. Although PON-MMR has a higher
sensitivity (0.97) compared with theMAPP + PolyPhen-2.1 (0.933),
we note some limitations of this study. Classification of the MMR
variant calibration set was based on functional data alone, and the
relationship between functional abrogation and pathogenicity as
defined by clinical phenotype was not calibrated. The probability
that a substitution will show dysfunction in a functional assay is a
proxy for, rather than a direct measure of, the probability in favor
of pathogenicity in humans. Furthermore, there is a risk that the
model is overfit because there was no clean separation between the
in silico program training sets and the sequence variant calibration
set. We have seen evidence that this can be very important in the
results of our own study. Additionally, the contribution of the in
silico programs to the PON-MMR output was not addressed, which
could also cause further overfitting. These concerns are explicitly
addressed in the model we present here.
Two studies, Barnetson et al. (2008) and Pastrello et al. (2011),
addressed classificationofMMRvariants by integrating in silico pre-
dictions with other lines of evidence. Barnetson et al. (2008) devised
an arbitrary scoring system for variant classification that included
SIFT and PolyPhen assessments as points of evidence, but there was
no attempt to calibrate the in silico predictions per se. Pastrello et al.
(2011) described a Bayesian approach to MMR missense variant
classification that included a LR for missense substitutions based on
in silico predictions using the tool Align-GVGD. However, the LRs
assigned for MMR substitutions were actually based on those de-
rived empirically for missense substitutions in BRCA1 and BRCA2
[Tavtigian et al., 2008a]. Because the LRs or probabilities associated
with the individual grades generated by Align-GVGDdepend on the
depth of alignment and because the program’s accuracy can degrade
badly if it is not used with carefully curated alignments [Hicks et al.,
2011; Tavtigian et al., 2008c], the approach taken by Pastrello et al.
(2011) was suboptimal.
Here, we have advanced the field by combining (1) a set of ref-
erence variants that have been classified using carefully considered
criteria vetted in the MMR variant community with (2) rigorously
controlled analytic conditions for computational methods. We an-
ticipate that a similar strategy applied to in vitro functional as-
says (MMR and other) would similarly advance the field of variant
classification. The probabilities in favor of pathogenicity that we
have derived can be used as a prior probability of pathogenicity
to feed into a multifactorial likelihood model for quantitative inte-
grated evaluation of unclassified variants. However, we note that the
clinical recommendations of the thresholds for “likely pathogenic”
and “likely not pathogenic” are posterior probabilities in favor of
pathogenicity of 0.95 and 0.05, respectively [Plon et al., 2008]. The
MAPP + PolyPhen-2.1 output is able to produce prior probabilities
that are more extreme than these thresholds. Because we view direct
classification on the basis of the prior probability alone as a misuse
of the Bayesian integrated evaluation model, we choose to truncate
the dynamic range of the prior probability database/calculator to a
maximumof 0.90 and aminimumof 0.10 so that additional sources
of information are required to reach posterior probabilities that alter
clinical management of patients with variants. The successful ap-
plication of this method for classification of MMR gene variants in
an integrated evaluation model that incorporates segregation and
tumor pathology information is described in the accompanying
manuscript humu-2012-0145.R1_001–010. Similarly, initial appli-
cation of our in silico tool to the 57 class 3 variants in our study
suggests that approximately 50% could be classified using Bayesian
integrated analysis with additional supporting information ofmod-
erate strength from only one other data source.
There are several caveats to our findings. Clear discordance be-
tween prior probabilities and qualitative classifications for a mi-
nority of variants indicates that the in silico modeling does not
adequately capture all alterations in protein function. In addition,
the in silico tools assessed do not account for missense substitutions
where the underlying sequence variant causes a splicing aberration.
Important statistical caveats to the calibration equation must also
be considered. First, the least squares regressions using logit(Pr) as
the dependent variable, which constrains the resulting probabilities
to fall between 0.00 and 1.00, assumes the probabilities assigned
to the groups of variants in each of the four qualitative categories
are reasonably accurate. The investigators who helped devise the
qualitative classification were explicitly aware of the quantitative
probability thresholds set for those categories in Plon et al. (2008)
and genuinely attempted to craft the qualitative categories to corre-
spond with the quantitative categories. But significant error, espe-
cially in the two extreme categories class 5 (pathogenic) and class 1
(not pathogenic), would alter the calibration. The main alternative
would have been to use the ordered logistic regressions to generate
the calibration, but two less obvious assumptions would have been
required here. The first is the proportional odds assumption that
underlies ordinal logistic regression, which is that the coefficients
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describing the relationship between the lowest versus all higher cat-
egories of the dependent variable are the same as those that describe
the relationship between the next lowest category and all higher
categories, and so on. The second is that converting the resulting
calibration from LRs to probabilities assumes an underlying overall
prior probability for the dataset. We prefer the least squares re-
gression because the underlying assumptions are more transparent.
Nonetheless, it is reassuring that least squares regression and or-
dered logistic regression gave the same ranking of the individual
in silico tools, and that the combination of MAPP + PolyPhen-2.1
emerged as the best pair using either forward selection or backward
selection with either regression method.
Finally, we specifically envision that the process of calibration
will be iterative. When a similarly sized independent series of mis-
sense substitutions have been classified qualitatively with reason-
able certainty (e.g., through the efforts of the InSiGHT Mutation
Interpretation Committee [Kohonen-Corish et al., 2011]), we will
analyze those variants using the models presented here for replica-
tion and refinement of the in silico missense prior probabilities of
pathogenicity. With the results of this work, all missense variants
can now be assigned a prior probability, using in silico tools. Thus,
any variants where another single source of reliable data exists (e.g.,
segregation, tumor histologic features) can now be assigned a poste-
rior probability, and thus lead to significant improvement in variant
classification.
Acknowledgments
For helpful discussions in refining the qualitative criteria that were used
for qualitative classification of missense variants in this study, we thank
the other members of the InSiGHT Mutation Interpretation Committee,
Inge Bernstein, Maurizio Genuardi, Annika Lindblom, Finlay Macrae, Pal
Moller, Brigitte Royer-Pokora, Rodney Scott, and Michael Woods. The fol-
lowing clinicians provided unpublished data regarding IHC,MSI, or clinical
features: Alessandra Viel (Centro Riferimento Oncologico, Aviano, Italy),
Dennis Dooijes (Erasmus University, Rotterdam, The Netherlands), An-
drea Ferrari and Sylviane Olschwang (French Cancer Genetic Network),
Trinidad Caldes (Hospital Clinico San Carlos, Madrid, Spain), Gabriel
Capella´ and Ignacio Blanco (Institut Catala d’Oncologia, Barcelona, Spain),
Annika Lindblom (Karolinska University Hospital, Sweden), Frans Hoger-
vorst (The Netherlands Cancer Institute, Amsterdam, The Netherlands),
Marjolijn Ligtenberg (Radbound University Nijmegen Medical Centre, The
Netherlands), Bharati Bapat (Samuel Lunenfeld Research Institute, Toronto,
Canada), Johan Gille (VU University Medical Centre, Amsterdam, The
Netherlands). B.A.T. was awarded a PhD scholarship from the Cancer Coun-
cil Queensland. A.B.S. is an NHMRC Senior Research Fellow.
Disclosure Statement: None of the contributing authors have a conflict of
interest.
References
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov
AS, Sunyaev SR. 2010. A method and server for predicting damaging missense
mutations. Nat Methods 7:248–249.
Ali H, Olatubosun A, VihinenM. 2012. Classification ofmismatch repair genemissense
variants with PON-MMR. HumMutat 33:642–650.
Arnold S, Buchanan DD, Barker M, Jaskowski L, Walsh MD, Birney G, Woods MO,
Hopper JL, Jenkins MA, Brown MA, Tavtigian SV, Goldgar DE, et al. 2009. Clas-
sifying MLH1 andMSH2 variants using bioinformatic prediction, splicing assays,
segregation, and tumor characteristics. HumMutat 30:757–770.
Barnetson RA, Cartwright N, van Vliet A, Haq N, Drew K, Farrington S, Williams
N, Warner J, Campbell H, Porteous ME, Dunlop MG. 2008. Classification of
ambiguous mutations in DNA mismatch repair genes identified in a population-
based study of colorectal cancer. HumMutat 29:367–374.
Chan PA, Duraisamy S, Miller PJ, Newell JA, McBride C, Bond JP, Raevaara T, Ollila
S, Nystrom M, Grimm AJ, Christodoulou J, Oetting WS, et al. 2007. Interpreting
missense variants: comparing computational methods in human disease genes
CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum Mutat 28:683–
693.
Chao EC, Velasquez JL, Witherspoon MS, Rozek LS, Peel D, Ng P, Gruber SB, Watson
P, Rennert G, Anton-Culver H, Lynch H, Lipkin SM. 2008. Accurate classifi-
cation of MLH1/MSH2 missense variants with multivariate analysis of protein
polymorphisms-mismatch repair (MAPP-MMR). HumMutat 29:852–860.
CouchFJ, Rasmussen LJ,HofstraR,MonteiroAN,GreenblattMS, deWindN. 2008. As-
sessmentof functional effects of unclassifiedgenetic variants.HumMutat 29:1314–
1326.
Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian
SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE. 2007. A systematic genetic
assessment of 1,433 sequence variants of unknown clinical significance in the
BRCA1 and BRCA2 breast cancer-predisposition genes. Am JHumGenet 81:873–
883.
GoldgarDE, EastonDF,DeffenbaughAM,Monteiro AN, Tavtigian SV, Couch FJ. 2004.
Integrated evaluation of DNA sequence variants of unknown clinical significance:
application to BRCA1 and BRCA2. Am J Hum Genet 75:535–544.
Greenblatt MS, Beaudet JG, Gump JR, Godin KS, Trombley L, Koh J, Bond JP. 2003.
Detailed computational studyof p53 andp16: using evolutionary sequence analysis
and disease-associated mutations to predict the functional consequences of allelic
variants. Oncogene 22:1150–1163.
Hicks S, Wheeler DA, Plon SE, Kimmel M. 2011. Prediction of missense mutation
functionality depends on both the algorithm and sequence alignment employed.
HumMutat 32:661–668.
Kohonen-Corish MR, Macrae F, Genuardi M, Aretz S, Bapat B, Bernstein IT, Burn J,
Cotton RG, den Dunnen JT, Frebourg T, Greenblatt MS, Hofstra R, et al. 2011.
Deciphering the colon cancer genes–report of the InSiGHT-Human Variome
Project Workshop, UNESCO, Paris 2010. HumMutat 32:491–494.
Kumar P, Henikoff S, Ng PC. 2009. Predicting the effects of coding non-synonymous
variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–
1081.
Li B, Krishnan VG,MortME, Xin F, Kamati KK, Cooper DN,Mooney SD, Radivojac P.
2009. Automated inference of molecular mechanisms of disease from amino acid
substitutions. Bioinformatics 25:2744–2750.
Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. 2009. Review of
the Lynch syndrome: history, molecular genetics, screening, differential diagnosis,
and medicolegal ramifications. Clin Genet 76:1–18.
Miller PJ, Duraisamy S, Newell JA, Chan PA, Tie MM, Rogers AE, Ankuda CK,
von Walstrom GM, Bond JP, Greenblatt MS. 2011. Classifying variants of
CDKN2A using computational and laboratory studies. Hum Mutat 32:900–
911.
Ng PC, Henikoff S. 2002. Accounting for human polymorphisms predicted to affect
protein function. Genome Res 12:436–446.
O’Neill SC, Rini C, Goldsmith RE, Valdimarsdottir H, Cohen LH, Schwartz MD.
2009.Distress amongwomen receiving uninformative BRCA1/2 results: 12-month
outcomes. Psychooncology 18:1088–1096.
Pastrello C, Pin E, Marroni F, Bedin C, Fornasarig M, Tibiletti MG, Oliani C, Ponz de
Leon M, Urso ED, Della Puppa L, Agostini M, Viel A. 2011. Integrated analysis of
unclassified variants in mismatch repair genes. Genet Med 13:115–124.
Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst
FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV. 2008. Sequence variant classifica-
tion and reporting: recommendations for improving the interpretation of cancer
susceptibility genetic test results. HumMutat 29:1282–1291.
Reva B, Antipin Y, Sander C. 2011. Predicting the functional impact of protein muta-
tions: application to cancer genomics. Nucleic Acids Res 39:e118.
Stone EA, Sidow A. 2005. Physicochemical constraint violation by missense substitu-
tions mediates impairment of protein function and disease severity. Genome Res
15:978–986.
Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A. 2008a. Classification of rare mis-
sense substitutions, using risk surfaces, with genetic- andmolecular-epidemiology
applications. HumMutat 29:1342–1354.
Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D,
Zharkikh A, Thomas A. 2006. Comprehensive statistical study of 452 BRCA1mis-
sense substitutions with classification of eight recurrent substitutions as neutral. J
Med Genet 43:295–305.
Tavtigian SV, Greenblatt MS, Goldgar DE, Boffetta P. 2008b. Assessing pathogenicity:
overview of results from the IARC Unclassified Genetic Variants Working Group.
HumMutat 29:1261–1264.
Tavtigian SV, GreenblattMS, Lesueur F, Byrnes GB. 2008c. In silico analysis ofmissense
substitutions using sequence-alignment based methods. Hum Mutat 29:1327–
1336.
Thompson B, Goldgar D, Paterson C, Clendenning M, Walters R, Arnold S, Parsons
M, Walsh M, Hopper J, Jenkins M, Greenblatt M, Registry CCF, et al. 2012.
Estimation of probabilities in favour of pathogenicity for missense substitutions
for use in clinical evaluation of mismatch repair gene variants. Hered Cancer Clin
Pract 10:A31.
264 HUMANMUTATION, Vol. 34, No. 1, 255–265, 2013
Thompson BA, Goldgar DE, Paterson C, Clendenning M,Walters R, Arnold S, Parsons
MT, Walsh MD, Gallinger S, Haile RW, Hopper JL, Jenkins MA, et al. 2012. A
multifactorial likelihoodmodel forMMRgene variant classification incorporating
probabilities basedon sequence bioinformatics and tumor characteristics: A report
from the colon cancer family registry. HumMutat (in press).
Thusberg J, Olatubosun A, Vihinen M. 2011. Performance of mutation pathogenicity
prediction methods on missense variants. HumMutat 32:358–368.
Vasen HF, Watson P, Mecklin JP, Lynch HT. 1999. New clinical criteria for heredi-
tary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the
International Collaborative group on HNPCC. Gastroenterology 116:1453–1456.
Viel A, Novella E, Genuardi M, Capozzi E, Fornasarig M, Pedroni M, Santarosa M, De
LeonMP,Della PuppaL,AntiM,BoiocchiM. 1998. Lack of PMS2 gene-truncating
mutations in patients with hereditary colorectal cancer. Int J Oncol 13:565–
569.
Wallace IM, O’Sullivan O, Higgins DG, Notredame C. 2006. M-Coffee: combining
multiple sequence alignment methods with T-Coffee. Nucleic Acids Res 34:1692–
1699.
Wang Q, Lasset C, Desseigne F, Saurin JC, Maugard C, Navarro C, Ruano E, Descos L,
Trillet-Lenoir V, Bosset JF, Puisieux A. 1999. Prevalence of germline mutations of
hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with
nonpolyposis colorectal cancer. Hum Genet 105:79–85.
WoodsMO,WilliamsP,CareenA,EdwardsL,Bartlett S,McLaughlin JR,Younghusband
HB. 2007. A new variant database formismatch repair genes associatedwith Lynch
syndrome. HumMutat 28:669–673.
HUMANMUTATION, Vol. 34, No. 1, 255–265, 2013 265
Thompson et al., Human Mutation 1 
Supp. Table S1. Summary of 143 mismatch repair missense variants 
 
Variant 
Evidence for Classification Classification Initial source References 
MSI 
Status 
IHC In healthy 
controls 
Segregation 
with disease 
In vitro MMR 
activity 
In vitro 
cellular 
localization 
In vitro 
subunit 
interaction 
 
 
 
MLH1 MSH2 MSH6 PMS2 
MLH1              
c.52C>T p.(Arg18Cys) MSS + + + + Unknown Unknown nt nt nt Uncertain 1  1,2 
c.65G>C p.(Gly22Ala) MSS + + + nt Yes No nt nt nt Uncertain 3,4  3-7 
c.67G>A p.(Glu23Lys) [MSI-H] nt nt nt nt Unknown Unknown nt nt nt Uncertain 4  4,8 
c.83C>T p.(Pro28Leu) MSI-H +/- + nt - No Unknown Deficient Decreased Deficient Likely pathogenic 4,9  2,4,10-24 
c.85G>T p.(Ala29Ser) [MSI-H] [-] [+] nt nt Unknown Unknown Normal Normal Normal Uncertain 4,9  4,10,18,20-23,25,26 
c.94A>G p.(Ile32Val) nt nt nt nt nt Yes (>1%) Unknown nt nt Normal Not pathogenic 4  4,10,16,22 
c.104T>G p.(Met35Arg) MSI-H - + + - No Unknown Deficient nt Decreased Pathogenic 4  1,4,13,15,16,20-23,27-35 
c.112A>C p.(Asn38His) MSI-H +/- +/- +/- +/- No Yes Deficient nt nt Pathogenic 4  1,4,36-39 
c.113A>G p.(Asn38Ser) MSI-H +/- + + - No Yes nt nt nt Uncertain 40  40,41 
c.122A>G p.(Asp41Gly) MSI-H + + + + Unknown Unknown na na na Splicing defect 4  2,4,21,42-45 
c.131C>T p.(Ser44Phe) MSI-H - + + - No Yes Decreased nt Decreased Pathogenic 4  1,4,15,16,21-23,27-31,33-35,38,42,46-53 
c.189C>A p.(Asp63Glu) MSI-H - nt nt nt Unknown Unknown Deficient Decreased nt Likely pathogenic 4,9  2,4,9,18,21,22,54 
c.199G>A p.(Gly67Arg) MSI-H +/- + + - No Yes Deficient Decreased Deficient Pathogenic 4  
1,2,4,13,15,16,18-23,26,27,29-
31,33,35,38,41,45,51,55-75 
c.199G>T p.(Gly67Trp) MSI-H nt nt nt nt Unknown Unknown Decreased nt nt Likely pathogenic 4  4,23,53,67,76-80 
c.200G>A p.(Gly67Glu) MSI-H - + nt nt No Yes Decreased nt nt Likely pathogenic 3,4  3,4,20,21,28,42,81-83 
c.229T>C p.(Cys77Arg) MSI-H nt nt nt nt Unknown Yes Deficient Decreased Normal Likely pathogenic 4,9  4,9,15,18,22,42,45,67,84-86 
c.230G>A p.(Cys77Tyr) MSI-H - + + - Unknown Unknown Deficient nt Decreased Likely pathogenic 4  2,4,15,16,22,23,33,87 
c.238T>G p.(Phe80Val) MSI-H +/- + nt nt Unknown Unknown Deficient Normal Normal Likely pathogenic 4,9  2,4,18,21-23,88 
c.250A>G p.(Lys84Glu) MSI-H nt nt nt nt Unknown Unknown Deficient Decreased Normal Likely pathogenic 4,9  2,4,12,15,18,22,23 
c.265G>C p.(Glu89Gln) nt nt nt nt nt No Unknown nt nt nt Uncertain 4  4,10 
c.277A>G p.(Ser93Gly) MSS/ MSI-H +/- + +/- - No Unknown Normal Normal Normal Uncertain 
3,4,9  3,4,9,15,18,20-23,37,38,51,52,85,86,89-91 
c.299G>C p.(Arg100Pro) MSI-H + + + + Unknown Unknown na na na Splicing defect 4  4,20,23,92 
c.320T>G p.(Ile107Arg) MSI-H - + + - Unknown Yes Deficient Decreased Decreased Likely pathogenic 4,9  4,15,16,18,20-23,33,51,85,93-101 
c.350C>T p.(Thr117Met) MSI-H - + + - No Yes Deficient Normal Decreased Pathogenic 4  
1,2,4,13-16,19-23,33,36,40,45,61,63,67,74-
77,79,102-126 
c.350C>G p.(Thr117Arg) MSI-H - nt nt nt Unknown Unknown Deficient nt Deficient Uncertain 4  2,4,15,16,22,23,33,38,51,58,63,127 
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controls 
Segregation 
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cellular 
localization 
In vitro 
subunit 
interaction 
 
 
 
MLH1 MSH2 MSH6 PMS2 
c.402A>T p.(Lys134Asn) MSS + nt nt nt Unknown Unknown nt nt nt Uncertain 1  1 
c.464T>G p.(Leu155Arg) MSI-H - + nt - Unknown Unknown Deficient Decreased Normal Likely pathogenic 4,9  2,4,17,18,21,22,54,128 
c.544A>G p.(Arg182Gly) MSI-H - nt nt - Unknown Unknown na na na Splicing defect 4  2,4,23,67,76,129 
c.554T>G p.(Val185Gly) MSI-L/H - + + nt Unknown Yes Deficient Decreased Decreased Likely pathogenic 4  4,15,16,18,20-23,25,33,114,130 
c.637G>A p.(Val213Met) MSI-L/H +/- +/- +/- + Yes (>1%) No Normal nt Normal Not pathogenic 4  2,4,10,16,18,21-23,45,64,66,67,131-134 
c.649C>T p.(Arg217Cys) MSI-H - nt nt nt Yes Unknown Inconclusive Normal Normal Uncertain 4  4,10,15,16,20-23,51,64,66,70-72,114,135-144 
c.655A>G p.(Ile219Val) MSS nt nt nt nt Yes (>1%) No Normal nt Normal Not pathogenic 4  4,10,18,22,23,33,38,73,114,125 
c.655A>C p.(Ile219Leu) nt nt nt nt nt Yes (>1%) No Normal nt Normal Not pathogenic 4  4,16,22,23,68,145 
c.731G>A p.(Gly244Asp) MSI-H - + nt nt No Unknown Decreased nt Deficient Likely pathogenic 4  1,4,13,15,16,22,23,41,68,114,146 
c.739T>C p.(Ser247Pro) MSI-H - + + - Unknown Yes Decreased Decreased Normal Likely pathogenic 4,9  2,4,17,18,21,22,54,67,115,147 
c.793C>T p.(Arg265Cys) MSI-H +/- + - + No Unknown na na na Splicing defect 4  
1,2,4,8,15,17,20-
23,28,30,31,38,41,45,51,52,54,75,90,114,125,148,149 
c.884G>A p.(Ser295Asn) MSI-H - + + - Unknown Unknown na na na Splicing defect 115  115 
c.911A>G p.(Asp304Gly) MSI-H nt nt nt nt Unknown Yes nt nt nt Uncertain 4  4,150 
c.974G>A p.(Arg325Gln) MSI-H - + nt nt Unknown Unknown nt nt nt Uncertain 4  4,101,151 
c.977T>C p.(Val326Ala) MSS/ MSI-H +/- +/- nt nt Yes No Normal nt Normal 
Likely not 
pathogenic 
4  
1,2,4,15,16,20-
23,33,45,51,63,73,106,114,126,127,134,152-156 
c.986A>C p.(His329Pro) MSI-H - + + nt Unknown Unknown na na na Splicing defect 4,9  2,4,10,12,15,17,18,20-23,54,88,129,148 
c.1151T>A p.(Val384Asp) MSS/ MSI-H +/- + nt nt Yes No Inconclusive nt Intermediate 
Likely not 
pathogenic 
4  4,21,23,63,64,66,70,72,74,117,124,141-144,157-167 
c.1217G>A p.(Ser406Asn) MSS/ MSI-H 
+/- +/- +/- + 
Yes No Normal nt Normal Likely not pathogenic 
4  
3,4,10,16,22,23,38,63,73,86,123,125,151,155,156,16
8-170 
c.1327A>C p.(Lys443Gln) MSI-H - + + nt Unknown Unknown Normal Normal Normal Uncertain 4,9  4,10,18,21,22,38 
c.1354A>T p.(Thr452Ser) nt nt nt nt nt Unknown Unknown nt nt nt Uncertain 4  4,10 
c.1517T>C p.(Val506Ala) MSI-H nt nt nt nt Unknown Unknown Decreased nt Decreased Uncertain 4  4,15,16,20,22,23,28,33,49,126,171 
c.1595G>T p.(Gly532Val) MSS + nt nt nt Unknown Unknown nt nt nt Uncertain 1  1 
c.1612T>G p.(Phe538Gly) MSS + nt nt nt Unknown Unknown nt nt nt Uncertain 1  1 
c.1646T>C p.(Leu549Pro) nt nt nt nt nt No Unknown Deficient nt Deficient Uncertain 4  4,15,20,23,45,70,71,86,136,172 
c.1649T>C p.(Leu550Pro) MSI-H - + + nt Unknown Unknown Inconclusive Decreased Inconclusive Likely pathogenic 4,9  2,4,17,18,21,22,38 
c.1652A>C p.(Asn551Thr) MSI-H - + nt nt Unknown Yes Decreased nt nt Likely pathogenic 4  4,15,20,23,45,57,67,129,173 
c.1676T>G p.(Leu559Arg) MSI-H - + nt nt Unknown Unknown nt nt Deficient Likely pathogenic 4  4,22,173-175 
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MLH1 MSH2 MSH6 PMS2 
c.1742C>T p.(Pro581Leu) MSI-H - nt nt nt No Unknown Decreased nt Decreased Uncertain 4  2,4,70,141-144 
c.1744C>T p.(Leu582Phe) MSI-H - + - - Unknown Unknown Deficient nt nt Likely pathogenic 4  2,4,21,37,38,90 
c.1766C>A p.(Ala589Asp) MSI-H - + nt nt Unknown Unknown Inconclusive Decreased Inconclusive Likely pathogenic 4,9  2,4,17,18,21,22,38,54 
c.1802A>G p.(Asp601Gly) MSI-H nt nt nt nt Unknown Unknown Normal nt Normal Uncertain 4  4,173,176 
c.1820T>A p.(Leu607His) MSS + + - nt No Unknown Normal nt Deficient (FANCJ) Uncertain 
10  3,4,10,21,23,45,131-133,177,178 
c.1852_1854delAAinsGC 
p.(Lys618Ala) 
MSS/ 
MSI-L/H +/- + + + Yes No Inconclusive nt Inconclusive Uncertain 
4 
 2-5,8,16,18,22,23,27-
29,34,36,38,44,45,49,67,68,73,88,115,123,131,134,14
9,169-171,173-175,178-197 
c.1853A>C p.(Lys618Thr) MSS/ MSI-H + + nt nt Yes Unknown Inconclusive Decreased Inconclusive Uncertain 
4,9 
 4,9,15,16,18,20-
23,33,49,63,111,113,114,132,133,145,150,155,178,19
8-204 
c.1865T>A p.(Leu622His) MSI-H - + + - No Yes Decreased nt Decreased Pathogenic 4  1,2,4,23,45,60,173,178,186,187,205,206 
c.1937A>G p.(Tyr646Cys) MSS/ MSI-L/H +/- + + - No Unknown Normal Normal Inconclusive Uncertain 
4,9  2,4,9,18,21,22,38,174,175,194,207 
c.1942C>T p.(Pro648Ser) MSI-H - + nt nt Yes Yes Inconclusive Decreased Inconclusive Likely pathogenic 4,9  2,4,10,18,21,22,53,112,132,174,175,208 
c.1943C>T p.(Pro648Leu) MSI-H +/- + nt nt Unknown Unknown Inconclusive Decreased Inconclusive Likely pathogenic 4,9  2,4,10,18,21-23,38,88,173 
c.1961C>T p.(Pro654Leu) MSI-H - nt nt - Unknown Unknown Decreased Decreased Inconclusive Likely pathogenic 4,9  2,4,17,18,20-23,38,54,173 
c.1963A>G p.(Ile655Val) MSI-L nt nt nt nt Yes Unknown Normal nt Normal Likely not pathogenic 
4  4,10,20,23,45,209-211 
c.1976G>T p.(Arg659Leu) MSI-H - + nt nt Unknown Yes na na na Splicing defect 4  4,21,131-133,173,212 
c.1976G>A p.(Arg659Gln) MSI-H - nt nt nt Yes Unknown Intermediate Normal Normal Uncertain 4,9  4,18,21-23,134,173 
c.1976G>C p.(Arg659Pro) MSI-H - nt nt nt Unknown Yes na na na Splicing defect 4,9  
2,4,15,16,18,20-23,33,38,45,49,51,85,93,95-
98,111,173,181,204,212 
c.1989G>T p.(Glu663Asp) nt nt nt nt nt Unknown Unknown na na na Splicing defect 4  2,4,23,45,67,76 
c.2059C>T p.(Arg687Trp) MSI-H +/- + +/- +/- No Yes Decreased Normal nt Likely pathogenic 4  
1,2,4,14,21,23,31,40,53,67,78,109,110,123,140,186,1
87,205,213,214 
c.2066A>G p.(Gln689Arg) MSS/ MSI-H + + + + Yes No Normal nt Normal Not pathogenic 
3,4  2-4,23,45,88,134 
c.2146G>A p.(Val716Met) MSS/ MSI-L/H +/- + + + Yes Inconclusive Normal Intermediate 
Normal/ 
Intermediate Not pathogenic 
4 
 1-4,8,9,15,18,21-
23,29,31,38,57,62,67,73,80,88,106,115,125,134,152,1
53,155,156,168,171,178,186,187,190,193,195,197,21
5-220 
c.2152C>T p.(His718Tyr) MSI-H - - nt nt Yes (>1%) Unknown Intermediate nt Normal Not pathogenic 3,4  
2-4,10,16,20-
23,63,80,81,106,171,182,196,201,215,221-224 
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MLH1 MSH2 MSH6 PMS2 
c.2185C>G p.(Leu729Val) nt nt nt nt nt Unknown Unknown Normal nt Normal Uncertain 4  4,10,16,22,23 
c.2210A>T p.(Asp737Val) [MSI-H] [-] nt nt nt Unknown Unknown nt nt nt Uncertain 4  2,4,54,128,225 
c.2246T>C p.(Leu749Pro) MSI-H +/- + + nt Unknown Unknown Decreased nt Deficient Likely pathogenic 4  4,21,173,226-229 
c.2252A>G p.(Lys751Arg) MSS + + + nt Yes No Normal nt Normal Likely not pathogenic 
3,4  3,4,14,22,23,48,86,109,185 
c.2265G>C p.(Arg755Ser) MSI-H nt nt nt nt Unknown Unknown Decreased nt Normal Likely pathogenic 4  2,4,23,171,173,195,230 
MSH2              
c.4G>A p.(Ala2Thr) MSI-H nt - nt nt Unknown Yes nt nt nt Uncertain 4  1,4,17,19-21,54,128 
c.7G>T p.(Val3Leu) MSS nt + nt nt Unknown Unknown nt nt nt Uncertain 1  1 
c.55T>C p.(Phe19Leu) MSS nt + nt nt Unknown Unknown nt nt nt Uncertain 1  1 
c.97A>C p.(Thr33Pro) MSI-H nt + nt nt Unknown Unknown Decreased nt Normal Uncertain 9  9,22,190,231 
c.277C>T p.(Leu93Phe) MSI-H nt - nt nt Unknown Unknown nt nt nt Uncertain 4  4,21,232 
c.287G>A p.(Arg96His) MSS + + + + Unknown No nt nt nt Uncertain 4  4,63,233,234 
c.308A>G p.(Tyr103Cys) nt nt nt nt nt Unknown Unknown nt nt nt Uncertain 4  4,20,235 
c.317G>A p.(Arg106Lys) MSS + + + nt Yes No nt nt nt Uncertain 3  3,24 
c.380A>G p.(Asn127Ser) MSS/ MSI-L/H +/- + + +/- Yes (>1%) No Normal nt Normal Not pathogenic 
4  4,10,20,67,170,176,190,223,231,236-241 
c.482T>A p.(Val161Asp) MSI-H + - + nt Unknown Unknown Decreased nt Normal Likely pathogenic 4  4,22,88,148,231,242,243 
c.484G>A p.(Gly162Arg) MSI-H + - - nt Unknown Unknown Deficient Decreased Normal Likely pathogenic 4  4,9,22,175,196,243,244 
c.488T>A p.(Val163Asp) MSI-H nt - nt nt Unknown Unknown nt nt nt Uncertain 4  4,21,115 
c.490G>A p.(Gly164Arg) MSI-H + +/- nt nt Unknown Unknown Decreased nt Normal Likely pathogenic 4,9  4,17,21,22,54,243 
c.499G>C p.(Asp167His) MSS/ MSI-L +/- + + nt Yes Unknown Inconclusive Normal Normal 
Likely not 
pathogenic 
4  4,21,22,145,170,175,194,240,244-247 
c.518T>C p.(Leu173Pro) MSI-H + - nt nt Unknown Unknown Deficient nt Normal Likely pathogenic 4  4,22,67,243 
c.524T>C p.(Leu175Pro) MSI-H nt - nt nt Unknown Unknown nt nt nt Uncertain 4  4,21,122,248 
c.560T>C p.(Leu187Pro) MSI-H + - nt nt Unknown Unknown Decreased nt Normal Likely pathogenic 4,9  4,9,17,21,22,54,243 
c.562G>C p.(Glu188Gln) MSS nt + nt nt Unknown Unknown nt nt nt Uncertain 1  1 
c.736A>C p.(Lys246Gln) MSI-H nt nt nt nt Unknown Unknown nt nt nt Uncertain 4  4,155 
c.742A>G p.(Lys248Glu) nt nt nt nt nt Unknown Unknown nt nt nt Uncertain 4  4,20,235 
c.815C>T p.(Ala272Val) MSI-H - + + nt Unknown Unknown na na na Splicing defect 4  4,9,20,22,45,171,231,243,249 
c.965G>A p.(Gly322Asp) MSS/ MSI-H +/- +/- + nt Yes (>1%) No Inconclusive nt Normal Not pathogenic 
4 
1,3,4,6,10,11,14,20,22,40,51,62,67,80,81,93,102,104,
111,117,124,125,131,132,150,154,155,169,171,185,1
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MLH1 MSH2 MSH6 PMS2 
89-
191,193,194,202,220,223,226,231,234,238,240,241, 
24,73,115,195,250-264 
c.989T>C p.(Leu330Pro) MSI-H nt - nt nt Unknown Unknown nt nt nt Uncertain 4  1,4,265 
c.998G>A p.(Cys333Tyr) MSI-H + - nt nt Unknown Unknown Deficient nt Inconclusive Likely pathogenic 4  4,20,22,240,243,266 
c.1022T>C p.(Leu341Pro) MSI-H nt - nt nt Unknown Yes nt nt nt Uncertain 4  1,4,67 
c.1024G>A p.(Val342Ile) MSS/ MSI-H + +/- nt nt Unknown Unknown nt nt nt Uncertain 
4  4,21,154,189,226 
c.1046C>G p.(Pro349Arg) MSI-H nt - nt nt Unknown Unknown nt nt nt Uncertain 4  1,4,73 
c.1168C>T p.(Leu390Phe) MSS/ MSI-H - + + nt Yes (>1%) Unknown Intermediate nt Normal Not pathogenic 
4  
4,10,14,22,63,67,117,124,171,222,223,240,252,267-
279 
c.1339T>G p.(Phe447Val) nt nt nt nt nt Unknown Unknown nt nt nt Uncertain 4  4,216 
c.1643G>A p.(Gly548Asp) MSS nt + nt nt Unknown Unknown nt nt nt Uncertain 1  1 
c.1660A>G p.(Ser554Gly) nt + - + nt Unknown Unknown na na na Splicing defect 41  41 
c.1661G>A p.(Ser554Asn) MSI-H + - - nt Unknown Unknown na na na Splicing defect 280  280 
c.1787A>G p.(Asn596Ser) MSI-L/H + +/- + nt No Unknown nt nt nt Uncertain 4  3,4,6,155,234,259,281 
c.1807G>A p.(Asp603Asn) MSS/ MSI-H + +/- - nt Unknown Unknown Deficient nt Inconclusive Likely pathogenic 
4  4,20,22,94,98,100,219,231,240,243,282 
c.1865C>T p.(Pro622Leu) MSI-H + - - + No Yes Decreased Deficient Deficient Pathogenic 4  4,10,20-22,40,51,190,240,245-247,252,283-289 
c.1886A>G p.(Gln629Arg) MSS/ MSI-L + + + nt Yes Unknown nt nt nt 
Likely not 
pathogenic 
4  4,63,64,66,72,117,124,172,269,272,275-278,290 
c.1906G>C p.(Ala636Pro) MSI-H + - - + No Yes Deficient nt Normal Pathogenic 4  4,10,21,22,26,190,196,214,231,243,291-305 
c.1916A>T p.(His639Leu) MSS nt + nt nt Unknown Unknown nt nt nt Uncertain 1  1 
c.2064G>A p.(Met688Ile) nt nt nt nt nt Yes Unknown Intermediate nt Normal Likely not pathogenic 
4  4,71,172,240,271,273,306 
c.2074G>C p.(Gly692Arg) MSI-H + - - + Unknown Unknown Decreased nt Deficient Likely pathogenic 4  1,4,240,307 
c.2089T>C p.(Cys697Arg) MSI-H nt - nt nt Unknown Yes Decreased nt Deficient Likely pathogenic 4  1,4,21,22,45,67,73,76,104,111,113,240,307,308 
c.2090G>T p.(Cys697Phe) MSI-H nt - nt nt Unknown Yes Decreased nt Decreased Likely pathogenic 4,9  4,11,12,20-22,224,231,240,243,252,254,309-311 
c.2110A>G p.(Ile704Val) MSS nt + nt nt Unknown Unknown nt nt nt Uncertain 1  1 
c.2203A>G p.(Ile735Val) nt nt nt nt nt Yes (>1%) Unknown nt nt nt Not pathogenic 10  10 
c.2245G>A p.(Glu749Lys) MSI-H +* + nt nt Unknown Unknown Decreased nt Normal Likely pathogenic 4,9  4,17,21,22,54,67,243 
c.2251G>A p.(Gly751Arg) MSI-H + + nt nt Unknown Yes Decreased nt Normal Likely pathogenic 4  4,20,21,106,240 
c.2500G>A p.(Ala834Thr) MSS/ MSI-H + - - + Yes Unknown Inconclusive nt Normal Uncertain 
4  4,17,20-22,54,73,155,156,181,216,224,243,246 
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Variant 
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Status 
IHC In healthy 
controls 
Segregation 
with disease 
In vitro MMR 
activity 
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MLH1 MSH2 MSH6 PMS2 
c.2503A>C p.(Asn835His) MSI-L + + + nt Yes Unknown nt nt nt Uncertain 3  3 
c.2732G>T p.(Leu911Arg) nt nt nt nt nt Unknown Unknown nt nt nt Uncertain 3  3,196 
c.2768T>A p.(Val923Glu) MSI-H + +/- - nt Unknown Unknown Intermediate nt Normal Uncertain 4  4,22,112,231,243,312 
MSH6              
c.116G>A p.(Gly39Glu) MSS/ MSI-L/H nt nt nt nt Yes (>1%) No nt nt nt Not pathogenic 
10  6,10,63,190,197,261,280,313-327 
c.1186C>G p.(Leu396Val) MSS/ MSI-L + + + + Yes (>1%) Unknown Normal nt nt Not pathogenic 
10  10,22,63,123,220,223,314,317,321,328 
c.1526T>C p.(Val509Ala) MSS nt nt nt nt Yes Unknown Normal nt nt Likely not pathogenic 
10  125,190,319,329,330 
c.1867C>G p.(Pro623Ala) nt nt nt nt nt Yes Unknown nt nt nt Uncertain 10  10,223 
c.2633T>C p.(Val878Ala) MSS + + + + Yes Inconclusive Intermediate nt Normal Not pathogenic 10  1,3,10,123,134,187,220,223,280,316,319,331-339 
c.2656A>G p.(Ile886Val) nt nt nt nt nt Yes (>1%) Unknown nt nt nt Not pathogenic 10  10,223 
c.2947G>C p.(Glu983Gln) MSI-H + - - + Unknown Unknown nt nt nt Uncertain 1  1 
PMS2              
c.59G>A  p.(Arg20Gln) nt nt nt nt nt Yes Unknown nt nt nt Uncertain 10  10,73,250,340-343 
c.137G>T  p.(Ser46Ile) MSI-H + + + - Unknown Unknown Deficient nt nt Likely pathogenic 10  10,207,344-346 
c.830C>A p.(Thr277Lys) nt nt nt nt nt Yes (>1%) Unknown nt nt nt Not pathogenic 10  10 
c.1408C>T p.(Pro470Ser) MSS/ MSI-H +/- +/- +/- +/- Yes (>1%) No nt nt nt Not pathogenic 
10  10,207,320,341-343,347-350 
c.1454C>A p.(Thr485Lys) MSI-H + + + - Yes (>1%) No nt nt nt Not pathogenic 10  10,76,207,342,343,350-352 
c.1789A>T p.(Thr597Ser) MSS/ MSI-H - + + - Yes (>1%) No nt nt Decreased Not pathogenic 
10  10,22,73,76,341-343,352-354 
c.1866G>A p.(Met622Ile) nt nt nt nt +/- Yes (>1%) No nt nt Decreased Not pathogenic 10  10,22,31,76,207,261,342,343,352,353 
c.2324A>G p.(Asn775Ser) MSS/ MSI-H nt nt nt nt Unknown Unknown nt nt nt Uncertain 
10  10,341,343,347,351 
 
+: at least one report of an immunostable tumor; -: at least one report of a tumor with immunoloss; +/-: at least one report each of immunoloss and immunostable tumors 
[ ]: tumor samples used for MSI and/or IHC testing taken from individual who is a carrier of a pathogenic MLH1 mutation  
*: heterogeneous staining 
In vitro results were defined as follows: normal – function comparable to wild-type; intermediate – slight reduction in function; decreased – function is somewhat reduced; 
deficient – no function; nt – not tested; na – not applicable 
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Supp. Table S2. Prior probabilities of pathogenicity for Class 3 missense variants 
 
Gene Protein PolyPhen-2.1 MAPP Prior Probability 
MLH1  p.(Arg18Cys) 0.99 29.01 0.936 
MLH1  p.(Gly22Ala) 1.00 22.05 0.888 
MLH1  p.(Glu23Lys) 1.00 19.98 0.864 
MLH1  p.(Ala29Ser) 0.74 23.39 0.751 
MLH1  p.(Asn38Ser) 1.00 13.40 0.721 
MLH1  p.(Glu89Gln) 0.98 6.24 0.299 
MLH1  p.(Ser93Gly) 0.11 7.17 0.014 
MLH1  p.(Thr117Arg) 0.98 32.95 0.948 
MLH1  p.(Lys134Asn) 0.99 13.10 0.705 
MLH1  p.(Arg217Cys) 0.99 10.30 0.578 
MLH1  p.(Asp304Gly) 1.00 20.85 0.876 
MLH1  p.(Arg325Gln) 0.49 1.87 0.003 
MLH1  p.(Lys443Gln) 0.00 2.74 0.001 
MLH1  p.(Thr452Ser) 0.00 1.58 0.000 
MLH1  p.(Val506Ala) 0.41 20.29 0.349 
MLH1  p.(Gly532Val) 1.00 29.36 0.938 
MLH1  p.(Trp538Gly) 0.15 6.41 0.013 
MLH1  p.(Leu549Pro) 0.98 36.32 0.958 
MLH1  p.(Pro581Leu) 0.98 26.92 0.919 
MLH1  p.(Asp601Gly) 0.98 20.85 0.866 
MLH1  p.(Leu607His) 1.00 20.32 0.869 
MLH1  p.(Lys618Ala) 1.00 23.13 0.899 
MLH1  p.(Lys618Thr) 1.00 24.98 0.913 
MLH1  p.(Tyr646Cys) 1.00 23.02 0.897 
MLH1  p.(Arg659Gln) 1.00 14.43 0.751 
MLH1  p.(Leu729Val) 0.01 3.83 0.002 
MLH1  p.(Asp737Val) 0.99 22.25 0.887 
MSH2  p.(Ala2Thr) 0.29 33.24 0.499 
MSH2  p.(Val3Leu) 0.00 4.21 0.003 
MSH2  p.(Phe19Leu) 0.97 12.82 0.672 
MSH2  p.(Thr33Pro) 0.97 43.72 0.971 
MSH2  p.(Leu93Phe) 1.00 12.59 0.691 
MSH2  p.(Arg96His) 0.39 9.44 0.079 
MSH2  p.(Tyr103Cys) 1.00 23.02 0.898 
MSH2  p.(Arg106Lys) 0.00 1.27 0.000 
MSH2  p.(Val163Asp) 0.98 38.46 0.963 
MSH2  p.(Leu175Pro) 0.75 16.13 0.579 
MSH2  p.(Glu188Gln) 1.00 13.20 0.713 
MSH2  p.(Lys246Gln) 0.69 14.08 0.431 
MSH2  p.(Lys248Glu) 0.00 5.04 0.004 
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Gene Protein PolyPhen-2.1 MAPP Prior Probability 
MSH2  p.(Leu330Pro) 1.00 36.32 0.961 
MSH2  p.(Leu341Pro) 1.00 36.32 0.961 
MSH2  p.(Val342Ile) 0.04 1.44 0.000 
MSH2  p.(Pro349Arg) 1.00 41.48 0.971 
MSH2  p.(Phe447Val) 0.77 17.61 0.643 
MSH2  p.(Gly548Asp) 1.00 35.86 0.960 
MSH2  p.(Asn596Ser) 0.02 1.99 0.001 
MSH2  p.(His639Leu) 1.00 25.24 0.916 
MSH2  p.(Ile704Val) 0.03 4.86 0.004 
MSH2  p.(Ala834Thr) 0.96 8.43 0.428 
MSH2  p.(Asn835His) 0.03 2.12 0.001 
MSH2  p.(Leu911Arg) 0.87 32.45 0.917 
MSH2  p.(Val923Glu) 0.32 29.29 0.456 
MSH6  p.(Pro623Ala) 0.03 4.55 0.004 
MSH6  p.(Glu983Gln) 0.85 3.67 0.067 
PMS2  p.(Arg20Gln) 0.49 5.65 0.040 
PMS2  p.(Asn775Ser) 1.00 4.21 0.157 
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This publication describes the development and successful application of a MMR gene 
multifactorial likelihood model to classify 44 sequence variants in MLH1, MSH2, and MSH6. Using 
data from the large Colon Cancer Family Registry (C-CFR) dataset, we estimated LRs for variant 
pathogenicity based on the phenotypic features of colorectal tumours: MSI, which is a positive 
predictor, but is also present in some sporadic tumours, and BRAF V600E, which is a negative 
predictor for colorectal cancer arising in MMR gene mutation carriers. This was the first MMR 
multifactorial likelihood model to use appropriate statistical measures for amino acid conservation 
(derived from Chapter 2), segregation with disease and tumour features. All the resulting 
classifications and supporting summary information have been placed onto the same publically 
accessible database as the in silico scores from Chapter 2 (hci-lovd.utah.edu). As the curator, I will 
maintain the database with new classifications using multifactorial likelihood analysis. 
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ABSTRACT Mismatch repair (MMR) gene sequence vari-
ants of uncertain clinical significance are often identified
in suspected Lynch syndrome families, and this consti-
tutes a challenge for both researchers and clinicians. Mul-
tifactorial likelihood model approaches provide a quan-
titative measure of MMR variant pathogenicity, but first
require input of likelihood ratios (LRs) for different MMR
variation-associated characteristics from appropriate, well-
characterized reference datasets. Microsatellite instability
(MSI) and somatic BRAF tumor data for unselected col-
orectal cancer probands of known pathogenic variant sta-
tus were used to derive LRs for tumor characteristics us-
ing the Colon Cancer Family Registry (CFR) resource.
These tumor LRs were combined with variant segrega-
tion within families, and estimates of prior probability of
pathogenicity based on sequence conservation and posi-
tion, to analyze 44 unclassified variants identified initially
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in Australasian Colon CFR families. In addition, in vitro
splicing analyses were conducted on the subset of variants
based on bioinformatic splicing predictions. The LR in fa-
vor of pathogenicity was estimated to be ∼12-fold for a
colorectal tumor with a BRAF mutation-negative MSI-H
phenotype. For 31 of the 44 variants, the posterior prob-
abilities of pathogenicity were such that altered clinical
management would be indicated. Our findings provide a
working multifactorial likelihood model for classification
that carefully considers mode of ascertainment for gene
testing.
Hum Mutat 34:200–209, 2013. C© 2012 Wiley Periodicals, Inc.
KEY WORDS: unclassified variants; mismatch repair; mul-
tifactorial likelihood model; BRAF; MSI
Introduction
Lynch syndrome is an autosomal dominantly inherited disorder
of predominantly colorectal and endometrial cancer predisposition
caused by germline pathogenic variants in the DNA mismatch re-
pair (MMR) genesMLH1 (MIM# 120436),MSH2 (MIM# 609309),
MSH6 (MIM#600678), and to a lesser degreePMS2 (MIM#600259)
[Lynch et al., 2009; Viel et al., 1998; Wang et al., 1999]. These
pathogenic variants cause a functional defect in the DNA MMR
complex, which leads to high levels of DNA microsatellite insta-
bility (MSI). Tumor MSI testing, and/or MMR protein immunos-
taining, is commonly used to identify potential Lynch syndrome
cases [Aaltonen et al., 1998; Lindor et al., 2002; Salovaara et al.,
2000; Terdiman et al., 2001]. However, 10–15% of colorectal tumors
C© 2012 WILEY PERIODICALS, INC.
detected in the general population have an MSI-H phenotype
[Cunningham et al., 1998; Herman et al., 1998; Miyakura et al.,
2001; Toyota et al., 1999], with molecular evidence indicating that
these are largely caused by epigenetic silencing of the MLH1 pro-
moter [Deng et al., 2004; Domingo et al., 2004, 2005; Lubomierski
et al., 2005; McGivern et al., 2004; Wang et al., 2003; Young et al.,
2005]. A single somatic mutation in the oncogene BRAF (MIM#
164757, BRAF c.1799T>A p.[Val600Glu]) is frequently present in
MSI-H cancers with MLH1 methylation [Davies et al., 2002; Ra-
jagopalan et al., 2002], but not in MSI-H cancers arising in patients
with a germline MMR gene pathogenic variant [Deng et al., 2004;
Domingo et al., 2005; Lubomierski et al., 2005;McGivern et al., 2004;
Wang et al., 2003]. Therefore, BRAF p.Val600Glu has potential as
a molecular marker to help distinguish MSI-H colorectal cancers
(CRCs) caused by germline MMR gene pathogenic variant.
Between 20% and 50% of MMR gene sequence variants found
by germline genetic testing in suspected Lynch syndrome colorectal
and endometrial cancer cases are reported to be of uncertain clinical
significance [Peltomaki and Vasen, 2004; Woods et al., 2007]. Es-
tablishing the pathogenicity of unclassified variants has direct clin-
ical relevance because pathogenic variant status determines clin-
ical management with respect to genetic counseling approaches,
presymptomatic screening, and choice/timing of possible prophy-
lactic surgery for carriers.
Multifactorial likelihood analysis (also termed Bayesian Inte-
grated evaluation) was established to address the issue of unclas-
sified variants in the breast cancer susceptibility genes BRCA1
(MIM# 113705) and BRCA2 (MIM# 600185) [Goldgar et al., 2004,
2008]. This approach provides a quantitative measure of variant
pathogenicity, but first requires input of likelihood ratios (LRs) for
different pathogenic variant-associated characteristics from appro-
priate, well-characterized reference datasets, with each LR compar-
ing the probability of the observed data under the hypothesis that
the variant is pathogenic compared to the corresponding proba-
bility that the variant is benign with respect to cancer risk. This
method has since been proposed to assess cancer risk associated
with rare variants of uncertain clinical significance for other cancer
gene syndromes [Goldgar et al., 2008; Tavtigian et al., 2008], partic-
ularly because it provides a measure of causality in the form of the
estimated posterior probability that a variant is pathogenic that can
then be categorized into a qualitative five-class scheme that is linked
to clinical recommendations [Plon et al., 2008].
We and others have proposed approaches to apply the multi-
factorial likelihood model to classification of MMR gene variants
[Couch et al., 2008; Hofstra et al., 2008; Spurdle, 2010], and have
developed methodology to estimate the likelihood of pathogenicity
based on variant segregation with disease in families [Arnold et al.,
2009]. The extension of themultifactorial approach to include other
features was recently reported in a study assessing 35 unclassified
variants identified in Italian clinic-based families [Pastrello et al.,
2011]. However, the stringent selection criteria for MMR gene se-
quencing of the reference sets used for derivation of LR estimates for
tumor characteristics by Pastrello et al. suggest that the LR estimates
for tumor characteristics assigned in this Italian study were likely
upwardly biased.
In this study, we have used a detailed set of qualitative criteria
to consistently assign pathogenicity of MMR gene variants for a
large set of CRC cases (probands) with well-documented selection
criteria for ascertainment and molecular characterization. We then
compared the tumor MSI and BRAF mutation characteristics of
probands with and without pathogenic MMR gene variants to esti-
mate tumor LRs. Separate LRs were derived based on ascertainment
criteria (i.e., clinic or population based) to provide unbiased predic-
tors of pathogenicity for inclusion in the multifactorial model, and
were only applied to the relevant group. These tumor LRs were used
together with existing approaches to assess variant segregation with
disease in families, and estimates of prior probability of pathogenic-
ity based on sequence conservation and position (see accompanying
article, Thompson et al., 2012), to analyze 54 sequence variants in
MLH1, MSH2, and MSH6 from 162 families. In addition, in vitro
splicing analysis was performed for the subset of variants for which
in silico analyses predicted a potential to cause splicing aberrations.
We demonstrate the utility of both multifactorial likelihood and
splicing analyses to classify exonic and intronic variants of MMR
genes.
Methods and Materials
Subjects used in this study were recruited as CRC probands into
the Colon Cancer Family Registry (Colon CFR) [Newcomb et al.,
2007]. This includes probands providing data for reference sets (out-
lined below), and families analyzed for unclassified variant evalua-
tion. Written informed consent was obtained from all participants.
Recruitment of subjects and this laboratory-based study have been
approvedby theHumanResearchEthicsCommittee of participating
institutions.
Selection criteria and testing for germline MMR gene sequence
variation in the Colon CFR probands is described in Figure 1. All
MMR gene sequence variants lodged in the Colon CFR database
as of August 2009 were converted to HGVS nomenclature using
the following cDNA reference sequences: NM_000249.3 forMLH1,
NM_000251.1 forMSH2 and NM_000179.2 forMSH6. Nucleotide
numbering reflects cDNA numbering with +1 corresponding to the
A of the ATG translation initiation codon in the reference sequence,
with the initiation codon as codon 1. All variants were reevaluated
based on standardized qualitative classification criteria (Supp. Table
S1). Probands with Class 5 pathogenic variants, or probands with
either Class 1 not pathogenic/no clinical significance sequence alter-
ationsornoknownpathogenic variant after extensive gene screening
were included in reference datasets used to estimate the LRs. Supp.
Table S2 lists all the Class 5 andClass 1MMRgene sequence variants
and the rationale or publications providing supportive information
for their classification.
Supp.Table S3 lists all variants selected for evaluationusingmulti-
factorial and splicing approaches. Variants denoted as Class 2 (likely
not pathogenic), Class 3 (uncertain), or Class 4 (likely pathogenic)
from patients ascertained from the Australasian Colorectal Cancer
Family Registry (ACCFR) were selected for evaluation in this study.
In addition, variants reported in Arnold et al. (2009) classified on
segregation and splicing data only were also reevaluated using the
multifactorial approach. Clinical information was collated for all
relevant ACCFR families, and when data became available for this
project, also for Colon CFR families ascertained from other sites of
the Colon CFR (Mayo Clinic, Ontario Familial Colorectal Cancer
Registry and Fred Hutchinson Cancer Research Center) that were
reported to carry at least one of the selected variants. Additional tu-
mor and segregation data were extracted from publications to aid in
the classification of some variants. The final sample set encompassed
a total of 54 variants in 162 Colon CFR families, plus information
from 26 families identified from the literature (188 families in to-
tal). All variants have been submitted to the InSiGHT locus-specific
database (www.insight-group.org).
Splicing analyses were conducted on RNA extracted from lym-
phoblastoid cell lines (LCLs) established fromavailable lymphocytes
using EBV transformation based on the principles of Sugden and
Mark [Sugden andMark, 1977]. cDNAs fromLCLs established from
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Figure 1. ColonCancer Family Registrymolecular testing schema. ∗somaticBRAF p.Val600Glumutation testing. Note:BRAF resultswere not used
inMMR gene testing selection criteria. USC, University of Southern California; QIMR, Queensland Institute of Medical Research; MSI-L/H, low/high
microsatellite instability; MSS, microsatellite stable; MLPA, multiplex ligase-dependent probe amplification; DHPLC, denaturing high-performance
liquid chromatography.
nine healthy Red Cross donors were used as controls for in vitro
splicing analyses.
Tumor Characteristics and Correlation with Pathogenic
Variant Status
Characterization of colorectal tumors fromColon CFR probands
was carried out previously as part of core Colon CFR activities
[Newcomb et al., 2007]. Briefly, formalin-fixed, paraffin-embedded
tissue sections were stained for MMR proteins MLH1, MSH2,
MSH6, and PMS2 [Lindor et al., 2002]. Tumors were analyzed for
MSI status using 10 microsatellite markers (BAT25, BAT26, BAT40,
BAT34, D5S346, D17S250, ACTC, D18S55, D10S197, and MYCL),
comparing to normal tissue as reference where possible, and clas-
sified according to number of markers demonstrating instability:
MSI-H for ≥3; MSI-L for 1–2; MSS for 0 unstable markers [Lin-
dor et al., 2002]. MSI data were only extracted from peer-reviewed
journal articles if at least five of the above markers were tested. So-
matic BRAF p.Val600Glu mutation testing was done in all available
CRCs as described previously [Buchanan et al., 2010]. Relevant in-
formation up to August 2009 was extracted from the Colon CFR
database for all CRC-affected probands and used to generate cross-
tabulations by pathogenic variant status, and by proband ascertain-
ment, as shown in Table 1. Statistical significance of differences in
distribution between pathogenic variant carriers and non-carriers
was assessed using a Pearson’s χ2 test using STATA. An LR for tumor
characteristics was derived forMSI status andBRAFmutation status
data using the formula:
LR of causality for tumor category = (% pathogenic variant car-
riers)/(% noncarriers).
The LRs for all the tumor categories are shown in Table 1.
Note: Because MSI status was a criterion for MMR gene variant
testing of population-based probands in the Colon CFR database,
but NOT for clinic-based probands (see Fig. 1) [Newcomb et al.,
2007], the MSI LRs for population-based probands were based on
estimations of the number of pathogenic variant carriers in all
population-based cases with tumor MSI data, as detailed in Supp.
Table S4.
BRAF mutation status provided no additional predictive capac-
ity over MSI status for MSS and MSI-L probands, and categories
were collapsed accordingly, to calculate a BRAF LR for the subset
of probands with an MSI-H tumor. The distribution of BRAF mu-
tations by MMR-mutation status differed between the clinic- and
population-based sample sets, and separate BRAF estimates were
thus generated and used for clinic-based versus population-based
probands.
Estimation of Prior Probability of Pathogenicity
Missense substitutions
The derivation of prior probabilities for missense substitu-
tions are described in detail elsewhere (accompanying article,
Thompson et al., 2012). Briefly, sequence conservation at relevant
positions in proteinmultiple sequence alignments ofMLH1,MSH2,
and MSH6 were assessed using a combination of MAPP [Stone and
Sidow, 2005] and a custom version of PolyPhen-2.1 [Adzhubei et al.,
2010] (http://hci-lovd.hci.utah.edu/). The MAPP impact score and
custom PolyPhen-2.1 output “pph2 probability” were used as con-
tinuous variables. A minimum and maximum prior probability of
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Table 1. Estimation of Likelihood Ratios for Tumor Microsatellite Instability and BRAFMutation Status
Tumor category Pathogenic variant carriers Noncarriers Likelihood ratio of causality: % MC/% NC P value: MC vs. NC
Clinic based n = 90 n = 190 P trend <10–6
MSS 3.33% (n = 3) 80.00% (n = 152) 0.04 (CI 95% 0.01, 0.13) <10–6
MSI-L 5.56% (n = 5) 9.47% (n = 18) 0.59 (CI 95% 0.23, 1.5) 0.2648
MSI-H 91.11% (n = 82) 10.53% (n = 20) 8.66 (CI 95% 5.69, 13.2) <10–6
Population-based∗ n = 137 n = 3893 P trend <10–6
MSS 7.30% (n = 10) 76.03% (n = 2960) 0.10 (CI 95% 0.05, 0.17) <10–6
MSI-L 3.65% (n = 5) 11.17% (n = 435) 0.33 (CI 95% 0.14, 0.78) 0.0055
MSI-H 89.05% (n = 122) 12.8% (n = 498) 6.96 (CI 95% 6.29, 7.70) <10–6
Clinic based n = 69 n = 14
MSI-H BRAF + 2.90% (n = 2) 28.57% (n = 4) 0.10 (CI 95% 0.02, 0.50) 0.005
MSI-H BRAF – 97.10% (n = 67) 71.43% (n = 10) 1.36 (CI 95% 0.97, 1.90)
Population based∗ n = 52 n = 189
MSI-H BRAF + 3.85% (n = 2) 47.62% (n = 90) 0.08 (CI 95% 0.02, 0.32) 0.0007
MSI-H BRAF – 96.15% (n = 50) 52.38% (n = 99) 1.84 (CI 95% 1.59, 2.13)
∗As noted in Figure 1, tumor MSI-H andMSI-L status was used to select population-based cases for MMR sequencing, with only a subset of population-based MSS cases selected
for sequencing. Therefore, the number of pathogenic variant carriers in the total population-based sample set was estimated separately for each MSI stratum based on the data
available for probands that had undergone sequencing. See “Methods and Materials” and Supp. Table S4 for more detailed explanation. Frequency of BRAF mutation in MSI-H
cases differs between population-based and clinic-based cases (Mantel–Haenszel X2: 13.83, P = 0.0002). BRAF+, positive for BRAF p.Val600Glu mutation; BRAF–, negative for
BRAF p.Val600Glu mutation; MC, mutation carrier; NC, noncarrier; CI, confidence interval.
pathogenicity of 0.10 and 0.90, respectively, was set to ensure that
additional sources of information were required to reach posterior
probabilities that alter clinicalmanagement of patients with variants
(i.e., Class 1, Class 2, Class 4, andClass 5), that is, direct classification
based on the prior probability alone was not possible. All synony-
mous substitutions were assigned a prior of 0.10. Prior probabilities
were derived from calibration of the above programs based on anal-
ysis of a consistently classified and carefully annotated reference set
of MMR missense alterations that excluded all missense alterations
known to alter splicing.
Intronic substitutions
There is a relative paucity of published information on splicing
assays for intronic MMR gene variants (Supp. Table S5). All MMR
gene variants located in the donor or acceptor dinucleotides assayed
in vitro have been reported to be associated with splicing aberra-
tions. However, the majority of variants reported in the literature
appear to have been selected for in vitro analysis on the basis of
bioinformatic prediction and the potential for negative publica-
tion bias for variants with no associated splicing aberration cannot
be discounted. In the absence of a large study that has assessed the
pathogenicity of intronicMMRgene variants without selection bias,
we thus conservatively assumed prior probabilities of pathogenic-
ity previously calculated for BRCA1 and BRCA2 variants based on
analysis of a large dataset [Easton et al., 2007]. Namely, variants lo-
cated in canonical GT-AG dinucleotides have a prior probability of
0.96 and other intronic variants and alterations in the 3′UTR were
assigned a prior probability of 0.26.
Multifactorial Likelihood Classification
LRs for segregation were derived by Bayes factor analysis adapted
from themethod of Thompson et al. (2003), as described previously
[Arnold et al., 2009]. Penetrance estimates for MLH1 and MSH2
variants were derived from Quehenberger et al.(2005) and those
for MSH6 variants were derived from Baglietto et al. (2010)]. The
variants MLH1 c.790+10A>G, MLH1 c.2146G>A (p.Val716Met),
MSH2 c.339G>A,MSH2 c.∗221G>T,MSH2 c.∗226A>G, andMSH6
c.1186C>G (p.Leu396Val) were present in multiple families and co-
occurred with pathogenic variants in some probands. The biallelic
families concernedwere excluded frommultifactorial analysis to en-
sure the segregation LR for estimating causality of the variant would
not be biased by the presence of a pathogenic variant in the family.
Bayesian scores were derived twice for those families in which two
different variants of unknown clinical significance were observed in
trans, analyzing risk associated with each variant separately, under
the assumption that only one variant was causal.
LRs for tumor characteristics shown in Table 1 were applied as
follows: clinic-based probands and all relatives with known MSI
status were assigned an LR according to MSI phenotype and re-
cruitment location. All probands and relatives with MSI-H status
and known BRAFmutation status were assigned an LR according to
BRAFmutation status and site of recruitment. The MSI and BRAF
LRs were used for CRCs only.
For each variant under study, the individual LRs available from
segregation and tumor characteristics were multiplied to calculate
an overall multifactorial LR, under the assumption that each factor
was statistically independent. Bayes rule was then used to calculate
a posterior probability that the variant was pathogenic from the
multifactorial LRs and the prior probability. Variants were classified
according to the five-class IARC quantitative scheme [Plon et al.,
2008], based on the posterior probability.
Splicing Assays and Bioinformatic Prediction of Splicing
Aberrations
Variants were selected for splicing analysis based on LCL or lym-
phocyte availability. LCL cycloheximide splicing assays, PCR sample
preparation, and sample sequencing were done using methods de-
scribed previously [Whiley et al., 2011]. cDNA (synthesized using
random hexamers [Sigma, St Louis MO]) was used as template in
PCR reactions with specific primers targeting the potential splice
sites (Supp. Table S6). PCR for variants was performed under the
conditions presented in Supp. Table S6. Each RT-PCR analysis in-
cluded a set of nine healthy Red Cross control LCLs (see “Methods
and Materials”). The long-range DNA polymerase Elongase (In-
vitrogen, Carlsbad, CA) was used to test for intron inclusion in
variant carriers. PCR products from MLH1 c.588+1G>T, MLH1
c.678-1G>C, MLH1 c.791-1G>C, MLH1 c.884G>A p.(Ser295Asn),
MLH1 c.1559-2A>T, MSH2 c.645+1G>A, and MSH2 c.1387-9T>A
were cloned using pGEMR©-T Vector (Promega, Madison, WI) and
verified by sequencing.
HUMANMUTATION, Vol. 34, No. 1, 200–209, 2013 203
Results from splicing assays were compared to bioinformatic pre-
dictions of splicing aberrations. We utilized Human Splicing Finder
version 2.4 (www.umd.be/HSF/), which evaluates splicing signals
present in any human gene by using matrices to predict 5′ and 3′
splice sites and splice regulatory sites using different algorithms,
including Human Splicing Finder (HSF) matrices and MaxEntScan
[Desmet et al., 2009; Yeo and Burge, 2004]. The coding DNA
HGVS nomenclature was input intoHSF for each variant.We deter-
mined the difference between variant and wild-type output scores
as a proportion of wild-type scores for HSF matrices and Max-
EntScan. NNSplice (http://www.fruitfly.org/seq_tools/splice.html)
[Reese et al., 1997] was also used to assess the effect of variants
on mRNA splicing, with the exact sequence input consecutively for
wild-type and variant sequences, and a default minimum score of
0.4was set for both 5′ and 3′ splice sites. The qualitative classification
criteria in Spurdle et al. (2008) for splicing assay interpretation was
applied in some instances to classify variants if it improved on the
multifactorial likelihood classification.
Results
In this study, we assessed 54 variants usingmultifactorial analysis,
with the addition of prior probabilities for missense variants and
an LR for tumor characteristics. We also carried out splicing assays
on all probands with LCLs available for in vitro analysis and no
previous reported splicing assay results, including alterations in the
splice consensus dinucleotides (MLH1 c.588+1G>T, MLH1 c.791-
1G>C,MLH1 c.1559-2A>T, andMSH2 c.645+1G>A).
Multifactorial Likelihood Analysis
We were able to classify 31 variants as either not pathogenic (9
variants) or pathogenic (22 variants) inMLH1,MSH2, andMSH6
using the multifactorial likelihood model (Table 2; detailed infor-
mation used to derive individual LRs is provided in Supp. Table
S7). In most instances, the LRs derived from tumor characteristics
provided more information toward the final classification than seg-
regation LRs, with obvious discordance between tumor results and
segregation for only one variant MSH2 c.488T>G. There were an
additional six variants considered likely not pathogenic and four
likely pathogenic. Tumors from three cases that are carriers of an
MSH2 variant in the 3′ untranslated region (MSH2 c.∗129T>C and
MSH2 c.∗226A>G) demonstrated a tumor phenotype indicative of
sporadic CRC (a positive mutation status for BRAF p.Val600Glu,
MSI-H, and MLH1 protein loss), which is consistent with the neu-
tral and likely neutral classifications observed.
The multifactorial classification, for each variant assessed in this
study, is reported on a newly created LOVD-based MMR database
(http://hci-lovd.hci.utah.edu/),whichdetails the prior probabilities,
LRs for the individual components, and posterior probabilities.
As shown in Table 2, there were nine variants that were observed
with known pathogenic variants, and eight variants that were ob-
served with another variant of unknown clinical significance. The
earliest age of onset of a Lynch cancer for these probands was 37
years old (range 37–64), and none had an abnormal clinical pheno-
type, suggesting that the carriers of these variants were not carriers
of two different bona fide pathogenic variants. Indeed, the final
classifications from multifactorial analysis (which at this point in
time does not incorporate an LR for co-occurrence) were Class 1
(4/9 variants), Class 2 (4/9 variants), and uncertain (1/9 variants)
for variants co-observed with a known pathogenic variant.
In Vitro Splicing Assays
Several of the cases assayed expressed varying levels of naturally
occurring alternative splicing isoforms, particularlyMLH1 ! exon
9/10,MLH1! exon 3, a 227 base-pair insertion of intron 1 and 145
base-pair insertion of intron 2 both in MLH1 (Fig. 2A). Splicing
aberrations not identified in controls were observed for 7 out of
the 26 variants assayed (Supp. Table S8, Fig. 2). The splicing pro-
grams predicted the interruption of the intron–exon junction for
five variants, all of which showed aberrant splicing in vitro. The
variants MLH1 c.588+1G>T, MLH1 c.791-1G>C, MLH1 c.884G>A
p.(Ser295Asn), andMLH1 c.1559-2A>T all result in exon skipping
(Fig. 2A–C). MSH2 c.645+1G>A produces multiple transcripts: an
in-frame deletion of exon 3 and an out-of-frame product from cryp-
tic donor site usage 154 base-pairs upstream of the wild-type donor
site (Fig. 2D). These splicing results were consistent with multifac-
torial likelihood classifications for these variants, Class 4 (MLH1
c.884G>A) or Class 5 (the remaining intron–exon junction vari-
ants). Moreover, analysis of cDNA sequence for the exonic variant
MLH1 c.884G>A indicated that the variant allele did not express
any full-length transcript, justifying that the classification for this
variant may be upgraded to Class 5 on the basis of the splicing data.
Bioinformatic prediction of aberrant splicing was consistent for
the remaining two variants displaying aberrant splicing. MLH1
c.678-1G>C interrupts the wild-type acceptor splice site and creates
a de novo acceptor leading to a 2-base-pair out-of-frame deletion
identified by sequencing (Fig. 2E), both of which were predicted by
all three of the bioinformatic splicing programs (Supp. Table S8).
MSH2 c.1387-9T>A creates a de novo acceptor site causing a 7-base-
pair inclusion of intron 8 (Fig. 2F), with de novo acceptor creation
and interruption of the wild-type acceptor site predicted by Max-
EntScan (Supp. Table S8). Although further quantitative splicing
analysis would be required to determine if the splicing aberrations
caused by MLH1 c.678-1G>C and MSH2 c.1387-9T>A are associ-
ated with a minor or major transcript, the Class 4 likely pathogenic
classification frommultifactorial analysis for these variants suggests
that these splicing aberrations are causative.
In addition, splicing assay results showed no evidence of an aber-
ration for the intronic variant MSH2 c.2005+8dupA, justifying that
this variant can be altered fromClass 3 uncertain (indicated bymul-
tifactorial analysis) to Class 2 likely not pathogenic. Splicing data
did not alter the classifications of any other variants.
Discussion
In this study, we derived LRs from the Colon CFR dataset for
the CRC characteristics of MSI and BRAF mutation status for use
in multifactorial analysis, carefully considering issues relating to as-
certainment bias in this large and well-characterized dataset. We
provide LRs that are applicable to variants discovered within clinic-
based or population-based datasets, with the caveat that the ref-
erence pathogenic variants in this study are also representative of
studies outside the Colon CFR dataset.
These LRs for tumor features were then used in a multifactorial
model together with a segregation LR and an estimated prior
probability to assess clinical significance of 54 MMR gene variants,
and contributed noticeably to classification. In total, application of
the model altered the class of 31 variants under study (21 as Class 1
or 5, and another 10 Class 2 or 4), with implications for the future
management of all families with these variants. In addition, we were
able to confirm the Class 5 classification for 10 variants consid-
ered pathogenic using largely qualitative information from Arnold
et al. (2009). The priors based on in silico analysis of the 25missense
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Table 2. Mismatch Repair Gene Multifactorial Likelihood Analysis Results
Prior probability Tumor Segregation Odds Posterior probability In vitro
Variant of pathogenicityf characteristics LR LR causality of pathogenicity results Classificationg
MLH1
c.112A>C p.(Asn38His) 0.750 3.73 × 108 1871.3 6.97× 1011 1.000 Wild type Class 5—pathogenic1
c.113A>G p.(Asn38Ser) 0.723 6.960 27.47 191.2 0.998 Wild type Class 5—pathogenic
c.116+5G>C 0.260 75.00 21.68 1625.9 0.998 Intron inclusion Class 5—pathogenic
c.198C>Ta 0.100 N/A 0.690 0.690 0.071 Wild type Class 3—uncertain
c.199G>A p.(Gly67Arg) 0.962→ 0.9 2210.3 2.148 4747.2 1.000 Wild type Class 5— pathogenic
c.230G>A p.(Cys77Tyr) 0.880 11.78 3.161 37.23 0.996 Not tested Class 5—pathogenic
c.303T>G 0.100 N/A 0.531 0.531 0.056 Wild type Class 3—uncertain
c.307-29C>Aa 0.260 4.10× 10–12 4.08× 10–4 1.67× 10–15 5.88× 10–16 Wild type Class 1—not pathogenic
c.350C>T p.(Thr117Met) 0.893 1.53 × 1011 1.04× 106 1.60× 1017 1.000 Wild type Class 5—pathogenic
c.389A>G p.(Tyr130Cys)b 0.757 1.360 1.1782 1.602 0.833 Wild type Class 3—uncertain
c.588+1G>T 0.960 883.3 3.706 3273.4 1.000 Exon skipping Class 5—pathogenic
c.589-2A>G 0.960 N/A 25.11 25.11 0.998 4 bp deletion Class 5—pathogenic
c.678-1G>C 0.960 N/A 1.671 1.671 0.976 2 bp deletion Class 4—likely pathogenic
c.702G>Ac 0.100 N/A 0.949 0.949 0.095 Wild type Class 3—uncertain
c.790+2dupT 0.960 6.960 312.8 2176.7 1.000 Exon skipping Class 5—pathogenic
c.790+10A>Ga 0.260 4.00 × 10–4 N/A 4.00 × 10–4 1.41 × 10–4 Wild type Class 1—not pathogenic2
c.791-1G>C 0.960 8.660 122.2 1057.8 1.000 Exon skipping Class 5—pathogenic
c.884G>A p.(Ser295Asn) 0.723 11.78 2.430 28.62 0.987 Exon skipping Class 5—pathogenic
c.1040C>A p.(Thr347Asn) 0.007→ 0.1 N/A 1.61× 10–3 1.61 × 10–3 1.79 × 10–4 Not tested Class 1—not pathogenic
c.1321G>A p.(Ala441Thr)b 0.011→ 0.1 1.360 0.577 0.784 0.080 Not tested Class 3—uncertain
c.1559-2A>T 0.960 102.0 1.762 179.7 1.000 Exon skipping Class 5—pathogenic
c.1852_1853delAAinsGC
p.(Lys618Ala)
0.899 2.78× 10–13 1.17× 10–1 3.26× 10–14 2.89× 10–13 Wild type Class 1—not pathogenic
c.1852_1854delAAG p.(Lys618del) 0.500 5,624.3 579.9 3.26 × 106 1.000 Wild type Class 5—pathogenic
c.1990-1G>A 0.96 N/A 28.44 28.44 0.999 Exon skipping Class 5—pathogenic 3
c.2059C>T p.(Arg687Trp) 0.429 8.660 4.769 41.30 0.969 Wild type Class 4—likely pathogenic3,4
c.2146G>A p.(Val716Met)a 0.327 4.16 × 10–4 0.204 8.48 × 10–5 4.12 × 10–5 Wild type Class 1—not pathogenic2,5,6,7,8
c.2153A>C p.(His718Pro) 0.931→ 0.9 N/A 0.811 0.811 0.880 Wild type Class 3—uncertain
MSH2
c.6G>T 0.100 0.100 0.696 0.070 0.008 Not tested Class 2—likely not pathogenic
c.339G>Aa 0.100 0.004 0.119 4.75 × 10–4 5.27 × 10–5 Wild type Class 1—not pathogenic
c.484G>A p.(Gly162Arg)d 0.962→ 0.9 8.660 1.636 14.17 0.992 Wild type Class 5—pathogenic
c.488T>G p.(Val163Gly)e 0.422 0.087 25.56 2.213 0.618 Wild type Class 3—uncertain
c.571_573delCTC p.(Leu191del) 0.500 11.78 19.81 233.3 0.996 Wild type Class 5—pathogenic
c.645+1G>A 0.960 11.78 7.870 92.70 1.000 154 bp deletion Class 5—pathogenic
c.913G>A p.(Ala305Thr) 0.929→ 0.9 N/A 0.520 0.520 0.824 Wild type Class 3—uncertain
c.942+3A>T 0.260 N/A 20871.32 20871.32 1.000 Exon skipping Class 5—pathogenic
c.1013G>A p.(Gly338Glu) 0.959→ 0.9 11.78 1.350 15.90 0.993 Wild type Class 5—pathogenic
c.1387-9T>A 0.260 75.00 1.682 126.1 0.978 Intron inclusion Class 4—likely pathogenic
c.1662-9G>A 0.26 2.80 × 10–12 N/A 2.80 × 10–12 9.85 × 10–13 Wild type Class 1—not Pathogenic
c.1666T>C 0.1 5.86 × 10–6 N/A 5.86 × 10–6 6.52 × 10–7 Wild type Class 1—not pathogenic
c.1865C>T p.(Pro622Leu) 0.927→ 0.9 75.00 67134.69 75.00 0.999 Wild type Class 5—pathogenic
c.1906G>C p.(Ala636Pro) 0.045→ 0.1 2.42 × 1011 4.142 1.00 × 1012 1.000 Wild type Class 5—pathogenic9,10
c.2005+8dupAa 0.260 1.840 N/A 1.840 0.393 Wild type Class 2—likely not pathogenic
c.2006-36_2006-33dupTTAA 0.260 N/A 1.000 1.000 0.260 Not tested Class 3—uncertain
c.∗129T>C 0.260 0.003 0.793 0.002 7.72 × 10–4 Not tested Class 1—not pathogenic
c.∗221G>Ta 0.260 0.040 1.351 0.054 0.019 Not tested Class 2—likely not pathogenic
c.∗226A>Ga 0.260 0.080 N/A 0.080 0.027 Not tested Class 2—likely Not pathogenic
MSH6
c.1019T>C p.(Phe340Ser) 0.002→ 0.1 0.100 1.000 0.100 0.011 Wild type Class 2-–likely not pathogenic
c.1164C>Td 0.100 N/A 1.07 × 10–4 1.07 × 10–4 1.19 × 10–5 Wild type Class 1—not pathogenic
c.1186C>G p.(Leu396Val)a 0.026→ 0.1 0.100 0.520 0.052 0.006 Wild type Class 2-–likely not pathogenic
c.1193T>A p.(Val398Glu) 0.913→ 0.9 11.78 1.523 17.93 0.994 Not tested Class 5—pathogenic
c.2057G>A p.(Gly686Asp) 0.916→ 0.9 1.840 1.998 3.676 0.971 Wild type Class 4—likely pathogenic
c.2341C>T p.(Pro781Ser)c 0.826 N/A 1.040 1.040 0.831 Wild type Class 3—uncertain
c.3226C>T p.(Arg1076Cys)e 0.805 N/A 1.113 1.113 0.821 Wild type Class 3—uncertain
c.∗24_28delGTTGA 0.260 N/A 0.907 0.907 0.242 Wild type Class 3—uncertain
aCo-occurrence or co-observation of variant with a pathogenic MMR gene variant in some families.
bCo-occurrence of both variants in the proband (phase unknown).
c,dCo-observation of both variants in the proband.
eCo-observation of both variants in a single family.
fPrior probability of pathogenicity <0.1 and >0.9 were set at 0.1 and 0.9, respectively. The prior was derived using the following equation Logit(Pr) = –9.20 + 2.27(M) + 4.26(P),
where Pr is the Prior probability, M is ln(MAPP score), and P is the “pph2 probability” output by PolyPhen-2.1 (retrained without MMR gene data); tumor characteristics
LR based on colorectal tumors only; the Odds for Causality are calculated as the product of the individual statistically independent components (tumor characteristics LR ×
segregation LR). The posterior probability = posterior odds/(posterior odds + 1), where the posterior odds = prior probability× odds for causality× (1/1-prior probability).
gBased on the criteria in Plon et al. (2008), additional data was extracted from peer-reviewed literature to achieve classification for six variants: 1—[Van Riel et al., 2010],
2—[Pastrello et al., 2011]; 3—[Caldes et al., 2002]; 4—[Gallinger et al., 2004]; 5—[Genuardi et al., 1998]; 6—[Muller-Koch et al., 2001]; 7—[Kamory et al., 2006]; 8—[Barnetson
et al., 2008]; 9—[Yuan et al., 1999]; 10—[Foulkes et al., 2002].
N/A, not applicable; LR, likelihood ratio.
HUMANMUTATION, Vol. 34, No. 1, 200–209, 2013 205
Figure 2. Splicing aberrations arising fromMLH1 andMSH2 variants detected using RT-PCR. Variant carrier and control cycloheximide treated
(+) and untreated (−) lymphoblastoid cell lines. A: Alternative splicing detected forMLH1 c.588+1G>T (P1),MLH1 c.678-1G>C (P2),MLH1 c.791-1G>C
(P3),MLH1 c.884G>A (P4) and two healthy controls (C1 and C2). The 227 base-pair insertion ofMLH1 intron 1, 145 base-pair insertion ofMLH1 intron
2,! exon 3,! exon 6,! exon 10, and! exon 9/10 are all naturally occurring isoforms.B:A schematic representing the splicing aberrations caused
byMLH1 c.588+1G>T (P1),MLH1 c.791-1G>C (P3) andMLH1 c.884G>A (P4).MLH1 c.588+1G>T causes exon 7 skipping and bothMLH1 c.791-1G>C
andMLH1 c.884G>A lead to upregulation of! exon 10. C:MLH1 c.1559-2A>T results in two aberrant transcripts not present in controls:! exon 14
and! exon 14/15. D:MSH2 c.645+1G>A (P6 and P7 are both variant carriers) causes an upregulation of exon 3 skipping and 154 bp partial deletion
of exon 3 as a minor transcript. E:MLH1 c.678-1G>C causes a 2 bp deletion at the start of exon 8. F:MSH2 c.1387-9T>A results in a 7 bp insertion of
intron 8 caused by the creation of a de novo acceptor site. M, marker; bp, base pair; fs, frameshift.
variants were in agreement with tumor and segregation data except
for the variantsMLH1p.(Lys618Ala) andMSH2p.(Ala636Pro).Un-
derestimation of the prior for the latter Ashkenazi Jewish founder
pathogenic variant traces to the observation that the position cor-
responding to Ala636 is quite variable in our protein multiple se-
quence alignments; moreover, mutS crystal structures do not place
the residue in anα-helix [Lamers et al., 2000;Obmolova et al., 2000].
Consequently, the substitution to proline is not obviously destabi-
lizing and neither MAPP nor PolyPhen gives the variant a high
prior probability. Nonetheless, Foulkes et al. (2002) suggested that
the substitution could cause steric hindrance that might interrupt
ATP hydrolysis. Still, in spite of the relatively low prior probability
for this variant, the data from tumor characteristics and cosegrega-
tion were sufficient to provide a posterior probability indicative of
pathogenicity. The classification ofMLH1 c.1852_1853delAAinsGC
p.(Lys618Ala) is a contentious issue with some functional assays
suggesting reduced protein function [Belvederesi et al., 2006; Blasi
et al., 2006; Guerrette et al., 1999; Kondo et al., 2003; Perera and
Bapat, 2008], but family studies (including this study) indicating it
is not pathogenic [Castillejo et al., 2011]. Consistent with these in-
conclusive findings, a recent case–control study concluded that the
variant was not fully penetrant, and was associated with a twofold
increase in risk of Lynch syndrome-associated tumors [Medeiros
et al., 2012].
There is currently no sufficiently large and well-characterized
dataset to estimate prior probabilities of pathogenicity based on in
silico splicing data for the MMR repair genes, and it is not feasible
to estimate a splicing prior from the literature due to bias in selec-
tion of variants for in vitro mRNA assays (including this study with
preselection by bioinformatic prediction splicing assays). Therefore,
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because the splicing machinery and regulatory elements are similar
between genes [Baralle and Baralle, 2005], the BRCA1/2 splicing
prior probabilities [Easton et al., 2007] were used in the multifacto-
rial analysis as a conservative estimate of prior probability for all in-
tronic variants (within and outside acceptor/donor dinucleotides).
Our analysis of possible splicing aberrations for a subset of vari-
ants supported the findings from multifactorial analysis, with 9/12
demonstrating splicing aberrations having a posterior probability
Class 5. The remaining three variants were Class 4 frommultifacto-
rial analysis, and semiquantitative allelic expression analysis for one
exonic variant indicated that it could be considered Class 5 using
qualitative interpretation [Spurdle, 2008].
It was not appropriate to utilize other LRs derived using BRCA
datasets such as co-occurrence and family history [Easton et al.,
2007; Goldgar et al., 2004] due to the different phenotypes present
for the MMR genes compared to BRCA1 and BRCA2. Although it is
known that co-occurrence or co-observation of pathogenic variants
in the MMR genes (also termed compound heterozygosity or bial-
lelic mutations) is associated with very early onset gastrointestinal
tumors (under 20 years old), hematologicmalignancies andneurofi-
bromatosis type 1-like features [Bandipalliam, 2005], further study
is required to assign with confidence the specific features that can
be used to derive LRs for pathogenic variants that co-occur (same
MMR gene) or are co-observed (different MMR genes). Similarly,
the family history profiles associated with MMR gene pathogenic
variant status will have to be assessed from large well-characterized
datasets to derive LRs for this component.
This is the first instance of incorporating BRAF mutation status
in the multifactorial model. Mining of the Colon CFR MSI and
somatic BRAF tumor data from unselected colon cancer patients
of known pathogenic variant status indicates that a BRAF muta-
tion negative MSI-H colon tumor is associated with a ∼12-fold
increase in likelihood of pathogenicity. This data also suggests that
MSI in a tumor is a better predictor of pathogenic variant carrier
status than absence of a BRAF mutation. Positive BRAF mutation
status was most informative in identifying probable nonpathogenic
variants, as was MSS tumors. These findings are reflected by ob-
servations in the literature [Lucci-Cordisco et al., 2006; Parsons
et al., 2012; Zaanan et al., 2011]. However, the incidence of MSI
in sporadic CRCs [Cunningham et al., 1998; Herman et al., 1998;
Miyakura et al., 2001; Toyota et al., 1999] highlights the importance
of a combinatorial tumor characteristic LR. Using MSI alone can
sometimes lead to overestimation of pathogenicity. For the variant
MLH1 c.2146G>A p.(Val716Met) there are two MSI-H tumors eli-
gible for analysis that have not had BRAF mutation testing, which
increase the odds of causality. However, additional evidence sug-
gests that this variant is not pathogenic and that something else
other than the missense substitution is causing the MSI. An LR
based on MLH1 promoter methylation would also be a beneficial
addition to themultifactorial model as a negative indicator of Lynch
syndrome.
BRAF mutation status is commonly associated with MLH1 pro-
moterhypermethylation inMSI-HsporadicCRCs [Denget al., 2004;
McGivern et al., 2004]. Therefore, thepresenceofBRAFp.Val600Glu
in a CRC should be sufficient to exclude MMR gene variant screen-
ing for Lynch syndrome [Bessa et al., 2008; Bouzourene et al., 2010;
Jensen et al., 2008; Loughrey et al., 2007]. However, there are seven
pathogenic MMR variants reported in probands from this Colon
CFR dataset and additional pathogenic variants reported in the lit-
erature [Lagerstedt Robinson et al., 2007; Walsh et al., 2009] that
have BRAF mutation positive tumors, suggesting that recognition
of bona fide Lynch tumors may be missed using such triaging for
gene variation screening.
Few studies have addressed classifying MMR gene variants using
multifactorial analysis. To our knowledge, three papers have tried
integrating tumor characteristics with multiple lines of evidence
to classify variants. Arnold et al. (2009) used Bayesian segregation
analysis, but used tumor pathology data qualitatively together with
other observational data (functional data and family history) and
in vitro splicing data to classify variants. Barnetson et al. (2008)
devised an arbitrary scoring system for variant classification, that
included IHC andMSI tumor status as points of evidence, but there
was no attempt to derive an empirical LR. Furthermore, Pastrello
et al. (2011) described a Bayesian approach to MMR variant classi-
fication that included an LR for clinicopathologic features such as
IHC and MSI based on a large tumor dataset [Engel et al., 2006].
Nevertheless, ascertainment bias in the dataset was not taken into
account in derivation of the LRs, therefore, leading to an overesti-
mation in the likelihood of pathogenicity for variant carriers. In the
estimation of the tumor characteristic LR, we have taken into ac-
count ascertainment bias for the tumors, and chose not to estimate
an LR based on IHC data due to the high correlation between tumor
protein loss and MSI, and because some missense substitutions can
lead to stably expressed nonfunctional proteins not identified using
IHC [Mangold et al., 2005; van Riel et al., 2010].
The tumor characteristics LR based on MSI and BRAFmutation
status was an integral component in the classification of nearly two
thirds of the variants reported in this study. Therefore, this LR used
in combination with segregation analysis and an in silico missense
prior probability is a beneficial addition to the MMRmultifactorial
model for variant classification. Although the strength of the mul-
tifactorial approach is the ability to draw on multiple data sources
readily available in the clinical setting, we do acknowledge a num-
ber of assumptions that underlie the basic model. Namely, that the
individual components are mutually independent, that all variants
off clinical significance have similar cancer penetrances to known
pathogenic variants, that estimates of penetrance used in segrega-
tionanalysis havebeenaccurately estimated, and that thephenotypic
features of different types of pathogenic variants (missense, splicing,
truncating) are sufficiently similar to allow LRs estimates from one
type of pathogenic variant to be relevant to other classes.
The results of the multifactorial analyses will affect the clinical
management of 76% (41/54) of the variants reported within. In ad-
dition, anMMRgene public LOVD-based database has been created
to report these classifications and future multifactorial likelihood
classifications.
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Supp. Table S1. Qualitative variant classification criteria applied to MMR gene variants at study initiation 
 
Class Criteria for qualitative classification Class 5 –  Pathogenic  All of the following characteristics – deficient protein function in in vitro/ex vivo functional assays; co-segregation with disease; not present in general population; plus MSI or immunoloss of MMR protein(s) consistent with the variant location 
Or a major transcript splicing aberration leading to premature stop codon/in-frame deletion disrupting a functional domain 
Or large genomic rearrangements and other variants producing a stop codon or nonsense mutation  Class 4 –  Likely pathogenic Deficiency in one or more of the following in vitro/ex vivo assays – MMR functional assays, subcellular localization, protein expression, and subunit interaction, plus MSI or immunoloss of MMR protein(s) consistent with the variant location 
Or variants at IVS±1,±2 Class 3 –  Uncertain Insufficient evidence to classify Class 2 –  Likely not pathogenic Variants	  reported	  to	  occur	  in	  a	  specific	  ethnic	  group	  at	  frequency	  ≥1% Or in vitro/ex vivo assays demonstrate normal: MMR function, subcellular localization, protein expression, subunit interaction, and splicing 
Or variants reported to occur in the normal population at a frequency <1%, with normal protein function and/or no aberrant splicing Class1 –  Not pathogenic Variants	  reported	  to	  occur	  in	  the	  normal	  population	  at	  frequency	  ≥1% MMR: mismatch repair; MSI: microsatellite instability  
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Supp. Table S2. Colon CFR MMR gene variants considered Class 1 Not Pathogenic/Low Clinical Significance and Class 5 Pathogenic for 
estimation of likelihood ratios Variant Classification Rationale For Classification Reference(s) MLH1 c.454-51T>C Class 1 - Not pathogenic/low clinical significance MAF 0.022 (n=629, global) [1] MLH1 c.474C>T  Class 1 - Not pathogenic/low clinical significance MAF 0.035 (n=629, global) [1] MLH1 c.637G>A p.Val213Met Class 1 - Not pathogenic/low clinical significance MAF 0.011 (n=1630, global) [1-4] MLH1 c.655A>G p.Ile219Val Class 1 - Not pathogenic/low clinical significance MAF 0.170 (n=629, global) [1] MLH1 c.1038+86T>C Class 1 - Not pathogenic/low clinical significance MAF 0.339 (n=629, global) [1] MLH1 c.1039-8T>A Class 1 - Not pathogenic/low clinical significance MAF 0.081 (n=273, Australia & UK) [5, 6] MLH1 c.1410-54C>T Class 1 - Not pathogenic/low clinical significance MAF 0.054 (n=629, global) [1] MLH1 c.1558+14G>A Class 1 - Not pathogenic/low clinical significance MAF 0.071 (n=850, Scandinavia) [7, 8] MLH1 c.1668-19A>G Class 1 - Not pathogenic/low clinical significance MAF 0.341 (n=629, global) [1] MLH1 c.1959G>T  Class 1 - Not pathogenic/low clinical significance MAF 0.015 (n=1415, global) [2, 7, 9] MLH1 c.1990-121C>T Class 1 - Not pathogenic/low clinical significance MAF 0.336 (n=629, global) [1] MLH1 c.*30_*32delTTC  Class 1 - Not pathogenic/low clinical significance MAF 0.03 (n=99, Italy) [10, 11] MLH1 c.*35_*37delCTT  Class 1 - Not pathogenic/low clinical significance MAF 0.034 (n=280, France & Australia) [5, 12] MSH2 c.211+9C>G Class 1 - Not pathogenic/low clinical significance MAF 0.374 (n=629, global) [1] MSH2 c.367-86A>C Class 1 - Not pathogenic/low clinical significance MAF 0.092 (n=629, global) [1] MSH2 c.380A>G p.Asn127Ser Class 1 - Not pathogenic/low clinical significance MAF 0.089 (n=629, global) [1] MSH2 c.965G>A p.Gly322Asp Class 1 - Not pathogenic/low clinical significance MAF 0.027 (n=4378, global) [2, 3, 5, 7, 13-21] MSH2 c.984C>T  Class 1 - Not pathogenic/low clinical significance MAF 0.012 (n=215, global) [1] MSH2 c.1077-10T>C Class 1 - Not pathogenic/low clinical significance MAF 0.015 (n=739, global) [1, 22, 23] MSH2 c.1511-9A>T Class 1 - Not pathogenic/low clinical significance MAF 0.064 (n=629, Europe) [1] MSH2 c.1661+12G>A Class 1 - Not pathogenic/low clinical significance MAF 0.491 (n=629, global) [1] MSH2 c.2006-6T>C Class 1 - Not pathogenic/low clinical significance MAF 0.131 (n=629, global) [1] MSH6 c.116G>A p.Gly39Glu Class 1 - Not pathogenic/low clinical significance MAF 0.138 (n=629, global) [1] MSH6 c.186C>A  Class 1 - Not pathogenic/low clinical significance MAF 0.081 (n=629, global) [1] 
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Variant Classification Rationale For Classification Reference(s) MSH6 c.276A>G  Class 1 - Not pathogenic/low clinical significance MAF 0.094 (n=629, global) [1] MSH6 c.540T>C  Class 1 - Not pathogenic/low clinical significance MAF 0.171 (n=629, global) [1] MSH6 c.642C>T  Class 1 - Not pathogenic/low clinical significance MAF 0.045 (n=629, global) [1] MSH6 c.3438+14A>T Class 1 - Not pathogenic/low clinical significance MAF 0.372 (n=629, global) [1] MLH1 c.1-?_1558+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MLH1 c.1-?_545+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MLH1 c.67delG p.Glu23fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.119_131del13ins11 p.Leu40fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.199G>A p.Gly67Arg Class 5 - Pathogenic Deficient protein function in in vitro functional assays, co-segregation with disease, not present in healthy population, plus MSI or immunoloss  
[8, 24-65] 
MLH1 c.208-?_306+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MLH1 c.208-3C>G Class 5 - Pathogenic Aberrant splicing: exon 3 skipping [66] MLH1 c.306+1G>A Class 5 - Pathogenic Aberrant splicing: exon 3 skipping [32, 35, 67-70] MLH1 c.307-?_380+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MLH1 c.346delA p.Thr116fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.350C>T p.Thr117Met* Class 5 - Pathogenic Deficient protein function in in vitro functional assays, co-segregation with disease, not present in healthy population, plus MSI or immunoloss  
[5, 27, 29, 34-36, 39, 46, 48-50, 54-56, 58, 61, 64, 65, 71-100] MLH1 c.380+1G>A Class 5 - Pathogenic Aberrant splicing: exon 4 skipping (out-of-frame) [67, 68] MLH1 c.381-?_453+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MLH1 c.503_504insA p.Asn168fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A 
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Variant Classification Rationale For Classification Reference(s) MLH1 c.525_534delAATTTTGGAA p.Lys175fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.588delA p.Lys196fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.589-2A>G Class 5 - Pathogenic Aberrant splicing: 4 bp deletion and exon 8 skipping (out-of-frame) [5, 42, 50, 101-109] MLH1 c.676C>T p.Arg226X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.677+3A>G Class 5 - Pathogenic Aberrant splicing: exon 8 skipping (out-of-frame) [42, 67, 68, 110, 111] MLH1 c.731G>A p.Gly244Asp Class 5 - Pathogenic Deficient protein function in in vitro functional assays, co-segregation with disease, not present in healthy population, plus MSI or immunoloss  
[29, 34, 36, 42, 47, 54-56, 86, 112] 
MLH1 c.76C>T p.Gln26X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.790+1G>A Class 5 - Pathogenic Aberrant splicing: exon 9/10 skipping [37, 42, 46, 51, 57, 68, 87, 98, 113-124] MLH1 c.790+1G>C Class 5 - Pathogenic Aberrant splicing: exon 9/10 skipping [26] MLH1 c.885-?_1038+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MLH1 c.962_963insAG p.Ser321fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.997_1000delAAGC p.Lys333fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.1451delA p.Asp484fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.1464_1468delGGAAA p.Lys488fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.1489dupC p.Arg497fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A 
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Variant Classification Rationale For Classification Reference(s) MLH1 c.1554_1555insT p.Glu519X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.1668-1G>A Class 5 - Pathogenic Aberrant splicing: exon 15 skipping (out-of-frame) [5, 125, 126] MLH1 c.1689_1690insA p.Leu564fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.1713_1716delTGGT p.Phe571fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.1731G>A Class 5 - Pathogenic Aberrant splicing: exon 15 skipping (out-of-frame) [46, 48, 58, 67-69, 81, 96, 98, 127-134] MLH1 c.1732-1G>A Class 5 - Pathogenic Aberrant splicing: exon 16 skipping  [5, 68, 121, 135] MLH1 c.1758delC p.Ala586fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.1790G>A p.Trp597X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.1801_1802delGAinsT p.Asp601fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.1852_1854delAAG p.Lys618del Class 5 - Pathogenic Deficient protein function in in vitro functional assays, co-segregation with disease, not present in healthy population, plus MSI or immunoloss  
[5, 10, 11, 27, 32, 33, 36, 38, 42, 45, 46, 48, 55, 75, 90, 97, 98, 104, 107, 123, 127, 136-156] MLH1 c.1946delC p.Pro649fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.1975C>T p.Arg659X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.1990-1G>A Class 5 - Pathogenic Aberrant splicing: exon 18 skipping [5, 14, 110] MLH1 c.2002G>T p.Glu668X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MLH1 c.2198_2199insAACA p.His733fs Class 5 - Pathogenic Sequence variation resulting in a N/A 
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Variant Classification Rationale For Classification Reference(s) stop codon MSH2 c.1-?_366+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MSH2 c.1-?_1076+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MSH2 c.1-?_1276+?del r.? p.?  Class 5 - Pathogenic Large genomic deletion N/A MSH2 c.1-?_1386+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MSH2 c.1-?_2458+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MSH2 c.138_166del29 p.His46fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.164delG p.Arg55fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.301G>T p.Glu101X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.363T>A p.Tyr121X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.508C>T p.Gln170X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.679_680ins37 p.Arg227fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.685A>T p.Lys229X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.715C>T p.Gln239X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.789_790delTC p.Asn263fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.790C>T p.Gln264X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.792+1G>A Class 5 - Pathogenic Aberrant splicing: exon 4 skipping [42, 114] MSH2 c.793-?_942+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MSH2 c.863delA p.Gln288fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.892C>T p.Gln298X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A 
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Variant Classification Rationale For Classification Reference(s) MSH2 c.942+3A>T Class 5 - Pathogenic Aberrant splicing: exon 5 skipping [5, 10, 11, 14, 21, 32, 37, 46, 48, 53, 63, 64, 67-69, 74, 75, 79, 80, 82, 85, 96, 100, 104-110, 112, 117, 123, 133, 138, 142-144, 147, 151, 157-199] MSH2 c.1034G>A p.Trp345X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1077-1G>T Class 5 - Pathogenic Aberrant splicing: 11 bp deletion (out-of-frame) [5] MSH2 c.1077-?_1276+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MSH2 c.1147C>T p.Arg383X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1165C>T p.Arg389X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1216C>T p.Arg406X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1222_1223insT p.Tyr408fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1226_1227delAG p.Gln409fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1277-?_1386+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MSH2 c.1277-?_2634+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MSH2 c.1566C>G p.Tyr522X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1609A>T p.Lys537X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A 
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Variant Classification Rationale For Classification Reference(s) MSH2 c.1705_1706delGA p.Glu569fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1738G>T p.Glu580X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1777C>T p.Gln593X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1786_1788delAAT p.Asn596del Class 5 - Pathogenic Deficient protein function in in vitro functional assays, co-segregation with disease, not present in healthy population, plus MSI or immunoloss  
[22, 28, 46, 54, 58, 75, 82, 97, 100, 104, 106, 109, 144, 151, 159, 161, 172, 178, 188, 195, 200-212] MSH2 c.1838_1838insA p.Asn613fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1865C>T p.Pro622Leu Class 5 - Pathogenic Deficient protein function in in vitro functional assays, co-segregation with disease, not present in healthy population, plus MSI or immunoloss  
[2, 5, 31, 49, 50, 54, 56, 138, 140, 141, 148, 177, 179, 202, 203, 213-217] MSH2 c.1889_1892delGAAG p.Gly630fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.1906G>C p.Ala636Pro Class 5 - Pathogenic Deficient protein function in in vitro functional assays, co-segregation with disease, not present in healthy population, plus MSI or immunoloss  
[2, 37, 50, 54, 56, 117, 138, 181, 218-234] MSH2 c.2038C>T p.Arg680X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.2135_2136insT p.Val712fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A 
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Variant Classification Rationale For Classification Reference(s) MSH2 c.2236_2238insAA p.Ile746fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.2459-?_2634+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MSH2 c.2502_2508delTAATTTC p.Ala834fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.2633_2634delAG p.Glu878fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH2 c.2634+5G>C Class 5 - Pathogenic Aberrant splicing: exon 15 skipping (out-of-frame) N/A MSH2 c.2680_2681insA p.Met894fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH6 c.10C>T p.Gln4X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH6 c.458-?_627+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A MSH6 c.467C>G p.Ser156X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH6 c.650_652insTT p.Asp217fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH6 c.1422GC>AT p.Gln475X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH6 c.1519_1520ins13 p.Arg507fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH6 c.3261_3262insC p.Phe1088fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH6 c.3439-2A>G Class 5 - Pathogenic Aberrant splicing: exon 6 skipping (out-of-frame) [235] MSH6 c.3528_3532delACTTG p.Arg1176fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH6 c.3725_3737del13 p.Arg1242fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH6 c.3866_3867insAATT p.Phe1289fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A MSH6 c.3939_3957del19 p.Ile1313fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A 
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Variant Classification Rationale For Classification Reference(s) PMS2 c.1-?_2589+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A PMS2 c.703-?_806+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A PMS2 c.736_741del6ins11 p.Pro246fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A PMS2 c.802_803insT p.Tyr268fs Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A PMS2 c.904-?_988+?del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A PMS2 c.989-296_1144+706del r.? p.? Class 5 - Pathogenic Large genomic deletion N/A PMS2 c.2402C>T p.Arg802X Class 5 - Pathogenic Sequence variation resulting in a stop codon N/A 
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Supp. Table S3. Australasian Colorectal Cancer Family Registry Variants selected for multifactorial and splicing analysis 
HGVS variant nomenclature 
Classification based on 5 class 
qualitative criteria (02/2010) Commentsa Evidence References MLH1 c.112A>C p.Asn38His Class 4 - Likely pathogenic MAF 0.00 (n=337, Australia); deficient MMR activity; MSI-H Deficient in in vitro MMR functional assay, plus MSI [1-6] MLH1 c.113A>G p.Asn38Ser Class 3 - Uncertain MAF 0.00 (n=180, Australia); MSI-H; MLH1 immunoloss & normal expression; no aberrant splicing Insufficient evidence to classify 
[7, 8] 
MLH1 c.198C>T Class 3 - Uncertain MAF 0.00 (n=180, Australia); no aberrant splicing Insufficient evidence to classify [7, 9-11] MLH1 c.230G>A p.Cys77Tyr Class 4 - Likely pathogenic Deficient MMR activity, reduced MLH1 expression and PMS2 interaction; MSI-H Deficient in in vitro MMR functional assay, protein expression and subunit interaction and MSI-H 
[3, 12-18] 
MLH1 c.303T>G Class 3 - Uncertain MAF 0.001 (n=416, global & Australia) Insufficient evidence to classify, variant reported in a normal population <1% 
[19]; This study 
MLH1 c.307-29C>A Class 2 - Likely not pathogenic MAF 0.004 (n=950, Denmark & Australia); no aberrant splicing Variant reported in a normal population <1% and no aberrant splicing [7, 20-22] MLH1 c.389A>G p.Tyr130Cys Class 3 - Uncertain MAF 0.00 (n=334, Australia) Insufficient evidence to classify This study MLH1 c.588+1G>T Class 4 - Likely pathogenic N/A Present in donor consensus splice dinucleotide [23] MLH1 c.678-1G>C Class 4 - Likely pathogenic N/A Present in acceptor consesus splice dinucleotide [24-27] MLH1 c.702G>A  Class 3 - Uncertain MAF 0.00 (n=484, Europe & Australia) Insufficient evidence to classify [19, 28-30]; This study 
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HGVS variant nomenclature 
Classification based on 5 class 
qualitative criteria (02/2010) Commentsa Evidence References MLH1 c.790+10A>G Class 2 - Likely not pathogenic MAF 0.005 (n=770, Denmark); ex vivo splicing assay weak exon 9 skipping, not concordant in patient RNA Variant reported in a normal population <1% and no aberrant splicing 
[20, 31, 32] 
MLH1 c.791-2A>G Class 4 - Likely pathogenic  Present in acceptor consesus splice dinucleotide [33] MLH1 c.884G>A p.Ser295Asn Class 3 - Uncertain Aberrant splicing predicted Insufficient evidence to classify [34] MLH1 c.1040C>A p.Thr347Asn Class 3 - Uncertain N/A Insufficient evidence to classify N/A MLH1 c.1321G>A p.Ala441Thr Class 3 - Uncertain MAF 0.00 (n=337, Australia); normal/intermediate MMR activity and intermediate MLH1 expression Insufficient evidence to classify 
[14, 17, 35-41] 
MLH1 c.1559-2A>T Class 4 - Likely pathogenic N/A Present in acceptor consensus splice dinucleotide [25-27] MLH1 c.2059C>T p.Arg687Trp Class 4 - Likely pathogenic MAF 0.00 (n=100, Spain); no aberrant splicing; reduced MMR activity and intermediate MLH1 expression; segregation with disease (not consistent); MLH1 immunoloss & normal expression; MSI-H Deficient in in vitro MMR functional assay, plus MSI 
[3, 7, 17, 18, 28, 37, 40, 42-53] 
MLH1 c.2146G>A p.Val716Met Class 2 - Likely not pathogenic MAF 0.003 (n=1343; UK & Australia); no aberrant splicing; proficient MMR activity, normal interaction with PMS2, intermediate MLH1 expression and subcellular localization Variant reported in a normal population <1% and no aberrant splicing 
 [3, 5, 14, 16-18, 22, 24, 28, 34, 36, 40, 47, 51, 52, 54-80]; This study MLH1 c.2153A>C p.His718Pro Class 3 - Uncertain N/a Insufficient evidence to classify N/A 
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HGVS variant nomenclature 
Classification based on 5 class 
qualitative criteria (02/2010) Commentsa Evidence References MSH2 c.6G>T  Class 3 - Uncertain MAF 0.00 (n=337, Australia) Insufficient evidence to classify This study MSH2 c.339G>A  Class 2 - Likely not pathogenic MAF 0.005 (n=463, Sweden & Australia); no aberrant splicing Variant reported in a normal population <1% and no aberrant splicing [10, 19, 21, 32, 81, 82]; This study MSH2 c.484G>A p.Gly162Arg Class 4 - Likely pathogenic Deficient MMR activity, reduced MSH2 expression and altered subcellular localization; MSH2 immunoloss; MSI-H Deficient in in vitro MMR functional assay, protein expression and subunit interaction and MSI-H 
[3, 16, 73, 83-86] 
MSH2 c.488T>G p.Val163Gly Class 3 - Uncertain MAF 0.00 (n=333, Australia) Insufficient evidence to classify [87]; This study MSH2 c.571_573delCTC p.Leu191del Class 3 - Uncertain MAF 0.00 (n=180, Australia); no aberrant splicing; MSH2 immunoloss and normal expression; MSI-H Insufficient evidence to classify 
[7] 
MSH2 c.645+1G>A Class 4 - Likely pathogenic N/A Present in donor consensus splice dinucleotide [1, 88] MSH2 c.913G>A p.Ala305Thr Class 3 - Uncertain MAF 0.00 (n=180, Australia); no aberrant splicing; proficient MMR activity, normal subcellular localization and interaction with MSH6/EXO1; MSS Insufficient evidence to classify 
[3, 7, 57, 89, 90] 
MSH2 c.1013G>A p.Gly338Glu Class 3 - Uncertain MAF 0.00 (n=337, Australia) Insufficient evidence to classify This study MSH2 c.1387-9T>A Class 3 - Uncertain MAF 0.00 (n=324, Australia) Insufficient evidence to classify This study 
MSH2 c.1662-9G>A Class 2 - Likely not pathogenic MAF 0.0073 (n=629, global); no aberrant splicing Variant reported in a normal population <1% and no aberrant splicing [19, 91] 
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HGVS variant nomenclature 
Classification based on 5 class 
qualitative criteria (02/2010) Commentsa Evidence References 
MSH2 c.1666T>C Class 2 - Likely not pathogenic MAF 0.0037 (n=629, global); no aberrant splicing  Variant reported in a normal population <1% and no aberrant splicing [11, 19, 32, 51, 81, 92-97] MSH2 c.2005+8dupA Class 3 - Uncertain No aberrant splicing Insufficient evidence to classify [51] MSH2 c.2006-36_2006-33dupTTAA Class 3 - Uncertain MSS Insufficient evidence to classify [98] MSH2 c.*129T>C Class 3 - Uncertain MAF 0.00 (n=289, Australia) Insufficient evidence to classify This study MSH2 c.*221G>T Class 3 - Uncertain MAF 0.00 (n=334, Australia) Insufficient evidence to classify This study MSH2 c.*226A>G Class 3 - Uncertain MAF 0.005 (n=420, global & Australia) Insufficient evidence to classify [19]; This study MSH6 c.1019T>C  p.Phe340Ser  Class 3 - Uncertain MAF 0.00 (n=458, Germany & Australia); MSI-H Insufficient evidence to classify [99] MSH6 c.1164C>T Class 3 - Uncertain MAF 0.00 (n=335, Australia); normal MSH6 expression Insufficient evidence to classify [80, 100, 101] MSH6 c.1186C>G p.Leu396Val Class 2 - Likely not pathogenic MAF 0.008 (n=725, USA, global, Europe & Australia); proficient MMR activity; normal MSH6 expression; MSI-L Proficient MMR activity, normal MSH6 expression and present in the normal population <1% 
[16, 19, 22, 53, 100, 102-106]; This study MSH6 c.1193T>A p.Val398Glu Class 3 - Uncertain MAF 0.00 (n=335, Australia) Insufficient evidence to classify This study MSH6 c.2057G>A p.Gly686Asp Class 3 - Uncertain MAF 0.00 (n=337, Australia); MSH6 immunoloss Insufficient evidence to classify, MSH6 immunoloss [107]; This study MSH6 c.2341C>T p.Pro781Ser Class 3 - Uncertain MAF 0.00 (n=336, Australia) Insufficient evidence to classify This study MSH6 c.3226C>T p.Arg1076Cys Class 3 - Uncertain Co-occurs with MSH6 mutation Insufficient evidence to classify [53, 108-110] MSH6 c.*24_28delGTTGA  Class 2 - Likely not pathogenic MAF 0.001 (n=334, Australia) Insufficient evidence to classify This study 
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aMAF - minor allele frequency in healthy controls; 337 Australian healthy controls were screened for variants using Sequenom MassArray (data not shown); Classification of variants in Arnold et al 2009 are based on the qualitative criteria, not classifications in the paper  
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Supp. Table S4. Estimated proportion of mutation carriers by MSI-status for population-based probands 
 
Probands with MMR Sequence data 
Proban
ds 
without 
MMR 
Sequenc
e data 
Total 
Proban
ds with 
MSI 
data     
Results from statistical 
analysis using 
estimated numbers of 
carriers and non-
carriers for all MSI-
tested cases 
Tu
m
ou
r 
M
SI
 C
at
eg
or
y 
 
n 
by
 M
SI
-s
ta
tu
s 
n 
Cl
as
s 
5 
Pa
th
og
en
ic
  b
y 
M
SI
 S
ta
tu
s 
%
 C
la
ss
 5
 P
at
ho
ge
ni
c 
by
 
M
SI
 s
ta
tu
s 
N
on
-c
ar
ri
er
s 
by
 M
SI
 
St
at
us
 
%
 N
on
-c
ar
ri
er
s 
by
 M
SI
 
st
at
us
 
Pr
op
or
ti
on
 (%
) C
la
ss
 5
 
Pa
th
og
en
ic
  w
it
hi
n 
M
SI
 
st
ra
tu
m
  
n 
by
 M
SI
-s
ta
tu
s 
n 
by
 M
SI
-s
ta
tu
s 
Es
ti
m
at
ed
 n
 C
la
ss
 5
 fo
r 
al
l M
SI
-t
es
te
d 
ca
se
s 
Es
ti
m
at
ed
 %
 C
la
ss
 5
 b
y 
M
SI
 s
ta
tu
s 
fo
r 
al
l M
SI
-
te
st
ed
 c
as
es
  
Es
ti
m
at
ed
 n
 N
on
-c
ar
ri
er
 
fo
r 
al
l M
SI
-t
es
te
d 
ca
se
s 
Es
ti
m
at
ed
 %
 N
on
-c
ar
ri
er
 
by
 M
SI
 s
ta
tu
s 
fo
r 
al
l M
SI
-
te
st
ed
 c
as
es
  
Χ
2 
  (
2x
2 
te
st
)  
P 
va
lu
e 
 
LR
 C
au
sa
lit
y 
 
MSS 304 1 1.15% 303 32.97% 1/304 (0.33%) 2666 304+2666  = 2970 0.33% x 2970  = 10 
10/137  = 7.30%  99.67% x 2970  = 2960 2960/3893  = 76.03% 322.55 <0.000001 0.1 
MSI-L  280 3 3.45% 277 30.14% 3/280 (1.07%) 160 280 + 160  = 440 1.07% x 440  = 5 5/137  = 3.65%  98.93% x 440  = 435 435/3893  = 11.17% 7.7 0.005511 0.33 
MSI-H 422 83 95.40% 339 36.89% 83/422 (19.67%) 198 422 + 198  = 620 19.67% x 620  = 122 
122/137  = 89.05%   80.33% x 620  = 498 
498/3893  = 12.8% 591.21 <0.000001 6.96 
Total 
n 
100
6 
8
7  919   3024 4030 137  3893       
 
 
 
Thompson et al., Human Mutation  34 
 
Supp. Table S5. Review of in vitro splicing assay results in the literature for intronic MMR variants Gene Variant In vitro splicing assay results References IVS±1,±2    MLH1 c.116+1G>A Aberrant splicing (IVSP) [1, 2] MLH1 c.306+1G>A Exon 3 skipping [3-5] MLH1 c.306+2dupT Exon 3 skipping & 5 bp deletion (out-of-frame) [6] MLH1 c.380+1G>A Exon 4 skipping (out-of-frame) [3] MLH1 c.381-2A>G 6 bp deletion [7] MLH1 c.454-2A>G Exon 6 skipping (out-of-frame) [8] MLH1 c.454-1G>A Exon 6 skipping (out-of-frame) [9-11] MLH1 c.545+1G>A Exon 6 skipping (out-of-frame) [3, 12] MLH1 c.546-2A>G Exon 7 skipping (out-of-frame) [5, 10, 13-15] MLH1 c.546-2A>C Exon 7 skipping (out-of-frame) [16] MLH1 c.588+1delG Exon 7 skipping (out-of-frame) [3] MLH1 c.589-2A>G Exon 8 skipping (out-of-frame) & 4 bp deletion(out-of-frame) [15, 17-20] MLH1 c.677+1G>A Exon 8 skipping (out-of-frame) [21] MLH1 c.677+1G>T Exon 8 skipping (out-of-frame) [10] MLH1 c.678-2A>G Exon 9 skipping (out-of-frame) German HNPCC consortium - [22] MLH1 c.678-1G>T Exon 9 skipping (out-of-frame) [5] MLH1 c.790+1G>A Exon 9/10 skipping [3, 8, 18] MLH1 c.790+1G>C Exon 9/10 skipping [23] MLH1 c.790+2dupT Exon 9 skipping (out-of-frame - Arnold et al) & exon 9/10 skipping [3, 17] MLH1 c.790+2T>C Exon 9/10 skipping [18] MLH1 c.1039-2A>G Exon 12 skipping (out-of-frame) [3] MLH1 c.1039-1G>A Exon 12 skipping (out-of-frame) [9] MLH1 c.1409+1G>C Exon 12 skipping (out-of-frame) [9, 14, 24] MLH1 c.1559-2A>C Exon 14 skipping (out-of-frame) [9] MLH1 c.1559-2A>G Exon 14/15 skipping (out-of-frame) [25] MLH1 c.1559-1G>T Exon 14 skipping (out-of-frame) [26] 
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Gene Variant In vitro splicing assay results References MLH1 c.1668-1G>A Exon 15 skipping (out-of-frame) [17] MLH1 c.1731+1G>A Exon 15 skipping (out-of-frame) [21, 27] MLH1 c.1732-2A>T Exon 16 skipping [27] MLH1 c.1732-1G>A Exon 16 skipping [3, 17] MLH1 c.1896+1G>A Exon 16 skipping [15] MLH1 c.1896+2T>C Exon 16 skipping [3] MLH1 c.1986_1989+1delTGAGGinsC Exon 17 skipping [6] MLH1 c.1989+1G>T Exon 17 skipping [3] MLH1 c.1989+1G>A Exon 17 skipping [3] MLH1 c.1990-1G>A Exon 18 skipping [17] MSH2 c.211+1G>C 17 bp deletion (out-of-frame) [28] MSH2 c.366+1G>T Exon 2 skipping (out-of-frame) [29] MSH2 c.367-1G>A 1 bp deletion (out-of-frame) [29] MSH2 c.645+1G>T Exon 3 skipping [14] MSH2 c.646-1G>A 27 bp intron 3 inclusion [30] MSH2 c.792+1G>A Exon 4 skipping [18] MSH2 c.793-2A>C Exon 5 skipping [8] MSH2 c.942+2delT Exon 5 skipping Berlin - [22] MSH2 c.1076+1G>A Exon 6 skipping (out-of-frame) [8, 31] MSH2 c.1077-1G>T 11 bp deletion (out-of-frame) [17] MSH2 c.1276+1G>A p.G410_E425del [3, 12] MSH2 c.1276+2T>A Exon 7 skipping (out-of-frame), r.1228_1276del48 [8] MSH2 c.1386+1G>A Exon 8 skipping (out-of-frame) [8] MSH2 c.1386+1G>C Exon 8 skipping (out-of-frame) [32] MSH2 c.2005+2del11 Exon 12 skipping (out-of-frame) [33] MSH2 c.2006-2A>G Exon 13 skipping (out-of-frame) [34] MSH2 c.2210+1G>A Exon 13 skipping (out-of-frame) [35] MSH2 c.2210+1G>C Exon 13 skipping (out-of-frame) [24] 
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Gene Variant In vitro splicing assay results References MSH2 c.2211-1G>T Exon 12-14 skipping (co-occurs with another variant, both contribute to aberrant splicing) [2] MSH2 c.2634+1G>A Exon 15 skipping (out-of-frame) [14] MSH2 c.2634+1G>T Exon 15 skipping (out-of-frame) [3] MSH6 c.3439-2A>G Exon 6 skipping (out-of-frame) [36] MSH6 c.3646_3646+3delGgta Aberrant splicing [37] Intronic Variants   MLH1 c.116+5G>C 227 bp intron 1 inclusion (out-of-frame) [17, 18, 38] MLH1 c.117-44_117-40del Wild-type [39] MLH1 c.117-11T>A Exon 2 skipping [40] MLH1 c.208-3C>G Exon 3 skipping [17] MLH1 c.306+3A>C Aberrant splicing [10] MLH1 c.306+4A>G Cryptic DS activation in exon 3 & exon 3 skipping [39] MLH1 c.306+5G>A 5 bp deletion (out-of-frame) [30, 41] MLH1 c.307-29C>A Wild-type [17] MLH1 c.307-19A>G Wild-type [39] MLH1 c.454-13A>G Aberrant splicing [10] MLH1 c.588+5G>A Partial exon 7 skipping (out-of-frame) & exon 7/8 skipping [6, 39, 42] MLH1 c.588+11G>C Wild-type [39] MLH1 c.589-10T>A 8 bp intron 7 inclusion (r.588_589ins5892-8_589-1) [29, 42] MLH1 c.589-5_589-8delTTTA Exon 8 skipping (out-of-frame) [32] MLH1 c.677+3A>G Exon 8 skipping (out-of-frame) [3, 12, 18, 43] MLH1 c.678-3delTA Exon 9 skipping (out-of-frame) [2] MLH1 c.790+3A>T Exon 9/10 skipping [44] MLH1 c.790+4A>T Partial exon 9 skipping & partial exon 9/10 skipping [45] MLH1 c.790+4A>G Partial exon 9 skipping & partial exon 9/10 skipping [3, 6] MLH1 c.790+5G>T Exon 9 skipping (out-of-frame) [39] MLH1 c.790+10A>G Wild-type [39] MLH1 c.791-23delG Wild-type [8] 
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Gene Variant In vitro splicing assay results References MLH1 c.791-5T>G Exon 10 skipping (out-of-frame) [8, 39] MLH1 c.884+4A>G Exon 10 skipping (out-of-frame) [39, 46] MLH1 c.885-24T>A Wild-type [39] MLH1 c.885-5G>T Wild-type [39] MLH1 c.1039-8T>A Wild-type [3, 17] MLH1 c.1039-7insA Wild-type [2] MLH1 c.1558+14G>A Wild-type [8, 24] MLH1 c.1668-19A>G Wild-type [8, 24, 26] MLH1 c.1731+3A>T Exon 15 skipping (out-of-frame) [47] MLH1 c.1731+5G>A Exon 15 skipping (out-of-frame) [28, 39] MLH1 c.1732-9T>C Wild-type [8] MLH1 c.1986_1989+1delTGAGGinsC Exon 17 skipping [6] MLH1 c.1989+3_4insC Exon 17 skipping [12] MLH1 c.1989+5G>C Exon 17 skipping [20, 48] MLH1 c.1990-16_-2del15 Exon 18 skipping [8, 31, 49] MLH1 c.1990-3C>G 83bp intron 17 inclusion (out-of-frame) [50] MLH1 c.2104-10_11delGTinsA Wild-type [10] MSH2 c.211+8C>G Wild-type [51] MSH2 c.211+9C>G Wild-type [24] MSH2 c.212-478T>G De novo exon intron 1, r.212-553_-479 (out-of-frame) [52, 53] MSH2 c.646-3T>G 24 bp intron 3 inclusion [54] MSH2 c.646-46delC Wild-type [38] MSH2 c.942+3A>T Exon 5 skipping [8, 17, 30, 49] MSH2 c.1077-10T>C Wild-type [39] MSH2 c.1277-14C>G Wild-type [6] MSH2 c.1387-8G>T Wild-type [39] MSH2 c.1661+6C>T Wild-type [2] MSH2 c.1661+5G>C Exon 10 skipping [14, 24] 
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Gene Variant In vitro splicing assay results References MSH2 c.1511-9A>T Wild-type [2, 24, 39] MSH2 c.1662-9G>A Wild-type [2] MSH2 c.2005+8dupA Wild-type [8] MSH2 c.1760-111_1760-109dupAGG Wild-type [39] MSH2 c.2006-6T>C Wild-type [39, 51] MSH2 c.2634+5G>C Exon 15 skipping (out-of-frame) [1, 18, 51, 55] MSH6 c.3439-16C>T Wild-type [41] MSH6 c.3556-3A>T Wild-type [55] MSH6 c.4002-31_4002-8delins24 Intron 8/9 retention & intron 9 retention [56] IVSP: in vitro splicing assay; DS: donor site; bp: basepair  
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Supp. Table S6. PCR primers and cycling conditions  
Variant Forward Sequence Reverse Sequence Product Size(bp) PCR cycling conditions MLH1 c.112A>C p.Asn38His 
ACGTTTCCTTGGCTCTTCTG GTCCTGGTAGCAAAGTCTGG 1,080 94°C for 2 min followed by 35 cycles of 94°C for 20 sec, 60°C for 30 sec and 72°C for 1 min, then a final elongation at 72°C for 7 min 
MLH1 c.303T>G MLH1 c.389A>G p.Tyr130Cys MLH1 c.588+1G>T MLH1 c.678-1G>C MLH1 c.702G>A MLH1 c.790+10A>G MLH1 c.791-1G>C MLH1 c.884G>A p.Ser295Asn MSH6 c.1019T>C  p.Phe340Ser ACTGAGAGCAATGCAACGTG GGTGTCAACCCAATGGAATC 1,503 MSH6 c.1164C>T MSH6 c.1186C>G p.Leu396Val MLH1 c.1559-2A>T TACTTCCAGCAACCCCAGAA CAATCAGGTTCCCTTCCTCA 520 94°C for 2 min followed by 35 cycles of 94°C for 20 sec, 58°C for 30 sec and 72°C for 1 min, then a final elongation at 72°C for 7 min 
MLH1 c.1569G>T p.Glu523Asp MSH2 c.1013G>A p.Gly338Glu CATGGGGAAACTGAGACAGATAAT CAATAATTTCTGGTGTTTTCCTTC 646 MSH2 c.1387-9T>A TTCATTTAAAGAAGTCAATTTGCTGT 1,057 MSH6 c.2057G>A p.Gly686Asp GATTCCATTGGGTTGACACC GGTATCTTCCGGCAACAGAA 1,267 MSH6 c.2341C>T p.Pro781Ser MSH6 c.3226C>T p.Arg1076Cys AACGGAGGGATGTATCATTGAA CACTAGCCAGGCAAACTTCC 954 MLH1 c.2146G>A p.Val716Met AGAGTGGCTGGACAGAGGAA GAACACATCCCACAGTGCAT 523 94°C for 2 min followed by 35 cycles of 94°C for 
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Variant Forward Sequence Reverse Sequence Product Size(bp) PCR cycling conditions MLH1 c.2153A>C p.His718Pro 20 sec, 61°C for 30 sec and 72°C for 30 sec, then a final elongation at 72°C for 7 min MSH2 c.484G>A p.Gly162Arg TTCAACCAGGAGGTGAGGAG CTGCAACCTGATTCTCCATTTC 827 MSH2 c.488T>G p.Val163Gly MSH2 c.645+1G>A   
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Supp. Table S7. Complete mismatch repair gene multifactorial likelihood analysis results 
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MLH1 c.112A>C p.Asn38His 14.29 1.000 0.750 
Normal protein expression (1) Negative (1) MSI-H (1) 11.78 1.722 20.28 1.000 wild-type Class 5 - Pathogenic1 N/A N/A MSI-H (8) 3.73E+08 1871.3 6.97E+11 MLH1 c.113A>G p.Asn38Ser 13.4 1.000 0.723 
PMS2 loss only (2), consistent with MLH1 mutation (1) 
Negative (1) MSI-H (3) 6.960 27.47 191.2 0.998 wild-type Class 5 - Pathogenic 
MLH1 c.116+5G>C N/A N/A 0.260 Consistent with MLH1 mutation (3) N/A MSI-H (3) 75.00 21.68 1625.9 0.998 intron inclusion Class 5 - Pathogenic MLH1 c.198C>Ta N/A N/A 0.100 PMS2 loss only (1) Negative (1) MSI-H (1) N/A 0.690 0.690 0.071 wild-type Class 3 - Uncertain 
MLH1 c.199G>A p.Gly67Arg 36.52 1.000 0.962  0.9 
Normal MLH1 expression (1), consistent with MLH1 mutation (4), heterogeneous PMS2 expression (1) 
Negative (4) MSI-H (6) 2210.3 2.148 4747.2 1.000 wild-type Class 5 - Pathogenic 
MLH1 c.230G>A p.Cys77Tyr 21.23 1.000 0.880 
PMS2 loss only (1), consistent with MLH1 mutation (1) 
Negative (1) MSI-H (1) 11.78 3.161 37.23 0.996 not tested Class 5 - Pathogenic 
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MLH1 c.303T>G N/A N/A 0.100 Normal protein expression (1) Negative (1) MSI-L (1) N/A 0.531 0.531 0.056 wild-type Class 3 - Uncertain MLH1 c.307-29C>Aa N/A N/A 0.260 Normal protein expression (10) 
Positive (1), Negative (2) 
MSI-L (1), MSS (9) 4.10E-12 4.08E-04 1.67E-15 5.88E-16 wild-type 
Class 1 - Not pathogenic MLH1 c.350C>T p.Thr117Met 22.93 0.988 0.893 
Consistent with MLH1 mutation (18); normal expression (1) 
Negative (11); Positive (2) 
MSI-H (14), MSI-L (1) 1.53E+11 1.04E+06 1.60E+17 1.000 wild-type 
Class 5 - Pathogenic MLH1 c.389A>G p.Tyr130Cysb 14.49 0.999 0.757 Consistent with MLH1 mutation (1) Negative (1) MSI-H (1) 1.360 1.1782 1.602 0.833 wild-type Class 3 - Uncertain MLH1 c.588+1G>T N/A N/A 0.960 Consistent with MLH1 mutation (5) Negative (1) MSI-H (3) 883.3 3.706 3273.4 1.000 exon skipping Class 5 - Pathogenic 
MLH1 c.589-2A>G N/A N/A 0.960 
Consistent with MLH1 mutation (3), normal protein expression (1) 
N/A MSI-H (3) N/A 25.11 25.11 0.998 4 bp exon deletion Class 5 - Pathogenic 
MLH1 c.678-1G>C N/A N/A 0.960 Consistent with MLH1 mutation (1) N/A MSI-H (1) N/A 1.671 1.671 0.976 2 bp exon deletion 
Class 4 - Likely pathogenic 
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MLH1 c.702G>Ac N/A N/A 0.100 Consistent with MSH6 mutation (1) N/A MSI-H (1) N/A 0.949 0.949 0.095 wild-type Class 3 - Uncertain MLH1 c.790+2dupT N/A N/A 0.960 Consistent with MLH1 mutation (2) N/A MSI-H (2) 6.960 312.8 2176.7 1.000 exon skipping Class 5 - Pathogenic 
MLH1 c.790+10A>Ga N/A N/A 0.260 
Consistent with MLH1 mutation (1), normal protein expression (4) 
Negative (1) 
MSI-H (1), MSI-L (1), MSS (2) 
0.010 N/A 0.010 1.41E-04 wild-type Class 1 - Not pathogenic2 N/A N/A MSS (1) 4.00E-04 N/A 4.00E-04 MLH1 c.791-1G>C N/A N/A 0.960 Consistent with MLH1 mutation (1) N/A MSI-H (1) 8.660 122.2 1057.8 1.000 exon skipping Class 5 - Pathogenic MLH1 c.884G>A p.Ser295Asn 14.09 0.975 0.723 Consistent with MLH1 mutation (1) Negative (1) MSI-H (1) 11.78 2.430 28.62 0.987 exon skipping Class 5 - Pathogenic MLH1 c.1040C>A p.Thr347Asn 2.46 0.513 0.0070.1 N/A N/A N/A N/A 1.61E-03 1.61E-03 1.79E-04 not tested 
Class 1 - Not pathogenic MLH1 c.1321G>A p.Ala441Thrb 7.83 0.001 0.0110.1 Consistent with MLH1 mutation (1) Negative (1) Msi-H (1) 1.360 0.577 0.784 0.080 not tested Class 3 - Uncertain 
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MLH1 c.1559-2A>T N/A N/A 0.960 Consistent with MLH1 mutation (3) Negative (1) MSI-H (3) 102.0 1.762 179.7 1.000 exon skipping Class 5 - Pathogenic 
MLH1 c.1852delAAinsGC p.Lys618Ala 23.13 0.998 0.899 
Normal protein expression (16), consistent with MSH2 mutation (1), consistent with MLH1 mutation (1), PMS2 loss only (1) 
Negative (8), Positive (1) 
MSI-H (2), MSI-L (5), MSS (11) 
2.78E-13 1.17E-01 3.26E-14 2.89E-13 wild-type Class 1 - Not pathogenic 
MLH1 c.1852_1854delAAG p.Lys618del N/A N/A 0.500 
Consistent with MLH1 mutation (6) Negative (4) MSI-H (6) 5624.3 579.9 3.26E+06 1.000 wild-type Class 5 - Pathogenic 
MLH1 c.1990-1G>A N/A N/A 0.96 Consistent with MLH1 mutation (1) N/A N/A N/A N/A N/A 0.999 exon skipping Class 5 - Pathogenic3 N/A N/A N/A N/A 28.44 28.44 MLH1 c.2059C>T p.Arg687Trp 11.91 0.772 0.429 N/A N/A 
MSI-H 1 (1) N/A 2.846 2.846 0.969 wild-type Class 4 - Likely pathogenic3,4 MSI-H (1) 8.660 4.769 41.30 
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MLH1 c.2146G>A p.Val716Meta 11.89 0.671 0.327 
Consistent with MLH1 mutation (2), normal protein expression (5) N/A 
MSI-H (3), MSI-L (2), MSS (1) 
7.500 0.775 5.809 4.12E-05 wild-type Class 1 - Not pathogenic2,5,6,7,8 N/A MSI-H (1), MSS (4) 4.16E-04 0.204 8.48E-05 MLH1 c.2153A>C p.His718Pro 29.70 0.964 0.9310.9 
Consistent with MLH1 mutation (1), MLH1/MSH2/PMS2 loss (2)  N/A N/A N/A 0.811 0.811 0.880 
wild-type Class 3 - Uncertain 
MSH2 c.6G>T N/A N/A 0.100 Normal protein expression (1) Negative (1) MSS (1) 0.100 0.696 0.070 0.008 not tested 
Class 2 - Likely not pathogenic 
MSH2 c.339G>Aa N/A N/A 0.100 
Consistent with MSH2 mutation (1), normal protein expression (9) 
Negative (5) 
MSI-H (3), MSI-L (4), MSS (3) 
0.004 0.119 4.75E-04 5.27E-05 wild-type Class 1 - Not pathogenic MSH2 c.484G>A p.Gly162Argd 36.52 0.999 0.9620.9 Consistent with MSH2 mutation (1) N/A MSI-H (1) 8.660 1.636 14.17 0.992 wild-type Class 5 - Pathogenic 
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MSH2 c.488T>G p.Val163Glye 8.650 0.936 0.421899562 
Normal protein expression (2), consistent with MSH2 mutation (3) 
Positive (1) MSI-H (3), MSS (2) 0.087 25.56 2.213 0.618 wild-type Class 3 - Uncertain 
MSH2 c.571_573delCTC p.Leu191del N/A N/A 0.500 
Normal protein expression (1), consistent with MSH2 mutation (1) 
Negative (1) MSI-H (1) 11.78 19.81 233.3 0.996 wild-type Class 5 - Pathogenic 
MSH2 c.645+1G>A N/A N/A 0.960 Consistent with MSH2 mutation (2) Negative (2) MSI-H (1) 11.78 7.870 92.70 1.000 154 bp exon deletion Class 5 - Pathogenic MSH2 c.913G>A p.Ala305Thr 33.24 0.898 0.929 0.9 Normal protein expression (1) Negative (1) MSI-L (1) N/A 0.520 0.520 0.824 wild-type Class 3 - Uncertain MSH2 c.942+3A>T N/A N/A 0.260 Consistent with MSH2 mutation (6) N/A MSI-H (6) N/A 20871.32 20871.32 1.000 exon skipping Class 5 - Pathogenic MSH2 c.1013G>A p.Gly338Glu 35.36 0.999 0.9590.9 Consistent with MSH2 mutation (1) Negative (1) MSI-H (1) 11.78 1.350 15.90 0.993 wild-type Class 5 - Pathogenic MSH2 c.1387-9T>A N/A N/A 0.260 Consistent with MSH2 mutation (2) N/A MSI-H (2) 75.00 1.682 126.1 0.978 intron inclusion 
Class 4 - Likely pathogenic 
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MSH2 c.1662-9G>A N/A N/A 0.26 N/A Negative (20), Positive (3) 
MSI-H (8), MSI-L (7), MSS (12) 
2.80414E-12 N/A 2.80414E-12 9.85E-13 wild-type Class 1 - Not Pathogenic 
MSH2 c.1666T>C N/A N/A 0.1 N/A Negative (1), Positive (2) 
MSI-H (4), MSI-L (2), MSS (3) 
5.8644E-06 N/A 5.8644E-06 6.52E-07 wild-type Class 1 - Not pathogenic MSH2 c.1865C>T p.Pro622Leu 26.92 1.000 0.9270.9 Consistent with MSH2 mutation (3) N/A MSI-H (2) 75.00 67134.69 75.00 0.999 wild-type Class 5 - Pathogenic MSH2 c.1906G>C p.Ala636Pro 10.4 0.196 0.0450.1 
Consistent with MSH2 mutation (1) Negative (1) MSI-H (1) 1.360 1.190 1.618 1.000 wild-type Class 5 - Pathogenic9,10 N/A N/A MSI-H (12) 2.42E+11 4.142 1.00E+12 MSH2 c.2005+8dupAa N/A N/A 0.260 Consistent with MSH2 mutation (1) Negative (1) MSI-H (1) 1.840 N/A 1.840 0.393 wild-type 
Class 2 - Likely not pathogenic MSH2 c.2006-36_2006-33dupTTAA N/A N/A 0.260 Normal protein expression (1) Negative (1) MSI-L (1) N/A 1.000 1.000 0.260 not tested Class 3 - Uncertain 
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MSH2 c.*129T>C N/A N/A 0.260 
Consistent with MLH1 mutation (2), normal protein expression (1) 
Negative (1), Positive (2) 
MSI-H (2), MSS (1) 0.003 0.793 0.002 7.72E-04 not tested 
Class 1 - Not pathogenic 
MSH2 c.*221G>Ta N/A N/A 0.260 Normal protein expression (1) Negative (1) MSS (1) 0.040 1.351 0.054 0.019 not tested 
Class 2 - Likely not pathogenic 
MSH2 c.*226A>Ga N/A N/A 0.260 
Consistent with MLH1 mutation (1), normal protein expression (2) 
Negative (1), Positive (2) 
MSI-H (1), MSI-L (2) 0.080 N/A 0.080 0.027 not tested 
Class 2 - Likely not pathogenic 
MSH6 c.1019T>C  p.Phe340Ser 3.500 0.017 0.002 0.1 Normal protein expression (1) Negative (1) MSS (1) 0.100 1.000 0.100 0.011 wild-type 
Class 2 - Likely not pathogenic 
MSH6 c.1164C>Td N/A N/A 0.100 
Consistent with MSH2 mutation (1), normal protein expression (1) 
N/A MSI-H (2) N/A 1.07E-04 1.07E-04 1.19E-05 wild-type Class 1 - Not pathogenic MSH6 c.1186C>G p.Leu396Vala 9.640 0.103 0.0260.1 Normal protein expression (4) Negative (2) MSI-L (1), MSS 0.100 0.520 0.052 0.006 wild-type Class 2 - Likely not pathogeni
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(1) c 
MSH6 c.1193T>A p.Val398Glu 29.83 0.901 0.9130.9 Consistent with MSH6 mutation (1) Negative (1) MSI-H (1) 11.78 1.523 17.93 0.994 not tested Class 5 - Pathogenic MSH6 c.2057G>A p.Gly686Asp 40.49 0.747 0.9160.9 Consistent with MSH6 mutation (1) Negative (1) MSI-H (1) 1.840 1.998 3.676 0.971 wild-type 
Class 4 - Likely pathogenic MSH6 c.2341C>T p.Pro781Serc 17.50 1.000 0.825950629 Consistent with MSH6 mutation (1) N/A MSI-H (1) N/A 1.040 1.040 0.831 wild-type Class 3 - Uncertain MSH6 c.3226C>T p.Arg1076Cyse 29.01 0.698 0.805 Consistent with MSH2 mutation (2) N/A MSI-H (2) N/A 1.113 1.113 0.821 wild-type Class 3 - Uncertain MSH6 c.*24_28delGTTGA N/A N/A 0.260 Normal protein expression (1) Positive (1) MSI-L (1) N/A 0.907 0.907 0.242 wild-type Class 3 - Uncertain  aCo-occurrence or co-observation of variant with a deleterious MMR gene mutation in some families; bco-occurrence of both variants in the proband (phase unknown); cco-observation of both variants in the proband; dco-observation of both variants in the proband; eco-observation of both variants in a single family; MSH2 c.484G>A p.Gly162Arg (in trans with MSH6 c.1164C>T), MSH2 c.488T>G p.Val163Gly (in trans with MSH6 c.3226 C>T p.Arg1076Cys) and MSH6 c.2341C>T p.Pro781Ser (in trans with MLH1 c.702G>A) were treated as the causative genotype based on immunohistochemistry results and segregation analysis. fused HumVar ("pph2 probability") output as a continuous variable for PolyPhen-2; gPrior probability of pathogenicity <0.1 and >0.9 were set at 0.1 and 0.9 respectively. The prior was derived using the following equation Logit(Pr)= -9.20 + 
2.27(M)	  +	  4.26(P),	  	  where	  Pr	  is	  the	  Prior	  probability,	  M	  is	  ln(MAPP	  score),	  and	  P	  is	  the	  “pph2	  probability”	  output	  by	  PolyPhen-2.1 (retrained without MMR gene data); Tumor likelihood ratio based on colorectal tumors only; bracketed numbers indicate the number of tumours fulfilling the cirteria for Lynch Syndrome; The Odds for Causality are calculated as the product of the individual statistically independent components (Tumor Characteristics LR 
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X Segregation LR). The Posterior Probability = Posterior Odds/(Posterior Odds + 1), where the Posterior Odds = Prior Probability X Odds for causality X (1/1-prior probability); hbased on the criteria in Plon et al 2008, additional data was extracted from peer-reviewed literature to achieve classification for six variants: 1 - Van Riel et al 2010, 2 - Pastrello et al 2011; 3 - Caldes et al 2002; 4 - Gallinger et al 2004; 5 - Genuardi et al 1998; 6 - Muller-Koch et al 2001; 7 - Kamory et al 2006; 8 - Barnetson et al 2008; 9 - Yuan et al 1999; 10 - Foulkes et al 2002; N/A - not applicable; MSI - microsatellite instability, see text for definitions of MSS, MSI-L and MSI-H. Note: Variants spanning 2 rows have data from the Colon CFR and from peer-reviewed publications (as noted), which have been combined to derive the tumor characteristics LR and segregation LR.   
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Supp. Table S8. In silico splicing analysis and in vitro splicing results 
Variant 
Proximal consensus site (distance to variant) 
Human Splicing Finder MaxEntScan NNsplice 
Summary 
Prediction† In vitro splicing result Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score     WT Variant   WT Variant   WT Variant       MLH1 c.112A>C p.Asn38His D (4 bp) 84.51 84.51 - 8.6 8.6 - 0.93 0.91 (-2%) - 3/3 predicted no aberration no aberration MLH1 c.230G>A p.Cys77Tyr A (22 bp) 80.69 80.69 - 8.11 8.11 - 0.67 0.67 - 3/3 predicted no aberration no aberration* 
MLH1 c.303T>G D (3 bp) 96.07 96.07 - 9.85 9.85 c.302 0.45 (105.6%) 1 0.98 (-2%) - 3/3 predicted no aberration no aberration MLH1 c.389A>G p.Tyr130Cys A (8 bp) 83.95 83.95 - 7.22 7.22 - 0.95 0.95 - 3/3 predicted no aberration no aberration 
MLH1 c.588+1G>T D (1 bp) 88.47 61.63 (-30.33
%) 
- 9.72 1.22 (-87.45%) - 0.97 0.00 (-100%) - 
3/3 
predicted 
interruption 
of intron-
exon 
junction 
exon 7 
deletion  
MLH1 c.678-1G>C A (1 bp) 81.96  53.01 (-35.32
%) 
c.680 
87.76 
(13.2
9%) 
4.78 -3.27 (-168.41%
) 
c.680 
5.93 
(195.
95%) 
0.88  0.00 (-100%) c.680 0.74 (74%
) 
3/3 
predicted 
interruption 
of intron-
exon 
junction; 3/3 
predicted 
creation of 
de novo 
2bp 
deletion 
start of 
exon 9 
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Variant 
Proximal consensus site (distance to variant) 
Human Splicing Finder MaxEntScan NNsplice 
Summary 
Prediction† In vitro splicing result Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score     WT Variant   WT Variant   WT Variant       
acceptor 
MLH1 c.702G>A A (24 bp) 81.96 81.96 c.705 74.17 (64%) 4.78 4.78 - 0.88 0.88 - 3/3 predicted no aberration no aberration 
MLH1 c.790+10A>G D (10 bp) 83.28 83.28 
c.790+5 69.88 (21.08%)  
10.43 10.43 c.790+5 2.06 (1816.67%) 0.96 0.96 - 3/3 predicted no aberration no aberration 
MLH1 c.791-1G>C A (1 bp) 80.8 51.85 (-35.83
%)  
- 9.42 1.36 (-85.56%) - 0.99 0.00 (-100%) - 
3/3 
predicted 
interruption 
of intron-
exon 
junction 
exon 10 
deletion 
MLH1 c.884G>A p.Ser295Asn D (0 bp) 85.75 75.17 (-12.34
%) 
- 9.43 2.09 (-77.84%) - 0.93 0.00 (-100%) - 
3/3 
predicted 
interruption 
of intron-
exon 
junction 
exon 10 
deletion 
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Variant 
Proximal consensus site (distance to variant) 
Human Splicing Finder MaxEntScan NNsplice 
Summary 
Prediction† In vitro splicing result Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score     WT Variant   WT Variant   WT Variant       MLH1 c.1040C>A p.Thr347Asn A (1 bp) 88.87 88.87 - 7.5 7.5 - 0.96 0.96 - 3/3 predicted no aberration not tested MLH1 c.1321G>A p.Ala441Thr D (88 bp) 89.26 89.26 c.1317 74.49 (12.61%) 9.99 9.99 
c.1317 0.42 (106.76%) 0.99 0.99 - 3/3 predicted no aberration not tested 
MLH1 c.1559-2A>T A (2bp) 90.3 61.35 (-32.06
%)  
- 10.44 2.07 (-80.17%) 
c.1566 2.12 (143.27%); c.1567 1.83 (135.88%) 
0.98 0.00 (-100%) - 
3/3 
predicted 
interruption 
of intron-
exon 
junction 
exon 14, 
exons 
14/15 
deletion 
MLH1 c.2146G>A p.Val716Met A (42 bp) 87.83 87.83 - 7.82 7.82 - 0.54 0.54 - 3/3 predicted no aberration no aberration MLH1 c.2153A>C p.His718Pro A (49 bp) 87.83 87.83 - 7.82 7.82 c.2168 1.38 (72.5%) 0.54 0.54 - 3/3 predicted no aberration no aberration MSH2 c.6G>T D (195 bp) 96.91 96.91 - 10.07 10.07 - 0.95 0.95 - 3/3 predicted no aberration not tested 
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Variant 
Proximal consensus site (distance to variant) 
Human Splicing Finder MaxEntScan NNsplice 
Summary 
Prediction† In vitro splicing result Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score     WT Variant   WT Variant   WT Variant       
MSH2 c.339G>A A (127 bp) D (27 bp) 
A: 87.5 D: 86.73 
A: 87.5 D: 86.73 
A: c.341 71.14 (68.61%) 
D: 8.83 D: 8.83 - D: 1 D: 1 - 3/3 predicted no aberration no aberration** 
MSH2 c.484G>A p.Gly162Arg A (117 bp) D (161 bp) 
A: 82.12; D: 97.83 
A: 82.12; D: 97.83 
D: c.480 92.64 (9.89%) 
A: 6.25 D: 9.88 A: 6.25 D: 9.88 
D: c.480 5.94  (6.26%)   
A: 0.98 D: 1 A: 0.98 D: 1 
D: c.480 0.83 (83%) 3/3 predicted no aberration no aberration 
MSH2 c.645+1G>A D (1 bp) 97.83 70.99 (-27.43
%)  
- 9.88 1.7 (-82.79%) - 1 0.00 (-100%) - 
3/3 
predicted 
interruption 
of intron-
exon 
junction 
154bp 
deletion 
end of 
exon 3, 
exon 3 
deletion MSH2 c.1013G>A p.Gly338Glu D (63 bp) 89.44 89.44 - 9.81 9.81 - 0.98 0.98 - 3/3 predicted no aberration no aberration 
MSH2 c.1387-9T>A A (9 bp) 95.06 91.84 (-3.39%) 
c.1387-7 84.65 (51.96%)  
11.59 4.21 (-63.68%) 
c.138
7-7 
5.69 
(313.
1%) 
0.98 0.89 (-9%) - 
1/3 
predicted 
interruption 
of intron-
exon 
junction; 1/3 
predicted 
7bp 
inclusion 
of intron 8 
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Variant 
Proximal consensus site (distance to variant) 
Human Splicing Finder MaxEntScan NNsplice 
Summary 
Prediction† In vitro splicing result Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score     WT Variant   WT Variant   WT Variant       
creation of 
de novo 
acceptor 
MSH2 c.2005+8dupA D (8 bp) 80.75 80.75 - 4.78 4.78 - 0.86 0.86 - 3/3 predicted no aberration no aberration*** MSH2 c.2006-36_2006-33dupTTAA A (36 bp) 86.07 86.07 - 8.23 8.23 - 0.95 0.95 - 3/3 predicted no aberration not tested MSH6 c.1019T>C p.Phe340Ser A (391 bp) 90.75 90.75 - 10.87 10.87 - 0.92 0.92 - 3/3 predicted no aberration no aberration MSH6 c.1164C>T A (536 bp) 90.75 90.75 - 10.87 10.87 - 0.92 0.92 - 3/3 predicted no aberration no aberration MSH6 c.1186C>G p.Leu396Val A (558 bp) 90.75 90.75 c.1187 83.67 (52.9%) 10.87 10.87 
c.1187 3.85 (191.67%) 0.92 0.92 - 3/3 predicted no aberration no aberration MSH6 c.1193T>A p.Val398Glu A (565 bp) 90.75 90.75 c.1195 69.64 (71.13%) 10.87 10.87 - 0.92 0.92 - 3/3 predicted no aberration not tested MSH6 c.2057G>A p.Gly686Asp D (1115 bp) 90.83 90.83 c.2053 84.54 (10.94%)  8.91 8.91 
c.2053 4.02 (536.96%) 0.86 0.86 
c.2053 0.74 (74%) 3/3 predicted no aberration no aberration 
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Variant 
Proximal consensus site (distance to variant) 
Human Splicing Finder MaxEntScan NNsplice 
Summary 
Prediction† In vitro splicing result Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score Consensus splice site 
De 
novo splice site location & score     WT Variant   WT Variant   WT Variant       MSH6 c.2341C>T p.Pro781Ser D (831 bp) 90.83 90.83 - 8.91 8.91 - 0.86 0.86 - 3/3 predicted no aberration no aberration  Bracketed percentages refer to the variation between the variant score and the wild type sequence as a proportion of the wild type score. WT – wild type; A – acceptor; D – donor; * – in vitro splicing results from Betz et al. 2010; ** – in vitro splicing results from Tournier et al. 2008; *** – in vitro splicing results from Auclair et al. 2006; †  – based on post-hoc	  assumptions	  as	  follows:	  a)	  variation	  in	  scores	  ≤	  -5% for HSF, -15% for MaxEntScan and -10% for NNSplice were interpreted as a loss of site; b) a de novo splice site score greater than the WT consensus splice site score (use variant consensus splice site score if WT site is interrupted) was interpreted as a creation of a de novo acceptor or donor.  
References                       Auclair, J., M. P. Busine, et al. (2006). "Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing." Hum Mutat 27(2): 145-154. Betz, B., S. Theiss, et al. (2010). "Comparative in silico analyses and experimental validation of novel splice site and missense mutations in the genes MLH1 and MSH2." J Cancer Res Clin Oncol 136(1): 123-134. Tournier, I., M. Vezain, et al. (2008). "A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects." Hum Mutat.       
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Presented in this publication are the first standardized MMR gene sequence variant classification 
criteria, and their application to >2,000 unique sequence variants submitted to the public InSiGHT 
MMR genes databases. Microattribution was also implemented to promote and acknowledge the 
submission of unpublished data. We have made all the classifications of the sequence variants 
public; thus this information is immediately translational to the clinics where suspected Lynch 
syndrome cases are managed. Incorporated in this analysis was the application of the multifactorial 
likelihood model that was described in Chapter 3, to 269 MLH1, MSH2, MSH6, and PMS2 
sequence variants. Supplementary Tables 1 and 8, initially published as excel spreadsheets, are 
included after the supplementary information in this chapter. 
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The clinical classification of hereditary sequence variants 
identified in disease-related genes directly affects clinical 
management of patients and their relatives. The International 
Society for Gastrointestinal Hereditary Tumours (InSiGHT) 
undertook a collaborative effort to develop, test and apply a 
standardized classification scheme to constitutional variants 
in the Lynch syndrome–associated genes MLH1, MSH2, MSH6 
and PMS2. Unpublished data submission was encouraged to 
assist in variant classification and was recognized through 
microattribution. The scheme was refined by multidisciplinary 
expert committee review of the clinical and functional data 
available for variants, applied to 2,360 sequence alterations, 
and disseminated online. Assessment using validated criteria 
altered classifications for 66% of 12,006 database entries. 
Clinical recommendations based on transparent evaluation 
are now possible for 1,370 variants that were not obviously 
protein truncating from nomenclature. This large-scale 
endeavor will facilitate the consistent management of families 
suspected to have Lynch syndrome and demonstrates the 
value of multidisciplinary collaboration in the curation and 
classification of variants in public locus-specific databases.
Identification of a high-risk disease-causing constitutional mutation 
in a cancer patient guides the clinical management of their whole 
family, with implications for counseling, cancer treatment options and 
presymptomatic surveillance, and considerations of risk-reducing sur-
gery and/or medication regimens1. Carriers of mutations in the mis-
match repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 causing 
Lynch syndrome1 have a substantially increased risk of colorectal and 
endometrial cancers, along with increased risk of ovarian, gastric, 
small bowel, urothelial, brain, hepatobiliary, pancreatic, bladder, 
kidney, prostate and breast cancers1–8. However, intensive manage-
ment reduces mortality9.
Sequence variants of uncertain functional and clinical relevance 
are common in genetic test reports. Although several lines of evi-
dence can be evaluated to assess the clinical implications of these 
variants, usually none of these approaches can be used on its own to 
obtain clinically useful interpretations and, for many variants, com-
prehensive data are lacking. Laboratories are generally conservative in 
designating pathogenic variants, defining variants as being of ‘uncer-
tain significance’ unless overwhelming evidence of pathogenicity 
exists. Several schemes for the classification of variants in genes 
associated with mendelian conditions have been proposed for use 
in the clinical setting. Because clinically useful actions are currently 
only considered for high-penetrance mutations, all of these systems 
are aimed at differentiating high-penetrance from low-penetrance 
and neutral variants and do not consider variants of intermedi-
ate risk. These schemes differ in the range and format of data used 
for classification and in the number of variant classes10–12. The 
International Agency for Research on Cancer (IARC) classification 
system, endorsed by the Human Variome Project (HVP), facilitates 
standardized categorization by defining classes that can be linked 
to validated quantitative measures of causality and/or pathogenicity 
from statistical models13–16 or to validated interpretation of qualita-
tive data17. Importantly, only the five-class IARC system has been 
linked to clinical recommendations for all classes, including clinical 
testing and full high-risk surveillance guidelines for class 5 (patho-
genic) and class 4 (likely pathogenic) variants; advice to treat as if 
“no mutation associated with disease has been detected” for class 1 
(not pathogenic) and class 2 (likely not pathogenic) variants; and 
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acquisition of additional data to provide more robust classification for 
class 2 (likely not pathogenic), class 3 (uncertain) and class 4 (likely 
pathogenic) variants.
Locus-specific databases (LSDBs) are an important source of infor-
mation for clinicians and researchers in assessing data and form-
ing opinions on the clinical relevance of disease-associated gene 
sequence variants, and these databases have a fundamental role in 
variant classification owing to their added value from having aggre-
gated data. Consistent and normalized data curation is critical to the 
value derived from databases in categorizing the relationship between 
genetic variation and disease—especially for clinical applications. 
It has previously been recommended by the IARC Working Group 
that a panel covering a range of expertise in variant classification 
provide consensus opinion on variant pathogenicity before publicly 
accessible display of such information18. Another important compo-
nent of the classifications provided by LSDBs is transparency regard-
ing the criteria and supporting information used for classification, 
which allows LSDB users to consider the information for their own 
applications in research or clinical settings18.
InSiGHT has merged multiple gene mutation and variant repositor-
ies to create the InSiGHT Colon Cancer Gene Variant Database for 
MMR and other colon cancer susceptibility genes19–23, hosted by the 
Leiden Open Variation Database (LOVD). Following recommenda-
tions for LSDB curation18, InSiGHT formed an international panel 
of researchers and clinicians to review MMR gene variants submitted 
to the database. To encourage the submission of unpublished clinical 
and research data to further facilitate variant classification, the micro-
attribution approach24 was implemented using Open Researcher and 
Contributor Identification (ORCID). Here we present the results 
of the InSiGHT Variant Interpretation Committee (VIC) effort to 
develop, test and apply a 5-tiered scheme to classify 2,360 unique 
constitutional MMR gene variants.
RESULTS
Curation of MMR gene variants
As of the end of December 2012, after 3,458 alterations to stand-
ardize nomenclature had been made, there were 12,635 submissions 
of 2,730 unique MMR gene variants lodged in the InSiGHT data-
base. Furthermore, 370 unique variants (13.6%) were not identified 
in constitutional (germline) DNA (see Supplementary Fig. 1 and 
Supplementary Table 1 for details) and were excluded from fur-
ther analyses because (i) no evidence existed that these occurred 
as constitutional variants and (ii) no clinical information was avail-
able to assess their potential roles in hereditary disease. The 2,360 
constitutional variants included 932 MLH1 (39%), 842 MSH2 
(36%), 449 MSH6 (19%) and 137 PMS2 (6%) variants. Most variants 
(800; 34%) were nonsense or frameshift changes predicted to cause 
protein truncation, with the next largest group (746; 32%) consist-
ing of nonsynonymous variants that were not obviously truncating, 
including missense substitutions, small in-frame insertion-deletion 
mutations (indels) and read-through alterations of the translation 
termination codon.
Variants had originally been assigned a classification by submit-
ters according to the following classes: pathogenic, probably patho-
genic, no known pathogenicity, probably no pathogenicity or effect 
unknown. No information was recorded to document the rationale 
for classification or the standards used to classify variants. When con-
sidering the 1,382 constitutional variants with multiple entries in the 
InSiGHT database, discordance in classification between submitters 
was found for 869 variants. Some of this discordance arose because 
of classification based on single data points or references, such as 
results from a single functional assay22 or inferences from individual 
publications originally lodged in the Mismatch Repair Genes Variant 
Database23 (see the example in Supplementary Table 2).
Development of a five-tiered system for classification
The InSiGHT VIC (Online Methods) was established in 2007 to 
address discrepancies in the classification of MMR gene variants 
lodged in the InSiGHT database. Since March 2011, the VIC has made 
a concerted effort to develop standardized criteria for variant classifi-
cation, employing a modified Delphi consensus process25 to evaluate 
current scientific evidence and reach consensus. In line with HVP26, 
the IARC classification system10 for variant categorization (Table 1) 
was adopted by InSiGHT for the classification of MMR gene variants. 
Briefly, multiple lines of evidence were required for classification, and 
evidence for each variant had to include data associating the variant 
with both clinical and functional consequences (Online Methods).
The scheme was first tested on a subset of 117 MMR gene variants, 
and the criteria evolved and were refined by consensus to accommo-
date new data and inconsistencies over multiple classification telecon-
ferences and face-to-face meetings. Final criteria were then applied 
retrospectively and to all remaining unique variants listed in the data-
base (Supplementary Table 3). An overview of the InSiGHT clas-
sification criteria is shown in Figure 1 (see Supplementary Table 4  
and the Supplementary Note for detailed criteria and justifications). 
At the close of each VIC teleconference or meeting, consensus clas-
sifications were noted. Where necessary, action items to improve or 
clarify classification included (i) calls for missing clinical and func-
tional information for specific variants to committee members and 
the general InSiGHT membership; (ii) requests for more detailed data 
or data clarification from the authors of original publications; and 
(iii) reassessment of classification after additional data were obtained. 
At the end of the process, the InSiGHT database was updated with the 
Table 1 InSiGHT variant classification scheme with accompanying 
recommendations for family management, adapted from the IARC 
five-tiered classification system
InSiGHT MMR gene 
variant class definition 
for Lynch syndromea
Predictive  
testing of  
at-risk relatives
Surveillance for at-risk 
relatives
Research  
testing of  
relatives
5 (pathogenic) Yes Full high-risk guidelines Not indicated
4 (likely pathogenic) Yesb Full high-risk guidelines Yes
3 (uncertain) Nob Family history and other 
risk factors
Yes
2 (likely not  
pathogenic)
Nob Family history and other 
risk factors; treated as  
having no mutation  
detected in this gene  
for this disorder
Yes
1 (not pathogenic) Nob Family history and other 
risk factors; treated as  
having no mutation  
detected in this gene  
for this disorder
Not indicated
Adapted from Plon et al.10. Full high-risk surveillance guidelines for cancers in the 
Lynch syndrome spectrum are outlined in Vasen et al.1. Research testing entails 
cascade testing for the variant in affected and unaffected family members to facilitate 
segregation analysis and is indicated for variants in classes 2–4 to refine classification. 
Consent from subjects through a protocol approved by a human subjects committee 
should be obtained.
aClass definition is described in detail in Supplementary Table 4, and the Supplementary Note 
and is based on quantitative evidence defined by multifactorial likelihood posterior probability 
(with cutoffs of >0.99 for class 5, 0.95–0.99 for class 4, 0.05–0.949 for class 3,  
0.001–0.049 for class 2 and <0.001 for class 1) or combined qualitative evidence  
determined by consensus opinion, as defined by the InSiGHT VIC. Pathogenic variants are 
defined as being clinically relevant in a genetic counseling setting, such that germline variant  
status will be used to inform patient and family management. bContinued testing of the 
proband is recommended for any additional available testing modalities available, for example, 
rearrangements (Online Methods).
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final consensus classifications and the sup-
porting data to ensure transparency.
The major issues faced by the commit-
tee in the review process included redun-
dancy across multiple sources (resolved through discussion with the 
authors of original publications), paucity of information, incomplete 
or inaccurate data and difficulties in the interpretation of the results 
of functional assays. To facilitate the interpretation of findings from 
functional assays, supporting information and flowcharts were 
developed (Fig. 1b and Supplementary Tables 5 and 6), and multi-
ple meetings were coordinated that were dedicated to the review of 
variants with apparently discordant results from functional assays 
(Supplementary Table 3).
Validation of the InSiGHT qualitative classification criteria
Nonsense or frameshift alterations or large genomic deletions inter-
rupting functionally important domains are generally considered 
pathogenic on the basis of DNA sequence alone; these variants were 
designated here as class 5a (assumed pathogenic). There were 990 
assumed pathogenic variants in the database, 640 of which were private 
mutations. To demonstrate the robustness of the qualitative classifica-
tion criteria, 170 assumed pathogenic variants (68 MLH1, 75 MSH2, 
13 MSH6 and 14 PMS2) were reviewed as a validation set against the 
class 5 (pathogenic) qualitative criteria required for the assignment 
of variants to class 5b (Online Methods and Supplementary Table 7). 
Designation of a variant as class 5b required evidence of abrogated 
protein function, at least two tumors with microsatellite instability 
(MSI) or appropriate loss of MMR protein expression and a segrega-
tion likelihood ratio of >10:1 (incorporating gene-specific cumulative 
risks27) or variant cosegregation with disease reported in at least two 
Amsterdam criteria–positive families. Class 5b was attained by all 
60 validation set variants that had sufficient clinical data to assess 
these required criteria. The other 110 validation set variants could 
not be assigned to class 5b, largely because family cosegregation 
and tumor data were scarce or unobtainable—presumably because 
these variants are accepted as disease causing and are routinely used 
for clinical presymptomatic testing in families (Online Methods). 
Of these variants, 72 were assigned to class 4 owing to lack of only 
1 point of evidence, and 38 variants were assigned to class 3 owing 
to insufficient data. However, only 2 of 13 MSH6 and 2 of 14 PMS2 
variants fulfilled class 5b criteria, reflecting the lower penetrance and 
later age of onset associated with deleterious variants in PMS2 (ref. 28) 
b
a
or
PP < 0.001
or
or
2 points of evidence
if proficient function,
otherwise 3 points of
evidence:
3 points of evidence
if proficient function,
otherwise 4 points of
evidence:
Proficient function
or co-occurrence
with no CMMRD
Proficient function
or co-occurrence
with no CMMRD
AF = 0.01–1%
AF = 0.01–1%
≥3 MSS CRC or
inconsistent IHC
tumors
≥3 MSS CRC or
inconsistent IHC
tumors
Odds ratio with
upper 95% CI < 4 in
case-control studies
Odds ratio with
upper 95% CI < 4 in
case-control studies
PP = 0.001–0.049
AF ≥ 1% in specific
ancestry group
AF ≥ 1% in control
reference groupsor
Synonymous or
intronic variant with
no mRNA aberration
or
Class 2
(likely not pathogenic)
Class 1
(not pathogenic)
PP = 0.05–0.949
or
Insufficient evidence
to classify
Class 3
(uncertain)
Canonical splice
site,untested for
splicing
or
PP = 0.95–0.99
or
2 points of evidence:
Abrogated function
or CMMRD or
different background
haplotypes
Class 4 
(likely pathogenic)
or
4 points evidence:
Co segregation with
disease(LR of 10:1)
Co segregation with
disease(LR of 5:1)
or
≥2 tumors with LS
molecular
phenotype
No co segregation
with disease
(LR of 0.01:1)
No co segregation
with disease
(LR of 0.01:1)
Abrogated function
or CMMRD or
different background
haplotypes
≥2 tumors with LS
molecular
phenotype
Absence in 1000
Genomes Project
PP > 0.99
Class 5
(pathogenic)
Nonsense/frameshift
or
Large deletion
or
Large duplication
confirmed to encode
a frameshift leading
to NMD
or
Full inactivation of
variant allele by
splicing aberration
or
MMR sequence
variant
Gene transcript assays:
optimally performed before protein assays, to
identify latent RNA or regulatory aberrations
Protein expression/stability: quantitative protein blot
in 2 independent assays
MMR activity (mammalian) assays: MMR complementation
assays from 2 independent laboratories
RNA aberration (i.e., splicing defect)
Yes
Intronic, UTR or
synonymous variant
No
Regulatory aberration (i.e., defective
transcription) or NMD/RNA aberration
(i.e., splicing defect)
Inconclusive
Further research
calibrating against
clinical data
Inconclusive
Partial
Subcellular localization and cellular-based
MMR activity in 2 independent assays
Demonstration of similar
repair levels to wild-type or
neutral controls
No
In-frame indel or
missense variant
≤25% relative expression
or similar to deficient cell
line control
≤75% relative
expression or similar to
wild-type control
Yes
Demonstration of similar repair
levels to deficient cell line or
pathogenic controls
Abrogated protein
function
Cytoplasmic, tolerant to
DNA damage or high
mutator phenotype
Nuclear, senstive to
DNA damage and no
mutator phenotype
Proficient protein
function
Figure 1 Overview of the five-tiered InSiGHT 
classification guidelines. (a) Simplified 
guidelines describing the levels and types 
of evidence required for each tier of the 
classification. Full guidelines are described 
in the Supplementary Note, and the detailed 
rationale behind each criterion is provided in 
Supplementary Table 3. The Lynch syndrome 
molecular phenotype described in classes 4 and 
5 includes information on MSI and/or loss of 
expression of relevant protein(s), as determined 
by immunohistochemistry. In this study, variants 
resulting in the introduction of a premature 
termination codon or large genomic deletions 
affecting functionally important domains, 
generally considered pathogenic on the basis 
of DNA sequence alone, are referred to as class 
5a (assumed pathogenic) variants. All other 
variants categorized in class 5 are termed class 
5b variants. (b) Flowchart used to assist in the 
interpretation of available data from functional 
assays. Assays reviewed for classification are 
shown in Supplementary Table 4, and the values 
used to define abrogated or normal function  
are shown in Supplementary Table 5. Cutoffs  
of <25% and >75% protein expression, as 
used in previous publications47,48, are very 
conservative given that abrogated function has 
been reported to be associated with a decrease  
in MLH1 expression of ~50% or more49.  
For variants that had normal, inconclusive or 
intermediate MMR activity in two independent 
assays but were deficient in protein function 
in two independent assays, abrogated function 
was assigned. AF, allele frequency; PP, 
posterior probability of pathogenicity derived 
by multifactorial likelihood analysis; CMMRD, 
constitutional MMR deficiency (MIM 276300); 
LR, likelihood ratio; LS, Lynch syndrome; MSS, 
microsatellite stable; CRC, colorectal cancer; 
IHC, immunohistochemistry; NMD, nonsense-
mediated decay.
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and MSH6 (ref. 29). Together, these results indicate that the criteria 
for classification using qualitative data were sufficiently stringent to 
ensure conservative classification.
Classification of 2,360 constitutional MMR gene variants
Of the 12,006 eligible variant entries in the InSIGHT database, sub-
mitter and final classifications differed for 7,935 (66%), including 
changes from class 1 (not pathogenic) to class 5 (pathogenic) and vice 
versa (Fig. 2a). The overall breakdown of final classifications is shown 
in Figure 2b. In addition to the 990 assumed pathogenic truncating 
or large-deletion variants (class 5a), consistent medical management 
is now also possible for the remaining 1,370 not obviously truncating 
variants; these include 167 class 5 (pathogenic) variants (class 5b) 
(12%), 183 class 4 (likely pathogenic) variants (14%), 86 class 2 
(likely not pathogenic) variants (6%) and 169 class 1 (not pathogenic) 
variants (12%).
Nonsynonymous variants made up the majority of class 3 variants 
(524/765; 68%) and newly assigned class 5b variants (91/167; 54%) (Fig. 3 
and Supplementary Fig. 2; see Supplementary Table 8 for detailed 
information supporting classifications). Substitutions at canonical 
dinucleotide splice sites fell predominantly in class 4 owing to lack 
of functional RNA analyses; however, if experimentally tested, these 
variants would likely be moved to class 5b. Intronic variants outside of 
conserved splice sites were the most prevalent variant type in class 1.
Final categorization (Online Methods) of not obviously truncat-
ing variants as class 1, 2, 4 or 5 was achieved by applying qualitative 
criteria for 391 variants, quantitative multifactorial likelihood analysis 
methodology (based on bioinformatic prior probabilities and evi-
dence from segregation and/or tumor data; see Thompson et al.16) 
for 192 variants and either quantitative or qualitative criteria for 26 
variants. Where classifications derived using quantitative criteria dif-
fered from those generated with qualitative criteria, this difference 
reflected the amount of data available rather than deficiencies in the 
classification criteria, with no variants considered to fall into class 1 or 
2 using one approach and class 4 or 5 using the other. Six synonymous 
variants were categorized in class 5b owing to their effects on splicing. 
Of the substitutions occurring in initiation codons (often assumed 
to be pathogenic30–32), only one of nine had sufficient evidence to 
determine pathogenicity.
Implementing microattribution
Microattribution is a means to incentivize the placement of unpub-
lished data in the public domain by assigning scholarly contribution 
to authors similar to the citation conventions afforded to journal 
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Figure 2 Outcome of standardized five-tiered InSiGHT classification of 
constitutional MMR gene variants. (a) The graph plots the proportion of 
five-tiered classifications for all documented constitutional variants in the 
database against the original LOVD database classifications assigned by 
submitters. Class 5a is a subset of class 5 containing assumed pathogenic 
nonsense mutations, small frameshift indels and large deletions. Class 5b 
includes variants that are not obviously truncating but are considered to 
be pathogenic on the basis of combined evidence (Supplementary Note). 
Results show that standardized classification led to altered classifications 
for a considerable proportion of variant entries, including the downgrading 
of variants submitted as pathogenic (24%) and the upgrading of variants 
with unknown pathogenicity to likely pathogenic (5.6%) or pathogenic 
(48%). In addition, clinically important misclassifications were identified 
for unique variants initially submitted as not pathogenic (54 unique 
variants reclassified as class 5b variants and 25 reclassified as class 
4 variants) and unique variants submitted as pathogenic (28 unique 
variants reclassified as class 1 variants, 16 reclassified as class 2 variants 
and 218 reclassified as class 3 variants). (b) Pie chart showing the 
distribution of final InSiGHT VIC consensus classifications.
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Figure 3 Classifications of all documented unique variants by variant 
type. The plot represents the proportion of the different variant types 
within the five classes. Class 5a is a subset of class 5 containing assumed 
pathogenic mutations (nonsense mutations, small frameshift indels and 
large deletions). All other variants placed in class 5 are termed class 5b 
variants (Supplementary Note). The different variant types include the 
following: ATG/UTR, variants in the initiation codon and the 5` or 3` UTR; 
I, intronic variants outside of the canonical splice-site dinucleotides; 
S, synonymous variants; NS, not obviously truncating nonsynonymous 
variants outside of the Kozak consensus sequence, i.e., missense, small 
in-frame indel and read-through translation termination codon alterations; 
SS, variants in the canonical splice-site dinucleotides; LGDup, large 
genomic duplications; LGDel, large genomic deletions or disrupting 
inversions; PTC, variants that introduce premature termination codons, 
i.e., nonsense mutations and small frameshift indels. See Supplementary 
Figure 2 for further details of variant types by MMR gene.
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articles33. Retrospective and prospective microattribution was imple-
mented to acknowledge and encourage the submission of unpublished 
data to the InSiGHT database, including the submission of additional 
detailed clinical information from authors of published reports. 
Microattribution was assigned for initial variant submission, segre-
gation and family history data, pathology diagnostics (MSI analysis 
and immunohistochemistry) information, data from in vitro func-
tional assays (mainly RNA splicing) and the determination of variant 
frequencies in normal individuals. As of July 2013, a total of 6,015 
microattributions were conferred, including 3,763 for variant sub-
mission, 2,111 for family and tumor pathology data, 97 for data from 
in vitro assays and 25 for frequency data. Notably, 19% of the micro-
attributions for clinical and functional data contributed additional 
information critical for the classification of variants in the class 5a 
(assumed pathogenic) validation subset. These data also highlighted 
the fact that clinical testing for these assumed pathogenic variants is 
mostly undertaken in the presymptomatic setting. The contribution of 
microattribution to the final classification of not obviously truncating 
variants is shown in Figure 4. Notably, classification was altered for 
57 of 169 (34%) variants for which unpublished data were obtained. 
Moreover, implementation of microattribution stimulated the submis-
sion of 128 new MMR gene variants yet to be classified.
Class 3 variants of uncertain relevance
Missense variants in MMR genes are abundant among class 3 
(uncertain) variants and present a considerable clinical problem. 
Quantitative multifactorial likelihood analysis is an effective approach 
for the classification of missense variants, as validated bioinformatic 
predictions34 based on amino acid conservation and physicochemical 
properties can be used as a surrogate for the in vitro effects of variants 
on protein function. In silico analyses previously shown to be highly 
accurate (area under receiving operator characteristic (ROC) curve 
of 0.93)34 were used to estimate the prior probability of pathogenicity 
for all 481 class 3 (uncertain) missense variants (Fig. 5) to prioritize 
requests for data to facilitate future multifactorial analysis. The distri-
bution of prior probabilities for MLH1 and MSH2 class 3 variants was 
clearly bimodal, suggesting that ~50% of MLH1 and MSH2 missense 
variants may be classified as pathogenic after further investigation. In 
total, 401 missense variants had extreme prior probabilities of a20% or 
q80%, with 270 having probabilities of <10% or >90%, indicating that 
classification of a variant as class 1 or class 5 could be easily performed 
by incorporating segregation or tumor information. It is also possible 
that some class 3 variants with low prior probability of pathogenicity 
based on the predicted missense alteration would cause splicing aber-
rations, as already observed for 42 of the 746 not obviously truncating 
nonsynonymous variants. Incorporation of validated bioinformatic 
splicing prediction tools into the MMR gene multifactorial model, as 
is under development for BRCA1 and BRCA2 (ref. 35), will assist in the 
prioritization of variants with the potential to disrupt splicing.
In investigation of the potential effects of class 3 regulatory vari-
ants (Online Methods), all 15 5` UTR variants fell within multiple 
transcription factor binding sites, but no evidence for interruption of 
microRNA binding was found for 6 variants in the 3` UTR (data not 
shown). Multifactorial analyses and transcription assays would help 
elucidate whether these variants affect gene function.
DISCUSSION
The InSiGHT VIC has successfully undertaken a collaborative effort 
to establish standardized variant interpretation guidelines, encour-
age data submission and provide objective assessment of MMR gene 
variants involved in Lynch syndrome. The criteria developed pro-
vide a basis for the standardized clinical classification of variants to 
inform patient and family management through genetic counseling10. 
This initiative has achieved the systematic evaluation of 2,360 con-
stitutional variants, which will benefit thousands of families interna-
tionally. Notably, 605 variants not resulting in the introduction of a 
premature termination codon, including 217 nonsynonymous sub-
stitutions, have now been assigned to class 5 (pathogenic) and class 4 
(likely pathogenic) or to class 1 (not pathogenic) and class 2 (likely 
not pathogenic). The assigned classes of these variants can now also 
be used as standards for the calibration of functional assays36,37.
The clinical relevance of 32% of the variants investigated remains 
uncertain. A large proportion of these (71%) were private variants 
occurring in only one family, and these variants are difficult to classify 
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Figure 4 Contribution of microattribution to the classification of 
variants that are not obviously truncating. Dark shading (yes) indicates 
the proportion of total variants for each class where the additional data 
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Figure 5 Probabilities of pathogenicity for 481 class 3 missense variants of uncertain effect derived by in silico analysis. (a–e) Distribution of 
probabilities of pathogenicity as estimated from a calibrated algorithm based on customized MAPP and PolyPhen-2 scores34 for MLH1, n = 186 (a), 
MSH2, n = 169 (b), MSH6, n = 145 (c), PMS2, n = 24 (d) and all four MMR genes (e), showing stratification of variants with prior probabilities of 
a20% or q80% to prioritize variants for further investigation and classification.
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owing to the paucity of available clinical information. Clinicians 
have a fundamental role in promoting the collection of segregation 
information and other data relevant for classification. We anticipate 
that the development of this interpretation scheme, along with the 
implementation of microattribution, will incentivize assistance in the 
accumulation of clinical data. The value of microattribution for data 
accrual has previously been demonstrated for hemoglobinopathies24, 
and the InSiGHT initiative now demonstrates the clinical usefulness of 
data collection. The promotion of standardized data formats will assist 
in the transition to fully quantitative, unbiased classification, eventu-
ally incorporating other components of the qualitative guidelines. 
In addition, the difficulties experienced in interpreting apparently 
discordant data from functional assays emphasize the importance 
of assay validation and standardization38,39. Such experience will be 
directly applicable to the functional analysis of deep intronic and 
regulatory variants, which are increasingly detected with the advance-
ment of DNA sequencing technologies.
To accommodate the lower penetrance and reported lower degrees 
of tumor MSI associated with MSH6 and PMS2 mutations28,29,40–44, 
gene-specific criteria should also be considered for future iterations 
of the classification guidelines, for example, stipulating the inclusion 
of segregation odds for MSH6 and PMS2 variants for classification or 
using modified panels to detect MSI status.
Another challenging issue to contemplate will be incorporating 
alleles of intermediate risk45 into classification schemes, including 
the clinical recommendations that might be linked to such variants. 
The identification of a subset of MMR gene alleles with apparently 
discordant clinical and functional features that renders them resist-
ant to classification will provide the basis for future studies to define 
the most appropriate methodology and criteria to identify such vari-
ants. Further studies will also be required to assess whether variants 
resulting in abrogated DNA damage response but normal MMR46 
are associated with the same clinical features as classical pathogenic 
mutations in MMR genes.
The InSiGHT database is a well-recognized resource for the clinical 
and research communities, receiving over 20,000 hits per month. The 
development and adoption of standard templates allows transparency 
in the review process. Database users can view relevant information 
and sources in relation to information on guideline interpretation 
when considering the classification provided by the committee. The 
guidelines must evolve to accommodate additional kinds of evidence, 
but we anticipate no clinical issues as long as variant classifications are 
dated and linked to a dated set of guidelines with the supporting infor-
mation used to derive classifications. Final classifications have also 
been submitted to the NCBI ClinVar database for higher exposure, 
but expert classifications and underlying data rest with InSiGHT.
To our knowledge, this is the first large-scale comprehensive clas-
sification effort demonstrating the value of evaluation by expert panel 
in the curation of an LSDB and providing summary information used 
to assign variant pathogenicity. This initiative also shows how clas-
sification may be assisted by promoting standardized data submission 
from stakeholders in the clinical and research settings, thereby allow-
ing access to unpublished clinical and functional information used to 
facilitate variant classification. Thus, the InSiGHT initiative provides 
a key model of LSDB-centric multidisciplinary collaboration for the 
transparent interpretation of DNA variants.
URLs. Clinical Molecular Genetics Society (CMGS) classification sys-
tem, http://cmgsweb.shared.hosting.zen.co.uk/BPGs/Best_Practice_
Guidelines.htm; Human Variome Project (HVP), http://www.
humanvariomeproject.org/; Leiden Open Variation Database (LOVD), 
http://www.lovd.nl/3.0/home; Open Researcher and Contributor 
Identification (ORCID), http://orcid.org/; International Society 
for Gastrointestinal Hereditary Tumours (InSiGHT), http://www.
insight-group.org/variants/classifications/; NCBI ClinVar, http://
www.ncbi.nlm.nih.gov/clinvar/; Mutalyzer, https://mutalyzer.nl/; 
Huntsman Cancer Institute LOVD for MMR gene missense substi-
tution prior probabilities of pathogenicity, http://hci-lovd.hci.utah.
edu/; UCSC Genome Browser, http://genome.ucsc.edu/; Nanopub, 
http://www.nanopub.org/; R project, http://www.r-project.org/.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. All data can be accessed at the InSiGHT website. 
Variants have been submitted to LOVD and ClinVar and are search-
able by the gene names MLH1, MSH2, MSH6 and PMS2. The RefSeq 
and ClinVar accessions (respectively) for the MMR genes are as fol-
lows: MLH1, NM_000249.3 and NG_007109.2; MSH2, NM_000251.2 
and NG_007110.2; MSH6, NM_000179.2 and NG_007111.1; PMS2, 
NM_000535.5 and NG_008466.1.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METHODS
InSiGHT Variant Interpretation Committee expertise. The InSiGHT VIC 
(current chair, M.G.) includes 40 multidisciplinary experts from 5 continents 
(see Supplementary Table 9 for disciplines covered by VIC members). The 
committee is responsible to its Governance Committee, which in turn is 
responsible to the InSiGHT Council. InSiGHT has recently joined HVP and 
is a founding member of its Gene and Disease Specific Council. The InSiGHT 
Council specifically considered the need and responsibility associated with 
classification assignment on its database and took all reasonable steps to both 
invite the highest possible expertise to contribute to the classification process 
and to ensure that its processes and legal standing are robust.
InSiGHT database curation. Mutalyzer50 was used to standardize the nomen-
clature of all variants present in the database as of December 2012. Variants 
with multiple submissions that were originally assigned a classification of 
pathogenic or probably pathogenic as well as no known pathogenicity or prob-
ably no pathogenicity were included in the group of discordant variants used 
to test the classification criteria. All unique variants identified in the database 
were assigned to one of the following sources: constitutional, somatic, artificial 
or unknown.
Development of five-tiered InSiGHT classification criteria. The InSiGHT 
classification criteria were developed using the Delphi method25. A five-
tiered classification system originally developed for consistent classification 
of MMR gene variants identified in participants of the Colon Cancer Family 
Registry16,34 was selected as a baseline for the InSiGHT classification criteria. 
This system included the option of classification on the basis of the posterior 
probabilities arising from multifactorial likelihood analysis15,16,51,52 as well 
as multiple combinations of qualitative data not yet calibrated for inclusion 
in quantitative analyses but that are often reported in the literature or avail-
able from clinical sources. These baseline classification criteria were critically 
reviewed by InSiGHT VIC members attending the InSiGHT San Antonio 
meeting in April 2011 and by VIC members via e-mail. In response to com-
ment, the rules were amended for clarity, to apply a more stringent interpreta-
tion of functional assay data and to consider additional points of evidence. 
These InSiGHT rules were used for variant classification over a series of 11 
meetings (10 teleconferences and 1 face-to-face meeting), with further changes 
incorporated after each meeting to include additional points of evidence iden-
tified to be relevant during the review process as the committee encountered 
different combinations of useful data from published and unpublished sources. 
For example, after discussion, co-occurrence of a variant with a pathogenic 
mutation in the same gene with clinical information regarding a constitutional 
MMR deficiency phenotype53 was included as an in vivo test of MMR func-
tion, and 1000 Genomes Project data54 were accepted as a test for population 
frequency. Consistency of the accumulative evidence required for a given class 
was reviewed by presentation of the rules at a face-to-face meeting of com-
mittee members. Supporting documentation was developed to assist in the 
interpretation of splicing and functional assay results by B.A.T. in consulta-
tion with a subset of committee members with specific expertise in this field 
(Fig. 1b and Supplementary Tables 4 and 5). Where necessary, rule altera-
tions were applied retrospectively to variants evaluated in previous meetings. 
The finalized rules (shown in simplified format in Fig. 1 and detailed in the 
Supplementary Note) were then used to assess all remaining variants lodged 
in the InSiGHT database.
Classification of MMR gene variants by literature review and data colla-
tion. Variants occurring in the 1000 Genomes Project54 with allele frequency 
greater than 1% were automatically classified as class 1 variants. Committee 
members were invited to participate in at least one classification meeting. A 
core group participated in each meeting, with attendance invited from VIC 
membership to make up the balance. Before each meeting, participants were 
assigned, through randomization, a subset of variants to be assessed. Each 
attendee was provided literature pertaining to the list of variants to be dis-
cussed and, where relevant, additional unpublished clinical or research infor-
mation submitted by committee members to InSiGHT curator J.-P.P. Meeting 
attendees were requested to thoroughly review and summarize all information 
pertaining to the subset of variants in a spreadsheet template and to provide a 
class assignment based on their interpretation of the information accessed. All 
reviewer summaries, submitted clinical information and results from causality 
analysis were compiled into a single file to allow the comparison of data and 
class assignments for each variant and were circulated to the teleconference 
participants. During committee meetings, variants were discussed one at a 
time, assessing the following: class assigned by each reviewer; rationale for 
classification according to the classification guidelines; difficulties in interpret-
ing specific data sources; assessment of possible redundancy of information 
due to multiple publications including all or some of the same information 
pertaining to a variant; differences in interpretation of the guidelines as pro-
vided and adjustments required to improve their clarity; the consensus view 
on variant class considering the preceding discussion; and action required to 
obtain additional information for refining the classification of variants that 
remained in class 2, 3 or 4 at the close of discussion. Where classifications 
differed using qualitative and quantitative criteria, these differences were due 
to differences in the availability of specific data types for the two approaches, 
and the most extreme classification was assigned for relevant variants. B.A.T. 
prioritized variants for examination by identifying and classifying any variants 
for which rules-based classification could be applied, such as variants that 
were truncating or comprised a large deletion from nomenclature, canonical 
splice site with no splicing data or frequency of >1% in a control reference 
group. B.A.T. then collated all information for all remaining unique variants 
(including those reviewed previously in teleconferences) and determined 
which variants had sufficient information to allow classification outside of 
class 3. Summary information for these variants was circulated for independ-
ent class assignment by at least three reviewers from the VIC, and classification 
was finalized at teleconferences or by e-mail.
Validation of qualitative criteria. A subset of truncating variants and large 
genomic deletions was selected to validate the qualitative classification criteria. 
Variants were selected on the basis of the availability of data from the first point 
of evidence in the qualitative class 5 criterion, i.e., in vitro functional assay 
results (for example, protein truncation test or genomic or mRNA confirma-
tion of large deletions); Constitutional MMR Deficiency Syndrome phenotype; 
or different haplotypes across multiple families. Published and unpublished 
data for these variants were then used to validate the other points of evidence 
required for classification as a class 5 (pathogenic) variant.
Preliminary analysis of class 3 (uncertain) variants. In silico probabilities 
of pathogenicity were estimated for all class 3 missense variants, as described 
elsewhere34. Preliminary bioinformatic analysis of class 3 regulatory variants 
was undertaken using Encyclopedia of DNA Elements (ENCODE) data55 on 
the UCSC Genome Browser.
Implementation of the microattribution process. The variant interpretation 
process uses both published and unpublished data. For published literature, 
the PubMed ID (PMID) was used to reference the original work. Some unpub-
lished data were recorded in the InSiGHT database at study initiation, and 
InSiGHT members were also requested by e-mail to contribute information 
important for variant classification using a standardized submission template. 
Data submitters were requested to provide a permanent, publicly searchable 
unique ID, preferably from the ORCID system, to facilitate the adoption of 
the microattribution approach. Microattribution was assigned for the differ-
ent types of information corresponding to the points of evidence required for 
classification—namely, submitters were allocated one credit of microattribu-
tion for each type of information received, including (i) a variant (mandatory), 
(ii) family history or pedigree, (iii) MSI information, (iv) immunohisto-
chemistry data, (v) in vitro functional data, (vi) data from RNA splicing assays 
and (vii) population frequency data. All unpublished data received by the VIC 
were recorded in microattribution tables for each element type, with each 
microattribution table listing a unique researcher ID along with submitted 
information. Microattribution counts for submitters are publically available 
on the InSiGHT website. Additionally, the data will be made available in nano-
publication format.
Statistical analysis. Multifactorial likelihood analysis was performed for vari-
ants with appropriate tumor and segregation data available, using previously 
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reported methods16,34,51 that are described briefly as follows. Bayes factor 
analysis was conducted by B.A.T. to assess MLH1, MSH2, MSH6 and PMS2 
variant causality from segregation data16,51 for both published and unpub-
lished pedigrees with sufficient relevant information on cancer and variant 
carrier status. Penetrance estimates from Senter et al.28 were used in the Bayes 
segregation analysis27 of PMS2 variants. Where family relationship status was 
unknown, a conservative segregation likelihood ratio was derived—i.e., setting 
affected carriers as first-degree relatives—which is less informative than seg-
regation between second-degree relatives. Colorectal tumor MSI and somatic 
BRAF mutation status were used to assign likelihood ratios according to tumor 
phenotype16. For each variant, the individual likelihood ratios (cosegregation, 
tumor) were multiplied to calculate the odds for causality. Then, a posterior 
probability was calculated by combining the prior probability (in silico for mis-
sense variants34 or on the basis of sequence location for all other variants13) 
and the odds for causality using Bayes rule where posterior = (prior × odds × 
(1/(1−prior)))/(prior × odds × (1/(1 − prior)) + 1). STATA 11 was used to 
calculate the sample size for the truncating variant validation set, H0: P = 0.01, 
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Supplementary Note  
Mismatch Repair Gene Variant Classification Criteria 
Version 2.0 October 2013 
 
Rules for Variant Classification: 
Rules describing the 5 class system for classification of MMR gene variants were 
devised and documented by Amanda Spurdle and Bryony Thompson in September 
2009 for standardised classification of variants in the Colon Cancer Family Registry 
database, and revised by Amanda Spurdle, Bryony Thompson, Sean Tavtigian and 
Marc Greenblatt during April 2011, in collaboration with the InSiGHT Variant 
Interpretation Committee (VIC), modulated by input from committee members during 
ongoing VIC meetings. They are based on the following:  
- The 5 class system described for quantitative assessment of variant 
pathogenicity in Plon et al.1, using a multifactorial likelihood model2-5 as 
applied to MMR gene variants6,7;  
- The 5 class system for interpretation of splicing variants and aberrations by 
Spurdle et al.8;   
- The classification of sequence changes according to standard clinical practice 
– that is, description of variants generally considered pathogenic (clinically 
relevant in a genetic counselling setting such that germline variant status is 
used to inform patient and family management) or non-pathogenic (significant 
evidence against being a dominant high-risk pathogenic mutation); and  
- The documentation of non-quantitative methods that have been used to 
classify variants in the literature.  
 
For a given class, a variant is required to satisfy all the criteria listed for at 
least one bullet-point that falls within that class.  The symbol “” represents 
an “AND” statement. The footnote # describes the rationale for suggested sample 
numbers, and the rationale for use of indicative MSI or IHC information. The 
interpretation of functional assays is assisted by a flowchart developed for this 
purpose (See Fig. 1b, main text). 
 
These criteria provide a baseline for standardized clinical classification of MMR gene 
sequence variation that may be linked to patient and family management in the 
genetic counseling arena according to published guidelines 1. Use of the InSiGHT 
database, and associated interpretation relating to pathogenicity, is subject to User 
discretion and responsibility.  Whereas InSiGHT has developed processes to assign 
pathogenicity utilizing high-level expertise available through its membership, such 
assignments are subject to change with the availability of new information and 
interpretation processes. Information submitted to the InSiGHT database is available 
for individual enquiry for clinical use, but any collective use of the data for research or 
other purposes transgresses agreements InSiGHT has with the valuable community 
of researchers, clinicians and diagnostic laboratories that generously support the 
database through their submissions. All users of the database are encouraged to 
submit their own variants to support the InSiGHT international collaboration to share 
gene variant data relating to gastrointestinal tumors. Submissions should be directed 
to the InSiGHT curator John-Paul Plazzer (johnpaul@variome.org). 
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Class 5 – Pathogenic  
• Variants with probability of pathogenicity >0.99 using a multifactorial likelihood 
model 
• Coding sequence variation resulting in a stop codon i.e. nonsense or frameshift 
pathogenic alteration that is predicted to result in interruption of known 
functional protein domains or highly conserved exonic sequences  
• Variants where mRNA assays in patient RNA indicate that the variant allele 
results in a splicing aberration (with evidence that the variant allele produces no 
wild-type transcript) leading to premature stop codon or in-frame deletion 
disrupting a functional domain or protein conformation 
• Large genomic deletions 
• Large genomic duplications shown by laboratory studies to result in a 
frameshift before the last splice junction 
• Variants demonstrating all of the following characteristics with no conflicting 
results (combined evidence achieves estimated LR >100:1, posterior >0.99 
with prior 0.5): 
 Variant-specific abrogated function in protein or mRNA based lab 
assays (see MMR functional assay supplementary material) 
- OR - for MLH1 and MSH2, co-occurrence in trans with a known pathogenic 
sequence variant in the same gene in a patient with clinical features 
consistent with Constitutional Mismatch Repair Deficiency (CMMRD) and 
reported LS cancer in the parent of origin for the variant to be classified. If 
parental genotype is unknown, then both parents should have early-onset 
LS cancer  
- OR - presence of the variant on different haplotypes across families 
indicating that reported LS clinical features are not due to an undiscovered 
sequence change in cis with the variant 
 Evidence for co-segregation with disease where pedigree information 
provided allows calculation of likelihood ratio (LR) of ≥10:1*  
- OR - at least one revised Amsterdam criteria 9 family with >4 affected 
carriers  
- OR - across >2 revised Amsterdam criteria families reported to show 
segregation with disease (no further information provided)  
- OR - >2 families with >3 affected non-proband carriers 
  >2 independent tumors with MSI using a standard panel of 5-10 
markers** and/or loss of MMR protein expression consistent with the variant 
location (may include tumor information from proband) 
 evidence that variant is not an undescribed polymorphism at allele 
frequency >1% (minor allele frequency [MAF] >0.01) in healthy controls from 
an appropriate population (i.e. 1000 genomes) 
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Class 4 – Likely pathogenic 
• Variants with probability of pathogenicity between 0.95-0.99 using a 
multifactorial likelihood model 
• Variants at IVS±1 or IVS±2, or G>non-G at last base of exon if first 6 bases of 
the intron are not GTRRGT, that are untested for splicing aberrations in vitro - 
irrespective of bioinformatic predictions 
• Variants demonstrating (combined evidence achieves LR >20:1, posterior 0.95-
0.99 with prior 0.5): 
 variant-specific abrogated function in protein or mRNA based lab 
assays (see MMR functional assay supplementary material) 
- OR - for MLH1 and MSH2, co-occurrence in trans with a known pathogenic 
sequence variant in the same gene in a patient with clinical features 
consistent with CMMRD and reported LS cancer in the parent of origin for 
the variant to be classified. If parental genotype is unknown, then both 
parents should have early-onset LS cancer  
- OR - presence of the variant on different haplotypes across families 
indicating that reported LS clinical features are not due to an undiscovered 
sequence change in cis with the variant 
 plus one of the following: 
         - co-segregation with disease assessed by available pedigree 
information allows calculation of LR of >5:1* 
- OR - at least one revised Amsterdam criteria family with >3 affected 
carriers 
- OR - >2 families with >2 affected non-proband carriers  
- OR - >2 independent tumours with MSI using a standard panel of 5-10 
markers** and/or loss of MMR protein expression consistent with the variant 
location (may include tumour information from proband) 
 
 
 
Class 3 – Uncertain 
• Variants with probability of pathogenicity between 0.05-0.949 using a 
multifactorial likelihood model  
• Variants that have insufficient evidence (molecular or otherwise) to classify, 
which may include large genomic duplications not yet shown by laboratory 
studies to result in a frameshift before the last splice junction, missense 
alterations, small in-frame insertions/deletions, silent variants, intronic 
variants, promoter and regulatory region variants 
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Class 2 – Likely not pathogenic/little clinical significance 
• Variants with probability of pathogenicity between 0.001-0.049 using a 
multifactorial likelihood model 
• Synonymous substitutions and intronic variants with no associated mRNA 
aberration (either splicing or allelic imbalance) as determined by laboratory 
assays conducted with nonsense-mediated decay inhibition. Whenever 
abnormal transcripts are identified at similar levels in controls they will be 
considered to be naturally occurring isoforms and not mRNA aberrations 
• Variants reported to occur in a specific ethnic group at allele frequency ≥1%, 
(MAF ≥ 0.01, tested in ≥ 160 individuals) and that have not yet been excluded 
as known founder pathogenic sequence variants (“founder mutations”) 
• Variants demonstrating: 
 variant-specific proficient function in protein and mRNA based lab 
assays (see MMR functional assay supplementary material) 
 - OR - co-occurrence in trans with a known pathogenic sequence variant in 
the same gene in a patient with colorectal cancer after age 45 (or other LS 
cancer above the median age of onset for that cancer in LS***), and who 
has no previous or current evidence of clinical manifestations of CMMRD 
 plus one of the following: 
            - present in control reference groups at allele frequency 0.01-1% 
(MAF 0.0001-0.01, tested in ≥ 160 individuals) 
   - OR - lack of co-segregation with disease consistent with a dominant high-
risk pathogenic sequence variant in pedigrees (LR≤ 0.01) 
   - OR - estimated risk with upper bound 95% confidence limit <4, as 
determined by large well-designed case-control studies that consider size, 
geography/ethnicity and quality control measures  
   - OR - >3 colorectal tumors with MSS and/or no loss of MMR protein 
expression and/or loss of MMR protein(s) in LS spectrum tumors, that is 
inconsistent with the gene demonstrating genetic variation 
• Variants demonstrating any three of the following: 
         - present in control reference groups at allele frequency 0.01-1% (MAF 
0.0001-0.01, tested in ≥ 160 individuals) 
- OR - lack of co-segregation with disease consistent with a dominant high-
risk pathogenic sequence variant in pedigrees (LR≤ 0.01) 
- OR - estimated risk with upper bound 95% confidence limit <4, as 
determined by large well-designed case-control studies that consider size, 
geography/ethnicity and quality control measures  
- OR - >3 colorectal tumors with MSS and/or no loss of MMR protein 
expression and/or loss of MMR protein(s) in LS spectrum tumors, that is 
inconsistent with the gene demonstrating genetic variation  
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Class1 – Not pathogenic/no clinical significance 
• Variants with probability of pathogenicity <0.001 using a multifactorial likelihood 
model 
• Variants reported to occur in control reference groups at allele frequency ≥1% 
(MAF ≥ 0.01, tested in ≥ 160 individuals) and excluded as founder pathogenic 
sequence variants 
• Variants demonstrating: 
 Variant-specific proficient function in protein and mRNA based lab 
assays (see MMR functional assay supplementary material) 
 - OR - co-occurrence in trans with a known pathogenic sequence variant in 
the same gene in a patient with colorectal cancer after age 45 (or other LS 
cancer above the median age of onset for that cancer in LS***), and who 
has no previous or current evidence of clinical manifestations of CMMRD 
 Plus any two of the following: 
            - present in control reference groups at allele frequency 0.01-1% 
(MAF 0.0001-0.01, tested in ≥ 160 individuals) 
   - OR - lack of co-segregation with disease consistent with a dominant high-
risk pathogenic sequence variant in pedigrees (LR≤ 0.01) 
   - OR - estimated risk with upper bound 95% confidence limit <4, as 
determined by large well-designed case-control studies that consider size, 
geography/ethnicity and quality control measures  
   - OR - >3 colorectal tumors with MSS and/or no loss of MMR protein 
expression and/or loss of MMR protein(s) in LS spectrum tumors, that is 
inconsistent with the gene demonstrating genetic variation 
• Variants demonstrating all of the following: 
Present in control reference groups at allele frequency 0.01-1% (MAF 0.0001-
0.01, tested in ≥ 160 individuals) 
 Lack of co-segregation with disease consistent with a dominant high-
risk pathogenic sequence variant in pedigrees (LR≤ 0.01) 
 Estimated risk with upper bound 95% confidence limit <4, as 
determined by large well-designed case-control studies that consider size, 
geography/ethnicity and quality control measures  
 >3 colorectal tumors with MSS and/or no loss of MMR protein 
expression and/or loss of MMR protein(s) in LS spectrum tumors, that is 
inconsistent with the gene demonstrating genetic variation  
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Footnotes to Mismatch Repair Gene Variant Classification Guidelines: 
# The upper 95% confidence limit of frequency for an allele observed once in 160 
individuals (320 chromosomes) is <0.01, the allele frequency considered sufficient for 
classification as class 1 (not pathogenic/low clinical significance). Characteristics of a 
pathogenic variant were selected to achieve a combined likelihood ratio of >100:1 in 
conjunction with a prior of 0.5 (estimated prior irrespective of in silico predictions). 
Namely, the co-segregation and family history descriptions were selected to estimate 
segregation odds of 10:1, results from functional assays were assumed to have 
likelihood ratio 5:1 and MSI/IHC data was conservatively assumed to carry a 
likelihood ratio of 5:1. Tumor data was based on two tumors for MSI and/or IHC to 
allow for the possibility that pathogenic missense alterations may not all demonstrate 
loss of MMR protein expression. Where both MSI and IHC information are available, 
MSI-H results will take precedence over normal immunohistochemical results, since 
MSI is more specific than MMR immunohistochemistry in colorectal cancers10,11.  For 
variants that demonstrate tumor MSS and loss of MMR protein expression, technical 
or other explanations10,12-14 for the discrepancy should be investigated. The need for 
multiple results was implemented to minimize the chance of a "sporadic" MSI-H or 
negative immunohistochemical result for MLH1 methylated tumors (0.15x0.15 = 
0.0225). Independent tumors can include multiple primary tumors from a single 
individual. 
 
* Likelihood ratios for segregation can be derived by Bayes factor analysis adapted 
from the method of Thompson et al15, as described previously6. Penetrance 
estimates for MLH1 and MSH2 variants to be derived from Quehenberger et al16 and 
those for MSH6 and PMS2 variants to be derived from Baglietto et al17 and Senter et 
al18. 
 
** Standard MSI markers panel: BAT25, BAT26, BAT40, BAT34, D5S346, D17S250, 
ACTC, D18S55, D10S197, MYCL 19; D2S123, D18S69 20; NR21, NR24, NR27 21 
 
*** Lynch syndrome tumors include: colorectal/colon/rectal, endometrial, ovarian, 
small bowel/small intestine, renal pelvis, ureter, and stomach/gastric carcinomas, 
sebaceous skin tumors (adenomas and carcinomas), gliomas. 
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Supplementary Figure 1 Distribution of unique MMR gene variants 
(constitutional and non-constitutional) on the InSiGHT database at study 
initiation. There were 2,370 unique variants in the database after 3,458 
nomenclature alterations due to formatting to standardized Human Genome Variation 
Society nomenclature22 and systematic review of the literature. There were 448 
somatic (tumor or cell line derived) entries in the InSiGHT database, 229 of which 
have not been reported as constitutional variants. There were 3,322 artificial 
(synthesized for in vitro or in vivo assays or subjected to in silico analyses) entries in 
the database, 137 of which have not been reported as constitutional variants. In 
addition, four variants were termed “unknown” since the source could not be 
established (n=1) or the nomenclature provided in the reference was inconsistent 
with sequence trace data provided in the source publication (n=3). Details of the non-
constitutional variants are shown in Supplementary Table 1.  
Nature Genetics: doi:10.1038/ng.2854
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Supplementary Figure 2 Breakdown by MMR gene, of the proportion of 
different variant types in the 5-tiered classifications. Class 5a is a subset of 
Class 5 containing the assumed pathogenic mutations caused by nonsense 
mutations, small frameshift indels, and large deletions. Class 5b includes not-
obviously truncating variants considered to be pathogenic on the basis of combined 
evidence (see Supplementary Note). The different variant types are: PTC – variants 
that introduce premature terminating codons, i.e. nonsense mutations and small 
frameshift indels; NS – not obviously truncating non-synonymous variants; I – intronic 
variants outside the canonical splicing dinucleotides; LGDel – large genomic 
deletions or disrupting inversions; LGDup – large genomic duplications; SS – variants 
in the canonical splice site dinucleotides; S – synonymous variants; ATG/UTR – 
variants in the initiation codon (n=9), and the 5’ or 3’ untranslated regions (n=49).  
 
A) All genes (n=2360) 
!
B) MLH1 (n=932) 
!
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C) MSH2 (n=842) 
 
D) MSH6 (n=449) 
 
E) PMS2 (n=137) 
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Supplementary Table 2 Database information used to select 
discordantly classified variants for detailed examination by the Variant 
Interpretation Committee: MLH1:c.731G>A p.(Gly244Asp) as an example.  
The current database contains data from three merged public databases: the original 
InSiGHT database23,24 (contributions from individual submitters); MMR Gene 
Unclassified Variants Database25 (functional assay results); and the Mismatch Repair 
Genes Variant Database26 publication database. Additionally, Human Variome 
Project country/regional LOVD sub-databases also contribute to the central database, 
e.g. the Chinese LOVD MMR database27. Classifications were commonly assigned to 
variants by submitters based on a single point of evidence. Variants with different 
submitter-assigned classifications were prioritized for initial review.!
Test Method Test Type Result Classification Reference 
dominant 
negative effect 
reporter assays 
in yeast 
DNE in 0 out of 3 tests PATHOGENIC Takahashi et 
al., 2007 
expression 
level of mutant 
allele 
in vivo assay in 
human cell line 
comparable to WT NEUTRAL Blasi et al., 
2006 
mutation rate 
at HPRT gene 
in vivo assay in 
human cell line 
increased mutation rate PATHOGENIC Blasi et al., 
2006 
tolerance to 
methylating 
agents 
in vivo assay in 
human cell line 
tolerance as in WT NEUTRAL Blasi et al., 
2006 
MMR activity 
assay 
in vitro assay 19,4% compared to 0% 
in MLH1 deficient cell 
line 
VUS Takahashi et 
al., 2007 
MLH1 
expression 
protein 
abundancy 
>75% of WT level NEUTRAL Takahashi et 
al., 2007 
comparison of 
mutation rate 
between 
haploid yeast 
functional 
assays using 
yeast 
mutation rate in a lys+ 
reporter gene 
comparable to a MLH1 
deficient haploid yeast 
PATHOGENIC Shcherbakova 
et al, 1999 
pSPL3 
minigene 
splicing assay no change in exon 
inclusion 
NEUTRAL Lastella et al., 
2006 
human cell 
extract+in vitro 
MMR assay 
cell based in 
vitro MMR 
functional 
assay using a 
human 
expression 
system 
reduced repair efficiency 
compared to the WT 
PATHOGENIC Trojan et al., 
2002 
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Supplementary Table 3 The InSiGHT Variant Interpretation Committee classification process. 
InSiGHT Variant Interpretation Committee: 40 members 
Purpose of 
VIC 
Meetings 
Classification Criteria testing: TCs or face-to-face 
meeting (June 2012) included variant 
classification, criteria amendments and 
clarifications. 
Average duration of TCs was 2 ½ hours. 
Functional 
assay 
interpretation 
TC 
TC for 
splicing 
variant 
classification 
Variant 
classification 
via email 
discussion 
Two TCs to 
reassess 
functional 
flowchart 
Re-assessment 
of classification 
for variants with 
functional assay 
data via email. 
 
Finalization of 
variant 
classifications 
Meeting 
date 
 
Oct 
2011 
Dec 
2011 
Jan 
2012 
May 
2012 
Jun 
2012 
Oct 
2012 
Dec 
2012 
Jan 
2013 
Feb 
2013 
Jun 
2013 
Jul 
2013 
Aug  
2013 
Participants  
(continents 
covered) 
14 
(3) 
11 
(3) 
15 
(4) 
10 
(3) 
39 
(5) 
14 
(4) 
8 
(3) 
10 
(2) 
11 
(2) 
9 & 6 
(3) 
6 
(3) 
20 
(3) 
Variants 
assessed 12 20 20 20 10 35 23 47 177 NA 36 128 
Reviews 
per variant 4-6 2-5 2-6 2-4 4 1-4 NA 2-4 3-7 NA 4 3-7 
 
TC – teleconference; VIC - Variant Interpretation committee; NA – not applicable. 
 
Note: A set of discordantly classified variants remaining after curation for nomenclature (n=117, see “curation” results section for further detail) were used to 
test the robustness of the guidelines in first set of teleconferences and a face-to-face meeting (June 2012). Due to apparent discordances in results from 
functional assays, several teleconferences were devoted solely to functional assay interpretation. Amendments and clarifications to classification criteria 
were incorporated through all these meetings. Documentation of evidence and preliminary classification of the remaining mismatch repair variants was 
performed by author BAT, and a subset of variants with available splicing data were discussed and classified in a teleconference in January 2013. Some 
variants were discussed on multiple teleconferences. Of the remaining mismatch repair variants, those with sufficient data to warrant examination against 
the classification criteria were assessed independently by at least 3 committee members and consensus classification reached through electronic 
discussion, or face-to-face meeting (August 2013). The Variant Interpretation committee covers the following continents: Australia, Europe, Asia, Africa, and 
North America.  
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Supplementary Table 4 Rationale for InSiGHT classification criteria 
Class Criteria Rationale 
Posterior probability of pathogenicity >0.99 IARC recommendation for Class 51 
Variant resulting in premature termination codon (PTC -nonsense/frameshift 
predicted to interrupt functional domains or conserved sequences) Treated clinically as pathogenic 
Full expression of aberrant splice transcripts by variant allele in lab assays, that 
leads to PTC/disruption of a domain Treated clinically as pathogenic 
Large genomic deletion (assumed PTC or domain deletion) Treated clinically as pathogenic 
Large genomic duplication resulting in frameshift (lab-tested) Treated clinically as pathogenic 
Variant-specific abrogated function: functional assays Excludes undetected causal mutation in cis; assumed LR 5:128 
CMMRD (MIM 276300) phenotype for co-occurrence with known pathogenic 
mutation in trans Clinical phenotype for “in vivo” functional abrogation 
Presence of variant on different haplotypes across families Excludes undetected causal mutation in cis 
Evidence that variant is not an undescribed polymorphism High-risk variants are not common in the general population 
Evidence for co-segregation with disease (segregation score, reported segregation 
in AM2 families, or reported variant status of multiple affected family members) 
Provides evidence that the variant is associated with the clinical phenotype. Total 
estimated segregation odds ≥10:1. 
Class 5: 
pathogenic 
Evidence that variant is associated with MMR deficiency in vivo (≥2 tumours with 
MSI and/or appropriate IHC loss) 
Provides evidence that the variant is associated with the clinical phenotype. Assumed 
conservative LR ≥5:1 for tumor data. 
Posterior probability of pathogenicity 0.95-0.99 IARC recommendation for Class 41 
Variants untested for splicing aberrations at IVS±1 or IVS±2 or G>non-G at last 
base of exon when adjacent intronic sequence is not GTRRGT 
Disruption of conserved bases at acceptor and donor splice sites results in splicing 
aberrations. 
Variant-specific abrogated function: functional assays Excludes undetected causal mutation in cis; assumed LR 5:128 
CMMRD (MIM 276300) phenotype for co-occurrence with known pathogenic 
mutation in trans Clinical phenotype for “in vivo” functional abrogation 
Presence of variant on different haplotypes across families Excludes undetected causal mutation in cis 
Evidence for co-segregation with disease (segregation score, or reported variant 
status of multiple affected family members – less stringent than class 5) 
Provides evidence that the variant is associated with the clinical phenotype. Total 
estimated segregation odds ≥5:1 
Class 4: likely 
pathogenic 
Evidence that variant is associated with MMR deficiency in vivo (≥2 tumors with MSI 
and/or appropriate IHC loss) 
Provides evidence that the variant is associated with the clinical phenotype. Assumed 
LR >≥5:1 for tumor data 
Posterior probability of pathogenicity 0.05-0.949 IARC recommendation for Class 31 Class 3: 
uncertain Insufficient evidence to classify variant Does not fit prescribed criteria for other classes 
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Posterior probability of pathogenicity 0.001-0.0049 IARC recommendation for Class 21 
Intronic and synonymous variants with no associated variant-specific mRNA 
aberration in lab assays 
(excludes naturally occurring isoforms at similar levels to controls) 
In the absence of mRNA aberrations, function is unlikely to be deficient for intronic 
and synonymous nucleotide substitutions 
Variant reported at ≥1% allele frequency, but in only one specific population and has 
not been excluded as “founder mutation” 
High-risk variants are not common in the general population, but may be increased in 
individuals from specific geographical regions or in specific ethinc groups. The 
prevalence of Lynch syndrome is 1-3% in colorectal and endometrial cancer patients, 
which corresponds to an incidence between 1:660 and 1:2000 when extrapolated to 
the general population29-31. 
Proficient protein function in protein and mRNA based lab assays In vitro evidence for proficient function. Assumed LR 0.228 
Co-occurrence in trans with a known pathogenic mutation with no unusual clinical 
features In vivo evidence for proficient function 
Variant with allele frequency of 0.01-1% 
Present in the general population/healthy controls, but not at frequency >1% 
consistent with no severe effect on function or risk. The prevalence of Lynch 
syndrome is 1-3% in colorectal and endometrial cancer patients, which corresponds to 
an incidence between 1:660 and 1:2000 when extrapolated to the general 
population29-31. 
≥3 MSS and/or no IHC loss and/or IHC loss inconsistent with gene involved, in 
colorectal tumors 
Provides evidence that the variant is not associated with the clinical phenotype.  
Estimated LR 0.1 for MSS32 
Lack of co-segregation with disease (LR≤0.01) Sufficient to derive posterior probability of 0.01 
Class 2: likely 
not 
pathogenic or 
of little 
clinical 
significance 
Odds Ratio with upper 95% CI <4 in case-control study 
Cut-off is indicative of a low/moderate risk variant33. Odds ratio below this level of risk 
would not lead to implementation of clinical management recommendations for Lynch 
syndrome. 
Posterior probability of pathogenicity <0.001 IARC recommendation for Class 11 
Variant with reported frequency ≥1% in the general population, and no evidence that 
it is a founder mutation 
High-risk variants are not common in the general population. The prevalence of Lynch 
syndrome is 1-3% in colorectal and endometrial cancer patients, which is an incidence 
between 1:660 and 1:2000 when extrapolated to the general population29-31. 
Proficient protein function in protein and mRNA based lab assays In vitro evidence for proficient function. Assumed LR 0.228 
Co-occurrence in trans with a known pathogenic mutation with no unusual clinical 
features In vivo evidence for proficient function 
Variant with allele frequency of 0.01-1% 
Present in the general population/healthy controls, but not at frequency >1% 
consistent with no severe effect on function or risk. The prevalence of Lynch 
Syndrome is 1-3% in colorectal and endometrial cancer patients, which is an 
incidence between 1:660 and 1:2000 when extrapolated to the general population29-31. 
≥3 MSS and/or no IHC loss and/or IHC loss inconsistent with gene involved in 
colorectal tumors 
Provides evidence that the variant is not associated with the clinical phenotype.  
Estimated LR 0.1 for MSS32 
Lack of co-segregation with disease (LR≤0.01) Sufficient to derive posterior probability of 0.01 
Class 1: not 
pathogenic or 
of no clinical 
significance 
Odds Ratio with upper 95% CI <4 in case-control study 
Cut-off is indicative of a low/moderate risk variant33. Odds ratio below this level of risk 
would not lead to implementation of clinical management recommendations for Lynch 
syndrome. 
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Supplementary Table 5 Description of assays used in the interpretation of mismatch repair gene variants 
Subclassification Functional Assays Assay details 
Considerations for Assay 
interpretation 
Required 
Controls 
MMR 
publications 
using assays 
Assays assessing impact on gene transcripts 
mRNA expression 
level and splicing 
analysis 
Reverse-
transcriptase PCR 
(RT-PCR) 
PCR amplication of cDNA 
fragments. Gel electrophoresis 
used to analyze transcript size 
and level of mRNA expression. 
Cloning can be used to 
separate out alternate 
transcripts for sequencing. 
Cells used in assay may not be 
tissue of interest. Naturally 
occurring alternate splicing 
isoforms may complicate 
interpretation. Semi-quantitative 
measure of expression. NMD 
inhibitors can be used to stabilise 
transcripts that contain premature 
stop codons. Different PCR 
designs can lead to different 
results. 
Wild type. 
Recommend minimum 
of 5 controls, in order 
to capture naturally 
occuring isoforms. 
6,34-79 
Minigene constructs 
Exonic and intronic gDNA 
inserted into a minigene 
construct, which is transfected 
into a cell line. RNA extracted 
from cells and subjected to RT-
PCR analysis 
Ex vivo system: different levels of 
exon inclusion between constructs 
and cell lines. Representative of 
genomic context but still a 
heterologous system 
Wild type. 45,56,65,70,71,80-83 
Diploid to haploid 
conversion analysis 
Hybrid cell lines containing 
separate alleles, generated by 
fusing lymphoblastoid cell line 
with a mouse embryonic cell 
line. RNA extracted from cells 
and subjected to RT-PCR 
analysis. 
Specialty laboratory: STR 
genotyping or cell treatment with 
negative selection reagents 
required to confirm cell line fusion. 
Interference associated with the 
use of a heterologous system. 
Wild type; unfused 
LCL and mouse 
embryonic cell line 
84-88 Splicing analysis 
Protein truncation test 
(PTT) or in vitro 
synthesized protein 
assay (IVSP) 
In vitro transcription and 
translation (IVTT) of cDNA 
transcripts 
In vitro system: small differences in 
protein sizes are difficult to 
visualize. 
Wild type. 45,89-109 
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Allelic expression Allelic expression ratios 
Heterozygous coding SNP or 
variant used as marker of allelic 
expression in single nucleotide 
extension assays, such as 
MassArray MALDI-ToF mass 
spectometry, Snapshot, Snupe, 
Pyrosequencing. 
Require the sequence information 
from samples to identify coding 
SNPs 
gDNA 65,72,79,110-112 
Promoter or 3'UTR 
activity Luciferase assay 
gDNA sequence of interest is 
inserted into a plasmid 
upstream of the luciferase gene. 
Construct transiently 
transfected into a cell line. 
Relative activity measured by 
the level of fluorescence from 
luciferase expression 
In vitro system: ensure full-
characterized promoter sequence 
is tested for 5'UTR variants. 
Wild type, positive & 
empty vector. 
113-115  
116 Empty vector & 
positive control were 
not used 
Assays assessing MMR protein repair capacity as a complete process 
Functional assays 
using cell-free 
systems 
In vitro MMR 
complementation 
assays 
An in vitro test of the repair of 
mismatched DNA by protein 
extracts. Baculovirus infected 
insect cell extracts are used to 
complement MMR-deficient cell 
extract; MMR genes transfected 
into MMR-deficient cell line; or 
IVTT of PCR fragments 
complement MMR-deficient cell 
extracts. DNA repair substrates: 
mismatch within restriction site 
or LacZ domain. 
False negative results possible for 
variants that are pathogenic due to 
poor expression or protein stability. 
Variants defective in nuclear import 
may yield false-positive results. 
Subtle defects will not be detected 
if amount of protein is saturating. 
Wild type; known 
defective 
(untransfected MMR 
deficient cell line or 
pathogenic control). 
Transfection efficiency 
for assays involving 
transient expression in 
cell lines. 
49,79,112,117-134 
135-137Transfection 
efficiency not 
measured 
66Level of MMR 
activity not quantified 
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Functional assays 
using mammalian 
cell-based systems 
Cellular-based MMR 
functional assay 
using a 
human/mouse 
expression system 
Monitor the repair capacity as a 
whole through expression of 
mutant human MMR gene 
constructs in human/mouse cell 
lines. MMR status measured 
using: cellular response to 
methylating agents (MMR-
deficient cells have acquired 
tolerance to these agents), 
spontaneous mutation rate at 
the endogenous HPRT gene, 
repair of an exogenously added 
mismatch-containing GFP 
plasmid, or measuring 
microsatellite instability. 
Best to use cell lines that lack 
endogenous expression of the 
MMR protein. Level of protein 
expression is critical: poor 
expression can produce false-
negative results; variant MMR 
gene expression is unregulated 
and may be toxic to cells. "Knock-
in" of the variant allele through 
oligonucleotide gene targeting 
avoids unregulated expression. 
Wild type; known 
defective. 
85,133,138-141 
Assays assessing MMR protein expression 
Mammalian assay 
Transient or stable 
expression of MMR 
genes  
Transient or stable expression 
of MMR genes in relevant 
MMR-deficient cell line: MLH1 
deficient - HCT116 (human 
CRC) or HEK293T (human 
embryonic kidney fibroblast); 
MSH2 deficient - LoVo (human 
CRC), Hec59 (human 
endometrial cancer); MSH6 
deficient - HCT15 (human 
CRC); PMS2 deficient - HEC1-
A (human endometrial cancer); 
knockout murine embryonic 
fibroblasts. Immunoblot of MMR 
proteins. 
Level of protein expression is 
unregulated and may be toxic to 
cells. C-terminal fluorescent 
labelling can affect MutLa 
expression. 
Wild type; known 
defective; internal 
loading. Transfection 
efficiency for assays 
involving transient 
expression in cell 
lines. 
72,76,79,85,112,125,1
34,138-143 
14,49,121,122,135-
137,144-
147Transfection 
efficiency not 
measured  
123,124& known 
defective not 
included  
144,148,149Internal 
loading control not 
shown 
Nature Genetics: doi:10.1038/ng.2854
 18!
Protein stability 
assays 
Pulse-chase 
assay/cycloheximide 
treatment 
Measure half-life of protein: 
radiolabelled for pulse-chase 
assay or inhibiting de novo 
protein expression with 
cycloheximide 
 
Wild type; known 
defective; tranfection 
efficiency 
72  
142Known defected 
not included 
Assays assessing a specific biological or biochemical function of a MMR protein 
MMR protein 
subcellular 
localization 
Localization 
experiments 
Expression of fluorescent MMR 
proteins in mammalian/yeast 
cells or immunostaining to 
localize the distribution of these 
proteins in the cell. 
Overexpression of MMR proteins 
might interfere with proper 
localization. Overexpression of 
MMR proteins might be toxic, can 
be assessed by investigating cell 
survival/apoptosis. C-terminal 
fluorescent labelling can affect 
MutLa expression. Mammalian 
assay would be superior. 
Wild type. 
79,112,122,128,143,14
4,147,149-152 
153Localization in 
yeast 
Note: Yeast-based assays76,125,154-169 were not used in variant classification, because of concerns about using non-mammalian systems for diagnostic 
purposes170,171. These concerns were corroborated by detailed examination of results from yeast-based assays for variants considered Class 1 (not 
pathogenic) based on multifactorial analysis posterior probability or allele frequency >1% in the population:  abrogated/intermediate function or discordant 
results were reported for 8/19 (42%) of variants assayed. This compares to only 1/18 (5.5%) for results from mammalian assays. Assays measuring 
specific functions in MMR, such as subunit interaction and ATPase assays were not used to assist variant interpretation, because these functions are 
tested in the MMR activity assays as a whole. 
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Supplementary Table 6 MMR activity and protein expression values for pathogenic and neutral controls, measured in different 
laboratories 
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HCT116 - 0% 1%     30%  10% 0-12%   
HEK293T -   0% 0% 15% 0% 0-30% 0%   0%  
LoVo -         5% 0-13%   
Msh2 -/- ESC -         13%    
HCT15 -          0%   
Hec259 -            9.7% 
MLH1 p.S44F 5 29% <25%       20%    
MLH1 p.G67R 5 7% 13.5% 5% 20%     5% 2.4%   
MLH1 p.T117M 5 44% <25%   5% 45% 6%  15%    
MLH1 p.L622H 5 87% 50%  25-48% 80% 42%       
MLH1 
p.E633_E663del -          2.3% 
  
MLH1 p.P654L 5 61% 51%   67% 25%  31% 10% 111% 8%  
MLH1 p.R659P - 31% <25%   4% 12%  <25% 15% 26% 42%  
MLH1 p.A681T 5 88% >75%   99% 51%    115% 41%  
MLH1 p.W714* - 0% 47%           
MLH1 p.L749P -   10% 50% 15% 85% 33% >75%     
MSH2 p.P622L 5         7%   9.7% 
MSH2 p.A636P 5         20% 16%   
MSH6 
p.G1139S -         5%  
  
MSH6 p.T1219I -         10%    
Variants 
included in 
studies as 
pathogenic 
controls 
PMS2 p.D70N -     10% 90%               
MLH1 p.M35R 5 29% 51%           
MLH1 p.N38K 5         15%    
MLH1 p.N38H 5     15% 15%   15%    
MLH1 p.C77Y 5 14% 46%           
MLH1 p.F80V 5 30% >75%        14% 96%  
Class 5: 
Pathogenic 
variants, 
classified 
using 
MLH1 p.T82I 5 34% >75%   5% 41%       
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MLH1 p.A128P 5 31% 66%     0%      
MLH1 p.V185G 5 11% 63%     5.8%   19%   
MLH1 p.G244D 5 24% >75%     23%      
MLH1 
p.K618del 5 49% 22%        86% 
  
MLH1 p.P648L 5 49% 25-75%   92% 22%  28% 85% 102% 64%  
MLH1 p.R659L 5     84% 28%  36%     
MLH1 p.R687W 5 72% 47%        123%   
MSH2 p.G162R 5          12%   
MSH2 p.G164R 5          14%   
MSH2 p.L187P 5          13%   
mutlifactorial 
likelihood 
analysis 
MSH2 p.C697F 5         0% 18%   
MLH1 p.I219V 1 76% 45% 95% 130% 96% 94% 100%  70% 88%   
MLH1 p.S406N 1 92% >75%       85%    
MLH1 p.E578G 1 64% 34%   90% 70%   70%    
MLH1 p.K618A 1 104% 35%   92% 78% 92%  80% 104%   
MLH1 p.V716M 1 94% 52%   86% 74%   65% 110%   
MLH1 p.H718Y 1 106% 54%   110% 72%       
MSH2 p.G322D 1         85% 
53%-
123% 
  
MSH2 p.A834T 2         100% >100%   
MSH6 p.S144I 1         55% 97%   
MSH6 
p.P1087R -         95% 106% 
  
MSH6 p.P1087T -         80% 100%   
Variants 
included in 
studies as 
neutral 
controls 
PMS2 p.R20Q 1   90% 85%         
MLH1 p.D132H 1 79% 50%     120%      
MLH1 p.I219L 1 107% >75%           
MLH1 p.V213M 1 107% >75%        93%   
MLH1 p.E268G 1 99% 25-75%           
MLH1 p.V326A 1 34% 68%     80%      
MLH1 p.V384D 1 81% >75%           
MLH1 p.L390F 1         90%    
MLH1 p.K618T 1 61% 66%           
MLH1 p.Q689R 1 85% 56%         7%  
MSH2 p.N127S 1          
107%-
116% 
  
Class 1: not 
pathogenic 
variants, 
classified 
using 
multifactorial 
likelihood 
analysis or 
MAF >1% in 
general 
population MSH6 p.L396V 1         85%    
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MSH6 p.V878A 1         85% 84%    
PMS2 p.P470S 1   90% 95%         
MLH1 p.K84E - 28% >75%   8% 85%    2% 36%  
MLH1 p.H329P - 32% >75%        71%   
MLH1 p.L550P -         30% 96% 22%  
MLH1 p.A586P - 35% 71%   21% 50% 24% 50%   37%  
MLH1 p.A589D -         25% 99% 10%  
MLH1 p.T662P - 80% 70%   93% 22% 89% 25%     
MLH1 p.R755W -     10% 72% 7% 68%     
MSH2 p.R524P -            9.7%‡ 
Additional 
variants with 
relevant 
functional 
data from at 
least two 
independent 
studies MSH2 p.E749K -         4% 18%   
†IARC class as defined by multifactorial likelihood analysis conducted as part of this study. ‡Also found to be deficient in Boyer et al174. 
Note: Red or blue highlighted cells with black text are the pathogenic or neutral controls (respectively) used in the studies tabulated. Colored font indicates 
interpretation of values by members of the Functional Assay Group within the Variant Interpretation Committee. Namely, protein expression within the 
conservative protein expression cut-offs set in Figure 1b ie <25% (red text) and >75% (blue text), and abrogated function (red text) or normal function (blue 
text) relative to the pathogenic and assay controls for MMR activity. For the study by Takahashi et al125, which reported results for only a single cell line 
control, assay interpretation was modulated by also considering results from at least two other studies that had assayed the same variant. This indicated 
35% activity as an appropriate upper % to indicate abrogated function, 64% activity as an upper % to indicate normal function, but also highlighted two 
variants with outlying results (purple text): MLH1 p.V326A variant classified as low clinical significance (and thus assumed to have normal MMR activity) 
with 34% activity; and MLH1 p.T117M with 44% activity, but evidence for abrogated function from three independent assays. Another clear outlier result 
was the low protein expression level for MLH1 p.Q689R (7%), classified as not pathogenic by multifactorial analysis. These discrepant findings highlight the 
need for caution when interpreting existing functional data that has been generated using assays not yet assessed for sensitivity and specificity. Therefore, 
concordant results from independent assays from 2 different laboratories are required to assign the functional effect of variants (See Fig 1b). 
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Supplementary Table 7 Validation set of 170 “assumed pathogenic” truncating/large deletion variants. Sufficient tumor data included the 
presence of microsatellite instability and/or loss of protein expression in two or more tumors. Sufficient segregation data included fulfilling the segregation 
requirements of Class 5 “pathogenic” (see supplementary note). In most cases the truncating variants that were in Class 3 and Class 4 had one or two 
affected carriers, or did not include informative meioses. None of the variants were found in the 1000 genomes data. NA – not available. 
 
InSiGHT 
Class Gene Variant Protein 
Evidence Variant  
Selected On Tumor Characteristics 
Family History and co-
segregation with disease 
5a MLH1 c.(?_-198)_1558+?del p.? 
Variant allele not expressed 
(diploid-haploid conversion 
analysis [pmid:12658575 
Wagner:2003]) 
2 MSI-H tumours: 1 
[pmid:19690142 Mueller:2009]; 
1 [USC CCFR] 
Sufficient segregation data: 2 ACI 
families (4 affected carriers & 3 
affected carriers [USC CCFR]) 
4a MLH1 c.-54519_1731+2263del p.? 
Exon 1-15 genomic deletion 
confirmed (LR-PCR & 
breakpoint analysis 
[pmid:16837128 Pistorius:2007]; 
diploid-haploid conversion 
analysis [pmid:18330910 
Staaf:2008]) 
2 MSI-H: 1 [pmid:15849733 
Mangold:2005], [pmid:16837128 
Pistorius:2007]; 1 
[lovd:Lagerstedt Robinson; 
00078] 
Summary family history only: ACI 
[lovd:Lagerstedt Robinson; 00078]. 
Bethesda [pmid:15849733 
Mangold:2005], [pmid:16837128 
Pistorius:2007]. 
4a MLH1 c.(?_-198)_207+?del c.-381_207+606del p.? 
Aberrant transcript (allelic 
imbalance [pmid:19173287 
Gylling:2009]; PTT 
[pmid:19459153 Chong:2009]) 
MSI-H: 1 [pmid:16423994 
Zhang:2006], [pmid:19173287 
Gylling:2009]. MLH1 absent: 1 
[pmid:19459153 Chong:2009] 
Summary family history only: 
Bethesda [pmid:16143124 
Baudhuin:2005]. 2 ACI families 
([pmid:16423994 Zhang:2006], 
[pmid:19173287 Gylling:2009], 
[pmid:19459153 Chong:2009]) 
3a MLH1 c.104_105insAA p.(Met35Ilefs*7) 
Allelic imbalance 
[pmid:20860725 Santibez 
Koref:2010] 
MSS: 1 [pmid:11720433 
Coleman:2001] 
Summary family history only: ACI 
[pmid:11720433 Coleman:2001] 
4a MLH1 c.1011dup p.Asn338Glnfs*24 
Aberrant transcript (IVSP 
[pmid:9833759 Hutter:1998]; 
PTT [pmid:19459153 
Chong:2009]) 
MSI-H: 1 [pmid:9833759 
Hutter:1998]. MLH1 absent: 1 
[pmid:19459153 Chong:2009] 
Summary family history only: 2 ACI 
families ([pmid:9833759 
Hutter:1998]; [pmid:19459153 
Chong:2009]) 
3a MLH1 c.1039-?_(*193_?)del p.? 
Truncated polypeptide (IVSP, 
nucleotide not identified 
[pmid:09718327 
Farrington:1998]) 
MSI-H: 1 [pmid:09718327 
Farrington:1998] Summary family history only 
5a MLH1 c.1039-?_1409+?del p.Thr347Lysfs*8 
Truncated polypeptide (IVSP & 
RT-PCR of patient RNA 
[pmid:8128251 
Papadopoulos:1994]; 
[pmid:08574961 Liu:1996]; RT-
PCR of patient RNA 
[pmid:8776590 Nystrom-
Lahti:1996]) 
5 MSI-H: 1 [pmid:08574961 
Liu:1996]; 2 [pmid:19690142 
Mueller:2009]; 1 [Aus CCFR]; 1 
[lovd:Elke Holinski-Feder and 
Moni Morak; 00057] 
Sufficient segregation data: 
Linkage to MLH1 in 2 families 
[pmid:8776590 Nystrom-
Lahti:1996]. 
Nature Genetics: doi:10.1038/ng.2854
 23!
3a MLH1 c.117-691_306+1011del p.Cys39Trpfs*6 
Confirmed genomic deletion 
(LR-PCR, non-homologous 
recombination [pmid:15942939 
van der Klift:2005]) 
MSI-H: 1 [pmid:15849733 
Mangold:2005] Summary family history only 
4a MLH1 
c.117-?_545+?del 
c.117-
707_545+1338delinsTCCCG
GGTTCAAGCGATTCT 
p.Cys39_Arg182delins
Trp 
Truncated polypedtide (PTT 
[Desiree du Sart]) 
MSI-H: 1 [pmid:16142001 
Becouarn:2005]. MLH1 absent: 
1 [Desiree du Sart]. 
Summary family history only 
3a MLH1 c.1217_1223dup p.Gln409Serfs*10 Frameshift aberration (PTT [pmid:10190329 Bapat:1999]) 
MSI-H: 1 [pmid:10190329 
Bapat:1999] Summary family history only 
5a MLH1 
c.1410-?_1558+?del 
c.1409+1156_1558+1385del 
c.1409+1127_1558+4255del 
p.Arg470Serfs*8 
Truncated polypeptide (~3kb 
deletion identified by IVSP 
[pmid:09718327 
Farrington:1998], 
[pmid:19459153 Chong:2009]) 
2 MSI-H: 2 [orcid:Tops; 0000-
0002-6769-7290] 
Sufficient segregation data: 2 
families, 4 affected carriers & 3 
affected carriers [Mayo CCFR]; 3 
affected carriers [orcid:Ian 
Frayling@Edinburgh; 0000-0002-
3420-0794]; 2 affected carriers 
[orcid:Tops; 0000-0002-6769-7290] 
3a MLH1 c.1410-?_1731+?del p.Lys471Serfs*13 
Aberrant transcript (RT-PCR of 
patient RNA [pmid:8971183 
Mauillon:1996]) 
NA Summary family history only 
5a MLH1 c.1411_1414del p.Lys471Aspfs*19 Truncated polypeptide (IVSP [pmid:08574961 Liu:1996]) 
3 MSI-H: 1 [pmid:08574961 
Liu:1996]; 1 [pmid:15926618 
Wolf:2005]; 1 [pmid:18389388 
Goldberg:2008]. MSS: 1 
[pmid:15926618 Wolf:2005] 
Sufficient segregation data: 
segregation LR 12:1 [Mayo CCFR] 
5a MLH1 c.1449del p.Asp484Metfs*7 
Truncated polypeptide (IVTT & 
RT-PCR of patient RNA 
[pmid:8880570 Froggatt:1996]) 
>2 MSI-H: number not specified 
[pmid:8880570 Froggatt:1996] 
Sufficient segregation data: LOD 
1.38, 6 affected [pmid:8880570 
Froggatt:1996] 
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5a MLH1 c.1459C>T p.Arg487* 
Truncated polypeptide (PTT 
[pmid:10713887 Fidalgo:2000]; 
no effect on splicing in diploid-
haploid conversion analysis 
[pmid:15713769 Casey:2005]) 
15 MSI-H: 1 [pmid:15849733 
Mangold:2005], [pmid:16216036 
Mangold:2005]; 1 
[pmid:18726168 Yap:2009]; 1 
[pmid:20924129 Giraldez:2010]; 
4 [orcid:Soto; 0000-0003-0234-
9188]; 4 CRC & 1 adenoma 
[orcid:Capella; 0000-0002-4669-
7320]; 1 [orcid: Leung et al; 
0000-0001-8614-4619; 0000-
0002-1768-4184; 0000-0002-
8420-6633; 0000-0002-8390-
2442; 0000-0002-4716-5000]; 2 
[orcid:Yuen; 0000-0002-1768-
4184]; 1 [lovd:Lagerstedt 
Robinson; 00078] 
Sufficient segregation data: 4 
affected carriers [orcid:Tops; 0000-
0002-6769-7290]; 16 affected 
carriers over 4 families 
[orcid:Capella; 0000-0002-4669-
7320] 
4a MLH1 c.1462A>T p.Lys488* Truncated polypeptide (PTT [Desiree du Sart]) 
2 MLH1 absent: 2 
[1003053][1003098] Summary family history only 
4a MLH1 c.1489del p.Arg497Glyfs*11 Truncated polypeptide (PTT [Desiree du Sart]) 
5 MSI-H: 1 [Desiree du Sart]; 1 
[pmid:15872200 Hampel:2005]; 
1  gastric, 1 renal & 1 CRC 
[orcid:Varesco; 0000-0003-
4871-6668] 
Insufficient segregation data: 
revised Bethesda, 2 affected 
carriers [orcid:Varesco; 0000-0003-
4871-6668] 
5a MLH1 c.1489dup p.Arg497Profs*6 
Frameshift aberration (PTT 
[pmid:10323887 Lamberti:1999]; 
[Desiree du Sart]) 
MSI-H: 3 [Mayo CCFR] 
Sufficient segregation data: 3 
families, segregation LR 56:1 
[Mayo CCFR]; 11 affected carriers 
over 4 ACI families [Moni Morak]. 
4a MLH1 c.1491del p.(Arg498Glufs*10) 
Defective PMS2 interaction 
(GST-fusion assay 
[pmid:12810663 Kondo:2003]) 
MSI-H: 2 [pmid:9500462 
Yamamoto:1998] Summary family history only 
5a MLH1 c.1554dup p.(Glu519*) 
Allelic imbalance 
[pmid:20860725 Santibez 
Koref:2010] 
MSI-H: 2 [Aus CCFR] Sufficient segregation data: 4 affected carriers [Aus CCFR] 
3a MLH1 c.1559-1322_1668-391del p.Leu521Lysfs*34 
Truncated polypeptide (PTT 
[pmid:10495924 
Wahlberg:1999]) 
MSI-H: 1 [pmid:17312306 
Lagerstedt Robinson:2007]; Summary family history only 
3a MLH1 c.1622del p.(Ala541Aspfs*50) 
Defective PMS2 interaction 
(GST-fusion assay 
[pmid:12810663 Kondo:2003]) 
MSI-H: 1 [pmid:15849733 
Mangold:2005], [pmid:16216036 
Mangold:2005]; 1 adenoma 
[Moni Morak] 
Summary family history only 
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4a MLH1 c.1669G>T p.Glu557* Truncated polypeptide (PTT [Desiree du Sart]) 
MSI-H: 1 [pmid:15655560 
Apessos:2005] 
Sufficient segregation data: 3 
affected carriers & 3 obligate 
carriers [pmid:15655560 
Apessos:2005] 
4a MLH1 c.1672G>T p.Glu558* Frameshift aberration (PTT [pmid:10480359 Wang:1999]) 
2 MSI-H: 1 [pmid:16216036 
Mangold:2005]; 1 [Moni Morak] Summary family history only 
5a MLH1 
c.1732-?_1896+?del 
c.1731+270_1896+73del 
c.1732-2243_1896+404del 
p.Pro579_Glu633del 
Aberrant transcript (3.5kb 
genomic deletion, Finnish 
Founder mutation, PTT 
[pmid:10200055 
Holmberg:1998]) 
6 MSI-H tumours (6 
[pmid:17312306 Lagerstedt 
Robinson:2007]) 
Sufficient segregation data: 
Finnish/Swedish founder mutation 
(>30 kindreds [pmid:8776590 
Nystrom-Lahti:1996]) 
4a MLH1 c.1758dup p.(Met587Hisfs*6) 
Defective PMS2 interaction 
(GST-fusion assay 
[pmid:12810663 Kondo:2003]) 
Absent: 1 EC [pmid:17973265 
Yoon:2008] 
Sufficient segregation data: 3 
affected carriers [pmid:7757073 
Han:1995]. Korean founder 
mutation (segregates in 11 families 
[pmid:15365995 Shin:2004]). 
4a MLH1 c.1764del p.Ala589Profs*2 Truncated polypeptide (PTT [pmid:19459153 Chong:2009]) 
MSI-H: 1 [pmid:09831355 
Yuan:1998]. MLH1 absent: 1 
[pmid:19459153 Chong:2009] 
Insufficient segregation data: ACI 
(French Canadian segregation LR 
7.8:1 [pmid:09831355 Yuan:1998]) 
4a MLH1 c.1772_1775del p.(Asp591Valfs*24) 
Defective PMS2 interaction 
(GST-fusion assay 
[pmid:12810663 Kondo:2003]) 
3 MSI-H: 1 [pmid:17312306 
Lagerstedt Robinson:2007], 
[orcid:Nordling; 0000-0002-
4047-4994]; 2 [pmid:8872463 
Moslein:1996] 
Insufficient segregation data: 
Bethesda family with segregation 
LR 1.9:1 [lovd:Lagerstedt 
Robinson; 00078], [orcid:Nordling; 
0000-0002-4047-4994] 
5a MLH1 c.1783_1784del p.(Ser595Trpfs*14) 
Defective PMS2 interaction 
(GST-fusion assay 
[pmid:12810663 Kondo:2003]) 
4 MSI-H: 1 [pmid:16216036 
Mangold:2005]; 1 
[pmid:10601588 
Fornasarig:2000]; 2 [0000-0002-
1768-4184] 
Sufficient segregation data: 5 
affected carriers [pmid:8571956 
Wijnen:1996]. 4 affected carriers 
[0000-0002-1768-4184] 
5a MLH1 c.1831_1832del p.Ile611Cysfs*2 Truncated polypeptide (PTT [pmid:15253764 Thiffault:2004]) 
MSI-H: 1 gastric 
[pmid:16237216 Bacani:2005]. 2 
MLH1 absent: 2 [pmid:15253764 
Thiffault:2004] 
Sufficient segregation data: 2 
families, 4 affected carriers each 
[pmid:15253764 Thiffault:2004] 
5a MLH1 c.184C>T p.Gln62* 
Truncated polypeptide (2 cases: 
PTT [pmid:10323887 
Lamberti:1999]) 
MSI-H: 1 [lovd:Elke Holinski-
Feder, Moni Morak; 00057]. 7 
MLH1 absent: 3 CRC & 1 EC 
[pmid:16034045 
Stormorken:2005], 
[pmid:20587412 Sjursen:2010], 
[Pal Moller]; 3 [Pal Moller] 
Sufficient data: 7 affected carriers 
over 2 families, 4 informative 
meioses [pmid:20587412 
Sjursen:2010], [Pal Moller] 
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3a MLH1 c.1852A>T p.Lys618* Truncated polypeptide (IVSP [pmid:9833759 Hutter:1998]) 
MSI-H: 1 BrCa [pmid:22034109 
Buerki:2012] 
Summary family history only: ACI 
(Swiss proband CRC age 34 
[pmid:9833759 Hutter:1998]) 
4a MLH1 c.1897-?_1989+?del p.(Glu633_Glu663del) 
Deficient MMR activity 
[pmid:16083711 
Raevaara:2005] 
2 MSI-H: 1 [pmid:10732761 
Dieumegard:2000]; 1 
[pmid:16837128 Pistorius:2007] 
Summary family history only 
5a MLH1 c.1975C>T p.[Glu633_Glu663del, Arg659*] 
r.[1897_1989del, 1975c>u] 
(Truncated polypeptide and 
partial splicing aberration, IVSP 
[pmid:09718327 
Farrington:1998]; PTT 
[pmid:10200055 
Holmberg:1998]; exon 17 
skipping: RT-PCR of patient 
RNA [pmid:10534773 Nystrom-
Lahti:1999], [pmid:15235038 
Renkonen:2004]; diploid-haploid 
conversion[pmid:15713769 
Casey:2005]) 
5 MSI-H: 1 [Ontario CCFR]; 2 
[Aus CCFR]; 1 [Moni Morak]; 1 
[orcid:Ian Frayling @ Dundee; 
0000-0002-3420-0794] 
Sufficient segregation data: 6 
affected carriers [Ontario CCFR];  3 
affected carriers [Aus CCFR] 
4a MLH1 c.1975_1976del p.(Arg659Thrfs*4) 
r.1897_1989del (exon 17 
skipping, RT-PCR of patient 
RNA [pmid:08808596 Kohonen-
Corish:1996]) 
NA 
Sufficient segregation data: 3 
affected carriers & 6 asymptomatic 
carriers [Aus CCFR] 
4a MLH1 c.1986_1989+1delinsC p.Glu633_Glu663del 
r.1897_1989del (Exon 17 
skipping, no full-length 
expressed by variant allele in 
RT-PCR of patient RNA 
[pmid:16341550 
Pagenstecher:2006]) 
MSI-H (1 CRC [pmid:16341550 
Pagenstecher:2006]) 
Sufficient segregation data: ACI 
(German family, at least 4 affected 
carriers [pmid:16341550 
Pagenstecher:2006]) 
5a MLH1 c.208-?_306+?del p.Lys70_Glu102del Truncated polypeptide (PTT [Desiree du Sart]) 
4 MLH1 absent: 1 EC [Desiree]; 
2 [Aus CCFR], [Rodney Scott]; 1 
[orcid:Capella; 0000-0002-4669-
7320] 
Sufficient segregation data: 3 
affected carriers & 2 obligate 
carriers [Aus CCFR] 
4a MLH1 c.208-?_453+?del p.Lys70_Thr151del 
Truncated polypeptide (RT-PCR 
of patient RNA [pmid:9593786 
Aaltonen:1998]; PTT & RT-PCR 
[pmid:10200055 
Holmberg:1998]) 
2 MSI-H: 1 [pmid:16423994 
Zhang:2006]; 1 [pmid:19173287 
Gylling:2009] 
Insufficient segregation data: 
Segregation with disease reported 
[pmid:19173287 Gylling:2009] 
5a MLH1 c.207+1560_546-871del p.Lys70Valfs*9 Truncated polypeptide (PTT [Desiree du Sart]) 2 MSI-H: 2 [Desiree du Sart] 
Sufficient segregation data: 2 
familes with 3 affected carriers 
each [Aus CCFR] 
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4a MLH1 c.210_213del p.[Glu71Ilefs*20, Lys70_Glu102del] 
Truncated polypeptide (partial 
exon 3 skipping in RT-PCR of 
patient RNA [pmid:15235038 
Renkonen:2004]; PTT [Desiree 
du Sart]) 
2 MSI-H: 1 [orcid:Genuardi; 
0000-0002-7410-8351]; 1 [Maria 
Grazia Tibiletti] 
Insufficient segregation data: 
Segregation with disease reported 
[pmid:15235038 Renkonen:2004] 
4a MLH1 c.2135G>A p.Trp712* Truncate polypeptide (IVSP [pmid:08574961 Liu:1996]) 
2 MSI-H: 1 [pmid:08574961 
Liu:1996]; 1 [pmid:11720433 
Coleman:2001] 
Summary family history only 
5a MLH1 c.2141G>A p.Trp714* 
Truncated polypeptide (IVSP 
[pmid:8863153 Hutter:1996], 
[pmid:9833759 Hutter:1998]) 
2 MSI-H: 1 [pmid:8880570 
Froggatt:1996]; 1 
[pmid:17054581 Sheng:2006] 
Sufficient segregation data: ACI 
(Swiss family, 7 affected carriers 
[pmid:8863153 Hutter:1996]) 
3a MLH1 c.2163T>A p.Tyr721* Truncated polypeptide (PTT [pmid:10713887 Fidalgo:2000]) NA Summary family history only 
5a MLH1 c.2195_2198dup p.His733Glnfs*14 Truncated polypeptide (PTT [pmid:10190329 Bapat:1999]) 
5 MSI-H: 1 BrCa [pmid:8646682 
Risinger:1996]; 1 
[pmid:15217520 
Kunstmann:2004]; 3 CRC 
[pmid:10190329 Bapat:1999] 
Sufficient segregation data: ACI 
(North American family, 
segregation LR 52:1 
[pmid:8646682 Risinger:1996]) 
5a MLH1 c.298C>T p.Arg100* 
Aberrant transcript & truncated 
polypeptide (PTT 
[pmid:10480359 Wang:1999]; 
SnuPe [pmid:14512394 
Renkonen:2003]) 
4 MSI-H: 1 [pmid:15872200 
Hampel:2005]; 1 [orcid:Soto; 
0000-0003-0234-9188]; 1 
[Ontario CCFR]; 1 [orcid:Tops; 
0000-0002-6769-7290] 
Sufficient segregation data: Finnish 
ACI family, 9 affected carriers 
[pmid:14512394 Renkonen:2003]. 
Dutch ACI family, 3 affected 
carriers [orcid:Tops; 0000-0002-
6769-7290]. 
4a MLH1 c.307-820_380+896del c.307-1420_380+624del p.Ala103Serfs*13 
Exon 4 deletion confirmed (LR-
PCR & breakpoint analysis, Alu-
Alu [pmid:12494471 
Wang:2003]) 
2 MSI-H: 1 [pmid:15849733 
Mangold:2005]; 1 [orcid:Capella; 
0000-0002-4669-7320] 
Summary family history only 
4a MLH1 c.307-245_454-365del p.Ala103_Thr151del Truncated polypeptide (PTT [Desiree du Sart]) 
2 MSI-H: 1 [Desiree du Sart]; 1 
[Aus CCFR] 
Insufficient segregation data: 
Bethesda proband segregation LR 
1.9:1 [Aus CCFR], [Rodney Scott] 
4a MLH1 c.307-?_545+?del p.Ala103Valfs*9 
Exon 4-6 deletion confirmed as 
contiguous exons in PCR 
[pmid:19173287 Gylling:2009]. 
2 MSI-H: 1 OvCa 
[pmid:16360201 
Malander:2006]; 1 
[pmid:19173287 Gylling:2009] 
Insufficient segregation data: 
segregation reported in ACI family 
[pmid:19173287 Gylling:2009]. 
5a MLH1 c.307-797_677+1061del p.Ala103Argfs*8 
Truncated polypeptide (PTT 
[pmid:10495924 
Wahlberg:1999]; RT-PCR of 
patient RNA & genotyping 
intragenic SNPs 
[pmid:11260232 Liu:2001]) 
2 MSI-H tumours 
[pmid:10564582 Liu:2000] 
Insufficient segregation data: 
Bethesda (Swedish family, 2 
affected carriers [pmid:11260232 
Liu:2001]) 
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3a MLH1 c.378del p.Tyr126* Frameshift aberration (PTT [pmid:10480359 Wang:1999]) NA Summary family history only 
4a MLH1 c.381-415_453+733del p.Ala128Trpfs*8 
Exon 5 deletion confirmed (RT-
PCR of patient RNA 
[pmid:12624159 
Sumitsuji:2003]) 
2 MLH1 absent: 2 [Aus CCFR] 
Insufficient segregation data: ACI 
fam with seg LR 1.9:1 [Aus CCFR]; 
Bethesda fam seg LR 1.4:1 [Hawaii 
CCFR]: total seg LR 2.7:1 
5a MLH1 
c.454-?_545+?del 
c.454-505_546-1102del 
c.454-665_545+49del 
c.454-432_546-1030del 
c.454-466_546-1062del 
p.Glu153Phefs*8 
Truncated polypeptide & exon 6 
deletion confirmed (LR-PCR 
[pmid:14635101 Taylor:2003], 
[pmid:12402334 Viel:2002]; PTT 
[Desiree du Sart]; breakpoint 
analysis [pmid:18330910 
Staaf:2008], [pmid:15942939 
van der Klift:2005]) 
8 MSI-H: 1 [pmid:18625694 
Ramsoekh:2008]; 2 [orcid:Leung 
et al; 0000-0001-8614-4619; 
0000-0002-1768-4184; 0000-
0002-8420-6633; 0000-0002-
8390-2442; 0000-0002-4716-
5000]; 1 duodenal & 1 CRC 
[orcid:Tops; 0000-0002-6769-
7290]; 2 [Robert Hofstra]; 1 
[pmid:21387278 Bozzao:2011] 
Sufficient segregation data: 
segregation LR 4.2:1 [Ian Frayling - 
Belfast]; Bethesda family 
segregation LR 1.9 [Robert 
Hofstra]; Italian family, 2 affected 
carriers [pmid:21387278 
Bozzao:2011]. 
3a MLH1 
c.[453+625_545+921delinsT
G;545+1271_677+737delins
CA] 
p.Val152Argfs*8 
Complex deletion of exons 6-7 
confirmed (PTT, 
g.37024184_37026321delinsTG 
+ 
g.37026671_37029331delinsCA 
[pmid:16098012 McVety:2005]) 
NA Summary family history only 
4a MLH1 c.546-?_790+?del p.Tyr183Serfs*42 
Exon 7-9 deletion confirmed 
(RT-PCR of patient RNA 
[pmid:16423994 Zhang:2006]) 
3 MSI-H: 1 OvCa, 2 CRC 
[pmid:16423994 Zhang:2006] 
Summary family history only: ACI 
(Swiss proband CRC age 61 
[pmid:16423994 Zhang:2006]) 
3a MLH1 c.546-361_885-811del p.Arg182_Leu294del 
Exon 7-10 deletion confirmed 
(8kb deletion identified by LR-
PCR and breakpoint analysis 
[pmid:12494471 Wang:2003]) 
MSI-H: 1 [pmid:16216036 
Mangold:2005] 
Insufficient segregation data: ACI 
family with 2 affected carriers 
[pmid:12494471 Wang:2003] 
3a MLH1 c.586A>T p.Lys196* Truncated polypeptide (PTT [pmid:10480359 Wang:1999]) NA Summary family history only 
3a MLH1 c.588del p.Lys196Asnfs*6 Truncated polypeptide (PTT [Desiree du Sart]) MLH1 absent: 1 [Aus CCFR] Summary family history only 
3a MLH1 c.673_676del p.Ser225Glufs*3 Truncated polypeptide (PTT [pmid:10480359 Wang:1999]) NA Summary family history only 
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5a MLH1 c.676C>T p.(Arg226*) 
Homozygote with CMMRD 
([pmid:9927033 
Ricciardone:1999], 
[pmid:17889038 Alotaibi:2008]) 
7 MSI-H: 1 [pmid:18307539 
Yan:2008]; 1 [pmid:19690142 
Mueller:2009]; 1 
[pmid:20045164 Chang:2010]; 1 
[pmid:20924129 Giraldez:2010]; 
1 [orcid:Soto; 0000-0003-0234-
9188]; 1 [orcid:Genuardi; 0000-
0002-7410-8351]; 1 [Moni 
Morak] 
Sufficient segregation data: 4 
affected non-proband carriers 
[pmid:9927033 Ricciardone:1999], 
[pmid:17889038 Alotaibi:2008]. 4 
affected non-proband carriers 
[pmid:21247423 Castillejo:2011], 
[pmid:21868491 Perez-
Carbonell:2012]. 3 affected non-
proband carriers [pmid:15655560 
Apessos:2005]. Segregation LR 
3.8:1 [Mayo CCFR]. 2 affected 
carriers [orcid:Genuardi; 0000-
0002-7410-8351]. German ACII 
family with segregation LR 3.5:1 
[Nils Rahner]: total segregation LR 
13.3:1 
3a MLH1 c.678-?_884+?del p.Glu227_Ser295del Truncated polypeptide (PTT [Desiree du Sart]) 
MLH1 absent: 1 [Desiree du 
Sart] Summary family history only 
3a MLH1 c.791-?_884+?del p.His264Leufs*2 
Exon 10 deletion confirmed (1kb 
deletion identified by LR-PCR & 
breakpoint analysis 
[pmid:16451135 
Kurzawski:2006]) 
NA Summary family history only 
5a MLH1 c.806C>G p.(Ser269*) CMMR-D family [pmid:15571801 Rey:2004]. 
2 MSI-H: 1 [pmid:12547705 
Hendriks:2003]; 1 [orcid:Tops; 
0000-0002-6769-7290] 
Sufficient segregation data: ACI 
family with 7 affected carriers & 
ACI fam with 4 affected carriers 
[orcid:Tops; 0000-0002-6769-
7290]. 
3a MLH1 c.884_884+3del p.(His264Leufs*2) 
r.791_884del (Exon 10 skipping: 
RT-PCR of patient RNA 
[pmid:12362047 
Kurzawski:2002], 
[pmid:16451135 
Kurzawski:2006]) 
NA Summary family history only 
4a MLH1 
c.885-?_1038+?del 
c.885-493_1039-372del 
c.885-594_1038+1123del 
p.Ser295Argfs*21 
Exon 11 deletion confirmed (LR-
PCR, homologous 
recombination [pmid:15942939 
van der Klift:2005], 
[pmid:11420710 Chan:2001]) 
MSI-H: 1 CRC  [pmid:11420710 
Chan:2001]. MLH1 absent: 1 
[orcid:Leung et al; 0000-0001-
8614-4619; 0000-0002-1768-
4184; 0000-0002-8420-6633; 
0000-0002-8390-2442; 0000-
0002-4716-5000] 
Insufficient segregation data: 2 
affected carriers [orcid:Leung et al; 
0000-0001-8614-4619; 0000-0002-
1768-4184; 0000-0002-8420-6633; 
0000-0002-8390-2442; 0000-0002-
4716-5000] 
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4a MLH1 c.885-206_997del p.? 
Large deletion confirmed by 
break-point analysis 
[pmid:18330910 Staaf:2008] 
2 MSI-H: 1 [pmid:17312306 
Lagerstedt Robinson:2007]; 1 
[lovd:Lagerstedt Robinson; 
00078] 
Summary family history only 
3a MLH1 c.889G>T p.Glu297* 
Truncated polypeptide (IVSP of 
patient RNA [pmid:09399661 
Wang:1997], [pmid:10480359 
Wang:1999]) 
NA 
Insufficient segregation data: 
Bethesda (French proband CRC 
age 35 [pmid:09399661 
Wang:1997]). German ACI family 
with segregation LR 4.3:1 [Nils 
Rahner]. 
5a MLH1 c.901C>T p.Gln301* 
Aberrant transcript (Allelic 
imbalance [pmid:20860725 
Santibez Koref:2010]) 
7 MSI-H: 1 [pmid:14871975 de 
Jong:2004]; 2 [pmid:10448273 
Capozzi:1999]; 1 
[pmid:18307539 Yan:2008]; 1 
[orcid:Tops; 0000-0002-6769-
7290]; 2 [orcid:Viel; 0000-0003-
2804-0840] 
Sufficient segregation data: AC1 
fam with segregation LR 1.9:1 
[pmid:08993976 Viel:1997], 
[orcid:Viel; 0000-0003-2804-0840]; 
Bethesda family with segregation 
LR 7.2:1 [orcid:Tops; 0000-0002-
6769-7290]: total seg LR 13.7:1 
4a MLH1 c.954del p.His318Glnfs*49 
Truncated polypeptide (PTT 
[pmid:10660333 
Panariello:1998]) 
MSI-H/ACII (1 [pmid:15849733 
Mangold:2005]) 
Sufficient segregation data: 4 
affected carriers & 3 affected 
carriers in 2 families 
[pmid:10660333 Panariello:1998]. 
5a MSH2 c.(?_-68)_(*272_?)del p.? 
Whole gene deletion (confirmed 
as contiguous exons 
[pmid:19173287 Gylling:2009]) 
2 MSI-H: 1 [pmid:16216036 
Mangold:2005]; 1 
[orcid:Genuardi; 0000-0002-
7410-8351] 
Sufficient segregation data: 
segregation with disease reported 
[pmid:19173287 Gylling:2009]. 6 
affected carriers [Aus CCFR]. 2 
families with 2 affected carriers 
each [orcid:Genuardi; 0000-0002-
7410-8351]. 
5a MSH2 
c.(?_-68)_1076+?del 
c.-11844_1077-
6021delins155 
c.-823_1076+5984del 
c.-956_1077-5607del 
p.? 
Truncated polypeptide (IVSP 
[pmid:07704024 Liu:1995]; 
conversion analysis 
[pmid:10693791 Yan:2000]) 
7 MSI-H: 1 [orcid:Leung et al; 
0000-0001-8614-4619; 0000-
0002-1768-4184; 0000-0002-
8420-6633; 0000-0002-8390-
2442; 0000-0002-4716-5000]; 1 
[Moni Morak]; 2 [pmid:12938096 
Nakagawa:2003]; 3 
[pmid:18809606 Hampel:2008] 
Sufficient segregation data: 7 
affected carriers [orcid:Ian Frayling 
@ Cardiff; 0000-0002-3420-0794]; 
North American founder mutation, 
segregates in 9 families 
[pmid:14871915 Lynch:2004]. 
5a MSH2 c.(?_-68)_1276+?del c.-47156_1277-4980del p.? 
Exon 1-7 deletion confirmed 
(conversion analysis 
[pmid:10693791 Yan:2000]; 
Southern Blot [pmid:15942939 
van der Klift:2005]; aCGH 
4 MSI-H tumours: 2 
[pmid:16251890 Pastrello:2006]; 
1 [orcid:Tops; 0000-0002-6769-
7290]; 1 [pmid:12938096 
Nakagawa:2003]. 
Segregation with sufficient data: 
segregation with disease in ACI 
family reported [pmid:15949572 
Zhu:2005]. ACI family with 4 
affected carriers [orcid:Tops; 0000-
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[pmid:18330910 Staaf:2008]; 
break-point analysis 
[pmid:12938096 
Nakagawa:2003]) 
0002-6769-7290]. 
5a MSH2 c.(?_-68)_1386+?del p.? Confirmed as contiguous exons [pmid:19173287 Gylling:2009] 
5 MSI-H tumours: 1 
[pmid:16251890 Pastrello:2006]; 
2 [orcid:Ian Frayling @ Cardiff; 
0000-0002-3420-0794]; 1 [Moni 
Morak]; 1 [lovd:Lagerstedt 
Robinson; 00078]. MSS: 1 
[lovd:Lagerstedt Robinson; 
00078]. 
Sufficient segregation data: 
segregation with disease in ACII 
family reported [pmid:19173287 
Gylling:2009]. 3 affected carriers 
[Aus CCFR]. 4 affected carriers 
[Mayo CCFR]. 2 affected carriers 
[orcid:Ian Frayling@Edinburgh; 
0000-0002-3420-0794]. 2 affected 
carriers [Moni Morak]. 
4a MSH2 c.(?_-68)_1759+?del c.-75398_1759+1708del p.? 
Exon 1-11 deletion confirmed 
[pmid:16885385 Hampel:2006] 
2 MSI-H tumours: 1 CRC 
[pmid:15872200 Hampel:2005]; 
1 EC [pmid:16885385 
Hampel:2006]. 
Summary family history only 
4a MSH2 c.(?_-68)_211+?del p.? 
Exon 1 deletion confirmed 2.1kb 
deletion identified by Southern 
blot [pmid:16826164 
Wijnen:1998]. Allele not 
transcribed [pmid:15870828 
Wehner:2005]. 
7 MSI-H tumours: 1 EC 
[orcid:Soto; 0000-0003-0234-
9188]; 1 [pmid:16142001 
Becouarn:2005]; 1 sebaceous 
epithelioma [pmid:16826164 
Ponti:2006]; 2 CRC & 1 EC 
[pmid:17453009 
Overbeek:2007]; 1 [Moni Morak] 
Insufficient segregation data: 2 
families: segregation LR 1.7 [Aus 
CCFR] 
5a MSH2 c.(?_-68)_366+?del c.-4729_367-353del p.? 
Exon 1-2 deletion confirmed by 
diploid-haploid conversion 
analysis [pmid:12938096 
Nakagawa:2003] 
4 MSI-H tumours: 1 [orcid:Soto; 
0000-0003-0234-9188]; 1 CRC 
[orcid:Leung et al; 0000-0001-
8614-4619; 0000-0002-1768-
4184; 0000-0002-8420-6633; 
0000-0002-8390-2442; 0000-
0002-4716-5000]; 1 EC 
[orcid:Capella; 0000-0002-4669-
7320]; 1 [pmid:12938096 
Nakagawa:2003] 
Sufficient segregation data: 4 
affected carriers [Aus CCFR]. 2 
affected carriers [orcid:Capella; 
0000-0002-4669-7320]. 
3a MSH2 c.(?_-68)_792+?del p.? 
Exon 1-4 deletion confirmed by 
LR-PCR [pmid:11830542 
Charbonnier:2002] 
MSI-H: 1 [pmid:18307539 
Yan:2008]; 1 adenoma 
[orcid:Viel; 0000-0003-2804-
0840] 
Insufficient segregation data: 
Bethesda fam with 2 affected 
carriers [orcid:Viel; 0000-0003-
2804-0840] 
4a MSH2 c.1034G>A p.Trp345* 
Loss of expression of affected 
allele due to NMD (diploid-
haploid conversion analysis 
[pmid:15713769 Casey:2005]) 
2 MSI-H tumours: 1 
[pmid:21387278 Bozzao:2011], 
[Monica Pedroni]; 1 
[pmid:16142001 Becouarn:2005] 
Insufficient segregation data: 
segregation LR 4.9 [Mayo CCFR] 
5a MSH2 c.1077-?_1276+?del p.Leu360Lysfs*16 Truncated polypeptide (PTT on 3 MSI-H tumours: 1 Sufficient segregation data: 
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c.1077-220_1276+6245del patient RNA [Desiree du Sart]) [pmid:19690142 Mueller:2009], 
1 [pmid:20924129 
Giraldez:2010]; 1 
[pmid:21778331 Perez-
Cabornero:2011]. MSS 
[pmid:19690142 Mueller:2009]. 
Spanish founder mutation, 3 
families: 4 affected carriers, 2 
affected carriers [pmid:21778331 
Perez-Cabornero:2011] 
4a MSH2 c.1077-?_1386+?del p.Leu360Trpfs*8 Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
7 MSI-H tumours: 1 
[pmid:16423994 Zhang:2006]; 1 
[pmid:16251890 Pastrello:2006], 
[Maria Grazia Tibiletti]; 1 
[pmid:16736289 Spaepen:2006]; 
1 [orcid:Leung et al; 0000-0001-
8614-4619; 0000-0002-1768-
4184; 0000-0002-8420-6633; 
0000-0002-8390-2442; 0000-
0002-4716-5000]; 1 [orcid:Tops; 
0000-0002-6769-7290]; 1 
[Robert Hofstra]; 1 [Paola Sala] 
Insufficient segregation data: 
segregation LR 1.94 [orcid:Leung 
et al; 0000-0001-8614-4619; 0000-
0002-1768-4184; 0000-0002-8420-
6633; 0000-0002-8390-2442; 
0000-0002-4716-5000]. 
4a MSH2 c.1077-?_1661+?del p.Arg359_Asn553del 
Exon 7-10 deletion confirmed 
(PTT & RT-PCR of patient RNA 
[pmid:10495924 
Wahlberg:1999]) 
3 MSI-H tumours: 1 
[pmid:19173287 Gylling:2009]; 1 
[Moni Morak]; 1 [orcid:Nordling; 
0000-0002-4047-4994]. 
Insufficient segregation data: 
segregation reported with disease 
[pmid:19173287 Gylling:2009]. 
3a MSH2 c.1077_1078ins173 p.? 
Truncated polypeptide (IVSP of 
patient RNA [pmid:08574961 
Liu:1996]) 
NA Summary family history only 
5a MSH2 c.1147C>T p.Arg383* Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
5 MSI-H tumours: 1 
[pmid:19731080 
Jasperson:2010]; 1 BrCa 
[pmid:22034109 Buerki:2012]; 1 
[0000-0002-1768-4184]; 1 
[orcid:Ian Frayling@Edinburgh; 
0000-0002-3420-0794]; 1 
Sebaceous adenoma 
[orcid:Capella; 0000-0002-4669-
7320] 
Sufficient segregation data: 3 ACI 
families (Combined segregation LR 
83.5, 1 ACI family [Aus CCFR] & 2 
ACI families [Mayo CCFR]). 2 
affected carriers [orcid:Ian 
Frayling@Edinburgh; 0000-0002-
3420-0794]. German Bethesda 
family with segregation LR 1.8:1 
[Nils Rahner]. Total segregation LR 
150.3:1 
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5a MSH2 c.1165C>T p.Arg389* 
Truncated polypeptide (PTT on 
patient RNA [Desiree du Sart], 
[pmid:19459153 Chong:2009]) 
7 MSI-H tumours: 1 
[pmid:21868491 Perez-
Carbonell:2012]; 1 
carcinosarcoma [pmid:19130300 
Nilbert:2009]; 1 [orcid:Genuardi; 
0000-0002-7410-8351]; 1 
[orcid:Leung et al; 0000-0001-
8614-4619; 0000-0002-1768-
4184; 0000-0002-8420-6633; 
0000-0002-8390-2442; 0000-
0002-4716-5000]; 2 [Moni 
Morak]; 1 [orcid:Ian 
Frayling@Liverpool; 0000-0002-
3420-0794]. 
Sufficient segregation data: 2 
affected carriers [orcid:Genuardi; 
0000-0002-7410-8351]. 4 affected 
carriers [Ontario CCFR]. 2 affected 
carriers [orcid:Leung et al; 0000-
0001-8614-4619; 0000-0002-1768-
4184; 0000-0002-8420-6633; 
0000-0002-8390-2442; 0000-0002-
4716-5000]. 
5a MSH2 c.1189C>T p.Gln397* 
Truncated polypeptide (IVSP on 
patient RNA [pmid:8880570 
Froggatt:1996]) 
4 MSI-H tumours: 1 
[pmid:15235030 Mangold:2004]; 
1 [orcid:Leung et al; 0000-0001-
8614-4619; 0000-0002-1768-
4184; 0000-0002-8420-6633; 
0000-0002-8390-2442; 0000-
0002-4716-5000]; 2 [Moni 
Morak] 
Sufficient segregation data: 5 
affected carriers [orcid:Leung et al; 
0000-0001-8614-4619; 0000-0002-
1768-4184; 0000-0002-8420-6633; 
0000-0002-8390-2442; 0000-0002-
4716-5000]. 
3a MSH2 c.1196_1197dup p.Asn400Glnfs*13 
Frameshift aberration (PTT on 
patient RNA [pmid:10882759 
Montera:2000]) 
MSI-H: 1 [pmid:10882759 
Montera:2000] Summary family history only 
5a MSH2 c.1216C>T p.Arg406* 
Truncated polypeptide (IVSP of 
patient RNA [pmid:08062247 
Liu:1994]; PTT of patient RNA 
[pmid:19459153 Chong:2009]; 
allele not expressed in diploid-
haploid conversion analysis 
[pmid:15713769 Casey:2005]) 
10 MSI-H tumours: 1 
[pmid:21590452 Perea:2011]; 8 
[pmid:10564582 Liu:2000]; 1 
[orcid:Genuardi; 0000-0002-
7410-8351] 
Sufficient segregation data: 2 
affected carriers [pmid:8261515 
Leach:1993]. 3 affected carriers 
[pmid:15952990 Sarroca:2005]. 8 
tumours from carriers in ACI family 
[pmid:10564582 Liu:2000]. 2 
affected carriers [orcid:Genuardi; 
0000-0002-7410-8351]. 3 families 
with 3 affected carriers each 
[orcid:Capella; 0000-0002-4669-
7320]. 
Nature Genetics: doi:10.1038/ng.2854
 34!
5a MSH2 c.1226_1227del p.Gln409Argfs*7 Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
7 MSI-H tumours: 1 
[pmid:21778331 Perez-
Cabornero:2011]; 1 [Mayo 
CCFR]; 2 [pmid:15955785 
Mueller-Koch:2005], [Moni 
Morak]; 1 [pmid:17312306 
Lagerstedt Robinson:2007]; 1 
[orcid:Tops; 0000-0002-6769-
7290]; 1 [Moni Morak] 
Sufficient segregation data: 2 
families with segregation LR 2.0:1 
[Aus CCFR], [Mayo CCFR]. Dutch 
family with segregation LR 3.7:1 
[orcid:Tops; 0000-0002-6769-
7290]. 5 affected carriers over 2 
ACI families [Moni Morak]. German 
ACI family with segregation LR 
0.9:1 [Nils Rahner]. Combined 
segregation LR 6.7:1 
4a MSH2 c.1255C>T p.Gln419* 
Truncated polypeptide (IVSP on 
patient RNA [pmid:10080150 
Lin:1999]) 
2 MSI-H tumours: 1 [orcid:Soto; 
0000-0003-0234-9188]; 1 
[pmid:10404063 Bai:1999] 
Summary family history only 
4a MSH2 c.1277-?_(*272_?)inv p.? 
Inversion of exons 8-16 
confirmed (LR-PCR of patient 
RNA [pmid:15942939 van der 
Klift:2005]; diploid-haploid 
conversion analysis 
[pmid:12658575 Wagner:2003]) 
NA 
Sufficient segregation data: ACI 
(North American, 5 affected 
carriers [pmid:12203789 
Wagner:2002]) 
5a MSH2 
c.1277-?_1386+?del 
c.1277-572_1386+2326del 
c.1276+232_1386+3798del 
p.Lys427Glyfs*4 
Exon 8 deletion confirmed (2 
cases: PTT & RT-PCR of patient 
RNA [pmid:10190329 
Bapat:1999]; RT-PCR of patient 
RNA [pmid:16451135 
Kurzawski:2006]; PTT on patient 
RNA [Desiree du Sart]) 
9 MSI-H: 1 [pmid:19173287 
Gylling:2009]; 1 [pmid:21590452 
Perea:2011]; 4 [pmid:20682701 
Woods:2010]; 1 [pmid:21636617 
Win:2011]; 1 [Moni Morak]; 1 
CRC [pmid:12938096 
Nakagawa:2003] 
Sufficient segregation data: 
Sardinian founder mutation, 13 
families: 3, 9 & 4 affected non-
proband carriers [pmid:22781090 
Borelli:2012] 
5a MSH2 c.1277-?_2634+?del p.Gly426Alafs*3 
Truncated polypeptide (IVSP & 
RT-PCR on patient RNA 
[pmid:08062247 Liu:1994]) 
2 MSH2 absent: 2 CRC [USC 
CCFR] 
Sufficient segregation data: 4 
affected carriers [USC CCFR]. 
4a MSH2 c.1373T>G p.Leu458* 
Truncated polypeptide (IVSP on 
patient RNA [pmid:08062247 
Liu:1994]) 
5 MSI-H tumours: 2 EC & 1 
OvCa [pmid:10432927 
Ichikawa:1999]; 1 
[pmid:11304573 
Salahshor:2001], 
[pmid:17312306 Lagerstedt 
Robinson:2007]; 1 
[pmid:16216036 Mangold:2005] 
Insufficient segregation data: 
German ACI family with 
segregation LR 6.7 [Nils Rahner] 
5a MSH2 c.1387-?_1510+?del p.Val463Alafs*22 
Exon 9 deletion confirmed (2 
families: RT-PCR of patient RNA 
[pmid:16451135 
Kurzawski:2006]) 
7 MSI-H tumours: 1 
[pmid:18931482 Sheng:2008]; 1 
EC [pmid:17453009 
Overbeek:2007]; 4 CRC & 1 EC 
[orcid:Tops; 0000-0002-6769-
7290] 
Sufficient segregation data: ACI 
fam with 10 affected carriers, 
Bethesda fam with 2 affected 
carriers, ACI fam with 3 affected 
carriers [orcid:Tops; 0000-0002-
6769-7290] 
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5a MSH2 c.1387-?_1661+?del p.Val463Glnfs*7 
Exon 9-10 deletion confirmed 
(RT-PCR of patient RNA 
[pmid:19173287 Gylling:2009]; 
PTT on patient RNA 
[pmid:19459153 Chong:2009]) 
6 MSI-H tumours: 1 
[pmid:19173287 Gylling:2009]; 1 
[pmid:16251890 Pastrello:2006]; 
1 [pmid:15235030 
Mangold:2004]; 3 [orcid:Capella; 
0000-0002-4669-7320] 
Sufficient segregation data: 
segregation with disease reported 
[pmid:19173287 Gylling:2009]. 13 
affected carriers [Aus CCFR]. 4 
affected carriers [orcid:Capella; 
0000-0002-4669-7320]. 
5a MSH2 c.1457_1460del p.Asn486Thrfs*10 
Frameshift aberration (2 cases: 
IVSP on patient RNA 
[pmid:10413423 Chan:1999]) 
11 MSI-H tumours: 2 
[pmid:10413423 Chan:1999]; 9 
[orcid:Leung et al; 0000-0001-
8614-4619; 0000-0002-1768-
4184; 0000-0002-8420-6633; 
0000-0002-8390-2442; 0000-
0002-4716-5000] 
Sufficient segregation data: 
Chinese founder mutation, 
segregates in 10 families 
[pmid:15042510 Chan:2004] & 
segregates in 8 families 
[orcid:Leung et al; 0000-0001-
8614-4619; 0000-0002-1768-4184; 
0000-0002-8420-6633; 0000-0002-
8390-2442; 0000-0002-4716-
5000]. 
5a MSH2 c.1552_1553del p.Gln518Valfs*10 
Frameshift aberration (PTT on 
patient RNA [pmid:10200055 
Holmberg:1998]) 
MSI-H in 4 tumours: 1 
[pmid:18307539 Yan:2008]; 3 
[pmid:10564582 Liu:2000] 
Sufficient segregation data: 2 ACI 
families (Finnish families, 11 
affected carriers over 2 kindreds 
[pmid:10200055 Holmberg:1998], 
[pmid:14574010 Peltomaki:2001] 
3a MSH2 c.1552C>T p.Gln518* 
Truncated polypeptide (PTT on 
patient RNA [pmid:10713887 
Fidalgo:2000]) 
MSH2 absent: 1 CRC [Kate 
Green] Summary family history only 
5a MSH2 c.1566C>G p.Tyr522* 
Low expression of affected allele 
(diploid-haploid conversion 
analysis [pmid:15713769 
Casey:2005]) 
MSI-H: 1 [orcid:Leung et al; 
0000-0001-8614-4619; 0000-
0002-1768-4184; 0000-0002-
8420-6633; 0000-0002-8390-
2442; 0000-0002-4716-5000]. 2 
MSH2 absent: 1 
[pmid:15713769 Casey:2005]; 1 
[Aus CCFR] 
Sufficient segregation data: 2 
families, segregation LR 36.5 [Aus 
CCFR], [Mayo CCFR], 
[pmid:15713769 Casey:2005]. 2 
affected carriers [orcid:Leung et al; 
0000-0001-8614-4619; 0000-0002-
1768-4184; 0000-0002-8420-6633; 
0000-0002-8390-2442; 0000-0002-
4716-5000]. 
4a MSH2 c.1578del p.Cys527Valfs*16 Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
MSI-H: 1 [pmid:15235030 
Mangold:2004]. MSH2 absent: 1 
[Desiree du Sart]. 
Insufficient segregation data: 
German MTS family 
[pmid:15235030 Mangold:2004]. 
ACII fam with seg LR 1.9:1 [Kate 
Green]. 
4a MSH2 c.1662-?_2458+?del c.1662-374_2458+467del p.Ser554Argfs*4 
Exon 11-14 deletion confirmed 
(8.4kb deletion identified by LR-
PCR & breakpoint analysis, Alu-
5 MSI-H tumours: 1 
[pmid:14645426 Berends:2003], 
[pmid:16636019 Niessen:2006]; 
Summary family history only 
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Alu [pmid:12494471 
Wang:2003]) 
2 [orcid:Tops; 0000-0002-6769-
7290]; 2 [pmid:16216036 
Mangold:2005]. 
5a MSH2 c.1738G>T p.Glu580* 
Truncated polypeptide (IVSP on 
patient RNA [pmid:10413423 
Chan:1999]; low expression of 
affected allele in conversion 
analysis [pmid:15713769 
Casey:2005]; PTT on patient 
RNA [Desiree du Sart]) 
4 MSI-H tumours: 3 CRC 
[pmid:15849733 Mangold:2005], 
[pmid:16216036 Mangold:2005]; 
1 [pmid:19731080 
Jasperson:2010] 
Sufficient segregation data: 8 
affected carriers [pmid:15713769 
Casey:2005], [Aus CCFR]. 
3a MSH2 c.1760-?_2005+?del c.1759+305_2006-34del p.Tyr588_Gly669del 
Exon 12 deletion confirmed 
(1.9kb deletion identified by LR-
PCR [pmid:18307539 
Yan:2008]) 
MSI-H: 1 [pmid:18307539 
Yan:2008] Summary family history only 
4a MSH2 c.1760-361_2634+838del p.Gly587Alafs*3 
Exon 12-15 deletion confirmed 
(7kb deletion identified by LR-
PCR & breakpoint analysis, Alu-
Alu [pmid:12494471 
Wang:2003]) 
MSI-H/ACII (1 CRC 
[pmid:15849733 Mangold:2005]) 
Sufficient segregation data: 4 
affected carriers In ACI family 
[pmid:12494471 Wang:2003] 
4a MSH2 c.1760del p.Gly587Alafs*3 
Frameshift aberration (IVSP on 
patient RNA [pmid:10413423 
Chan:1999]) 
2 MSI-H tumours: 1 glioma 
[pmid:9777949 Leung:1998]; 1 
CRC [pmid:12386821 
Yuen:2002] 
Summary family history only 
4a MSH2 c.1801C>T p.Gln601* 
Truncated polypeptide (IVSP on 
patient RNA [pmid:07585065 
Liu:1995], [pmid:09718327 
Farrington:1998]) 
MSI-H: 1 [pmid:07704024 
Liu:1995] 
Sufficient segregation data: 6 
affected carriers, LOD 3.08 
[pmid:7713503 Kolodner:1994]. 
3a MSH2 c.1885C>T p.Gln629* 
Truncated polypeptide (PTT on 
patient RNA [pmid:15991306 
Kohonen-Corish:2005]) 
NA Summary family history only 
5a MSH2 c.1889_1892del p.Gly630Glufs*4 Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
MSH2 absent in 3 tumours: 3 
[Aus CCFR] 
Sufficient segregation data: 4 
families, segregation LR 18.6:1 
[Aus CCFR] 
3a MSH2 c.1996_1997del p.Ile666Hisfs*9 
Truncated polypeptide (PTT on 
patient RNA [pmid:10080150 
Lin:1999]) 
NA Summary family history only 
5a MSH2 c.2006-?_2210+?del p.Pro670Leufs*7 
Truncated polypeptide (IVSP & 
RT-PCR of patient RNA 
[pmid:08062247 Liu:1994]) 
2 MSI-H tumours: 1 [Aus CCFR]; 
1 [pmid:11407044 Soravia:2001] 
Sufficient segregation data: 4 
affected carriers [pmid:15951966 
Akrami:2005] 
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5a MSH2 c.2038C>T p.Arg680* Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
7 MSI-H tumours: 1 CRC 
[pmid:18809606 Hampel:2008]; 
1 CRC [pmid:20305446 
Alvarez:2010]; 1 malignant 
fibrous histiocytoma 
[pmid:21598002 Brieger:2011]; 
2 [orcid:Genuardi; 0000-0002-
7410-8351]; 2 [Moni Morak] 
Sufficient segregation data: 4 
affected carriers [Aus CCFR]. 2 
affected carriers [orcid:Genuardi; 
0000-0002-7410-8351]. 5 affected 
carriers [orcid:Ian 
Frayling@Edinburgh; 0000-0002-
3420-0794]. 4 affected carriers 
[Moni Morak]. 5 informative 
meisoses [Pal Moller]. 
3a MSH2 c.2074_2081del p.Gly692Cysfs*4 Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
MSI-H: 1 CRC [pmid:16116158 
Southey:2005], [Desiree du Sart] Summary family history only 
4a MSH2 c.212-?_1276+?del c.211+1566_1277-3954del p.Ala72_Gly426del 
Truncated polypeptide (PTT on 
patient RNA [Desiree du Sart]) 
2 MSH2 absent: 1 OvCa 
[pmid:16034045 
Stormorken:2005];  1 [Desiree 
du Sart] 
Summary family history only 
4a MSH2 c.212-?_1386+?del p.Ala72Glyfs*4 
Exon 2-8 deletion confirmed 
(PTT & RT-PCR of patient RNA 
[pmid:10190329 Bapat:1999]) 
MSI-H: 1 [pmid:11074494 
Davoodi-Semiromi:2000] 
Sufficient segregation data: 3 
affected carriers in ACI family 
[pmid:10190329 Bapat:1999] 
5a MSH2 c.212-?_366+?del p.Ala72Phefs*9 
Exon 2 deletion confirmed 
(5.4kb deletion identified by 
southern blot [pmid:16826164 
Wijnen:1998], [pmid:15942939 
van der Klift:2005]; RT-PCR of 
patient RNA [Moni Morak]) 
8 MSI-H tumours: 1 
[pmid:12373605 Gille:2002]; 1 
EC [pmid:14645426 
Berends:2003]; 1 
[pmid:15289847 Caldes:2004]; 1 
[pmid:17312306 Lagerstedt 
Robinson:2007], 
[lovd:Lagerstedt Robinson; 
00078]; 3 [pmid:17453009 
Overbeek:2007]; 1 [orcid:Tops; 
0000-0002-6769-7290]. 
Sufficient segregation data: ACI 
family with 7 affected carriers, 2x 
ACI families with 2 affected 
carriers, ACI fam with 3 affected 
carriers [orcid:Tops; 0000-0002-
6769-7290]. 
5a MSH2 c.2131C>T p.Arg711* Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
7 MSI-H tumours: 1 
[pmid:21387278 Bozzao:2011]; 
1 [pmid:21868491 Perez-
Carbonell:2012]; 1 [orcid:Soto; 
0000-0003-0234-9188]; 1 EC & 
2 CRC [orcid:Genuardi; 0000-
0002-7410-8351]; 1 
[lovd:Lagerstedt Robinson; 
00078]. 
Sufficient segregation data: 4 
affected carriers [Aus CCFR]. 
5a MSH2 c.226C>T p.(Gln76*) 
Homozygote (CMMRD in 2 
families [pmid:17483304 
Barwell:2007]; [pmid:17601929 
Scott:2007]) 
MSI-H: 1 CRC [pmid:22480969 
Bonnet:2012]. MSH2 absent: 1 
CRC [pmid:16034045 
Stormorken:2005], [Pal Moller] 
Sufficient segregation data: ACII (2 
Kuwaiti families, 15 affected 
carriers [orcid:Marafie; 0000-0003-
0853-2039]) 
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4a MSH2 c.2294del p.Ala765Valfs*47 
Truncated polypeptide (IVSP on 
patient RNA [pmid:9218993 
Pensotti:1997]) 
NA 
Sufficient segregation data: 4 
affected carriers [pmid:9218993 
Pensotti:1997]. 
5a MSH2 c.2347del p.(His783Ilefs*29) 
Loss of MSH2 expression in 
transfected LoVo cells 
[pmid:12377806 Brieger:2002] 
MSI-H: 1 [pmid:11601928 
Raedle:2001]. MSH2 absent:  1 
EC [pmid:11291077 
Berends:2001] 
Sufficient segregation data: 3 
affected carriers & 3 obligate 
carriers [pmid:7726159 
Wijnen:1995] 
5a MSH2 c.2459-?_(*272_?)del p.? 
Complete loss of one copy of 
MSH2 gene (FISH on patient 
DNA [pmid:15943554 
Grabowski:2005]) 
3 MSI-H tumours: 3 
[pmid:15943554 
Grabowski:2005], [Moni Morak] 
Sufficient segregation data: 4 
affected carriers [Moni Morak]. 
4a MSH2 c.2466_2467del p.Cys822* Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
2 MSI-H tumours: 1 [Desiree du 
Sart]; 1 [pmid:15365996 
Kruger:2004] 
Summary family history only 
3a MSH2 c.2485del p.His829Metfs*12 
Frameshift aberration (PTT on 
patient RNA [pmid:15991306 
Kohonen-Corish:2005]) 
MSH2 absent: 1 [Desiree du 
Sart] Summary family history only 
4a MSH2 c.2502_2508del p.Asn835Leufs*4 Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
MSI-H: 1 [pmid:11720433 
Coleman:2001]. 3 MSH2 absent: 
2 [Aus CCFR]; 1 [Diane Cairns] 
Insufficient segregation data: 3 
families, segregation LR 3.7:1 [Aus 
CCFR] 
3a MSH2 c.2581C>T p.Gln861* 
Frameshift aberration (PTT on 
patient RNA [pmid:10480359 
Wang:1999]) 
NA Summary family history only 
5a MSH2 c.2633_2634del p.Glu878Alafs*3 
Frameshift aberration (PTT on 
patient RNA [pmid:10190329 
Bapat:1999]) 
11 MSI-H tumours: 4 
[orcid:Soto; 0000-0003-0234-
9188]; 1 [Aus CCFR]; 1 
[pmid:8690195 Konishi:1996]; 1 
[pmid:11208710 
Terdiman:2001]; 1 [Moni Morak]; 
3 [Robert Hofstra] 
Sufficient segregation data: 
Bethesda family, with 2 affected 
carriers [Robert Hofstra]. ACI 
(Canadian family, segregation LR 
15:1 [pmid:10196371 Millar:1999], 
[pmid:15845562 Durno:2005]. 
4a MSH2 c.269_290dup p.Tyr98Argfs*9 
Truncated polypeptide (PTT on 
patient RNA [pmid:10323887 
Lamberti:1999]) 
2 MSI-H tumours: 1 sebaceous 
epithelioma & 1 sebaceous 
adenoma [pmid:08931714 
Kruse:1996] 
Insufficient segregation data for 
Class 5: German ACI family with 
segregation LR 5.5:1 [Nils Rahner 
& Brigitte Royer-Pakora] 
4a MSH2 c.367-?_1386+?del p.Ala123_Gln462del 
Exon 3-8 deletion confirmed by 
LR-PCR, homologous 
recombination [pmid:15942939 
van der Klift:2005] 
2 MSI-H: 1 CRC & 1 sebaceous 
carcinoma [Maria Grazia 
Tibiletti] 
Summary family history only: ACI 
(North American proband CRC age 
<50 [pmid:12658575 
Wagner:2003]) 
5a MSH2 
c.367-?_645+?del 
c.367-480_645+644del 
c.367-681_646-956del 
c.367-371_646-513del 
p.Ala123_Gln215del 
Exon 3 deletion comfirmed (PTT 
& RT-PCR on patient RNA 
[pmid:10190329 Bapat:1999]; 
LR-PCR [pmid:12494471 
Wang:2003]; PTT on patient 
9 MSI-H tumours: 1 CRC 
[orcid:Mensenkamp & 
Ligtenberg; 0000-0003-3805-
877X]; 1 [pmid:12547705 
Hendriks:2003]; 1 
Sufficient segregation data: 2 
families: 1 affected non-proband 
carrier & 7 affected carriers 
[orcid:Genuardi; 0000-0002-7410-
8351]. Segregates with disease in 
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RNA [Desiree du Sart], 
[pmid:19459153 Chong:2009]; 
Southern blot [pmid:16826164 
Wijnen:1998]) 
[pmid:10190329 Bapat:1999]; 2 
[pmid:12373605 Gille:2002]; 1 
[pmid:16216036 Mangold:2005]; 
1 [orcid:Genuardi; 0000-0002-
7410-8351]; 1 [pmid:12547705 
Hendriks:2003]; 1 
[pmid:12373605 Gille:2002]. 
3 families [orcid:Tops; 0000-0002-
6769-7290]; 3 affected carriers 
[pmid:15655560 Apessos:2005]. 
Segregates with disease in 2 
families [orcid:Tops; 0000-0002-
6769-7290]. 
4a MSH2 c.367-?_942+?del p.Ala123_Gln314del Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
MSI-H: 1 [pmid:15943554 
Grabowski:2005]. MSH2 absent: 
1 [Desiree du Sart] 
Insufficient segregation data: 
segregation LR 2.67:1 
[orcid:Capella; 0000-0002-4669-
7320]. 
5a MSH2 c.388_389del p.(Gln130Valfs*2) 
15 Portuguese families: different 
haplotypes [pmid:23170986 
Pinheiro:2012] 
MSI-H: 1 [pmid:22480969 
Bonnet:2012]. 10 MSH2 absent: 
1 [pmid:22480969 Bonnet:2012]; 
9 [pmid:23170986 
Pinheiro:2012] 
Sufficient segregation data: 55 
affected carriers in 15 Portuguese 
families: different haplotypes 
[pmid:23170986 Pinheiro:2012] 
4a MSH2 c.508C>T p.Gln170* Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
MSI-H: 1 [Aus CCFR]. MSH2 
absent: 1 BrCa [Aus CCFR] 
Sufficient segregation data for 
Class 4: ACI family with 
segregation LR 4.3:1 [Aus CCFR]. 
German ACI family with 
segregation LR 1.6:1 [Nils Rahner]. 
Total segregation LR 6.9. 
3a MSH2 c.513del p.Lys172Asnfs*2 
Frameshift aberration (IVSP on 
patient RNA [pmid:10413423 
Chan:1999]) 
MSI-H: 1 [pmid:10413423 
Chan:1999] 
Insufficient segregation data: 
segregation with disease reported 
[pmid:10413423 Chan:1999]. 
3a MSH2 c.547C>T p.Gln183* 
Truncated polypeptide (PTT on 
patient RNA [pmid:10713887 
Fidalgo:2000]) 
MSI-H: 1 [pmid:12200596 
Ward:2002] Summary family history only 
3a MSH2 c.643C>T p.Gln215* Truncated polypeptide (PTT [pmid:10190329 Bapat:1999]) 
MSI-H: 1 [pmid:10190329 
Bapat:1999] Summary family history only 
4a MSH2 
c.645+791_1076+4894del 
c.645+967_1076+5075del 
c.646-?_1076+?del 
c.645+539_1077-3451del 
p.Ile217Glufs*28 
Exon 4-6 deletion (Alu-Alu 
recombination identified by 
aCGH & breakpoint analysis - 
[pmid:18330910 Staaf:2008]) 
NA 
Sufficient segregation data for 
Class 4: ACI (3 affected carriers 
[pmid:19760518 Martinez-
Bouzas:2009]) 
5a MSH2 c.646-?_1386+?del p.Ile216_Gln462del 
Truncated polypeptide (IVSP on 
cell line [pmid:07704024 
Liu:1995]) 
3 MSI-H tumours: 2 
[pmid:21778331 Perez-
Cabornero:2011]; 1 
[orcid:Capella; 0000-0002-4669-
7320]. 
Sufficient segregation data: 
Spanish founder mutation, 
segregates in 4 families; 2 affected 
carriers, 3 affected carriers, 4 
affected carriers [pmid:21778331 
Perez-Cabornero:2011]. 
Nature Genetics: doi:10.1038/ng.2854
 40!
4a MSH2 c.646-?_792+?del p.Ile216_Gln264del 
Truncated polypeptide (PTT on 
patient RNA [pmid:10480359 
Wang:1999]) 
2 MSI-H: 1 [Robert Hofstra]; 1 
[Mayo CCFR] Summary family history only 
4a MSH2 c.687del p.Ala230Leufs*16 
Frameshift aberration (PTT on 
patient RNA [pmid:10480359 
Wang:1999]) 
3 MSI-H tumours: 1 
[pmid:10404063 Bai:1999]; 1 
[pmid:15926618 Wolf:2005]; 1 
[Moni Morak] 
Summary family history only 
4a MSH2 c.754C>T p.Gln252* 
Truncated polypeptide (IVSP on 
patient RNA [pmid:07585065 
Liu:1995], [pmid:09718327 
Farrington:1998]) 
3 MSI-H tumours: 1 
[pmid:07585065 Liu:1995]; 2 
[pmid:16807412 
Barnetson:2006] 
Sufficient segragation data for 
Class 4: 2 affected carriers 
[pmid:16807412 Barnetson:2006]. 
Segregation LR 3.4:1 [orcid:Ian 
Frayling@Edinburgh; 0000-0002-
3420-0794]. 
3a MSH2 c.793-?_1386+?del p.Ala266_Val463del Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) NA Summary family history only 
5a MSH2 
c.793-?_942+?del 
c.793-6_942+450del 
c.792+8_943-450del 
p.Val265_Gln314del 
Exon 5 deletion confirmed (RT-
PCR [pmid:15063132 
Miyaki:2004]; PTT on patient 
RNA [Desiree du Sart]; 
breakpoint analysis 
[pmid:10850409 
Charbonnier:2000], 
[pmid:15942939 van der 
Klift:2005]) 
2 MSH2 absent: 1 [Aus CCFR]; 
1 [pmid:15942939 van der 
Klift:2005] 
Sufficient segregation data: 3 
families: 4 affected carriers, 3 
affected carriers & 2 affected 
carriers [Aus CCFR] 
4a MSH2 c.811_814del p.Ser271Argfs*2 
Frameshift aberration (IVSP on 
patient RNA [pmid:07585065 
Liu:1995], [pmid:09718327 
Farrington:1998]) 
3 MSI-H tumours: 1 
[pmid:09718327 
Farrington:1998]; 1 transitional 
cell Roupret 2004; 1 
[pmid:17312306 Lagerstedt 
Robinson:2007], 
[lovd:Lagerstedt Robinson; 
00078] 
Summary family history only 
5a MSH2 c.943-?_1076+?del c.943-926_1077-1449del p.Gly315Ilefs*29 
Exon 6 deletion (Southern blot & 
breakpoint analysis 
[pmid:16826164 Wijnen:1998], 
[pmid:15942939 van der 
Klift:2005]) 
3 MSI-H tumours: 1 EC 
[pmid:17453009 
Overbeek:2007]; 1 [orcid:Leung 
et al; 0000-0001-8614-4619; 
0000-0002-1768-4184; 0000-
0002-8420-6633; 0000-0002-
8390-2442; 0000-0002-4716-
5000]; 1 [Moni Morak] 
Sufficient segregation data: 3 
affected carriers [orcid:Leung et al; 
0000-0001-8614-4619; 0000-0002-
1768-4184; 0000-0002-8420-6633; 
0000-0002-8390-2442; 0000-0002-
4716-5000]; 7 affected carriers & 4 
affected carriers [orcid:Tops; 0000-
0002-6769-7290]. 
4a MSH2 c.970C>T p.Gln324* Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
3 MSI-H tumours: 2 
[pmid:16142001 
Becouarn:2005]; 1 [Moni Morak] 
Summary family history only 
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4a MSH6 c.(?_-152)_457+?del c.-3097_457+2010del p.? 
Exon 1-2 deletion (LR-PCR 
[pmid:12920072 
Plaschke:2003]) 
3 MSI-H tumour: 1 uroethial cell 
tumour [pmid:17453009 
Overbeek:2007]; 1 [Daniela 
Barana]; 1 [pmid:15483016 
Plaschke:2004]. 
Summary family history only 
3a MSH6 c.762_763del p.Ser256* 
Truncated polypeptide (PTT on 
patient RNA [pmid:19459153 
Chong:2009]) 
MSH6 absent 1 in tumour 
[pmid:19459153 Chong:2009] 
Summary family history only: ACI 
[pmid:19459153 Chong:2009] 
4a MSH6 c.1139_1143del p.Asp380Alafs*6 Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
MSH6 absent in 2 tumours: 1 
[Desiree du Sart]; 1 OvCa 
[orcid:Tops; 0000-0002-6769-
7290]. 
Insufficient segregation data for 
Class 5: ACII fam with seg LR 
7.4:1 [orcid:Tops; 0000-0002-6769-
7290]. 
4a MSH6 c.1628_1629del p.Lys543Argfs*19 Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
MSI-H: 1 OvCa [orcid:Tops; 
0000-0002-6769-7290]. MSS: 1 
[Aus CCFR]. MSI-L: 1 [Desiree 
du Sart]. MSH6 absent: 1 [Aus 
CCFR]. 
Insufficient segregation LR: 
Bethesda proband segregation LR 
1.8:1 [orcid:Tops; 0000-0002-6769-
7290]. 
4a MSH6 c.2150_2153del p.Val717Alafs*18 Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
5 MSI-H tumours: 1 OvCa 
[pmid:22006311 Walsh:2011]; 1 
[Robert Hofstra]; 1 CRC, 1 EC, 1 
sebaceous [orcid:Viel; 0000-
0003-2804-0840]. 
Insufficient segregation data: 
Bethesda MTS family with 
segregation LR 3.7:1 [orcid:Viel; 
0000-0003-2804-0840]. 
4a MSH6 c.2765del p.Arg922Glnfs*23 Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
MSH6 absent in 2 tumours 
[Desiree du Sart]. MSS: 1 
[Desiree du Sart] 
Summary family history only 
3a MSH6 c.3053_3054del p.Leu1018Hisfs*4 
Truncated polypeptide (PTT on 
patient RNA [pmid:11245474 
Huang:2001]) 
MSS: 1 [pmid:17312306 
Lagerstedt Robinson:2007] 
Insufficient segregation data: ACI 
(Swedish family, segregatio LR  
2.1:1 [pmid:11245474 
Huang:2001]) 
4a MSH6 c.3103C>T p.Arg1035* 
Truncated polypeptide (PTT on 
patient RNA [pmid:10471527 
Planck:1999]) 
2 MSI-H tumours: 1 
[pmid:10471527 Planck:1999]; 1 
OvCa [pmid:22006311 
Walsh:2011] 
Summary family history only 
3a MSH6 c.3173-433_3556+228del p.Asp1058_Ser1185del 
Exon 5-6 deletion confirmed 
(breakpoint analysis 
[pmid:16885385 Hampel:2006]) 
MSH6 absent: 1 EC 
[pmid:16885385 Hampel:2006] Summary family history only 
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5a MSH6 c.3202C>T p.Arg1068* Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
MSI-H: 1 [orcid:Tops; 0000-
0002-6769-7290]. MSH6 absent 
in 7 tumours: 2 [pmid:18301448 
Steinke:2008]; 2 [Desiree du 
Sart]; 1 EC & 1 CRC [Moni 
Morak]; 1 [orcid:Capella; 0000-
0002-4669-7320] 
Sufficient segregation data: Total 
segregation LR 10.2:1. 
Segregation LR ~3.5:1 in revised 
Bethesda family [orcid:Capella; 
0000-0002-4669-7320]. 
Segregation LR 0.79:1 [orcid:Ian 
Frayling @ Cardiff; 0000-0002-
3420-0794]; segregation LR 3.7:1 
[Aus CCFR]. 
5a MSH6 c.3261del p.Phe1088Serfs*2 Truncated polypeptide (PTT on patient RNA [Desiree du Sart]) 
3 MSI-H tumours: 1 
[pmid:22480969 Bonnet:2012]; 1 
EC [orcid:Mensenkamp & 
Ligtenberg; 0000-0003-3805-
877X]; 1 [orcid:Capella; 0000-
0002-4669-7320] 
Sufficient segregation data: 4 
affected carriers [pmid:10508506 
Wijnen:1999]. 2 affected carriers 
[Rodney Scott]. Revised Bethesda 
with 2 affected carriers & ACI 
family with 3 affected carriers 
[orcid:Capella; 0000-0002-4669-
7320]. 
4a MSH6 c.3939_3957dup p.Ala1320Serfs*5 
Truncated polypeptide (PTT on 
patient RNA [pmid:19459153 
Chong:2009], [Desiree du Sart]) 
3 MSI-H tumours: 1 
[pmid:18809606 Hampel:2008]; 
1 [pmid:16807412 
Barnetson:2006]; 1 [Aus CCFR]. 
MSS: 1 rectal [pmid:16807412 
Barnetson:2006], [orcid:Ian 
Frayling@Edinburgh; 0000-
0002-3420-0794]. 
Summary family history only 
4a MSH6 c.3991C>T p.Ala1268Glyfs*6 
r.3802_4001del (exon 9 skipping 
causing frameshift, no full-length 
expressed by mutant allele: RT-
PCR of patient RNA 
[pmid:16418736 
Plaschke:2006]) 
MSI-H: 1 [pmid:18301448 
Steinke:2008]. MSH6 absent in 
2 tumours: 2 EC 
[pmid:16034045 
Stormorken:2005], 
[pmid:20587412 Sjursen:2010]. 
Insufficient segregation data: 
Bethesda (German proband rectal 
cancer age 19 & EC age 24 
[pmid:18301448 Steinke:2008]). 5 
carriers & 10 carriers in 2 revised 
Behtesda families, affected status 
unknown [pmid:20587412 
Sjursen:2010]. 
4a PMS2 c.1145-1350_ *20545del p.? 
Exon 11-15 deletion (36kb 
deletion identified by Southern 
blot [pmid:16472587 
Hendriks:2006]) 
PMS2 absent in 2 tumours 
[pmid:16472587 Hendriks:2006] 
Insufficient segregation data: 
segregation LR 2.7:1 
[pmid:16472587 Hendriks:2006], 
[orcid:Tops; 0000-0002-6769-7290] 
4a PMS2 c.164-518_803+252delinsCG p.? 
Exon 3-7 skipping frameshift 
(RT-PCR of patient RNA 
[pmid:20186688 van der 
Klift:2010]) 
PMS2  absent in 2 tumours 
[orcid:Tops; 0000-0002-6769-
7290] 
Insufficient segregation data: 2 
families: segregation LR 4.23:1 
[orcid:Tops; 0000-0002-6769-7290] 
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4a PMS2 c.1882C>T p.Arg628* 
RNA subject to NMD (RT-PCR 
of patient RNA [pmid:20186688 
van der Klift:2010]) 
2 MSI-H tumours: 1 CRC 
[orcid:Mensenkamp & 
Ligtenberg; 0000-0003-3805-
877X]; 1 [orcid:Tops; 0000-
0002-6769-7290] 
Insufficient segregation data for 
Class 5: 2 families: segregation LR 
5.0:1 (1) [pmid:16472587 
Hendriks:2006], [orcid:Tops; 0000-
0002-6769-7290] 
4a PMS2 c.219_220dup p.Gly74Valfs*3 
RNA subject to NMD (RT-PCR 
of patient RNA [pmid:20186688 
van der Klift:2010]) 
MSI-H: 1 uterine [orcid:Tops; 
0000-0002-6769-7290], [Robert 
Hofstra]. MSI-L: 1 [orcid:Tops; 
0000-0002-6769-7290]. PMS2 
absent in 3 tumours: 1 
lymphoma homozygote & 1 
CRC [orcid:Tops; 0000-0002-
6769-7290], [pmid:20186688 
van der Klift:2010]; 1 [Robert 
Hofstra]. 
Insufficient segregation data: 
segregation LR 2.73:1 [orcid:Tops; 
0000-0002-6769-7290] 
4a PMS2 c.2192_2196del p.Leu731Cysfs*3 
RNA subject to NMD (RT-PCR 
of patient RNA [pmid:20186688 
van der Klift:2010]) 
PMS2 absent in 4 tumours: 1 
Nagakawa 2004; 1 
[pmid:20186688 van der 
Klift:2010]; 2 [orcid:Tops; 0000-
0002-6769-7290] 
Insufficient segregation data: 
Bethesda family segregation LR 
1.7:1 [orcid:Tops; 0000-0002-6769-
7290]. 
4a PMS2 c.2276-113_2445+1596del p.Ala759Glyfs*8 
Exon 14 skipping frameshift 
(RT-PCR of patient RNA 
[pmid:20186688 van der 
Klift:2010]) 
PMS2 absent in 2 tumours: 2 
[pmid:20186688 van der 
Klift:2010]. 
Summary family history only 
4a PMS2 c.2404C>T p.(Arg802*) 
Deficient (in vivo function Hec-
1A EC cell line [pmid:07629132 
Risinger:1995]) 
PMS2 absent in 2 tumours: 1 
[pmid:18602922 Senter:2008]; 1 
[Aus CCFR] 
Summary family history only 
5a PMS2 c.24-12_107delinsAAAT p.Ser8Argfs*5 
r.24_163del (Exon 2 skipping 
causing frameshift: RT-PCR of 
patient RNA [pmid:20186688 
van der Klift:2010]) 
PMS2 absent in 3 tumours: 2 
[pmid:20186688 van der 
Klift:2010]; 1 [Kate Green]. 
PMS2 present: 1 [Kate Green]. 
MSS: 1 [orcid:Tops; 0000-0002-
6769-7290] 
Sufficient segregation data: 
segregation LR 2.1:1 [orcid:Tops; 
0000-0002-6769-7290]. ACI family 
with segregation LR 5.5:1 [Kate 
Green]. Combined segregation LR 
11.6:1. 
4a PMS2 c.400C>T p.Arg134* Frameshift aberration (PTT [pmid:7661930 Hamilton:1995]) 
PMS2 absent in 2 tumours: 1 
[pmid:18602922 Senter:2008], 
[Mayo CCFR]; 1 [Moni Morak] 
Summary family history only 
3a PMS2 c.697C>T p.Gln233* 
RNA subject to NMD (RT-PCR 
of patient RNA [pmid:20186688 
van der Klift:2010]) 
PMS2 absent: 1 EC [orcid:Tops; 
0000-0002-6769-7290] Summary family history only 
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5a PMS2 c.736_741delinsTGTGTGTGAAG p.Pro246Cysfs*3 
RNA subject to NMD (RT-PCR 
of patient RNA [pmid:20186688 
van der Klift:2010]) 
MSI-H: 1 [pmid:22120844 
Schofield:2011]. PMS2 absent in 
15 tumours: 1 EC & 1 CRC 
[pmid:20205264 Vaughn:2010]; 
1 CRC [pmid:20682701 
Woods:2010]; 2 [Aus CCFR]; 4 
CRC, 2 duodenal, 2 EC 
[orcid:Tops; 0000-0002-6769-
7290]; 1 [Pal Moller]; 3 
[lovd:Lagerstedt Robinson; 
00078]. Present: 1 [Aus CCFR]. 
Sufficient segregation data: 3 
Australian probands, segregation 
LR 1.9:1 [Aus CCFR]. CMMRD fam 
seg LR 3.7, Bethesda fam with seg 
LR 2.4:1 [orcid:Tops; 0000-0002-
6769-7290]. Combined segregation 
LR 16.9:1 
3a PMS2 c.804-?_2006+?del p.Ile269_Ser669del 
Exon 8-11 deletion in frame 
(IVSP & RT-PCR of patient RNA 
[pmid:8072530 
Nicolaides:1994]) 
MSI-H (1 [pmid:8072530 
Nicolaides:1994]) 
Summary family history only: ACI 
([pmid:8072530 Nicolaides:1994]) 
4a PMS2 c.861_864del p.Arg287Serfs*19 
RNA subject NMD (RT-PCR of 
patient RNA [pmid:20186688 
van der Klift:2010]) 
2 MSI-H tumours: 1 EC & 1 CRC 
[pmid:16472587 Hendriks:2006], 
[orcid:Tops; 0000-0002-6769-
7290] 
Insufficient segregation data: 
segregation LR 1.9:1 
[pmid:16472587 Hendriks:2006], 
[orcid:Tops; 0000-0002-6769-7290] 
4a PMS2 c.989-296_1144+706del p.Glu330_Glu381del 
PMS2 exon 10 deletion 
(Southern blot analysis 
[pmid:16472587 Hendriks:2006]; 
RT-PCR of patient RNA 
[pmid:20186688 van der 
Klift:2010]) 
2 MSI-H tumours: 1 [Aus CCFR]; 
1 
Trichoepithelioma/trichoblastom
a [pmid:17453009 
Overbeek:2007] 
Insufficient segregation data: 3 
Australian probands with common 
haplotype, segregation LR 1.53:1 
[pmid:22577899 Tomsic:2012], 
[Aus CCFR] 
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Supplementary Table 9 Qualifications and expertise covered by the 40 members 
of the InSiGHT Variant Interpretation Committee (VIC) 
VIC member Affiliation Academic Qualifications and Expertise 
Dr Kiwamu Akagi 
Div. Molecular Diagnosis and 
Cancer Prevention, Saitama Cancer 
Center, Saitama, Japan 
MD, PhD: Molecular Pathology 
Prof Fahd Al-Mulla 
Department of Pathology, Faculty of 
Medicine, Health Sciences Center, 
Kuwait University, Safat, Kuwait 
BSc, M.B.,Ch.,B., PhD, FRCPE: 
Molecular Pathology 
Prof Bharati Bapat 
Department of Lab Medicine and 
Pathobiology, University of Toronto, 
Canada 
BSc, MSc, PhD:  Cancer 
Genetics, Molecular Pathology 
Dr Inge Bernstein 
Surgical Gastroenterology 
Department, Aalborg University 
Hospital, Aalborg, Denmark; Danish 
HNPCC Registry, Copenhagen, 
Denmark 
MD, PhD, MHM: Gastrointestinal 
Surgery 
Dr Gabriel Capella 
Hereditary Cancer Program. Catalan 
Institute of Oncology-IDIBELL, 
Barcelona, Spain 
MD PhD: Molecular Pathology 
and Genetic Oncology Research 
Dr Desirée du Sart 
Molecular Genetics Lab, Victorian 
Clinical Genetics Services, Murdoch 
Childrens Research Institute, 
Melbourne, Australia 
PhD: Diagnostic molecular 
genetics 
Aurelie Fabre 
INSERM UMR S910, Department of 
Medical Genetics and Functional 
Genomics, Marseille, France 
Cancer Genetics Research 
Michael Farrell 
Department of Cancer Genetics, 
Mater Private Hospital, Dublin, 
Ireland 
R.G.N., H. Dip. Applied Science, 
B.Sc. in Computing, Grad. Dip. 
in Oncology Nursing, M. Sc. in 
Molecular Medicine:  Genetic 
counseling 
Dr Susan M Farrington 
Colon Cancer Genetics Group, 
Institute of Genetics and Molecular  
Medicine, University of Edinburgh, 
Scotland 
BSc, PhD: Cancer and 
Molecular Genetics Research 
Dr Ian Frayling 
Institute of Medical Genetics, 
University Hospital of Wales, Cardiff, 
UK 
MA (Cambridge; Medical 
Sciences with Honours in 
Biochemistry), MB BChir 
(Cambridge), PhD (Manchester: 
DNA repair), FRCPath (Clinical 
Molecular and Cytogenetics), 
FEBLM (Founder Fellow 
European Board of Laboratory 
Medicine): Molecular Pathology 
Prof Thierry Frebourg 
Inserm U614, Faculty of Medicine, 
Institute for Biomedical Research, 
University of Rouen, France 
PhD: Molecular genetics 
diagnostic and research 
Prof Maurizio Genuardi 
(committee chair) 
1: Department of Biomedical, 
Experimental and Clinical Sciences, 
University of Florence, Italy; 2: 
Fiorgen Foundation for 
Pharmacogenomics, Sesto 
Fiorentino, Italy 
MD: Clinical genetics 
Dr David Goldgar 
Department of Dermatology; 
University of Utah Medical School; 
Salt Lake City, Utah, U.S. 
PhD: Genetic epidemiology 
Dr Marc Greenblatt University of Vermont; Burlington, Vermont, U.S. MD: Medical Oncology 
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Dr Christopher D. Heinen 
Neag Comprehensive Cancer 
Center & Center for Molecular 
Medicine, UConn Health Center, 
Farmington, CT, U.S. 
PhD: Cancer Genetics Research 
(functional assays) 
Prof Elke Holinski-Feder 
Klinikum der Universität München, 
Campus Innenstadt, Medizinische 
Klinik und Poliklinik IV, Munich, 
Germany; MGZ – Medizinisch 
Genetisches Zentrum, Munich, 
Germany 
MD, PhD: Diagnostic molecular 
genetics 
A/Prof Maija Kohonen-Corish 
Garvan Institute of Medical 
Research, Kinghorn Cancer Centre 
& St Vincent's Clinical School, 
University of NSW & School of 
Medicine, University of Western 
Sydney, Sydney, Australia 
BSc, MSc, PhD, MHGSA: 
Cancer genetics research 
Dr Kristina Lagerstedt-
Robinson 
Department of Molecular Medicine 
and Surgery, Karolinska Institutet, 
Department of Clinical Genetics, 
Karolinska University Hospital, 
Stockholm, Sweden 
PhD: Diagnostic molecular 
genetics 
Prof Suet Yi Leung 
Hereditary Gastrointestinal Cancer 
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Supplementary Table 1 Details of non-constitutional variants on the InSiGHT database
Gene Variant Protein RNA
MLH1 c.? p.(Ser44Gly) r.(?)
MLH1 c.? p.(Arg100Ala) r.(?)
MLH1 c.? p.(Asp72Lys) r.(?)
MLH1 c.? p.(Gly101Ala) r.(?)
MLH1 c.? p.(Leu85Ser) r.(?)
MLH1 c.? p.(Phe99Ala) r.(?)
MLH1 c.? p.(Ser83Phe) r.(?)
MLH1 c.? p.(Ser83Pro) r.(?)
MLH1 c.? p.(Thr81Met) r.(?)
MLH1 c.? p.(Thr82Lys) r.(?)
MLH1 c.? p.(Thr82Met) r.(?)
MLH1 c.? p.(Gly133Asn) r.(?)
MLH1 c.? p.(Asp154Lys) r.(?)
MLH1 c.? p.(Tyr157Lys) r.(?)
MLH1 c.? p.(Cys756Ala) r.(?)
MLH1 c.? p.(Cys756Ser) r.(?)
MLH1 c.? p.(Glu754Asp) r.(?)
MLH1 c.? p.(Leu749*) r.(?)
MLH1 c.? p.(Lys751Glu) r.(?)
MLH1 c.? p.(Phe753Ala) r.(?)
MLH1 c.101A>C p.(Glu34Ala) r.(?)
MLH1 c.1038+9G>A p.(=) r.(?)
MLH1 c.1056T>A p.= r.1056u>a
MLH1 c.1062C>A p.= r.1062c>a
MLH1 c.109_110insCTCAATCAT p.(Glu37_Cys756delinsAlaGlnSer) r.(?)
MLH1 c.117-2A>T p.(=) r.(?)
MLH1 c.1238C>T p.(Thr413Ile) r.(?)
MLH1 c.124G>A p.(Ala42Thr) r.(?)
MLH1 c.1254T>R p.(Asp418Glu) r.(?)
MLH1 c.125C>A p.(Ala42Glu) r.(?)
MLH1 c.129del p.(Lys43Asnfs*7) r.(?)
MLH1 c.130T>G p.(Ser44Ala) r.(?)
MLH1 c.134C>T p.(Thr45Ile) r.(?)
MLH1 c.1354A>T p.(Thr452Ser) r.(?)
MLH1 c.1376C>T p.Ser459Leu r.1376c>u
MLH1 c.137G>C p.(Ser46Thr) r.(?)
MLH1 c.1380_1381insT p.(Lys461*) r.(?)
MLH1 c.1383G>T p.Lys461Asn r.1383g>u
MLH1 c.1389A>C p.= r.1389a>c
MLH1 c.1406C>T p.(Pro469Leu) r.(?)
MLH1 c.140T>C p.(Ile47Thr) r.(?)
MLH1 c.140T>G p.(Ile47Ser) r.(?)
MLH1 c.142_144delinsTAT p.(Gln48Tyr) r.(?)
MLH1 c.145_148del p.(Val49Leufs*7) r.(?)
MLH1 c.145G>A p.(Val49Met) r.(?)
MLH1 c.146T>C p.(Val49Ala) r.(?)
MLH1 c.1487C>T p.(Pro496Leu) r.(?)
MLH1 c.1479_1489dup p.? r.(?)
MLH1 c.1497del p.(Ile500Serfs*8) r.(?)
MLH1 c.152T>A p.(Val51Asp) r.(?)
MLH1 c.152T>C p.(Val51Ala) r.(?)
MLH1 c.1543G>A p.(Glu515Lys) r.(?)
MLH1 c.154A>T p.(Lys52*) r.(?)
MLH1 c.1558+17G>A p.(=) r.(?)
MLH1 c.1559-9dup p.(=) r.(?)
MLH1 c.155A>T p.(Lys52Ile) r.(?)
MLH1 c.1561C>A p.(Leu521Ile) r.(?)
MLH1 c.1564C>T p.(Arg522Trp) r.(?)
MLH1 c.1565G>T p.(Arg522Leu) r.(?)
MLH1 c.1573T>C p.(=) r.(?)
MLH1 c.1576C>T p.(His526Tyr) r.(?)
MLH1 c.157G>T p.(Glu53*) r.(?)
MLH1 c.158A>C p.(Glu53Ala) r.(?)
MLH1 c.158A>T p.(Glu53Val) r.(?)
MLH1 c.1596C>T p.(=) r.(?)
MLH1 c.160G>A p.(Gly54Arg) r.(?)
MLH1 c.161G>A p.(Gly54Glu) r.(?)
MLH1 c.1630C>T p.(Gln544*) r.(?)
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MLH1 c.163G>A p.(Gly55Ser) r.(?)
MLH1 c.164G>A p.(Gly55Asp) r.(?)
MLH1 c.1667+8A>G p.(=) r.(?)
MLH1 c.1668-3C>T p.(=) r.(?)
MLH1 c.166C>A p.(Leu56Met) r.(?)
MLH1 c.167T>C p.(Leu56Pro) r.(?)
MLH1 c.169A>G p.(Lys57Glu) r.(?)
MLH1 c.169A>T p.(Lys57*) r.(?)
MLH1 c.171G>C p.(Lys57Asn) r.(?)
MLH1 c.1759A>G p.(Met587Val) r.(?)
MLH1 c.175A>T p.(Ile59Phe) r.(?)
MLH1 c.176T>A p.(Ile59Asn) r.(?)
MLH1 c.176T>C p.(Ile59Thr) r.(?)
MLH1 c.1788C>T p.(=) r.(?)
MLH1 c.179A>C p.(Gln60Pro) r.(?)
MLH1 c.180G>A p.(=) r.(?)
MLH1 c.182T>A p.(Ile61Asn) r.(?)
MLH1 c.1852A>C p.(Lys618Gln) r.(?)
MLH1 c.= p.(=) r.(?)
MLH1 c.187G>T p.(Asp63Tyr) r.(?)
MLH1 c.1897-2_1905del p.? r.(?)
MLH1 c.1897del p.(Glu633Lysfs*4) r.(?)
MLH1 c.1900G>A p.(Gly634Arg) r.(?)
MLH1 c.1912G>T p.(Gly638*) r.(?)
MLH1 c.1916T>G p.(Leu639*) r.(?)
MLH1 c.1918C>A p.(Pro640Thr) r.(?)
MLH1 c.191A>T p.(Asn64Ile) r.(?)
MLH1 c.1924_1925del p.(Leu642Aspfs*2) r.(?)
MLH1 c.193G>A p.(Gly65Ser) r.(?)
MLH1 c.194G>C p.(Gly65Ala) r.(?)
MLH1 c.194G>T p.(Gly65Val) r.(?)
MLH1 c.1990-7_1999del p.? r.(?)
MLH1 c.2000A>G p.(Asp667Gly) r.(?)
MLH1 c.2002G>A p.(Glu668Lys) r.(?)
MLH1 c.200G>T p.(Gly67Val) r.(?)
MLH1 c.202A>G p.(Ile68Val) r.(?)
MLH1 c.202A>T p.(Ile68Phe) r.(?)
MLH1 c.2032_2045del p.(Lys678Valfs*11) r.(?)
MLH1 c.203T>G p.(Ile68Ser) r.(?)
MLH1 c.205A>G p.(Arg69Gly) r.(?)
MLH1 c.206G>A p.(Arg69Lys) r.(?)
MLH1 c.2081_2082insT p.(Glu694Aspfs*10) r.(?)
MLH1 c.209A>T p.(Lys70Ile) r.(?)
MLH1 c.210A>C p.Lys70Asn r.210a>c
MLH1 c.211G>A p.(Glu71Lys) r.(?)
MLH1 c.214G>T p.[Lys70_Glu102del, Asp72Tyr] r.[208_306del, 214g>u]
MLH1 c.214G>C p.Lys70_Glu102del r.208_306del
MLH1 c.215A>G p.(Asp72Gly) r.(?)
MLH1 c.215A>T p.(Asp72Val) r.(?)
MLH1 c.216T>C p.Lys70_Glu102del r.208_306del
MLH1 c.217C>A p.(Leu73Met) r.(?)
MLH1 c.218T>A p.(Leu73Gln) r.(?)
MLH1 c.2246T>A p.(Leu749Gln) r.(?)
MLH1 c.2271A>T p.(*757Tyrext*36) r.(?)
MLH1 c.227T>A p.(Val76Glu) r.(?)
MLH1 c.229T>G p.(Cys77Gly) r.(?)
MLH1 c.230G>C p.(Cys77Ser) r.(?)
MLH1 c.231T>A p.(Cys77*) r.(?)
MLH1 c.233A>T p.(Glu78Val) r.(?)
MLH1 c.235A>T p.(Arg79Trp) r.(?)
MLH1 c.238T>A p.(Phe80Ile) r.(?)
MLH1 c.238T>C p.(Phe80Leu) r.(?)
MLH1 c.239T>C p.(Phe80Ser) r.(?)
MLH1 c.242C>T p.(Thr81Ile) r.(?)
MLH1 c.244A>T p.(Thr82Ser) r.(?)
MLH1 c.251A>G p.(Lys84Arg) r.(?)
MLH1 c.253C>T p.(=) r.(?)
MLH1 c.261C>T p.(=) r.(?)
MLH1 c.265G>C p.(Glu89Gln) r.(?)
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MLH1 c.266A>T p.(Glu89Val) r.(?)
MLH1 c.272T>A p.(Leu91*) r.(?)
MLH1 c.291T>A p.(Tyr97*) r.(?)
MLH1 c.295T>A p.(Phe99Ile) r.(?)
MLH1 c.307G>A p.(Ala103Thr) r.(?)
MLH1 c.308C>T p.(Ala103Val) r.(?)
MLH1 c.311T>A p.(Leu104*) r.(?)
MLH1 c.331G>A p.(Ala111Thr) r.(?)
MLH1 c.334_335delinsGC p.(His112Ala) r.(?)
MLH1 c.334C>G p.(His112Asp) r.(?)
MLH1 c.341C>T p.(Thr114Ile) r.(?)
MLH1 c.343A>T p.(Ile115Phe) r.(?)
MLH1 c.344T>A p.(Ile115Asn) r.(?)
MLH1 c.344T>G p.(Ile115Ser) r.(?)
MLH1 c.346A>T p.(Thr116Ser) r.(?)
MLH1 c.352A>G p.(Lys118Glu) r.(?)
MLH1 c.353A>T p.(Lys118Ile) r.(?)
MLH1 c.354A>T p.(Lys118Asn) r.(?)
MLH1 c.361G>C p.(Asp121His) r.(?)
MLH1 c.367A>G p.(Lys123Glu) r.(?)
MLH1 c.376_377delinsGC p.(Tyr126Ala) r.(?)
MLH1 c.379_380delinsGA p.(Arg127Glu) r.(?)
MLH1 c.381-1G>A p.(=) r.(?)
MLH1 c.388_389delinsGC p.(Tyr130Ala) r.(?)
MLH1 c.389A>T p.(Tyr130Phe) r.(?)
MLH1 c.398G>A p.(Gly133Glu) r.(?)
MLH1 c.400_401delinsGG p.(Lys134Gly) r.(?)
MLH1 c.400A>G p.(Lys134Glu) r.(?)
MLH1 c.410C>T p.(Ala137Val) r.(?)
MLH1 c.418A>G p.(Lys140Glu) r.(?)
MLH1 c.460dup p.(Asp154Glyfs*18) r.(?)
MLH1 c.469_470delinsGC p.(Tyr157Ala) r.(?)
MLH1 c.469del p.(Tyr157Thrfs*3) r.(?)
MLH1 c.472A>C p.(Asn158His) r.(?)
MLH1 c.490A>G p.(Lys164Glu) r.(?)
MLH1 c.544_545delinsGA p.(Arg182Glu) r.(?)
MLH1 c.546-32T>C p.(=) r.(?)
MLH1 c.588dup p.(Gln197Thrfs*7) r.(?)
MLH1 c.607G>A p.(Asp203Asn) r.(?)
MLH1 c.638T>C p.(Val213Ala) r.(?)
MLH1 c.677+16del p.(=) r.(?)
MLH1 c.693T>C p.(=) r.(?)
MLH1 c.697T>C p.(Cys233Arg) r.(?)
MLH1 c.753C>T p.(=) r.(?)
MLH1 c.755C>A p.Ser252* r.?
MLH1 c.765G>A p.(=) r.(?)
MLH1 c.769del p.(Ile257Serfs*11) r.(?)
MLH1 c.776T>C p.(Leu259Ser) r.0
MLH1 c.791-34G>A p.(=) r.(?)
MLH1 c.815T>C p.Leu272Ser r.815u>c
MLH1 c.855C>T p.= r.855c>u
MLH1 c.872del p.(Phe291Serfs*6) r.(?)
MLH1 c.885-13_885-12ins2 p.(=) r.(?)
MSH2 c.? p.(Tyr619Lys) r.(?)
MSH2 c.? p.(Gln823Glu) r.(?)
MSH2 c.101T>A p.(Val34Glu) r.(?)
MSH2 c.1134_1136del p.(Glu378del) r.(?)
MSH2 c.1160T>C p.(Leu387Pro) r.(?)
MSH2 c.1168C>G p.(Leu390Val) r.(?)
MSH2 c.1178A>T p.(Lys393Met) r.(?)
MSH2 c.117G>A p.(=) r.(?)
MSH2 c.1182dup p.(Gln395Serfs*22) r.(?)
MSH2 c.124_126delinsGCA p.(Phe42Ala) r.(?)
MSH2 c.129T>A p.(Tyr43*) r.(?)
MSH2 c.1442_1445dup p.(Arg482Serfs*7) r.(?)
MSH2 c.1560A>G p.(=) r.(?)
MSH2 c.1569del p.(Arg524Valfs*2) r.(?)
MSH2 c.1715_1717del p.(Glu572del) r.(?)
MSH2 c.1737dup p.(Glu580Argfs*18) r.(?)
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MSH2 c.1741dup p.(Ile581Asnfs*17) r.(?)
MSH2 c.1753del p.(Ser585Leufs*5) r.(?)
MSH2 c.1807G>T p.(Asp603Tyr) r.(?)
MSH2 c.1939G>T p.(Glu647*) r.(?)
MSH2 c.1983dup p.(Gln662Thrfs*14) r.(?)
MSH2 c.1987delinsTG p.(Met663Cysfs*13) r.(?)
MSH2 c.1999_2000delinsGG p.(Ile667Gly) r.(?)
MSH2 c.2018del p.(Gly673Glufs*12) r.(?)
MSH2 c.2020G>A p.(Gly674Ser) r.(?)
MSH2 c.2021G>C p.(Gly674Ala) r.(?)
MSH2 c.2024A>G p.(Lys675Arg) r.(?)
MSH2 c.2026T>G p.(Ser676Ala) r.(?)
MSH2 c.2044A>G p.(Thr682Ala) r.(?)
MSH2 c.2053_2056dup p.(Val686Aspfs*14) r.(?)
MSH2 c.2061C>G p.(=) r.(?)
MSH2 c.2071del p.(Ile691Leufs*19) r.(?)
MSH2 c.2080T>C p.(Phe694Leu) r.(?)
MSH2 c.2082del p.(Phe694Leufs*16) r.(?)
MSH2 c.2105T>A p.Val702Glu r.2105u>a
MSH2 c.2114T>A p.(Val705Glu) r.(?)
MSH2 c.2164G>A p.(Val722Ile) r.(?)
MSH2 c.2171C>A p.(Thr724Lys) r.(?)
MSH2 c.2233_2234insG p.(Ile745Serfs*5) r.(?)
MSH2 c.2245G>T p.(Glu749*) r.(?)
MSH2 c.2293G>A p.(Ala765Thr) r.(?)
MSH2 c.2363_2364del p.(Thr788Serfs*10) r.(?)
MSH2 c.2375A>G p.(Asn792Ser) r.(?)
MSH2 c.2407A>G p.(Thr803Ala) r.(?)
MSH2 c.2466T>A p.(Cys822*) r.(?)
MSH2 c.2470_2471insCG p.(Gln824Profs*18) r.(?)
MSH2 c.2479G>A p.(Gly827Arg) r.(?)
MSH2 c.247dup p.(Met83Asnfs*4) r.(?)
MSH2 c.2631A>Y p.Arg877Ser r.(=)
MSH2 c.2663T>G p.(Leu888Arg) r.(?)
MSH2 c.2671G>Y p.(Val891Leu) r.(?)
MSH2 c.2744T>A p.(Val915Glu) r.(?)
MSH2 c.278T>C p.(Leu93Pro) r.(?)
MSH2 c.296del p.(Arg99Lysfs*75) r.(?)
MSH2 c.366+35del p.(=) r.(?)
MSH2 c.495T>G p.(Tyr165*) r.(?)
MSH2 c.517_528delinsA p.(Leu173Argfs*4) r.(?)
MSH2 c.546_564dup p.(Ala189Serfs*6) r.(?)
MSH2 c.606C>T p.= r.606c>u
MSH2 c.607G>A p.(Gly203Arg) r.(?)
MSH2 c.619G>T p.Ala207Ser r.619c>u
MSH2 c.658G>T p.(Gly220*) r.(?)
MSH2 c.709A>G p.(Ile237Val) r.(?)
MSH2 c.777A>G p.(=) r.(?)
MSH2 c.89_641delinsAATTCTTCTGCCTCAGCCTCCTGAGTAGCTGGGATT p.? r.(?)
MSH2 c.893A>C p.(Gln298Pro) r.(?)
MSH2 c.934del p.(Leu312Phefs*19) r.(?)
MSH6 c.? p.(Trp365*) r.(?)
MSH6 c.1170T>C p.(=) r.(?)
MSH6 c.1190A>G p.(Tyr397Cys) r.(?)
MSH6 c.1294_1296delinsGCA p.(Phe432Ala) r.(?)
MSH6 c.1453C>T p.(Gln485*) r.(?)
MSH6 c.1594T>G p.Ser532Ala r.1594u>g
MSH6 c.1602del p.(Tyr535Thrfs*36) r.(?)
MSH6 c.1723G>T p.(Asp575Tyr) r.(?)
MSH6 c.2079dup p.(Cys694Metfs*4) r.(?)
MSH6 c.2166_2186del p.(Gly723_Ala729del) r.(?)
MSH6 c.2315G>A p.(Arg772Gln) r.(?)
MSH6 c.2389del p.(Asp797Thrfs*13) r.(?)
MSH6 c.2399T>C p.(Val800Ala) r.(?)
MSH6 c.2425del p.(Val809*) r.(?)
MSH6 c.2912G>A p.(Gly971Glu) r.(?)
MSH6 c.3028_3032del p.(Thr1010*) r.(?)
MSH6 c.3092A>T p.(Asp1031Val) r.(?)
MSH6 c.325C>G p.(Leu109Val) r.(?)
61
Gene Variant Protein RNA
MSH6 c.3260_3261dup p.(Phe1088Profs*3) r.(?)
MSH6 c.3419A>G p.(Lys1140Arg) r.(?)
MSH6 c.3452C>T p.(Ala1151Val) r.(?)
MSH6 c.3472T>C p.(Cys1158Arg) r.(?)
MSH6 c.3511_3516delinsT p.(Asp1171Cysfs*4) r.(?)
MSH6 c.3581dup p.(Leu1194Phefs*3) r.(?)
MSH6 c.3638A>T p.Asp1213Val r.3638a>u
MSH6 c.3641A>C p.(Glu1214Ala) r.(?)
MSH6 c.3778G>A p.Val1260Ile r.3778g>a
MSH6 c.384del p.(Val129Phefs*20) r.(?)
MSH6 c.3907G>A p.(Ala1303Thr) r.(?)
MSH6 c.4075G>T p.(Glu1359*) r.(?)
MSH6 c.560A>C p.(Lys187Thr) r.(?)
MSH6 c.741del p.(Lys247Asnfs*32) r.(?)
MSH6 c.747G>A p.(=) r.(?)
MSH6 c.794T>G p.(Phe265Cys) r.(?)
MSH6 c.868del p.Leu290* r.?
MSH6 c.944C>T p.(Ser315Phe) r.(?)
PMS2 c.? p.(Lys465Val) r.(?)
PMS2 c.? p.(Ser459Trp) r.(?)
PMS2 c.? p.(Ser478Tyr) r.(?)
PMS2 c.-120del p.(=) r.(?)
PMS2 c.1335C>G p.(Ser445Arg) r.(?)
PMS2 c.1336C>T p.(Pro446Ser) r.(?)
PMS2 c.1363T>G p.(Ser455Ala) r.(?)
PMS2 c.1364C>G p.(Ser455Cys) r.(?)
PMS2 c.1385T>C p.(Ile462Thr) r.(?)
PMS2 c.1386C>G p.(Ile462Met) r.(?)
PMS2 c.1394A>T p.(Lys465Ile) r.(?)
PMS2 c.1400T>G p.(Val467Gly) r.(?)
PMS2 c.1402C>G p.(Leu468Val) r.(?)
PMS2 c.1402C>T p.(=) r.(?)
PMS2 c.1406G>A p.(Arg469Lys) r.(?)
PMS2 c.1409C>A p.(Pro470His) r.(?)
PMS2 c.1411C>T p.(Gln471*) r.(?)
PMS2 c.1418A>G p.(Glu473Gly) r.(?)
PMS2 c.1430C>T p.(Ser477Phe) r.(?)
PMS2 c.1506T>A p.Asp502Glu r.1506u>a
PMS2 c.1507_1508delinsGG p.Ser503Gly r.1507_1508delinsgg
PMS2 c.1519A>T p.Ser507Cys r.1519a>u
PMS2 c.1522A>C p.Ile508Leu r.1522a>c
PMS2 c.1526C>A p.Pro509Gln r.1526c>a
PMS2 c.1530C>A p.Asp510Glu r.1530c>a
PMS2 c.1532_1533delinsAC p.Thr511Asn r.1532_1533delinsAC
PMS2 c.1537_1538delinsGA p.Ser513Asp r.1537_1538delinsGA
PMS2 c.1556A>G p.Tyr519Cys r.1556a>g
PMS2 c.1559C>T p.Ala520Val r.1559c>u
PMS2 c.1567T>A p.(Ser523Thr) r.(?)
PMS2 c.1571C>A p.Pro524Gln r.1571c>a
PMS2 c.1576G>A p.Asp526Asn r.1576g>a
PMS2 c.1578C>A p.Asp526Glu r.1578c>a
PMS2 c.1618C>A p.Pro540Thr r.1618c>a
PMS2 c.1660A>C p.Asn554His r.1660a>c
PMS2 c.1688G>A p.Arg563Gln r.1688g>a
PMS2 c.1714G>A p.Ala572Thr r.1714g>a
PMS2 c.1717A>T p.Thr573Ser r.1717a>u
PMS2 c.1733G>T p.Arg578Leu r.1733g>u
PMS2 c.1741A>G p.Lys581Glu r.1741a>g
PMS2 c.1744G>A p.Glu582Lys r.1744g>a
PMS2 c.1747G>A p.Glu583Lys r.1747g>a
PMS2 c.1759_1760delinsGA p.Ser587Asp r.1759_1760delinsga
PMS2 c.1760_1761delinsCG p.Ser587Thr r.1760_1761delinscg
PMS2 c.1768A>C p.Ile590Leu r.1768a>c
PMS2 c.1774C>T p.(Gln592*) r.(?)
PMS2 c.1780T>G p.Leu594Val r.1780u>g
PMS2 c.1793A>C p.Gln598Pro r.1793a>c
PMS2 c.1794G>C p.Gln598His r.1794g>c
PMS2 c.1795_1796delinsCC p.Asp599Pro r.1795_1795delinscc
PMS2 c.1798A>C p.Met600Leu r.1798a>c
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PMS2 c.1801T>C p.(Ser601Pro) r.(?)
PMS2 c.1802C>T p.Ser601Leu r.1802c>u
PMS2 c.1805C>G p.Ala602Gly r.1805c>g
PMS2 c.1810C>T p.(Gln604*) r.(?)
PMS2 c.1822G>T p.Ala608Ser r.1822c>u
PMS2 c.1837A>T p.(Lys613*) r.(?)
PMS2 c.1853T>G p.Leu618Arg r.1853u>g
PMS2 c.1870T>G p.Ser624Ala r.1870u>g
PMS2 c.1874T>A p.(Leu625*) r.(?)
PMS2 c.1875A>Y p.(Leu625Phe) r.(?)
PMS2 c.1883G>C p.(Arg628Pro) r.(?)
PMS2 c.1885A>T p.Ile629Leu r.1885a>u
PMS2 c.1898A>T p.His633Leu r.1898a>u
PMS2 c.1903G>A p.(Glu635Lys) r.(?)
PMS2 c.1931A>T p.Asn644Ile r.1931a>u
PMS2 c.1934A>T p.(Tyr645Phe) r.(?)
PMS2 c.1948G>C p.(Ala650Pro) r.(?)
PMS2 c.1952A>G p.Lys651Arg r.1952a>g
PMS2 c.1954A>C p.Ile652Leu r.1954a>c
PMS2 c.1957T>G p.Cys653Gly r.1957u>g
PMS2 c.1976C>T p.(Ala659Val) r.(?)
PMS2 c.2019T>G p.Phe673Leu r.2019u>g
PMS2 c.2023G>T p.(Glu675*) r.(?)
PMS2 c.2035A>T p.Ile679Leu r.2035a>u
PMS2 c.646T>G p.(Cys216Gly) r.(?)
PMS2 c.835G>T p.(Gly279*) r.(?)
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Class 5: pathogenic MLH1 c.1038G>C p.[Arg265Phefs*14, Thr347Valfs*14] Variant causes splicing aberration predicted to produce truncated protein: full inactivation of variant allele
Class 5: pathogenic MLH1 c.1038G>T p.[Ser295Argfs*21, Thr347Valfs*14] Variant causes splicing aberration predicted to produce truncated protein: full inactivation of variant allele
Class 5: pathogenic MLH1 c.104_105delinsAC p.(Met35Asn) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.104T>G p.(Met35Arg) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.112A>C p.Asn38His
Abrogated function, >2 MSI-H tumours, co-segregation with disease & MAF 0.00. Multifactorial likelihood analysis 
posterior probability >0.99
Class 5: pathogenic MLH1 c.113A>G p.(Asn38Ser) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.114C>G p.(Asn38Lys) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.1153C>T p.(Arg385Cys) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 4: likely pathogenic MLH1 c.116G>A p.(Cys39Tyr) G>non-G at last base of exon with first 6 intronic bases not GTRRGT
Class 4: likely pathogenic MLH1 c.116G>T p.(Cys39Phe) G>non-G at last base of exon with first 6 intronic bases not GTRRGT
Class 4: likely pathogenic MLH1 c.121G>C p.Asp41His Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.122A>G p.Cys39* Variant causes splicing aberration leading to truncated protein: full inactivation of variant allele
Class 5: pathogenic MLH1 c.131C>T p.(Ser44Phe)
Abrogated function, >2 MSI-H tumours, co-segregation with disease & MAF 0.00. Multifactorial likelihood analysis 
posterior probability >0.99
Class 4: likely pathogenic MLH1 c.143A>C p.(Gln48Pro) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.146T>A p.Val49Glu Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.1588_1590del p.(Phe530del) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.1649T>C p.(Leu550Pro) Abrogated function (reduced expression in 2 inpedendent assays) & 2 MSI-H tumours
Class 4: likely pathogenic MLH1 c.1664T>C p.(Leu555Pro) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.1667G>T p.Ser556Argfs*2 Variant causes splicing aberration predicted to produce truncated protein: full inactivation of variant allele.
Class 4: likely pathogenic MLH1 c.1676T>G p.(Leu559Arg) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 4: likely pathogenic MLH1 c.1721T>C p.(Leu574Pro) Abrogated function & co-segregation with disease
Class 5: pathogenic MLH1 c.1745T>C p.(Leu582Pro) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.1766C>A p.(Ala589Asp) Abrogated function (reduced expression in 2 inpendent assays) & 2 MSI-H tumours
Class 4: likely pathogenic MLH1 c.1823C>A p.(Ala608Asp) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 4: likely pathogenic MLH1 c.1835_1837del p.(Val612del) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.1852_1854del p.Lys618del
Abrogated function (reduced expression in 2 inpendent assays), >2 MSI-H tumours, co-segregation with disease & 
MAF 0.00. Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.1865T>A p.Leu622His Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.189C>A p.(Asp63Glu) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.191A>G p.(Asn64Ser) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.1942C>T p.(Pro648Ser) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.1943C>T p.(Pro648Leu) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.194G>A p.(Gly65Asp) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.1961C>T p.[Glu633_Glu663del, Pro654Leu] Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.1976G>C p.[Glu633_Glu663del, Arg659Pro]
Abrogated function (MMR activity & aberrant splicing), >2 MSI-H tumours, co-segregation with disease & absent in 
1000 genomes
Class 5: pathogenic MLH1 c.1976G>T p.(Glu633_Glu663del) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.1984A>C p.[Glu633_Glu663del, Thr662Pro] Abrogated function (2 indpendent assays with reduced expression) & 6 MSI-H tumours
Class 4: likely pathogenic MLH1 c.1988A>C p.(Glu663Ala) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.1989G>T p.Glu633_Glu663del Variant causes splicing aberration, interrupting functional domain (full inactivation of variant allele)
Class 5: pathogenic MLH1 c.199G>A p.Gly67Arg
Abrogated function, >2 MSI-H tumours, co-segregation with disease & MAF 0.00. Multifactorial likelihood analysis 
posterior probability >0.99
Class 5: pathogenic MLH1 c.199G>T p.Gly67Trp Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.200G>A p.Gly67Glu Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.2038T>C p.(Cys680Arg) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 4: likely pathogenic MLH1 c.203T>A p.(Ile68Asn) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.2041G>A p.Ala681Thr Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.2059C>T p.Arg687Trp Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.2103G>C p.Val664_Gln701del Variant causing splicing aberration predicted to interrupt known functional domains: full inactivation of variant allele
Class 5: pathogenic MLH1 c.2105_2114del p.(Ser702Metfs*78) Frameshift interrupting C-terminus interaction domain
Class 5: pathogenic MLH1 c.2111_2117del p.(Val704Alafs*77) Frameshift interrupting C-terminus interaction domain
Class 5: pathogenic MLH1 c.213_215del p.Lys70_Glu102del Variant allele causes in-frame splicing aberration interrupting ATPase domain: full inactivation of variant allele
Class 5: pathogenic MLH1 c.2149_2195dup p.(His733Asnfs*66) Multifactorial likelihood analysis posterior probability >0.99
Supplementary Table 8 Summary justifications for Class 4: likely pathogenic and Class 5: pathogenic “not obviously truncating” non-synonymous variants classified by the 
InSiGHT Variant Interpretation Committee 
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Class 5: pathogenic MLH1 c.2154_2155dup p.(Ile719Thrfs*65) Frameshift interrupting C-terminus interactions domain
Class 5: pathogenic MLH1 c.2179_2182del p.(His727Phefs*55) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.2221_2224delins30 p.? Frameshift interrupting C-terminus interaction domain
Class 5: pathogenic MLH1 c.2224del p.(Gln742Serfs*41) Frameshift interrupting C-terminus interaction domain
Class 5: pathogenic MLH1 c.2246T>C p.(Leu749Pro) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.2265G>C p.(Arg755Ser) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.2266_2269dup p.*757Leuext*34 Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.2269dup p.*757Leuext*33 Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.229T>C p.Cys77Arg Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.230G>A p.Cys77Tyr Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.238T>G p.(Phe80Val) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.244A>G p.Thr82Ala Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.245C>T p.(Thr82Ile) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.250A>G p.Lys84Glu Abrogated function & >2 MSI-H tumours
Class 4: likely pathogenic MLH1 c.293_304del p.Gly98_Gly101del Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.306G>C p.Lys70_Glu102del Variant causing splicing aberration predicted to interrupt known functional domains: full inactivation of variant allele
Class 4: likely pathogenic MLH1 c.306G>T p.(Glu102Asp) G>non-G at last base of exon with first 6 bases of the intron not GTRRGT
Class 5: pathogenic MLH1 c.320T>G p.Ile107Arg Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.332C>T p.Ala111Val Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.350C>T p.Thr117Met
Abrogated function, >2 MSI-H tumours, co-segregation with disease & MAF 0.00. Multifactorial likelihood analysis 
posterior probability >0.99
Class 4: likely pathogenic MLH1 c.380G>A p.(Arg127Lys) G>non-G at last base of exon with first 6 intronic bases not GTRRGT
Class 5: pathogenic MLH1 c.382G>C p.(Ala128Pro) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.464T>G p.Leu155Arg Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.544A>G p.Glu153Phefs*8 Variant causes splicing aberration which introduces frameshift (no full-length expressed from allele)
Class 5: pathogenic MLH1 c.545G>A p.[Glu153Phefs*8, Arg182Ilefs*19] Variant causes splicing aberration leading to truncated protein: full inactivation of variant allele
Class 5: pathogenic MLH1 c.554T>G p.Val185Gly
Abrogated function, 1 MSI-H tumour & 1 tumour with MLH1 immunoloss, co-segregation with disease & absent in 
1000 genomes. Multifactorial likelihood analysis posterior probability >0.99.
Class 5: pathogenic MLH1 c.62C>A p.(Ala21Glu) Multifactorial likelihood analysis posterior probability <0.001
Class 4: likely pathogenic MLH1 c.62C>T p.(Ala21Val) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.677G>A p.Gln197Argfs*8 Variant causes splicing aberration leading to truncated protein: full inactivation of variant allele
Class 4: likely pathogenic MLH1 c.677G>T p.(Gln197Argfs*8)
G>non-G at last base of exon with first 6 bases of the intron not GTRRGT (splicing aberration reported, but not 
quantified)
Class 5: pathogenic MLH1 c.731G>A p.Gly244Asp
Abrogated function, >2 MSI-H tumours, co-segregation with disease & MAF 0.00. Multifactorial likelihood analysis 
posterior probability >0.99
Class 5: pathogenic MLH1 c.739T>C p.Ser247Pro Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.73A>T p.(Ile25Phe) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.779T>G p.Leu260Arg Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MLH1 c.793C>A p.(Arg265Ser) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.793C>T p.His264Leufs*2 Variant causes aberrant splicing leading to truncated protein: full inactivation of variant allele.
Class 5: pathogenic MLH1 c.83C>T p.(Pro28Leu) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MLH1 c.842C>T p.His264Leufs*2 Variant causes aberrant splicing leading to truncated protein: full inactivation of variant allele.
Class 5: pathogenic MLH1 c.86C>G p.[Ala29Valfs*2, Ala29_Leu40del] Variant causes splicing aberrations: full inactivation of variant allele. In-frame transcript interrupts ATPase domain.
Class 5: pathogenic MLH1 c.883A>C p.His264Leufs*2 Variant allele results in splicing abberation leading to premature stop codon: full inactivation of variant allele
Class 5: pathogenic MLH1 c.883A>G p.Glu227_Ser295del
Variant causes aberrant splicing leading to protein conformational change and inactive protein: full inactivation of 
variant allele.
Class 5: pathogenic MLH1 c.884G>A p.His264Leufs*2 Variant allele results in splicing abberation leading to premature stop codon: full inactivation of variant allele
Class 4: likely pathogenic MLH1 c.884G>C p.(Ser295Thr) G>non-G at last base of exon with first 6 intronic bases not GTRRGT
Class 4: likely pathogenic MLH1 c.911A>T p.Asp304Val Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MLH1 c.986A>C p.[Glu227Leufs*20, Arg265Phefs*14] Variant causes splicing aberrations (full inactivation of variant allele)
Class 5: pathogenic MSH2 c.1013G>A p.(Gly338Glu) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MSH2 c.1022T>C p.Leu341Pro Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 4: likely pathogenic MSH2 c.1046C>G p.(Pro349Arg) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MSH2 c.1046C>T p.(Pro349Leu) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.1077A>T p.Arg359Ser Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.1319T>C p.(Leu440Pro) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.1358T>A p.Ile454_Gln462del Variant causes in-frame splicing aberration interrupting multiple functional domains
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Class 4: likely pathogenic MSH2 c.1510G>C p.(Gly504Arg) G>non-G at last base of exon with first 6 intronic bases not GTRRGT
Class 4: likely pathogenic MSH2 c.1571G>C p.Arg524Pro Abrogated function & 2 MSI-H tumours
Class 4: likely pathogenic MSH2 c.1571G>T p.(Arg524Leu) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MSH2 c.1660A>G p.Gly504Alafs*3 Variant causes splicing aberration leading to frameshift: full inactivation of variant allele
Class 5: pathogenic MSH2 c.1660A>T p.[Gly504Alafs*3, Gly548Alafs*3] Variant causes splicing aberration leading to frameshift: full inactivation of variant allele
Class 5: pathogenic MSH2 c.1661G>C p.Gly504Alafs*3 Variant causes splicing aberration (full inactivation of variant allele)
Class 5: pathogenic MSH2 c.1759G>C p.Ser554Argfs*11 Variant causes splicing aberration (full inactivation of variant allele)
Class 5: pathogenic MSH2 c.1786_1788del p.Asn596del Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MSH2 c.1808A>G p.(Asp603Gly) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MSH2 c.1865C>T p.Pro622Leu
Abrogated function, >2 MSI-H tumours, co-segregation with disease & MAF 0.00. Multifactorial likelihood analysis 
posterior probability >0.99
Class 5: pathogenic MSH2 c.1906G>C p.Ala636Pro
Abrogated function & CMMRD, >2 MSI-H tumours, co-segregation with disease & MAF 0.00. Multifactorial likelihood 
analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.1915C>T p.His639Profs*6 Variant causes splicing aberration (full inactivation variant allele)
Class 4: likely pathogenic MSH2 c.1955C>A p.(Pro652His) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 4: likely pathogenic MSH2 c.2005G>C p.(Gly669Arg) G>non-G at last base of exon with first 6 intronic bases not GTRRGT
Class 5: pathogenic MSH2 c.2006G>T p.Pro670Leufs*7 Variant causes splicing aberration (full inactivation of variant allele)
Class 4: likely pathogenic MSH2 c.2020G>C p.(Gly674Arg) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 4: likely pathogenic MSH2 c.2021G>A p.(Gly674Asp) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MSH2 c.2047G>A p.(Gly683Arg) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.2063T>G p.(Met688Arg) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MSH2 c.2074G>C p.(Gly692Arg) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MSH2 c.2087C>T p.Pro696Leu Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.2089T>C p.Cys697Arg Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.2090G>T p.Cys697Phe Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MSH2 c.2245G>A p.Glu749Lys Abrogated function & 2 MSI-H tumours
Class 5: pathogenic MSH2 c.2251G>A p.Gly751Arg Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MSH2 c.2634G>C p.(Glu878Asp) G>non-G at last base of exon with first 6 intronic bases not GTRRGT
Class 4: likely pathogenic MSH2 c.277C>T p.(Leu93Phe) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 4: likely pathogenic MSH2 c.301_306del p.(Glu101_Val102del) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MSH2 c.484G>A p.Gly162Arg Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.488T>A p.(Val163Asp) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.490G>A p.(Gly164Arg) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.4G>A p.Ala2Thr Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.560T>C p.(Leu187Pro) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.560T>G p.Leu187Arg Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.571_573del p.(Leu191del) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH2 c.595T>C p.Cys199Arg Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MSH2 c.792G>C p.(Gln264His) G>non-G at last base of exon with first 6 intronic bases not GTRRGT
Class 5: pathogenic MSH2 c.929T>C p.(Leu310Pro) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MSH2 c.989T>C p.(Leu330Pro) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MSH6 c.1193T>A p.(Val398Glu) Multifactorial likelihood analysis posterior probability >0.99
Class 5: pathogenic MSH6 c.1346T>C p.(Leu449Pro) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic MSH6 c.2057G>A p.(Gly686Asp) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 4: likely pathogenic MSH6 c.2117T>C p.(Phe706Ser) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 4: likely pathogenic MSH6 c.3724_3726del p.(Arg1242del) Multifactorial likelihood analysis posterior probability 0.95-0.99
Class 5: pathogenic MSH6 c.4001G>A p.(Arg1334Gln) Multifactorial likelihood analysis posterior probability >0.99
Class 4: likely pathogenic PMS2 c.903G>T p.(Tyr268*) G>non-G at last base of exon with 6 bases of the intron not GTRRGT (splicing aberration has not been quantified)
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As part of the 5-tiered classification criteria presented in Chapter 4, we created a complimentary 
flowchart to aid in the interpretation of assays measuring MMR gene/protein function. The first step 
in this process is assessing gene transcription to identify potential mRNA or regulatory aberrations. 
Some alternatively spliced transcripts identified in these assays are found in healthy controls and 
not associated with disease. It is important to distinguish these transcripts from sequence variant-
associated aberrant splicing. This chapter contains the first catalogue of naturally occurring MMR 
gene alternative transcripts compiled from review of the literature and public databases. These 
alternative transcripts need to be taken into account when designing and using splicing analyses to 
aid in the classification of variants of uncertain clinical significance.  
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A review of mismatch repair gene transcripts:
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Thompson BA, Martins A, Spurdle AB. A review of mismatch repair gene
transcripts: issues for interpretation of mRNA splicing assays.
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Many mismatch repair (MMR) gene disease-causing mutations identi!ed in
cancer patients result in aberrant messenger RNA (mRNA) splicing.
However, mRNA assay interpretation can be complicated by the existence of
naturally occurring alternative mRNA transcripts, most of which have not
been formally described or fully characterized. Here, we provide a
comprehensive catalogue of all MMR transcripts described to date, and a
review of MMR nucleotide variants associated with an apparent upregulation
of alternatively spliced transcripts. This work sets reference starting points
for designing and interpreting MMR RNA analyses. Our database and
literature searches retrieved 30MLH1, 22 MSH2, 4 MSH6 and 9 PMS2
alternative transcripts, many predicted to introduce premature termination
codons. Furthermore, we collected information on 66MLH1, 24 MSH2 and
6 PMS2 nucleotide variants reported to be associated with altered expression
of at least one of these alternative transcripts, and in many instances reported
as splicing mutations. This review shows that there are many alternatively
spliced MMR transcripts, which have potential to confound interpretation of
splicing assays. These !ndings highlight the need to perform RNA analysis
of patients systematically in parallel with control individuals, and call for the
implementation of quantitative assessment of transcript levels for informed
interpretation of mRNA assays.
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Germline mutations in the DNA mismatch repair
(MMR) genes MLH1, MSH2, MSH6, and PMS2, are
the cause of Lynch syndrome (formerly termed as
hereditary non-polyposis colorectal cancer, HNPCC),
and other related hereditary cancer conditions, including
Muir-Torre syndrome and constitutional mismatch repair
de!ciency syndrome (CMMR-D) (1–3). Identi!cation
of mutation-positive families is important for identi-
fying at-risk relatives for pre-symptomatic screening
and risk-reducing management, and for implementing
clinical strategies to reduce risk of secondary cancers in
patients (4).
There is a growing awareness that a considerable
proportion of germline variants detected in disease-
associated genes, including the MMR genes, cause
splicing anomalies (5). These ‘spliceogenic’ variants
result from alterations in cis-acting splicing signals,
namely in splice sites (e.g. disruption of canonical splice
sites or usage of de novo sites due to creation of new
splice sites and/or activation of cryptic sites) or in splic-
ing regulatory elements (e.g. exonic splicing enhancers
and silencers, ESEs and ESSs, respectively) (6). As out-
lined in Fig. 1, such alterations often lead to events such
as complete or partial deletion of exons (including total
exon skipping) and exonization of intronic sequences
(intron retention, pseudoexon inclusion) (7, 8).
Because of their very high likelihood to alter splicing,
nucleotide variants altering the consensus intronic din-
ucleotides at the natural 5′-donor (GT) and 3′-acceptor
(AG) sites are often considered pathogenic mutations
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Fig. 1. Structural types of alternative splicing. Black denotes exons from the example reference sequence.White are exonic regions that become intronic
(relative to reference sequence) due to alternative splicing events. Grey indicates intronic/intergenic regions that become exonic (relative to reference
sequence) due to alternative transcription or/and splicing events. Solid lines between exon boundaries indicate splicing events also present in the example
reference sequence, whereas dashed lines represent alternative splicing events.
without need for messenger RNA (mRNA) assays and
used alone to direct patient management (5). As for
the remaining intronic and exonic variants, it is rou-
tine for many clinical laboratories to conduct mRNA
assays to assess their clinical signi!cance (9), after a
preliminary selection based on bioinformatic predictions
of variant-induced splicing alterations. The most highly
used approaches for detecting the transcripts of inter-
est rely on reverse transcriptase polymerase chain reac-
tions (RT-PCR) followed by: agarose gel electrophoresis
and sequencing of gel-puri!ed products (10); capillary
electrophoresis using "uorescently labelled primers (11);
and/or molecular cloning of RT-PCR products (12). A
PCR-based method for enriching alternatively spliced
isoforms (EASI) has also been developed to identify
novel transcript variants (13). Minigene assays provide
an ex vivo method to assess the effects of a variant on
splicing. Thus, they are particularly useful when patient
RNA is unavailable, or when variant-induced aberrantly
spliced transcripts occur in vivo but are dif!cult to detect
due to degradation by nonsense-mediated decay (NMD)
(14–16). Moreover, minigene assays can directly assess
cause–effect relationships, namely between a variant and
an unexpected variant-induced splicing defect. Altered
splicing patterns identi!ed through the aforementioned
experimental assays can be used to help determine the
molecular consequences, and thereby, the clinical signif-
icance of nucleotide variants (5).
Alternative splicing is a common occurrence in eukary-
otes and has important biological consequences as it
may contribute to regulate gene expression and to
increase the diversity of protein isoforms produced from
each gene. For example, alternative splicing can reg-
ulate tissue-speci!c expression in a number of genes
(17, 18). In addition to functional protein isoforms, alter-
native splicing can lead to the production of transcripts
with premature stop codons (PTCs) that are degraded by
NMD. It has been suggested that many of these tran-
scripts are not functionally relevant, as most appear not to
be conserved in mammals, but that they rather represent
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biological noise caused by splicing errors, sometimes
termed illegitimate splicing,(19–21). However, some
PTC-containing transcripts have been shown to result
from regulated alternative splicing events that contribute
to the regulation of protein expression, also called reg-
ulated unproductive splicing and translation (RUST)
(22, 23).
In the case of the MMR and other cancer genes,
several alternatively spliced mRNA transcripts with no
apparent association with mutations have been reported
(7, 10). These alternative transcripts can mask the pres-
ence of similarly sizedmutation-associated aberrant tran-
scripts in RT-PCR assays, or can even be mistaken as
patient-speci!c splicing aberrations. Evidence to date
from largely semiquantitative assays shows that the num-
ber and level of alternative transcripts, potentially carry-
ing PTCs, can vary markedly between individuals, and
also between tissues within a given individual (10, 11,
24, 25). Thus, it is very important to establish a baseline
of the number and expression level of naturally occurring
alternatively spliced transcripts for a given gene, against
which assay data can be interpreted.
This is the !rst systematic review focused on naturally
occurring alternatively spliced transcripts of the MMR
genes MLH1, MSH2, MSH6 and PMS2. The aim of the
review was to identify all MMR transcripts reported in
public domains (public databases and/or the literature),
in order to provide a catalogue for design and interpre-
tation of splicing assays. Additionally, the same data
sources were mined to identify MMR gene nucleotide
variants reported to be associated with altered expres-
sion of any naturally occurring alternatively spliced
transcripts. These nucleotide variants were also bioin-
formatically evaluated to assess if the altered tran-
script pro!les reported were consistent with effect of
the variant on splicing signals. This review shows the
importance of prior knowledge of naturally occurring
alternative splice transcripts to variant interpretation, and
provides a catalogue of naturally occurring MMR tran-
scripts, which can be used as a baseline reference to
inform the design and interpretation of clinical mRNA
assays.
Materials and methods
Retrieval of MMR gene mRNA sequences
Alternatively spliced MMR transcripts were de!ned
as mRNA transcripts naturally occurring in healthy
control individuals, i.e. in addition to the full-length
reference mRNA. The following sequences were used
as full-length transcript references: NM_000249.3
(MLH1), NM_000251.2 (MSH2), NM_000179.2 (MS
H6) and NM_000535.5 (PMS2). First, naturally occur-
ring MMR transcripts were identi!ed through a sys-
tematic literature review using PubMed (www.ncbi.
nlm.nih.gov/pubmed/) and Embase (http://www.elsevier.
com/online-tools/embase) until December 2013. The
following search terms were used: ‘isoform’, ‘alternative
splicing’, ‘transcript’ combined with ‘MMR’, ‘MLH1’,
‘MSH2’, ‘MSH6’ or ‘PMS2’.
Then, unpublished transcripts were identi!ed by min-
ing mRNA expression data for each MMR gene on UC
SC genome browser (genome.ucsc.edu/) using Galaxy
web-based software (https://usegalaxy.org/), which in-
cluded retrieval of all annotated MMR transcripts
reported by GENCODE (26) and GenBank (https://
www.ncbi.nlm.nih.gov/genbank/).
Annotation of MMR gene alternative splicing events
Each MMR gene transcript was annotated based on
guidelines reported by Colombo et al. (27) and Mudge
et al. (8). The symbols used in Fig. 2 to name the
transcripts denote the following:Δ – partial or complete
exon deletion; ▾ – inclusion of intronic sequence within
the transcript’s body or inclusion of non-coding or
intronic sequence as an alternative !rst or !nal exon;
p – acceptor-site shift; and q – donor-site shift.
MMR gene reported spliceogenic variants and bioinformatic
predictions
The InSiGHT database (http://insight-group.org/classi!-
cations) was used to identify MMR gene sequence vari-
ants reportedly associated with altered mRNA splicing
(termed spliceogenic variants) that were not identi!ed by
the search terms above. Human Genome Variation Soci-
ety (HGVS) nomenclature was used to annotate all the
sequence variants (28).
The MMR gene variants reported to be associated with
dysregulated expression of alternative transcripts were
analysed using splicing bioinformatic programs to deter-
mine if observed splicing alterations were predicted to
result from the genetic variant assessed. Variants were
evaluated using Human Splicing Finder (HSF) version
2.4.1 (www.umd.be/HSF/), which incorporates matrices
to predict existence or alteration of 5′ and 3′ splice
sites and splicing regulatory elements using different
algorithms, including HSF matrices and MaxEntScan
(29, 30). Score variations of at least −5% for HSF or
−15% for MaxEntScan were interpreted as a signi!cant
decrease in predicted splice site strength to predict loss
of the wild-type site (31). For exonic variants, if there
was no predicted effect on donor/acceptor sites, then ESE
loss caused by the variant was predicted using default
cut-offs. Additionally, the HSF and MaxEntScan algo-
rithms were used to analyse the scores of the alterna-
tive donor and acceptor sites for comparison to those for
donors and acceptors of the reference transcript.
Results
Characteristics of naturally occurring MMR transcripts
In addition to the full-length transcripts, 30 MLH1, 22
MSH2, 4MSH6 and 9 PMS2 alternative transcripts (n=
65, Fig. 2a–d) were identi!ed from the literature (Table
S1, Supporting Information) and/or database searches
(Table S2). Another !ve alternatively spliced MLH1
transcripts (MLH1Δ4/9/10,Δ9/15,Δ10/14_16,Δ14/15,
Δ15/16) reported in the literature cannot be considered
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Fig. 2. Mismatch repair gene naturally occurring mRNA transcripts identi!ed from the literature and public sequence database searches:MLH1, n= 31
(a), MSH2, n= 23 (b); MSH6, n= 5 (c); and PMS2, n= 10 (d). A full explanation of the symbols used to annotate the transcripts is presented in the
Methods section. Asterisks denote transcripts identi!ed in public databases only. Solid lines denote predicted open reading frame (coding sequence)
derived from exonic sequence (grey shading) and/or intronic/intergenic sequence (black shading). Predicted coding sequences were based onGENCODE
annotated transcripts or recommendations in Mudge et al. (8). Light shading denotes predicted non-coding sequence, derived from exonic sequence
(dashed lines) and/or intronic/intergenic sequence (dot-dash lines). FL, full-length reference transcript sequences (RefSeq): NM_ 000249.3 (MLH1),
NM_000251.2 (MSH2), NM_000179.2 (MSH6) and NM_000535.5 (PMS2). Δ: partial or complete exon deletion; ▾: inclusion of intronic sequence
within the transcript’s body or inclusion of non-coding or intronic sequence as an alternative !rst or !nal exon; p: acceptor-site shift; q: donor-site shift.
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Fig. 2. Continued.
naturally occurring, because they were identi!ed in
Epstein-Barr virus (EBV)-transformed lymphoblasts and
in peripheral blood lymphocytes from Lynch Syndrome
cases (32, 33).
A total of 23 alternative transcripts were present on
UCSC genome browser only (Table S2), including all
MSH6 alternative transcripts described in this review.
Transcripts with alternative transcription start sites (ter-
minal modi!cation transcripts, see Fig. 1) may not
have been reported in the literature because they are
not detectable by traditional MMR RT-PCR analyses,
which generally use primers targeting the 5′ untrans-
lated region of the reference transcripts (RefSeq). An
additional 31 novel alternatively spliced ESTs have
not been fully annotated, and are thus not included
in the catalogue in Fig. 2. Caution should particu-
larly be employed in the interpretation of PMS2 tran-
scripts due to the presence of multiple pseudogenes on
the same chromosome and extensive gene conversion
reported between the PMS2 and pseudogene PMS2CL
(34, 35). At least two of the ESTs identi!ed via Genome
Browser, appear, from nucleotide matches and tran-
script structure, to be sequenced from the pseudogene
PMS2CL. Currently eight MMR transcripts identi!ed
via the UCSC genome browser cannot be considered
naturally occurring (MLH1 Δ11; MLH1 Δ10/11, Δ16;
MLH1 Δ10_15; MLH1 Δ14_17; MLH1 Δ16_18; MSH2
Δ2q(c)_4p; MSH2 15A, Δ16, ▾16A_16B; PMS2 ▾1q,
▾4q, Δ5_15, ▾15) because they are found only in cancer
cell lines or tumour tissue.
MLH1 alternative transcripts are the most abundantly
reported in publications (Table S1), in particular Δ9/10
(n= 11 publications), followed by Δ6, Δ16 and Δ17 (all
n= 6). As shown in Fig. 2a, the most common mode
of alternative splicing in MLH1 is exon skipping (‘cas-
sette’), with 61% of all reportedMLH1 transcripts show-
ing this type of alteration, and an additional 10% show-
ing exon skipping combined with other splicing events.
Exons 4, 6, 9, 10, 11, 15, 16 and 17 are apparently those
exons most prone to skipping, as the majority of reported
alternativeMLH1 transcripts represent various combina-
tions of skipping of these cassette exons (Fig. 2a).
In contrast to MLH1, the most abundant mechanism
of alternative splicing in MSH2 and MSH6 transcripts
resembles cryptic splice site utilization (65% of MSH2,
and 60% of MSH6 transcripts) (Fig. 2b,c; Table S1).
Relative to the reference transcripts, for all four genes
combined, there were 47 ‘cryptic’ splice sites utilized
in the alternatively spliced transcripts (Table S3). The
majority of these ‘cryptic’ sites had the same splice
site dinucleotide sequence as observed for 99% of all
native donor or acceptor sites in known genes (36), with
GT dinucleotide for 14/23 (61%) ‘cryptic’ donor sites
and AG dinucleotide for 18/24 (75%) ‘cryptic’ acceptor
sites. Based on bioinformatic analyses using HSF and/or
MaxEntScan, only 9/47 (19%) of these alternative splice
sites have greater scores than those of the actual splice
sites of the reference transcript, ranging from marginal
increase to up to twofold increase. Furthermore, six of
these nine ‘cryptic’ sites cause intron retention when
utilized, leading to insertion of new cassette exons or
terminal modi!cation events relative to the reference
sequence.
Differential tissue expression was reported for a num-
ber of naturally occurring MMR alternative transcripts
(Tables S1 and S2). In particular, some transcripts
reported in lymphocytes were not detected in colon tis-
sue (10, 25). Only a few studies attempted to quan-
tify the level of alternative MMR transcripts in tissue
samples (11, 24, 25, 37). Level of upregulation quan-
ti!ed for six alternative MLH1 transcripts showed rela-
tive expression up to 77% of the full-length transcript in
lymphocytes from control individuals: Δ9/10 (4–77%),
Δ9_11 (21–64%), Δ10/11 (4–50%), Δ15 (5–40%),
Δ16 (5–60%), andΔ17 (6–15%) (11, 24, 25). Addition-
ally, the relative expression of an MLH1 transcript with
an alternative transcription start site (▾1, Fig. 2a, Table
S1) was quanti!ed in multiple colorectal cell lines (37).
5
Thompson et al.
Interestingly, this alternative transcript was expressed in
three different MLH1-de!cient cell lines, which exhibit
MLH1 promoter hypermethylation (RKO and SW48) or
a hemizygous nonsense mutation (HCT116) (37, 38).
It is expected that the majority of the alternatively
spliced MMR transcripts would encode proteins with
abrogated function due to protein truncation, dominant
negative effects or concomitant decrease in full-length
reference transcript levels. NMD through introduction
of premature termination codons is predicted for 57%
(n= 37) of transcripts, and 20% (n= 13) are predicted
to be entirely non-coding or to use alternative tran-
scription or translation start sites (Fig. 2). The effect
on MMR function has been investigated experimen-
tally for only three of the MLH1 protein isoforms. In
in vitro assays, both MLH1 p.Glu578_Glu632del (Δ16)
and p.Glu633_Glu663del (Δ17) showed de!cient inter-
actionwith PMS2 (39–41), as expected from the location
of the deletions in the PMS2 binding domain (42, 43).
Additionally, MLH1 p.Glu227_Ser295del (Δ9/10) dis-
played de!cientMMR function in an in vitroMMRassay
(44), and a dominant negative effect in MMR-pro!cient
cell lines (45). The results of all these in vitro assays indi-
cate that expression of MMR protein isoforms encoded
by known alternative MMR transcripts can lead to defec-
tive MMR. This highlights the importance of investigat-
ing transcript expression levels, including estimating rel-
ative allele-speci!c expression and comparing the overall
expression levels of full-length reference transcripts in
variant carriers relative to a set of control individuals.
Alternatively spliced MMR transcripts reported to be
expressed in carriers of MMR gene variants
There are 66 nucleotide variants inMLH1, 24 variants in
MSH2, and 6 variants in PMS2 reported to be associated
with an altered expression of naturally occurring alter-
natively spliced transcripts, none of which were stud-
ied using truly quantitative assays. Eighty-two of the
variants associated with altered splicing are likely to be
or are bona !de pathogenic (disease-causing) mutations
causing aberrant splicing (Table S4). This includes 39
sequence variants affecting the canonical AG-GT dinu-
cleotides.
As denoted in Table S4, the bioinformatic predictions
for 19/96 (20%) of the variants are inconsistent with the
alternative transcript reported, or indicate inconclusive
evidence to support the reported splicing event (only
one of four programs predict loss of an ESE). All 19
of these variants were exonic. Five were proven to
cause splicing aberrations (three with inconclusive ESE
predictions, and two not predicted to alter splicing at
all). Of the remaining 14, 2 have not been tested for
allele-speci!c expression and thus their association with
aberrant splicing has not been determined, whereas the
other 12 were reported using semiquantitative assays
to show partial expression of the full-length transcript
from the variant allele. That is, there is a possibility
that some splicing aberrations reported to be associated
with sequence variants may represent naturally occurring
alternatively spliced transcripts demonstrating the need
for quantitative assays to assess the clinical signi!cance
of potentially spliceogenic variants.
Further, 41 variants were assessed in more than one
study (Table S4), and reported mRNA assay results were
inconsistent between studies for 8 of them, highlighting
issues with interpretation or detection sensitivity. For
example, variant MLH1 c.113A>G p.Asn38Ser was
reported to result in minor upregulation of the MLH1
▾1q transcript – a splicing event inconsistent with
bioinformatic predictions (46) but was not detected
in allele-separation assays assessing the same variant
(47). Further, as expected from bioinformatic pre-
dictions, MLH1 c.544A>G was shown to increase
the production of MLH1 Δ6 transcripts (r.454_545del,
p.Glu153Phefs*8) in two studies using RT-PCRmethod-
ology (48, 49). This effect was not detected in two other
studies using the less sensitive protein truncation test
(50, 51). These !ndings show the importance of suitable
experimental design for detection and interpretation of
dysregulated splicing patterns.
In contrast to MLH1 and MSH2, there are not many
reported MSH6 and PMS2 variant-associated splic-
ing aberrations, which re"ects the proportions of
disease-causing mutations reported for each gene (5).
There are six PMS2 variants reported to be associated
with PMS2 alternative transcripts (Table S4):Δ6p upreg-
ulation was con!rmed through allele-speci!c expression
assays (52); two variants associated with PMS2 Δ2 (53)
and three variants associated with PMS2 Δ10 (52–54)
interrupt canonical splice sites; and another four PMS2
and !ve MSH6 variant-associated splicing aberrations
reported in the literature (52, 55–61) are plausibly
caused by the relevant sequence alteration. The splicing
aberrations reported for the !ve MSH6 and four PMS2
variants mentioned above, do not include alternative
transcripts detectable in control individuals, and were
consistent with strong bioinformatic predictions of splic-
ing alterations for all but one variant:MSH6 c.3991C>T
p.(Arg1331*) (55) was shown to be associated with
exon 9 skipping, and is probably due to alteration of
exonic splicing regulatory elements (disruption of an
ESE and/or creation of an ESS) or nonsense-associated
altered splicing (6).
Discussion
This is the !rst systematic review conducted to catalogue
naturally occurring alternatively spliced MMR mRNA
transcripts. Our !ndings, which are derived from com-
prehensive scrutiny of peer-reviewed publications and
public databases, indicate that MLH1 and MSH2 tran-
scripts undergo multiple alternative splicing events, with
a total of 30 MLH1 and 22 MSH2 alternative transcripts
reported to date. This high level of alternative splic-
ing complicates interpretation of RNA data derived from
patients carrying nucleotide variations in these genes, as
shown by con"icting reports of splicing dysregulation
over multiple studies describing mRNA assays for iden-
tical nucleotide variants (Table S4).
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Reported associations between MMR alternative tran-
scripts and nucleotide variants were not always sup-
ported by bioinformatic predictions. For MLH1, ∼20%
of studies (Table S4) reported alterations in the level of
naturally occurring transcripts in association with exonic
sequence variation that were inconsistent with bioinfor-
matic predictions. The discrepancy may in part be due
to inaccurate in silico predictions, in particular those
related to alterations of splicing regulatory elements
(62). However, misreporting of alternative transcripts as
variant-induced aberrations is likely to contribute. Fur-
thermore, 89% (66/74) of published studies reviewed
here did not denote that certain patient-associated tran-
scripts are also reported as naturally occurring alterna-
tive transcripts in control individuals. Importantly, none
of the studies used truly quantitative methods to assess
transcript levels. In the absence of such information it is
dif!cult to distinguish between natural expression "uc-
tuation and mutation-induced aberrant splicing. Thus,
allele-speci!c quantitative studies should be advised for
any variant that lies in a region that is prone to alterna-
tive splicing. We note that the InSiGHT Variant Inter-
pretation Committee currently recommends additional
clinical evidence (e.g. segregation, tumour pathology)
to support causality for all potential splicing mutations,
if the mRNA transcript has not been assessed using
allele-speci!c assays (5).
The biological relevance of MMR alternative tran-
scripts is largely unknown, and probably depends on
the relative level of alternatively spliced transcripts com-
pared to the absolute level of concomitantly downregu-
lated full-length transcript. It is expected that many of
the alternatively spliced transcripts that introduce prema-
ture termination codons will probably be eliminated, to
some extent, by post-transcriptional surveillance mech-
anisms, such as NMD (63). Many of the in-frame cod-
ing alternative transcripts may also be ‘non-functional’.
It has been shown using in vitro analysis that expres-
sion of MLH1 protein isoforms carrying in-frame dele-
tions (MLH1 Δ9/10, Δ16 and Δ17) can cause abrogated
DNA repair function (39–41, 44, 45). However, it should
be noted that not all in-frame alternatively spliced tran-
scripts will necessary cause loss of protein function. For
instances, in BRCA2, the Δ12 protein isoform, which
has been identi!ed in control individuals (James Facken-
thal, personal communication) and normal breast tissue
(64), shows full DNA repair function (65). This high-
lights the importance of understanding the phenotypic
consequences of mutation-induced upregulation of nat-
urally occurring alternative splicing events.
These transcripts could possibly be involved in the reg-
ulation of gene expression through unproductive splicing
and translation, which has been reported for some splic-
ing factors (66, 67). Alternatively spliced transcripts of
human MMR gene appear not to be conserved in mouse
(data not shown), which may indicate their lack of bio-
logical relevance. However, a correlation between the
frequency of unproductive splice variants for the ubiqui-
tously expressed DNA polymerase B and life span in pri-
mates has been reported (68), so there may be an equally
adaptive signi!cance to the increased alternative splicing
observed in humans forMLH1 andMSH2. Further inves-
tigation is required to determine which MMR alternative
transcripts may result from regulated events, and which
may represent illegitimate splicing.
Some of the MMR alternative splice variants reported
could be consequences of illegitimate splicing caused by
stress-induced reduction in splicing machinery !delity
(69, 70). In this case, the presence of some alternatively
spliced MMR transcripts in potentially ‘aged’ periph-
eral blood lymphocytes compared to lymphoblastoid cell
lines (LCLs – derived from EBV-immortalized B lym-
phocytes) (12, 71) could eventually be explained by a
potential restoration of splicing !delity through the lym-
phocyte immortalization process (70, 72). High levels of
alternative transcript expression have been measured in
lymphocyte RNA from control individuals using semi-
quantitative methods (11, 24, 25), but the relationship to
‘age’ of the processed cells is not reported.
There are reports of differential expression of some
MMR transcripts between normal tissues (10, 71). This
is not unexpected considering that there are many
instances of tissue-speci!c regulation of gene expres-
sion through alternative splicing (73). Absence of alter-
native transcripts in a tissue may be due in part to the
use of low sensitive techniques for assaying alterna-
tive transcripts. Using more sensitive techniques, recent
investigations into BRCA1 alternative splicing have
showed that mRNA transcripts were all expressed in
blood-based RNA sources and breast tissue, but the ratio
of transcripts differed (27). Testing a large number of
matched lymphocytes and other normal tissues, partic-
ularly those vulnerable to MMR defects, such as colon
and endometrium, would be an ideal approach to inves-
tigate tissue-speci!c MMR alternative splicing patterns.
Together, these observations highlight the importance of
analysing samples from the same tissue type under stan-
dardized conditions that can control for differences in
transcript expression due to illegitimate splicing or dif-
ferences due to tissue type.
This review highlights the prevalence of alternatively
spliced MMR transcripts and provides a catalogue to
assist in the design and interpretation of splicing assays
for these genes. Our !ndings indicate that identi!cation
and quanti!cation of naturally occurring transcripts in
multiple healthy controls (from appropriately processed
tissue samples) is required to determine the range of
variability associated with a normal MMR splicing pat-
tern, and thereby further assist in interpretation of tran-
script dysregulation in MMR variant carriers. This will
require the application of robust techniques. Capillary
electrophoresis is a sensitive transcript detection method
(27, 74) but it does not reach nucleotide-resolution level.
In this sense, the recently developed transcriptomics
approaches, RNAseq (75) and now the more sensitive
RNA capture-seq (76) hold great promise for a deep char-
acterization of the alternative splicing pattern of many
disease-associated genes such as MLH1, MSH2, MSH6
and PMS2, both in healthy control individuals, and in
variant carriers (patients and asymptomatic relatives).
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Supplementary Table 1: Summary of naturally occurring MMR transcripts reported in the literature 
Alternative 
splicing event 
Predicted 
transcriptc Predicted protein
c 
Functional 
annotation 
relative to 
RefSeqd 
Transcript typed Summary of alternative transcript expression Refs 
MLH1 (NM_000249.3) 
▼1a,b r.? p.? Alternative UTR 
with internal 
ATG 
Terminal modification Multiple colorectal cell lines (1) 
▼1qa r.116_117ins116+1
_116+227 
p.Cys39Trpfs*11 Intronic STOP + 
polyA 
Terminal modification Normal testis tissue. (2) 
Δ2pa r.117_121del p.Cys39* PTC-NMD Splice acceptor shift PBMCs (ALL cases & healthy control individuals). (3) 
Δ3qa r.302_306del p.Glu102Phefs*18 PTC-NMD Splice donor shift LCLs (LS cases & healthy control individuals). (4) 
Δ4a r.307_380del p.Ala103Serfs*13 PTC-NMD Cassette PBMCs (asymptomatic sibling). (5) 
Δ4, Δ10 
 
r.[307_380del; 
791_884del] 
p.Ala103Serfs*13 PTC-NMD Cassette PBMCs (asymptomatic sibling). (5) 
Δ6a r.454_545del p.Glu153Phefs*8 PTC-NMD Cassette PBMCs & LCLs (healthy control individuals, 
asymptomatic sibling, ALL case), & normal testis 
tissue. 
(2, 3, 5, 6) 
Δ6, Δ9 r.[454_545del; 
678_790del] 
p.Glu153Phefs*8 PTC-NMD Cassette PBMCs & LCLs (healthy control individuals, LS case, 
asymptomatic sibling), normal extra-colonic tissues, 
CRCs & tumour cell lines.  
Not expressed in normal colon tissue. 
(5, 7) 
Δ6, Δ9, Δ10 r.[454_545del; 
678_884del] 
p.Glu153Phefs*8 PTC-NMD Cassette PBMCs (LS case & asymptomatic sibling). (5) 
Δ6, Δ10 r.[454_545del; 
791_884del] 
p.Glu153Phefs*8 PTC-NMD Cassette PBMCs (healthy donor). (5) 
Δ9 r.678_790del p.Glu227Serfs*42 PTC-NMD Cassette PBMCs & LCLs (healthy control individuals, LS 
cases, ALL cases, asymptomatic siblings), normal 
colonic & extra-colonic tissues, & tumour cell lines. 
(3, 5-9) 
Δ9/10a r.678_884del p.Glu227_Ser295del No FS Multi-cassette PBMCs & LCLs (healthy control individuals, LS 
cases, ALL cases, asymptomatic siblings), normal 
colonic & extra-colonic tissues, CRCs, & tumour cell 
(2-12) 
! 2!
lines. 
Δ9_11a r.678_1038del p.Glu227Leufs*20 PTC-NMD Multi-cassette PBMCs & LCLs (healthy control individuals, LS 
cases, ALL cases, asymptomatic siblings), normal 
colonic & extracolonic tissues, & tumour cell lines. 
(3, 7, 8, 10) 
Δ10a r.791_884del p.His264Leufs*2 PTC-NMD Cassette PBMCs & LCLs (LS cases, asymptomatic siblings, 
healthy control individuals), & normal testis tissue. 
(2, 5, 6, 13) 
Δ10/11a r.791_1038del p.Arg265Phefs*14 PTC-NMD Multi-cassette PBMCs & LCLs (healthy control individuals, ALL 
cases), normal colonic & extracolonic tissues, & 
tumour cell lines. 
(3, 7, 8, 10) 
Δ10q_12p r.880_1100del p.Ser295Valfs*7 PTC-NMD Splice donor shift + 
cassette + splice 
acceptor shift 
PBMCs (healthy control individuals). (8) 
Δ12a r.1039_1409del p.Thr347Lysfs*8 PTC-NMD Cassette PBMCs & LCLs (healthy control individuals, ALL 
cases), normal colonic & extracolonic tissues, CRCs, 
& tumour cell lines. 
(3, 7) 
Δ14_18a r.1559_2103del p.Val520Glufs*2 PTC-NMD Multi-cassette Normal testis tissue. (2) 
Δ15  r.1668_1731del p.Ser556Argfs*14 PTC-NMD Cassette PBMCs (healthy control individuals) and LCLs (LS 
case). 
(6, 14) 
Δ15_18a r.1668_2103del p.Ser556Argfs*82 PTC-NMD Multi-cassette Normal testis tissue. (2) 
Δ16a r.1732_1896del p.Pro579_Glu633del No FS Cassette PBMCs & LCLs (healthy control individuals, ALL 
cases, LS case), normal colonic & extracolonic tissue, 
CRCs, & tumour cell line. Not expressed in normal 
colon epithelium. 
(3, 6, 7, 12, 
14, 15) 
Δ17a r.1897_1989del p.Glu633_Glu663del No FS Cassette PBMCs & LCLs (healthy control individuals, LS 
cases, ALL cases), normal colonic tissue, CRCs, & 
tumour cell line.  
Not expressed in normal colon epithelium. 
(3, 6, 7, 15-
17) 
MSH2 (NM_000251.2) 
Δ1q(a)_12p r.73_1867del p.Gly25Profs*12 PTC-NMD Splice donor shift + 
multi-cassette + splice 
acceptor shift 
PBMCs and T-lymphocytes (healthy control 
individuals).  
Not expressed in B-lymphocytes or LCLs (healthy 
control individuals). 
(8) 
Δ1q(b)_5p(b) r.115_939del p.Arg39Serfs*5 PTC-NMD Splice donor shift + 
multi-cassette + splice 
acceptor shift 
PBMCs (healthy control individuals). (8) 
! 3!
Δ2_6 r.212_1076del p.Gly71Aspfs*2 PTC-NMD Multi-cassette PBMCs and T-lymphocytes (healthy control 
individuals, LS case).  
Not expressed in B-lymphocytes or LCLs (healthy 
control individuals). 
(8, 9, 18) 
Δ2_7 r.212_1276del p.Ala72_Gly426del No FS Multi-cassette PBMCs (healthy control individuals) & CRC. (7) 
Δ2_8 r.212_1386del p.Ala72Glyfs*4 PTC-NMD Multi-cassette PBMCs (healthy control individuals).  
Not expressed in CRCs. 
(7) 
Δ2q(a)_5p(a) r.229_799del p.Ser77Phefs*7 PTC-NMD Splice donor shift + 
multi-cassette + splice 
acceptor shift 
PBMCs (healthy control individuals). (8, 18) 
Δ2q(d)_6p r.320_1071del p.Ala107Glyfs*31 PTC-NMD Splice donor shift + 
multi-cassette + splice 
acceptor shift 
PBMCs and T-lymphocytes (healthy control 
individuals).  
Not expressed in B-lymphocytes or LCLs (healthy 
control individuals). 
(8) 
Δ3a r.367_645del p.Ala123_Gln215del No FS Cassette PBMCs (LS case) & normal testis tissue. (2, 19) 
Δ3q(a)_13p(a) r.446_2075del p.Lys151Leufs*16 PTC-NMD Splice donor shift + 
multi-cassette + splice 
acceptor shift 
PBMCs (healthy control individuals). (8) 
Δ4_13p(b) r.646_2150del p.? PTC-NMD Multi-cassette + splice 
acceptor shift 
PBMCs and T-lymphocytes (healthy control 
individuals).  
Not expressed in B-lymphocytes or LCLs (healthy 
control individuals). 
(8) 
Δ5a r.793_942del p.Val265_Gln314del No FS Cassette PBMCs & LCLs (healthy control individuals, LS 
cases), normal colonic & testis tissue, & CRCs. 
(2, 4, 7, 8, 11) 
Δ8 r.1277_1386del p.Lys427Glyfs*4 PTC-NMD Cassette PBMCs (healthy control individuals, suspected-LS 
case). 
(13) 
▼9a r.1510_1511ins15
10+1126_1510+1
258 
p.Leu505_Thr933delins
GlySerLeuGlnProArgS
erSerArgLeuAlaCysAla 
No FS Cassette Normal testis tissue. (2) 
Δ10a r.1511_1661del p.Gly504Alafs*3 PTC-NMD Cassette Normal testis tissue. (2) 
Δ12q_13p(c) r.1898_2156del p.Ile633Argfs*26 PTC-NMD Splice donor shift + 
splice acceptor shift 
Normal colonic & extracolonic tissues. (20) 
! 4!
Δ13 r.2006_2210del p.Pro670Leufs*7 PTC-NMD Cassette PBMCs & macrophage (healthy control individuals, 
LS cases, FAP cases, sporadic CRC cases), CRC 
(1/14), & foetal skin.  
Not expressed in foetal or adult normal colon mucosa 
& crypt epithelial cells, OvCa, BrCa, & Lymphoma. 
(7, 8, 16, 20, 
21) 
PMS2 (NM_000535.5) 
Δ2p r.24_28del p.Ser8Argfs*7 Alternative UTR 
with internal 
ATG 
Splice acceptor shift Phytohemaglutinine-stimulated lymphocytes (healthy 
control individuals & suspected-LS cases) 
(22) 
Δ4q r.301_353del p.Val101Argfs*20 PTC-NMD Splice donor shift Phytohemaglutinine-stimulated lymphocytes (healthy 
control individuals, suspected-LS cases & 
constitutional MMR-deficiency case) 
(22, 23) 
Δ6p r.538_586del p.Glu180Glnfs*5 PTC-NMD Splice acceptor shift Phytohemaglutinine-stimulated lymphocytes (healthy 
control individuals, suspected-LS cases & 
constitutional MMR-deficiency case) 
(22, 23) 
Δ10 r.989_1144del p.Glu330_Glu381del No FS Cassette Phytohemaglutinine-stimulated lymphocytes (healthy 
control individuals & suspected-LS cases) 
(22) 
Alternative splicing events are described relative to MLH1, MSH2 and PMS2 reference sequences NM_000249.3, NM_000251.2 and NM_000535.5 
respectively. No naturally occurring MSH6 mRNA alternative splicing events have been reported in the literature. 
Δ: partial or complete exon deletion; ▼: inclusion of intronic sequence in transcript or inclusion of non-coding or intronic sequence as an alternative 
first or final exon; p: acceptor site shift; q: donor site shift 
aAlso reported on public databases. 
bTranscript has an alternative promoter and transcription start site (TSS) 3’ to the reference sequence transcription start site 
cAccording to HGVS guidelines (http://www.hgvs.org/mutnomen) 
dAccording to Mudge et al (24) and Colombo et al (25).  
UTR: untranslated region; PTC-NMD: premature termination codon predicted to induce nonsense mediated decay; FS: frame-shift; PBMC: peripheral 
blood mononuclear cell; ALL: acute lymphoblastic leukemia; LCL: lymphoblastoid cell line; LS: Lynch syndrome; CRC: colorectal cancer; OvCa: 
ovarian cancer; BrCa: breast cancer. 
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7Supplementary Table 2: Mismatch repair gene alternative transcripts on UCSC genome browser (see Fig. 1 and Supplementary Table 1 for description of functional annotations and transcript types)
Gene GenBank ID Source Transcript* RNA Functional annotation Transcript type Cell line (as recorded by GenBank) Tissue (as recorded by GenBank) Chromosome
MLH1 AB209848 mRNA Δ17/18 r.1897_2103del no FS multi-cassette n/a aorta endothelial cell chr3
MLH1 AK295359 mRNA ▼1A, Δ2p r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.117_121del) alternative UTR with internal ATG
terminal modification + 
splice acceptor shift n/a corpus callosum chr3
MLH1 AK298324 mRNA ▼1A, Δ3q r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.302_306del) alternative UTR with internal ATG
terminal modification + 
splice donor shift n/a kidney chr3
MLH1 AK298583 mRNA ▼1A, Δ3q r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.302_306del) alternative UTR with internal ATG
terminal modification + 
splice donor shift n/a n/a chr3
MLH1 AK302807 mRNA ▼1A, Δ19, ▼19
r.? (alternative TSS 3' of NM_000249.3 TSS & uses 
cryptic donor site @ c.116+227, plus 
r.2104_*delinsNM_001134369.1:r.729_808+194)
alternative UTR with internal ATG 
& alternative final exon with STOP terminal modification n/a testis chr3
MLH1 AK311326 mRNA ▼1q r.116_117ins116+1_116+227 PTC induces NMD splice donor shift n/a brain chr3
MLH1 AK311365 mRNA ▼1A r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a n/a chr3
MLH1 AK316074 mRNA ▼1A, Δ6 r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.454_545del) alternative UTR with internal ATG terminal modification + cassetten/a substantia nigra chr3
MLH1 AK316264 mRNA Δ2 r.117_207del PTC induces NMD cassette n/a brain chr3
MLH1 BX648844 mRNA ▼1A, ▼2
r.? (alternative TSS 3' of NM_000249.3 TSS & uses 
cryptic donor site @ c.116+227, plus 
r.207_208ins207+447_207+591)
alternative UTR with internal ATG terminal modification + cassette n/a human colon endothel primary cell culture chr3
MLH1 DQ648888 mRNA ▼1q r.116_117ins116+1_116+227 PTC induces NMD splice donor shift n/a testis chr3
MLH1 DQ648889 mRNA Δ6 r.454_545del PTC induces NMD cassette n/a testis chr3
MLH1 DQ648890 mRNA Δ10 r.791_884del PTC induces NMD cassette n/a testis chr3
MLH1 DQ648891 mRNA Δ9/10 r.678_884del no FS multi-cassette n/a testis chr3
MLH1 DQ648892 mRNA Δ15_18 r.1668_2103del alternative STOP multi-cassette n/a testis chr3
MLH1 DQ648893 mRNA Δ14_18 r.1559_2103del PTC induces NMD multi-cassette n/a testis chr3
MLH1 EU188665 mRNA Δ17 r.1897_1989del no FS cassette Vaco432 n/a chr3
MLH1 EU188666 mRNA Δ16 r.1732_1896del no FS cassette Vaco432 n/a chr3
MLH1 EU188667 mRNA Δ11 r.885_1038del PTC induces NMD cassette Vaco432 n/a chr3
MLH1 EU188668 mRNA Δ10 r.791_884del PTC induces NMD cassette Vaco432 n/a chr3
MLH1 EU188669 mRNA Δ10/11 r.791_1038del PTC induces NMD multi-cassette Vaco432 n/a chr3
MLH1 EU188670 mRNA Δ10/11, Δ16 r.[791_1038del; 1732_1896del] PTC induces NMD multi-cassette Vaco432 n/a chr3
MLH1 EU188671 mRNA Δ12 r.1039_1409del PTC induces NMD cassette Vaco432 n/a chr3
MLH1 EU188672 mRNA Δ9_11 r.678_1038del PTC induces NMD multi-cassette Vaco432 n/a chr3
MLH1 EU188673 mRNA Δ14_17 r.1559_1989del PTC induces NMD multi-cassette Vaco432 n/a chr3
MLH1 EU188674 mRNA Δ16_18 r.1732_2103del no FS multi-cassette Vaco432 n/a chr3
MLH1 EU188676 mRNA Δ10_15 r.791_1731del PTC induces NMD multi-cassette Vaco432 n/a chr3
MLH1 AL042015 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a testis chr3
MLH1 AU127122 EST ▼1A r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification NT2 n/a chr3
MLH1 AU128510 EST ▼1A r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification NT2 n/a chr3
MLH1 AU310097 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a neuroblastoma chr3
MLH1 BE871360
EST 
(GENCODE 
mRNA)
▼1A, ▼1C(a)
r.? (alternative TSS 3' of NM_000249.3 TSS & uses 
cryptic donor site @ c.116+227, plus 
r.116_117ins116+1167_116+1240)
alternative UTR with internal ATG terminal modification n/a adenocarcinoma chr3
MLH1 BE884841 EST Δ3 r.208_306del no FS cassette n/a leiomyosarcoma chr3
MLH1 BF206894 EST Δ7 r.546_588del PTC induces NMD cassette n/a neuroblastoma chr3
MLH1 BF306562 EST Δ3q r.302_306del PTC induces NMD splice donor shift n/a rhabdomyosarcoma chr3
MLH1 BF306562 EST Δ2p, Δ3q r.[117_121del; 302_306del] PTC induces NMD splice acceptor shift + splice donor shift n/a rhabdomyosarcoma chr3
MLH1 BG177520 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a lymphoma, cell line chr3
MLH1 BG186321 EST Δ17 r.1897_1989del no FS cassette HT1080 n/a chr3
MLH1 BG205466 EST Δ17 r.1897_1989del no FS cassette HT1080 n/a chr3
MLH1 BG216393 EST Δ17 r.1897_1989del no FS cassette HT1080 n/a chr3
MLH1 BG684901 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a primary b-cells from tonsils (cell line) chr3
8Gene GenBank ID Source Transcript* RNA Functional annotation Transcript type Cell line (as recorded by GenBank) Tissue (as recorded by GenBank) Chromosome
MLH1 BG714918 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a hypothalamus chr3
MLH1 BG748242 EST ▼1A, Δ3q r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.302_306del) alternative UTR with internal ATG
terminal modification + 
splice donor shift n/a normal pigmented retinal epithelium chr3
MLH1 BG755193 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a primary b-cells from tonsils (cell line) chr3
MLH1 BG755996 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a primary b-cells from tonsils (cell line) chr3
MLH1 BG822578 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a adenocarcinoma cell line chr3
MLH1 BI459835 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a n/a chr3
MLH1 BI598630 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a hypothalamus chr3
MLH1 BI600968 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a hypothalamus chr3
MLH1 BI835081 EST Δ2p, Δ3 r.[117_121del; 208_306del] PTC induces NMD splice acceptor shift + cassette n/a n/a chr3
MLH1 BJ990914 EST Δ17 r.1897_1989del no FS cassette n/a hepatoblastoma chr3
MLH1 BM456081 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a lymphoma, cell line chr3
MLH1 BM465789 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a retinoblastoma chr3
MLH1 BP196034 EST Δ6 r.454_545del PTC induces NMD cassette n/a adrenal gland chr3
MLH1 BP276503 EST Δ2p, Δ5q_6p(b) r.[117_121del; 398_531del] PTC induces NMD splice acceptor shift + splice donor shift n/a kidney chr3
MLH1 BP344681 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a synovial membrane chr3
MLH1 BP373445 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a umbilical cord chr3
MLH1 BQ213057 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a melanotic melanoma chr3
MLH1 BQ217408 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a melanotic melanoma chr3
MLH1 BU149161 EST ▼11 r.1038_1039ins1039-1771_1039-1679 PTC induces NMD cassette n/a sympathetic trunk chr3
MLH1 BU188024 EST ▼1A, Δ3q r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.302_306del) alternative UTR with internal ATG
terminal modification + 
splice donor shift n/a leiomyosarcoma chr3
MLH1 BU684387 EST Δ17 r.1897_1989del no FS cassette n/a primary lung cystic fibrosis epithelial cells chr3
MLH1 BU789168 EST Δ17 r.1897_1989del no FS cassette n/a insulinoma chr3
MLH1 BX365547 EST Δ1q r.-63_116del alternative UTR with internal ATG splice donor shift JURKAT n/a chr3
MLH1 BX396841 EST Δ4 r.307_380del PTC induces NMD cassette n/a placenta cot 25-normalized chr3
MLH1 BX477517 EST ▼1A, ▼1C(b)
r.? (alternative TSS 3' of  NM_000249.3 TSS & uses 
cryptic donor site @ c.116+227, plus 
r.116_117ins116+1167_116+1290)
alternative UTR with internal ATG terminal modification + cassette n/a n/a chr3
MLH1 CB529333 EST Δ17 r.1897_1989del no FS cassette n/a alveolar macrophage chr3
MLH1 CB957093 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a n/a chr3
MLH1 CD704317 EST ▼1A, Δ2p r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.117_121del) alternative UTR with internal ATG
terminal modification + 
splice acceptor shift n/a normal nasopharynx chr3
MLH1 CN414952 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a embryonic stem cell, retinoic acid and mitogen-treated hes cell line h7 chr3
MLH1 CN414953 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a
embryonic stem cells, dmso-treated h9 cell 
line chr3
MLH1 DA042139 EST ▼1A, ▼1C(b)
r.? (alternative TSS 3' of  NM_000249.3 TSS & uses 
cryptic donor site @ c.116+227, plus 
r.116_117ins116+1167_116+1290)
alternative UTR with internal ATG terminal modification + cassette n/a bladder chr3
MLH1 DA070867 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a cerebellum chr3
9Gene GenBank ID Source Transcript* RNA Functional annotation Transcript type Cell line (as recorded by GenBank) Tissue (as recorded by GenBank) Chromosome
MLH1 DA073874 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a cerebellum chr3
MLH1 DA106361 EST Δ6 r.454_545del PTC induces NMD cassette n/a cerebellum chr3
MLH1 DA156778 EST ▼1A, ▼4
r.? (alternative TSS 3' of NM_000249.3 TSS & uses 
cryptic donor site @ c.116+227, plus r.380_381ins381-
1131_381-1025)
alternative UTR with internal ATG terminal modification + cassette n/a amygdala chr3
MLH1 DA166268 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a amygdala chr3
MLH1 DA172498 EST ▼1q r.116_117ins116+1_116+227 PTC induces NMD splice donor shift n/a amygdala chr3
MLH1 DA275297 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a corpus callosum chr3
MLH1 DA296090 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a hippocampus chr3
MLH1 DA303777 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a hippocampus chr3
MLH1 DA343206 EST ▼1A, Δ6 r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.454_545del) alternative UTR with internal ATG
terminal modification + 
cassette n/a substantia nigra chr3
MLH1 DA352218 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a substantia nigra chr3
MLH1 DA385243 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a thalamus chr3
MLH1 DA430514 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a colon chr3
MLH1 DA433294
EST 
(GENCODE 
mRNA)
▼1A, ▼1C(a)
r.? (alternative TSS 3' of NM_000249.3 TSS & uses 
cryptic donor site @ c.116+227, plus 
r.116_117ins116+1167_116+1240)
alternative UTR with internal ATG terminal modification + cassette n/a cord blood chr3
MLH1 DA476068 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a n/a chr3
MLH1 DA499490 EST ▼1q r.116_117ins116+1_116+227 PTC induces NMD splice donor shift n/a brain chr3
MLH1 DA506267 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a brain chr3
MLH1 DA517219 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a brain chr3
MLH1 DA566031 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a heart chr3
MLH1 DA580525 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a n/a chr3
MLH1 DA582466 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a lung chr3
MLH1 DA653050 EST Δ1q, ▼1B r.-60_116delins116+563_116+683 alternative UTR with internal ATG splice donor shift + cassette n/a n/a chr3
MLH1 DA664790 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification NB9 n/a chr3
MLH1 DA748219 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification NT2 n/a chr3
MLH1 DA749519 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification NT2 n/a chr3
MLH1 DA750838 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification NT2 n/a chr3
MLH1 DA776094 EST Δ2 r.117_207del PTC induces NMD cassette n/a brain chr3
MLH1 DA814707 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a n/a chr3
MLH1 DA815001 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a n/a chr3
MLH1 DA821467 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a pericardium chr3
MLH1 DA866298 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a prostate chr3
MLH1 DA868597 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a prostate chr3
MLH1 DA921733 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a small intestine chr3
MLH1 DA922309 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a small intestine chr3
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MLH1 DA927898 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a small intestine chr3
MLH1 DA930241 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a small intestine chr3
MLH1 DA935122 EST ▼1A, ▼6q
r.? (alternative TSS 3' of NM_000249.3 TSS & uses 
cryptic donor site @ c.116+227, plus 
r.545_546ins545+1_545+5)
alternative UTR with internal ATG terminal modification + splice donor shift n/a spleen chr3
MLH1 DA937893
EST 
(GENCODE 
mRNA)
▼1A, ▼1C(a)
r.? (alternative TSS 3' of NM_000249.3 TSS & uses 
cryptic donor site @ c.116+227, plus 
r.116_117ins116+1167_116+1240)
alternative UTR with internal ATG terminal modification + cassette n/a spleen chr3
MLH1 DA952805 EST Δ4q_6p(a) r.380_490del no FS
splice donor shift + 
splice acceptor shift + 
cassette
n/a spleen chr3
MLH1 DA955738 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a spleen chr3
MLH1 DA963961 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a stomach chr3
MLH1 DB012054 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a esophageal, tumor tissue chr3
MLH1 DB012065 EST Δ2p, Δ6q(b)_14 r.[117_121del; 497_1667del] PTC induces NMD
splice acceptor shift + 
splice donor shift + 
multi-cassette
n/a esophageal, tumor tissue chr3
MLH1 DB018927 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a esophageal, tumor tissue chr3
MLH1 DB025714 EST ▼1q r.116_117ins116+1_116+227 PTC induces NMD splice donor shift n/a testis chr3
MLH1 DB114802 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a thymus chr3
MLH1 DB139980 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a thymus chr3
MLH1 DB157098 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a thymus chr3
MLH1 DB204422 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a trachea chr3
MLH1 DB246315 EST Δ6q(a)_7 r.493_588del no FS splice donor shift + cassette n/a uterus, tumor tissue chr3
MLH1 DB252510 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a uterus chr3
MLH1 DB253300 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a uterus chr3
MLH1 DB259565 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a uterus chr3
MLH1 DB287548 EST Δ2p r.117_121del PTC induces NMD splice acceptor shift n/a uterus chr3
MLH1 DB447950 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a testis chr3
MLH1 DB458726 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a testis chr3
MLH1 DB502676 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a hypothalamus chr3
MLH1 DC300233 EST ▼1A, Δ3q r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.302_306del) alternative UTR with internal ATG
terminal modification + 
splice donor shift n/a n/a chr3
MLH1 DC313239 EST ▼1A, Δ3q r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.302_306del) alternative UTR with internal ATG
terminal modification + 
splice donor shift n/a amygdala chr3
MLH1 DC328233 EST ▼1A, Δ2p r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.117_121del) alternative UTR with internal ATG
terminal modification + 
splice acceptor shift n/a corpus callosum chr3
MLH1 DC360503 EST Δ2p, Δ3q r.[117_121del; 302_306del] PTC induces NMD splice acceptor shift + splice donor shift IMR32 n/a chr3
MLH1 DC362091 EST ▼1A, Δ3q r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.302_306del) alternative UTR with internal ATG
terminal modification + 
splice donor shift n/a kidney chr3
MLH1 DC364540 EST ▼1A, Δ3q r.? (alternative TSS 3' of NM_000249.3 TSS & uses cryptic donor site @ c.116+227, plus r.302_306del) alternative UTR with internal ATG
terminal modification + 
splice donor shift n/a n/a chr3
MLH1 DC378522 EST ▼1A, ▼1C(a), Δ3q
r.? (alternative TSS 3' of  NM_000249.3 TSS & uses 
cryptic donor site @ c.116+227, plus 
r.116_117ins116+1167_116+1240 & r.302_306del)
alternative UTR with internal ATG
terminal modification + 
cassette + splice donor 
shift
n/a n/a chr3
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MLH1 DC402731 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a testis chr3
MLH1 ES312847 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a beard hair chr3
MLH1 N55844 EST ▼1A r.? (alternative TSS 3' of  NM_000249.3 TSS & uses cryptic donor site @ c.116+227) alternative UTR with internal ATG terminal modification n/a n/a chr3
MSH2 AK222860 mRNA Δ16, ▼16A r.? (alternative final exon with cryptic acceptor site @ XM_002342217.1:c.-319-8466) alternative final exon with STOP terminal modification HepG2 liver chr2
MSH2 AK223284 mRNA Δ16, ▼16A/16C_16E
r.? (alternative final exons inserted @ 
XM_002342217.1:c.-319-8466_-319-8349, 
NC_000002.11:g.47888112_47888252, 
NC_000002.11:g.47905388_47905469 & 
NC_000002.11:g.47906239_47906509)
alternative final exon with STOP terminal modification n/a synovial membrane (knee) chr2
MSH2 AK296831 mRNA Δ2q(c)_4p r.304_737del PTC induces NMD
splice donor shift + 
splice acceptor shift + 
cassette
n/a tongue, tumor tissue chr2
MSH2 AK297763 mRNA Δ2q(b)_3p r.230_436del no FS splice donor shift + splice acceptor shift n/a n/a chr2
MSH2 AK299667 mRNA 3Δ149, Δ5 r.[474_622del; 793_942del] PTC induces NMD intronization + cassette n/a brain chr2
MSH2 AK304496 mRNA 1Δ184 r.-16_168del alternative UTR with internal ATG intronization n/a uterus chr2
MSH2 AK310679 mRNA Δ16, ▼16A r.? (alternative final exon with cryptic acceptor site @ XM_002342217.1:c.-319-8466) alternative final exon with STOP terminal modification n/a thymus chr2
MSH2 AK311330 mRNA Δ3q(b)_5p(c) r.511_894del no FS
splice donor shift + 
splice acceptor shift + 
cassette
n/a brain chr2
MSH2 DQ648894 mRNA Δ3 r.367_645del no FS cassette n/a testis chr2
MSH2 DQ648895 mRNA Δ5 r.793_942del no FS cassette n/a testis chr2
MSH2 DQ648896 mRNA ▼9 r.1510_1511ins1510+1126_1510+1258 no FS cassette testis chr2
MSH2 DQ648897 mRNA Δ10 r.1511_1661del PTC induces NMD cassette n/a testis chr2
MSH2 AA587597
EST 
(GENCODE 
mRNA)
15A, Δ16, ▼16A_16B
r.? (alternative TSS @ r.2560 of NM_000251.2 & 
alternative final exons inserted at XM_002342217.1:c.-
319-8466_-319-8349 & 
KCNK12:c.391+7630_391+7852)
UTR terminal modification n/a ovary bulk tumor chr2
MSH2 BE671648 EST ▼8B r.? (alternative final exon with cryptic acceptor @ r.1386+2785 in NM_000251.2) alternative final exon with STOP terminal modification n/a pooled germ cell tumors chr2
MSH2 BM471936 EST Δ1q(c) r.144_211del PTC induces NMD splice donor shift n/a melanotic melanoma chr2
MSH2 BP208284 EST 3Δ149 r.474_622del PTC induces NMD intronization n/a cerebellum chr2
MSH2 DA502422 EST Δ3q(b)_5p(c) r.511_894del no FS
splice donor shift + 
splice acceptor shift + 
cassette
n/a brain chr2
MSH2 DA514205 EST 1Δ93 r.6_98del no FS intronization n/a brain chr2
MSH2 DB150259 EST Δ16, ▼16A r.? (alternative final exon with cryptic acceptor site @ XM_002342217.1:c.-319-8466) alternative final exon with STOP terminal modification n/a thymus chr2
MSH2 DC346610 EST Δ2q(c)_4p r.304_737del PTC induces NMD
splice donor shift + 
splice acceptor shift + 
cassette
n/a tongue, tumor tissue chr2
MSH2 DC355646 EST Δ2q(b)_3p r.230_436del no FS splice donor shift + splice acceptor shift n/a n/a chr2
MSH2 DC375714 EST 3Δ149, Δ5 r.[474_622del; 793_942del] PTC induces NMD intronization + cassette n/a brain chr2
MSH2 DC412423 EST 1Δ48 r.43_90del no FS intronization n/a kidney, tumor tissue chr2
MSH2 DC419765 EST 1Δ184 r.-16_168del alternative UTR with internal ATG intronization n/a uterus chr2
MSH2 HY032016 EST ▼1A, Δ1 r.? (alternative TSS 5' of  NM_000251.2 TSS, alternative first exon spanning c.-3156_-2952) alternative UTR with internal ATG terminal modification n/a testis chr2
MSH2 HY373219 EST ▼8A r.? (alternative final exon with cryptic acceptor site @ r.1386+2671 in NM_000251.2) alternative final exon with STOP terminal modification n/a n/a chr2
MSH6 AK293921 mRNA Δ1q(b)_3 r.238_627del no FS splice donor shift + multi-cassette n/a cerebellum chr2
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MSH6 AK304735 mRNA ▼1C, Δ4p r.? (alternative TSS 3' of NM_000179.2 TSS using cryptic donor @ r.260+612, plus r.628_631del) alternative UTR with internal ATG
terminal modification + 
splice acceptor shift n/a uterus chr2
MSH6 BC071594 mRNA Δ3 r.458_627del PTC induces NMD cassette n/a testis chr2
MSH6 D89646 mRNA ▼4q r.3172_3173ins3172+1_3172+177 intronic STOP with polyadenylation splice donor shift n/a n/a chr2
MSH6 BG818586 EST ▼1E(a) r.? (alternative final exon spanning r.260_261ins260+995_260+1482 of NM_000179.2) UTR terminal modification n/a
anaplastic oligodendroglioma with 1p/19q 
loss chr2
MSH6 BM834755 EST 1Δ120 r.79_198del no FS intronization SNU-1 stomach chr2
MSH6 BQ772835 EST Δ10p r.4002_4006del FS; alternative STOP splice acceptor shift n/a chondrosarcoma cell line chr2
MSH6 CN354854 EST Δ2 r.261_457del PTC induces NMD cassette n/a embryonic stem cell, retinoic acid and mitogen-treated hes cell line h7 chr2
MSH6 DA118957 EST ▼1E(b) r.260_261ins260+1379_260+1474 no FS cassette n/a cerebellum chr2
MSH6 DA316936 EST ▼1B r.? (alternative TSS 3' of NM_000179.2 TSS using cryptic donor site @ r.260+513) alternative first exon with ATG terminal modification n/a hippocampus chr2
MSH6 DA327773 EST Δ2 r.261_457del PTC induces NMD cassette n/a hippocampus chr2
MSH6 DB062479 EST Δ1q(a) r.-2_260del alternative UTR with internal ATG terminal modification n/a testis chr2
MSH6 DB069413 EST Δ4q r.1285_3172del PTC induces NMD splice donor shift n/a testis chr2
MSH6 DB071173 EST ▼1B r.? (alternative TSS 3' of NM_000179.2 TSS using cryptic donor site @ r.260+513) alternative first exon with ATG terminal modification n/a testis chr2
MSH6 DB089447 EST ▼1D r.? (alternative TSS 3' of NM_000179.2 TSS using cryptic donor site @ r.260+745) alternative UTR with internal ATG terminal modification n/a testis chr2
MSH6 DB100026 EST ▼1A r.? (alternative TSS 3' of NM_000179.2 TSS using cryptic donor site @ r.260+285) alternative first exon with ATG terminal modification n/a testis chr2
MSH6 DB220634 EST Δ2/3 r.261_627del PTC induces NMD multi-cassette n/a trachea chr2
MSH6 DC309007 EST Δ1q(b)_3 r.238_627del no FS splice donor shift + multi-cassette n/a cerebellum chr2
MSH6 DC422671 EST ▼1C r.? (alternative TSS 3' of NM_000179.2 TSS using cryptic donor @ r.260+612) alternative UTR with internal ATG terminal modification n/a uterus chr2
PMS2 AB103082 mRNA Δ11q_14p r.1679_2318del PTC induces NMD splice donor shift + splice acceptor shift n/a n/a chr7
PMS2 AB103083 mRNA Δ8_11 r.804_2006del no FS multi-cassette n/a n/a chr7
PMS2 AB103085 mRNA Δ6p r.538_586del PTC induces NMD splice acceptor shift n/a n/a chr7
PMS2 AB103086 mRNA ▼3A, Δ4 r.? (alternative TSS 3' of NM_000535.5 TSS translation begins at r.215, r.251_353del)
alternative first exon with ATG & 
no FS
terminal modification + 
cassette n/a n/a chr7
PMS2 AB103087 mRNA Δ2q_12p r.63_2092del UTR
splice donor shift + 
splice acceptor shift + 
multi-cassette
n/a n/a chr7
PMS2 AK294661 mRNA Δ2 r.24_163del alternative UTR with internal ATG cassette n/a brain chr7
PMS2 BC031832 mRNA Δ2p r.24_28del alternative UTR with internal ATG splice acceptor shift n/a lymph, lymphoma chr7
PMS2 BC143397 mRNA Δ6p r.538_586del PTC induces NMD splice acceptor shift n/a brain, cerebellum, pcr rescued clones chr7
PMS2 BX537558 mRNA ▼1q, ▼4q, Δ5_15, ▼15 r.[23_24ins23+1_23+190; 353_354ins353+1_354-488; 354_*delins*1538_*2475]
intronic STOP with 
polyadenylation
splice donor shift + 
terminal modification n/a human endometrium carcinoma cell line chr7
PMS2 AA206606 EST Δ2p r.24_28del alternative UTR with internal ATG splice acceptor shift n/a n/a chr7
PMS2 AI092272 EST Δ14p r.2276_2318del PTC induces NMD splice acceptor shift n/a parathyroid tumor chr7
PMS2 BF840055 EST Δ13 r.2175_2275del PTC induces NMD cassette n/a n/a chr7
PMS2 BG177103 EST Δ2p r.24_28del alternative UTR with internal ATG splice acceptor shift n/a lymphoma, cell line chr7
PMS2 BG720607 EST ▼9p r.? (alternative TSS: EST start at c.904-20 & transcribed into exon 9 of NM_000535.5) alternative first exon with ATG terminal modification n/a n/a chr7
PMS2 BU171754 EST Δ10 r.989_1144del no FS cassette n/a melanotic melanoma chr7
PMS2 BX385541 EST Δ2p, Δ6 r.[24_28del; 538_705del] alternative UTR with internal ATG splice acceptor shift + cassette RAMOS CELL LINE n/a chr7
PMS2 C15868 EST Δ14p r.2276_2318del PTC induces NMD splice acceptor shift n/a n/a chr7
PMS2 C15875 EST Δ14p r.2276_2318del PTC induces NMD splice acceptor shift n/a n/a chr7
PMS2 D81337 EST Δ14p r.2276_2318del PTC induces NMD splice acceptor shift n/a n/a chr7
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PMS2 DA258950 EST Δ2p r.24_28del alternative UTR with internal ATG splice acceptor shift n/a caudate nucleus chr7
PMS2 DA297540 EST Δ2p r.24_28del alternative UTR with internal ATG splice acceptor shift n/a hippocampus chr7
PMS2 DA300079 EST ▼8 r.? (alternative final exon using cryptic acceptor site @ r.903+145 in NM_000535.5) alternative final exon with STOP terminal modification n/a hippocampus chr7
PMS2 DA728941 EST Δ6p r.538_586del PTC induces NMD splice acceptor shift NT2 n/a chr7
PMS2 DA772250 EST Δ2p, 4Δ49 r.[24_28del; 260_308del] alternative UTR with internal ATG splice acceptor shift + intronization n/a brain chr7
PMS2 DB146922 EST ▼5p r.? (alternative TSS: EST start at c.354-488 & transcribed into exon 5 of NM_000535.5) alternative first exon with ATG terminal modification n/a thymus chr7
PMS2 DC319772 EST Δ2 r.24_163del alternative UTR with internal ATG cassette n/a brain chr7
PMS2 T93906 EST ▼14p r.2275_2276ins2276-33_2276-1 no FS splice acceptor shift n/a n/a chr7
PMS2 BX342212 EST Δ14q_15, ▼15A
r.? (cryptic donor site used in exon 14 @ r.2421 & 
alternative final exon using cryptic acceptor site @ 
r.*1604 in NM_000535.5)
alternative final exon with STOP splice donor shift + terminal modification HeLa n/a chr7
PMS2CL BQ050630 EST NA NA NA NA leiomyosarcoma n/a chr7
PMS2CL BE932845 EST NA NA NA NA n/a n/a chr7
* Coding for highlighted cells is as follows:
Novel alternatively spliced ESTs that have not been fully annotated
mRNA transcript identified in cancer cell line or tumour tissue, and thus currently not considered to be naturally occurring
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Gene Exon Transcript Location of cryptic splice site Type of splice site utilized Alternative splice site sequence
Splice 
dinucleotide 
used
MAXENT score for 
adjacent wild-type 
splice site
MAXENT score for 
cryptic splice site
HSF score for 
adjacent wild-
type splice site
HSF score for 
cryptic splice site
MLH1 1i ▼1q & ▼1 c.116+227 donor AGTgtaagt GT 8.6 8.46 84.51 83.32
MLH1 2 Δ2p c.122 acceptor ttgccagtttagAT AG 7.22 2.8 84.1 78.21
MLH1 2i ▼2 c.207+447 acceptor cttggcttacagAA AG 7.22 5.08 84.1 88
MLH1 2i c.207+591 donor AAGgtaaaa GT 10.45 8.38 94.19 84.55
MLH1 3 Δ3q c.301 donor CAGgtgagg GT 9.85 8.41 96.07 95.15
MLH1 10 Δ10q_12p c.879 donor ACctcagttt CT 9.43 -5.14 85.75 NP
MLH1 12 c.1101 acceptor ctgacCTC AC 7.5 -27.09 88.87 NP
MLH1 3'UTR ▼19 NM_001134369.1:c.729 acceptor attgccttacagTG AG 7.82 7.83 87.83 87.45
MSH2 1 1Δ184 c.-15 donor GAGgtgagg GT 10.07 8.41 96.91 95.15
MSH2 1 c.169 acceptor ccgcccgggagGT AG NA -3.02 NA 76.64
MSH2 1 Δ1q(a)_12p c.72 donor CAGggcatg GG 10.07 -4.29 96.91 NP
MSH2 12 c.1868 acceptor atgtacgaccagCCA AG 9.05 2.07 90.8 78.92
MSH2 1 Δ1q(b)_5p(b) c.114 donor GACcggggc CG 10.07 -15.75 96.91 NP
MSH2 5 c.940 acceptor tcagagcccttaacctttttCAG TT 10.35 -15.33 83.98 NP
MSH2 2 Δ2q(a)_5p(a) c.228 donor GAGctggaa CT 8.83 -9.65 86.73 NP
MSH2 5 c.800 acceptor ttcttaattttaggttgcagTTT AG 10.35 1.03 83.98 86.05
MSH2 2 Δ2q(b)_3p c.229 donor AGAgtgttg GT 8.83 -13.26 86.73 NP
MSH2 3 c.437 acceptor tgatatgtcagcttccattgGTG TG 6.25 -5.66 82.12 NP
MSH2 2 Δ2q(Δ)_6p c.319 donor GAGctggaa CT 8.83 -9.65 86.73 NP
MSH2 6 c.1072 acceptor tggataagaacagaatagagGAG AG 9.59 -21.36 83.38 68.66
MSH2 3 Δ3q(a)_13p(a) c.445 donor TGGgtgtta GT 9.88 -6.01 97.83 68.55
MSH2 13 c.2076 acceptor gtactcatggcccaaattggGTG GG 8.23 -4.72 86.07 NP
MSH2 3 3Δ149 c.473 donor CCAgagaca GA 9.88 -13.88 97.83 NP
MSH2 3 c.623 acceptor acccggaggagagactgctgGAG TG 6.25 -25.23 82.12 NP
MSH2 3 Δ3q(b)_5p(c) c.510 donor CAGaggaaa AG 9.88 -10.76 97.83 NP
MSH2 5 c.895 acceptor gacttcagccagTAT AG 10.35 -0.98 83.98 79.49
MSH2 13 Δ4_13p(b) c.2151 acceptor cgagtaggggctggtgacagTCA AG 8.23 -3.75 86.07 77.34
MSH2 9i ▼9 c.1510+1126 acceptor ctataatcccaatactttagGAG AG 11.59 4.37 95.06 78.19
MSH2 9i c.1510+1258 donor GAGgtgaga GT 8.85 7.66 90.03 94.75
MSH2 12 Δ12q_13p(c) c.1897 donor TTAtattaa TA 4.78 -38.5 80.75 NP
MSH2 13 c.2157 acceptor ggggctggtgacagtcaattGAA TT 8.23 -24.39 86.07 NP
MSH2 3'UTR ▼16A XM_002342217.1:c.-319-8466 acceptor tctcttctccttcctttcagAAC AG 6.11 12.78 82.26 91.69
MSH2 3'UTR XM_002342217.1:c.-319-8349 donor GTGgtgagc GT NA 6.64 NA 90.16
MSH2 3'UTR ▼16C g.47905388 acceptor tctggtgcttcatttcctagGCC AG 6.11 9.49 82.26 84.97
MSH2 3'UTR g.47905469 donor CAGgtgaga GT NA 9.22 NA 96.51
MSH2 3'UTR ▼16D g.47906239 acceptor attaaacttctttgttgcagTGG AG 6.11 6.16 82.26 88.75
MSH6 1 Δ1q(b)_3 c.237 donor TCGgtagcg GT 7.38 1.37 77.71 70.98
MSH6 1i ▼1C c.260+612 donor TAGgtgagg GT 7.38 7.65 77.71 94.93
MSH6 4 Δ4p c.632 acceptor tttccttgcctggcaggtagGCA AG 10.87 -0.09 90.75 75.07
PMS2 1i ▼1q c.23+190 donor GAGgcaagc GC 8.7 2.09 94.91 69.23
PMS2 2 Δ2p c.29 acceptor tctctagtacagAAC AG 4.33 2.32 79.37 85.84
PMS2 2 Δ2q_12p c.62 donor GAAgtcagt GT 10.47 1.02 93.27 82.64
PMS2 12 c.2093 acceptor gaatgaggatatcttcatagTGG AG 8.61 -0.55 91 78.36
PMS2 4 Δ4q c.300 donor CAGgttgaa GT 3.13 1.26 82.43 72.14
PMS2 6 Δ6p c.587 acceptor gtatcatttcagCAG AG 9.96 5.83 90.67 84.83
PMS2 11 Δ11q_14p c.1678 donor GATgtaaat GT 9.06 2.29 84.95 75.21
PMS2 14 c.2319 acceptor cttgccaactagTAA AG 6.62 4.17 79.58 75.92
Supplementary Table 3: Bioinformatic scores cryptic splice sites identified in MMR gene alternative mRNA transcripts 
(Bold indicates cryptic splice site scores greater than wild-type scores. NP - not predicted; NA - not applicable)
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Supplementary Table 4: Alternatively spliced MMR transcripts reported to be expressed in carriers of MMR gene sequence variants 
Gene Exon Associated nucleotide variant 
Transcript(s) 
reported 
Expression of 
alternative transcript 
from variant allelea 
Additional 
aberrant 
transcripts 
References 
Splicing aberration predicted by 
in silico tools (relative to 
reference sequence) 
Variants likely to be/ shown to be associated with aberrant splicing 
MLH1 1 c.116+5G>C ▼1q Full   (1-3) Donor site loss 
 2 c.117-2A>G Δ2p Full   (1) Acceptor site loss 
  c.117-11T>A Δ2 Not determined  (4) Acceptor site variation (HSF) & 
loss (MES) 
  c.122A>G Δ2 Full  (5, 6) ESE loss by 2/4 programs 
  c.207+1_207+2del Δ2 Not determined  (7) Donor site loss 
 3 c.306+2dup Δ3q Partial †  Yes (8) Donor site loss 
  c.306+4A>G Δ3q Partial †  Yes (6) Donor site loss (HSF) & variation 
(MES) 
  c.306+5G>A Δ3q Not determined  (9-11) Donor site loss 
 6 c.454-2A>G Δ6 Not determined  (12) Acceptor site loss 
  c.454-1G>A Δ6 Full  (13-15) Acceptor site loss 
  c.544A>G Δ6 Full §16,17  (12, 16-18) Donor site loss 
  c.545G>A Δ6 Partial †  Yes InSiGHT* Donor site loss 
   c.545+1G>A Δ6 Full  (19) Donor site loss 
 9 c.678-3_678-2del Δ9/10 Not determined  (20, 21) Acceptor site loss 
  c.678-1G>T Δ9 Not determined  (22) Acceptor site loss 
  c.[780C>G;788A>C] Δ9 Full  (23) Inconclusive ESE predictions 
  c.790+1G>A Δ924 & Δ9/10 Full  (1, 3, 12, 24) Donor site loss 
  c.790+1G>C Δ9/10 Full  (25) Donor site loss 
  c.790+2T>C Δ9/10 Full  (1) Donor site loss 
  c.790+2dup Δ9, Δ9/10 Partial †  (2), InSiGHT* Donor site loss 
  c.790+4A>T Δ9, Δ9/10 Partial †  (26) Donor site loss 
  c.790+4A>G Δ9, Δ9/10 Partial †  (8) Donor site loss 
  c.790+5G>T Δ9 Not determined  (6, 27) Donor site loss 
 10 c.791-7T>A Δ10 Not determined  (23) Acceptor site loss 
  c.791-5T>G Δ10 Not determined  (6, 12) Acceptor site loss 
  c.791-1G>C Δ10 Not determined  (28) Acceptor site loss 
  c.793C>T Δ10 & Δ9/101 Partial #30/Full ¶1  (1, 6, 29-31), No 
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InSiGHT* 
  c.842C>T Δ10 Full  (6, 30), InSiGHT* Inconclusive ESE predictions 
  c.882C>T  Δ10 Full  (6, 12, 32) Donor site loss 
  c.883A>C Δ10 Full  (33, 34) Donor site loss 
  c.883A>G Δ9/10 Full ¶   (1, 35) Donor site loss 
  c.884G>A Δ10 Full  (28) Donor site loss 
  c.884_884+3del Δ10 Not determined  (33, 36) Donor site loss 
  c.884+4A>G Δ10 Not determined  (6, 37, 38) Donor site loss 
 11 c.986A>C Δ9_11, Δ10/11 Partial †§39  (39, 40), InSiGHT* Inconclusive ESE predictions 
  c.1038G>C Δ10/11 Partial † Yes (8) Donor site loss 
 12 c.1039-1G>A Δ12 Not determined  (14) Acceptor site loss 
  c.1039-2A>G Δ12 Not determined  (19) Acceptor site loss 
  c.1409+1G>C Δ12 Not determined  (14, 33, 36) Donor site loss 
 15 c.1668-1G>A Δ15 Not determined  (2, 41) Acceptor site loss 
  c.1689dup Δ15 Full  (1) No 
  c.1731G>A  Δ15 Full  (6, 8, 12, 19, 42-44) Donor site loss 
  c.1731+1G>A Δ15 Not determined  (45, 46) Donor site loss 
  c.1731+3A>T Δ15 Not determined  (47, 48) Donor site loss 
  c.1731+4A>G Δ15 Not determined ¶  (49) Donor site loss 
  c.1731+5G>A Δ15 Full  (6, 50) Donor site loss 
 16 c.1732-2A>T Δ16 Not determined  (51, 52) Acceptor site loss 
  c.1732-1G>A Δ16 Not determined  (2, 53) Acceptor site loss 
  c.1896G>A  Δ16 Full  (45), InSiGHT* Donor site loss 
 17 c.1986_1989+1delinsC Δ17 Full  (8) Donor site loss 
  c.1988A>G Δ17 Not determined  (54) Donor site loss 
  c.1989G>T Δ17 Partial † Yes §16 (6, 12, 16) Donor site loss 
  c.1989+1G>T Δ17 Not determined  (55) Donor site loss 
  c.1989+3dup Δ17 Not determined  (19) Donor site loss 
  c.1989+5G>C Δ17 Not determined  (56, 57) Donor site loss 
MSH2 3 c.645+1G>A  Δ3 Partial Yes (28) Donor site loss 
  c.645+1G>T Δ3 Not determined  (33) Donor site loss 
 5 c.793-2A>C Δ5 Not determined  (12) Acceptor site loss 
  c.806C>T Δ5 Full  (6, 30) ESE loss by 2/4 programs 
  c.942G>A Δ5 Not determined  (58) Donor site loss 
! 17!
  c.942+2del Δ5 Not determined  InSiGHT* Donor site loss 
  c.942+2T>A Δ5 Not determined  InSiGHT* Donor site loss 
  c.942+3A>T Δ5 Full   (1, 2, 9, 12, 17, 46, 
56, 59, 60) 
Donor site loss 
 8 c.1277-2A>G Δ8 Not determined  (61) Acceptor site loss 
  c.1277-1G>C Δ8 Not determined  InSiGHT* Acceptor site loss 
  c.1386+1G>A Δ8 Not determined  (12, 19) Donor site loss 
 10 c.1660A>T Δ10 Partial † Yes (6) Donor site loss 
  c.1660A>G Δ10 Full ¶  (1) Donor site loss 
  c.1661G>C Δ10 Full  (62) Donor site loss 
  c.1661+5G>C Δ10 Not determined  (33, 36) Donor site loss 
 13 c.2006-5T>A Δ13 Partial † Yes (63) Acceptor site loss 
  c.2006-2A>G Δ13 Full  (64) Acceptor site loss 
  c.2006G>T Δ13 Full  InSiGHT* Acceptor site loss 
  c.2135dup Δ13 Full ¶  (1) ESE loss by 2/4 programs 
  c.2210+1G>A Δ13 Not determined  (65, 66) Donor site loss 
  c.2210+1G>C Δ13 Not determined  (33, 36) Donor site loss 
PMS2 2 c.24-12_107delinsAAAT Δ2 Not determined  (67) Acceptor site loss 
 2 c.163+2T>C Δ2 Not determined  (67) Donor site loss 
 6 c.538-3C>G Δ6p Partial † Yes (68) Acceptor site loss 
 10 c.989-2A>G Δ10 Not determined  (68) Acceptor site loss 
  c.989-1G>T Δ10 Partial † Yes (61, 69, 70) Acceptor site loss 
  c.1144+2T>A Δ10 Not determined  (67) Donor site loss 
Variants uncertain or unknown if associated with aberrant splicing 
MLH1 1 c.113A>G ▼1q Partial §1  (1, 2) No 
 3 c.299G>C Δ3q Partial  InSiGHT* Cryptic donor site variation 
  c.304G>A Δ3q Partial §12  (12, 71) No 
 10 c.794G>A Δ10 Partial  (6) Inconclusive ESE predictions 
 12 c.1381A>T Δ12 Partial  (72, 73) ESE loss by 4/4 programs 
 17 c.1961C>T Δ17 Partial  (19, 30) Inconclusive ESE predictions 
  c.1975C>T Δ17 
Partial §14,21 
 (1, 14, 15, 21, 74) ESE loss by 1/4 programs 
  c.1975_1976del Δ17 Not determined  (42) Inconclusive ESE predictions 
  c.1976G>C Δ17 Partial  (6, 30, 74) Inconclusive ESE predictions 
  c.1976G>T Δ17 Not determined  (74) Inconclusive ESE predictions 
! 18!
  c.1984A>C Δ17 
Partial §6 
 (6, 8) Inconclusive ESE predictions 
MSH2 5 c.815C>T Δ5 Partial  (6, 30, 61) Inconclusive ESE predictions 
 10 c.1516G>T Δ10 Partial  (6, 30) Inconclusive ESE predictions 
  c.1600C>T Δ10 Partial  (6, 30) ESE loss by 1/4 programs 
a”Full” expression of the alternative transcript from variant allele was defined as no expression of full-length reference transcript, based on: (i) diploid 
to haploid conversion analysis results reporting only a single alternative transcript expressed from the variant allele; (ii)  sequencing of the coding 
variant, or an in cis coding polymorphism in the case of intronic variants, to investigate whether the variant allele expressed any full-length transcript. 
Note: Variants were included in the “likely to be/or shown to be a splicing aberration” group based on experimental evidence (i.e. no expression of 
full-length transcript from the variant allele) and/or based on bioinformatic predictions of loss of canonical acceptor/donor sites. The remaining 
variants were considered “uncertain if associated with aberrant splicing” if reported to show partial expression of the full-length transcript from the 
variant allele, or “unknown if associated with aberrant splicing” if allele-specific assays were not conducted. Bold text indicates variants where in 
silico predictions are inconsistent with the alternative transcript reported, or indicate inconclusive evidence for transcript dysregulation (only one of 
four programs predicting loss of an ESE).  
Δ: partial or complete exon deletion; ▼: inclusion of intronic sequence in transcript or inclusion of non-coding or intronic sequence as an alternative 
first or final exon; p: acceptor site shift; q: donor site shift; § Transcript not detected in all studies; * Further splicing information is available on 
www.insight-group.org/classifications/; † Variant allele expresses combination of transcripts, excluding full-length; ¶ Low expression of variant allele; 
# Comparable to wild-type expression in Lastella et al (30); HSF, human splicing finder; MES, MaxEntScan; ESE, exonic splicing enhancer. MLH1, 
RefSeq NM_ 000249.3; MSH2, RefSeq NM_000251.2; PMS2, RefSeq NM_000535.5 
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Chapter 6: Discussion and Future Directions 
6.1 Overview 
In this project, standardized criteria were developed to establish methods for determining the 
clinical significance of MMR gene unclassified variants. Both quantitative and qualitative 
approaches were incorporated into the 5-tiered variant classification criteria to maximize effective 
use of all available points of evidence (e.g. clinical, experimental) to categorize sequence variants.  
 
The quantitative component, which uses multifactorial likelihood analysis, provides a statistical 
measure of probability that a sequence variant is pathogenic (i.e. disease-causing). The most 
important principle behind using this statistical method is that at least two independent sources of 
data should be used for variant classification. Preferably, at least one of the sources addresses 
functionality of the variant and at least one links the human allele to the disease. The approach 
taken integrated in silico predictions with other lines of evidence. As demonstrated in chapter 4, 
missense substitutions are the most common type of variant of uncertain clinical significance (i.e. 
class 3). Thus, in silico prediction tools were calibrated to provide preliminary evidence (prior 
probability of pathogenicity) of the effects of missense variants, based on conservation and changes 
in amino acid physiochemical properties. The combined MAPP + PolyPhen-2.1 output (described 
in chapter 2) was found to be the most accurate at predicting the effect of missense substitutions on 
protein function. We were able to successfully implement it into MMR multifactorial likelihood 
analysis in chapter 3. It should be noted that the bioinformatic tools assessed do not take into 
account the effect of the underlying sequence alteration on mRNA splicing, however none of the 74 
missense variants used to calibrate the predictive tools are predicted to cause a splicing aberration, 
and all those tested for splicing aberrations (40/74) were not observed to cause a splicing aberration. 
Possible solutions for incorporating splicing predictions into the prior probability used in the model 
are explored in section 6.2. 
 
Statistical measures based on colorectal tumour features and variant segregation were incorporated 
into the MMR multifactorial model (presented in chapter 3), to ensure at least one additional piece 
of evidence was combined with the bioinformatically derived probabilities. LRs for CRC MSI and 
BRAF V600E status were derived using the large and well-characterised C-CFR dataset, and 
applied in the model carefully considering issues relating to ascertainment bias. These analyses 
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demonstrated that a MMR gene variant present in an MSI-H colorectal tumour, with wild-type 
BRAF has a 12 to13-fold increase in the likelihood of being disease causing. As seen in Figure 6.1, 
this measure of LS-associated tumour features played an integral part in the categorization of 65% 
of MMR gene variants into classes associated with management recommendations (i.e. classes 1, 2, 
4 and 5).  
 
 
Figure 6.1: Contributions to MMR gene multifactorial likelihood analysis. For each variant that was analysed the 
initial bioinformatically derived prior probability and final posterior probability of pathogenicity after incorporation of 
tumour and segregation information is shown. The dashed lines represent the upper cut-off for class 2 (0.049) and lower 
cut-off for class 4 (0.95) in the 5-tiered classification system. The clear diamonds represent all the variants that had 
appropriate data available for multifactorial likelihood analysis (see chapter 4). Variants with posterior probabilities 
associated with management recommendations (i.e. classes 1, 2, 4 and 5 – n=195) are also shown based on the type of 
data that was the major contributor to categorization: colorectal tumour features (red diamonds) or segregation (blue 
diamonds). 
 
The strength of the multifactorial likelihood model is its ability to utilize multiple sources of data 
readily available in the clinical setting. However, as touched on in chapter 3 there are assumptions 
that underlie the basic model. Specifically, mutual independence of individual components, that all 
variants that are disease causing have similar penetrance or associated tumour phenotypes (i.e. 
frameshift/nonsense versus missense), and that there is not another unidentified causal sequence 
alteration in cis with the variant being analysed. This last assumption of complete mutation 
screening was inadvertently overlooked for an MSH2 missense variant that was analysed using the 
multifactorial model (in chapter 4), leading to initial misclassification as pathogenic. The missense 
substitution (MSH2 c.4G>A p.Ala2Thr) was found to be in cis with an EPCAM deletion (leading to 
MSH2 inactivation) in a haplotype that may be present in multiple families around the world 
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(Verena Steinke, Monika Morak, Brigitte Royer-Pokora, Amie Blanco, and Alexandra Martins, 
personal communication). There was overwhelming clinical data supporting pathogenicity of the 
variant, with a combined odds in favour of causality of 16,955:1. While the missense substitution is 
predicted to have an intermediate effect on function, with a prior probability of 0.5. The initial 
reports of this variant249,286,287,390,391 predated the discovery 3’ EPCAM deletions as LS 
predisposition mutations in 2009122,123. This example highlights the importance of ensuring 
mutation screening is done to the full extent and that findings are updated in a publically accessible 
manner when new information arises. 
 
Development of the MMR multifactorial model is ongoing (as discussed in section 6.2.1). In the 
interim there are instances where qualitative data not yet incorporated into statistical modelling, can 
aid in the interpretation of sequence variants. To prevent ad hoc interpretation of qualitative data, in 
collaboration with the InSiGHT VIC, I developed standardized guidelines for determining the 
amount of qualitative evidence required to categorize the pathogenicity of a MMR gene sequence 
variant (see chapter 4), and then applied them to the variants on the InSiGHT database. This 
database is a well-recognized resource for clinical and research communities with growing numbers 
of “hits” as InSiGHT’s exposure increases (John-Paul Plazzer, personal communication). 
Importantly, database users are able to view the relevant information (and the source) used in the 
classification process, and the VIC’s reasoning behind the classification. Furthermore, to aid in 
variant interpretation, the InSiGHT VIC are actively promoting standardized submission of 
unpublished data from stakeholders in the clinical and research settings, which is acknowledged 
through the implementation of microattribution.  
 
6.2 Future directions 
Even with standardized MMR gene classification criteria, uncertain variants (i.e. class 3) account 
for 32% of variants on the InSiGHT classifications database. Moreover, we still need to continue to 
refine the classification of class 2 (likely not pathogenic) and class 4 (likely pathogenic) MMR gene 
sequence variants. Many of these will be private mutations; their clinical significance is relatively 
difficult to access due to paucity of information. Thus, it is important to exploit as much of the data 
that is available as possible. As the work of the InSiGHT VIC is ongoing, we will need to call in 
more data and generate experimental data to use in classifications. There are still phenotypic 
features and functional data that could be utilized in the MMR multifactorial model as discussed 
below.  
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6.2.1 Future versions of the MMR multifactorial likelihood model 
Bioinformatic predictions 
There are a number of additions that can be made to improve the multifactorial likelihood model 
(outlined in Figure 6.2). Firstly, further calibration of the bioinformatic inputs used for the prior 
probability is required to incorporate splicing predictions for an underlying variant. This could be 
accomplished by computing probabilities for de novo splice site creation and loss of wild-type 
canonical splice sites for all possible substitutions in exons and adjacent intronic sequence using 
splicing algorithms, such as MaxEntScan326. Then using a training set of experimentally validated 
variants to calibrate the in silico predictions. This approach is currently being used to develop 
splicing priors for BRCA1 and BRCA2 (Sean Tavtigian, personal communication). 
 
 
Figure 6.2: Future iteration of the MMR multifactorial model. Dashed lines represent new additions to the model. 
The genetic data referred to includes segregation analysis of the variant in families. The tumour features will 
incorporate an updated model, including MSI, IHC, BRAF V600E status, MLH1 promoter methylation, tumour location 
and somatic mutations, for colonic and possibly extracolonic tumours (e.g. endometrial). 
 
Otherwise, using the recently developed Combined Annotation-Dependent Depletion (CADD) tool 
a more global approach could be employed (represented as “integrated” predictions in Figure 6.2). 
CADD scores the deleteriousness of single nucleotide variants and indel variants by integrating 63 
distinct types of annotation (i.e. conservation metrics, functional genomic data, transcript 
information, protein-level scores) into a single metric, with a focus on evolutionary selection by 
contrasting variants that survived natural selection with simulated mutations325. This tool could be 
calibrated against the classifications of variants from the InSiGHT efforts using similar approach to 
that described in chapter 2. However, a disadvantage of using a general framework such as CADD 
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is that the generated score does not indicate the nature of the effect a variant, but downstream 
functional assays may be able to elucidate this information. Further analysis would be required to 
determine whether CADD, which can score all variety of sequence alterations, would be a better 
predictor than the compartmentalized approach of probabilities based on splicing signals or amino 
acid conservation and physicochemistry. 
 
Family History 
Typically, in cases where a variant of uncertain clinical significance is identified cascade testing of 
relatives is only initiated in the research setting. Segregation data was only available for 16% of the 
“not obviously truncating” variants (n=1,370) on the InSiGHT database, and it contributed to 
classification for 12% of these variants as (likely) not pathogenic (classes 1 and 2) or (likely) 
pathogenic (classes 4 and 5). However, personal and family history (i.e. type of cancer and age of 
onset) summary information is invariably collected for diagnostic purposes in the clinical setting. 
Therefore, it is expected that predicting the probability that an individual is a mutation carrier given 
their personal and family history (when segregation information is unavailable) will aid in defining 
the effect of a variant of uncertain clinical significance. To construct a predictive model, a logistic 
regression model comparing the family histories of individuals with known damaging mutations to 
individuals with no gene mutations in a large dataset (such as the C-CFR) can be used. This 
approach was used to derive a family history LR that is applied in the BRCA1/BRCA2 multifactorial 
likelihood model384. Furthermore, the value of already existing prediction models for MMR gene 
mutations such as MMRpro226 and PREMM229 (developed using different methods) could also be 
tested.  
 
Tumour features 
BRAF V600E and MSI are not the only clinicopathological characteristics routinely tested in the 
clinical setting that could be used in defining the clinical significance of MMR gene variants. 
Defining the best predictors of mutation or non-mutation status based on colorectal tumour features, 
such as MSI, IHC, MLH1 promoter methylation, BRAF and tumour location, will be done by 
logistic regression modelling using an updated C-CFR dataset. It has recently been shown that there 
is no significant difference in the number of global genomic MSI events between MSI-L and MSS 
colorectal and endometrial tumours86, thus I will explore a binary output of MSS and MSI 
(previously MSI-H) in the model. With the recent technological advances in sequencing it may also 
be beneficial to incorporate MMR gene somatic mutations into the model as a predictor of non-
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mutation status. It has recently been shown that acquired events in both alleles caused MMR 
deficiency in more than 50% of colorectal and endometrial tumours without a germline MMR gene 
mutation or MLH1 promoter methylation392,393. 
 
Due to the high correlation between MSI and IHC233 only one of these measures should be included 
for each tumour. Preferably it should be MSI status as some deleterious missense mutations can be 
immunostable116,249. However, IHC can be a better predictor than MSI for MSH6 mutation carriers, 
particularly when the Bethesda/NCI panel is used to test MSI. Therefore for MSH6, one might 
consider a model where IHC loss takes precedence over MSI results when an MSH6 variant is 
identified or for endometrial tumours (see below). A mononucleotide marker panel is more effective 
at identifying MSH6 defective tumours244, because the MutSα heterodimer (which includes MSH6) 
primarily participates in the repair of base-base mismatches and single nucleotide IDLs243. As 
uptake of the quasimonomorphic marker panel for tumour MSI assessment increases due to superior 
performance over the Bethesda/NCI panel240, the current MSI LR would need to be updated. 
 
There is also a high correlation between BRAF V600E status and MLH1 promoter methylation. 
However, the latter is likely to be a better negative predictor as not all tumours with MLH1 
promoter methylation have the BRAF mutation263. It is likely the current BRAF LR will be replaced 
with MLH1 promoter methylation, when both have been tested. This will be especially important 
for endometrial tumours (see below). 
 
Moreover, as MSI/IHC status usually triggers MMR gene mutation screening in a proband 
(particularly with the implementation of universal testing for CRCs), these phenotypic features from 
the tested tumour cannot be applied in the model, as it would upwardly bias the probability output 
in favour of pathogenicity. However, in the absence of MSI/IHC tumour testing information from 
genotyped relatives, the additional clinicopathological features not used in ascertainment (BRAF, 
MLH1 promoter methylation, and tumour sidedness) could be assayed in the proband’s tumour to 
aid in the interpretation of uncertain variants.  
 
As the risk of endometrial cancer can be as high as CRC in LS, incorporating LRs for endometrial 
tumour features would increase the utility of the model in classifying MMR gene sequence variants. 
A population-based study, such as ANECS, could be used to estimate statistical measures for 
tumour features (i.e. IHC and MLH1 promoter methylation) of endometrial tumours17. If MSI were 
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to be incorporated into the model for endometrial tumours, a mononucleotide marker panel would 
be more suitable than the NCI panel for testing endometrial cases394,395. Furthermore, using large 
cancer-specific studies the positive or negative predictive value of tumour features for interpreting 
the clinical significance of MMR gene variants in other LS spectrum cancers could also be 
explored.  
 
As the cost of panel predisposition testing falls and the perceived utility of testing multiple genes in 
parallel increases, a move to a universal testing system where essentially all breast, ovarian, colon 
(and possibly endometrial) cancer cases get a panel test could be expected. For the purpose of the 
multifactorial model, subjects would no longer be ascertained based on personal and family history 
and MSI/IHC. Thus, ascertainment-based confounding would be removed. Then the appropriate 
tumor test could become a reflex assay to help evaluate unclassified variants using the 
model. Furthermore, an online tool will be developed to perform all the associated calculations for 
multifactorial likelihood analysis using inputted data to make the analysis more accessible to 
stakeholders (i.e. clinicians and genetic counselors).  
 
Functional assays 
Finally, work is underway to incorporate a LR based on functional assay results into the model. Our 
experiences with functional assay interpretation in chapter 4, demonstrate the importance of 
combining results for different assays to get a comprehensive representation of the variants effect 
on protein function. As a starting point, a rapid cell-free “complete in vitro MMR assay” 
(CIMRA)297-299,396 will be validated against 159 non-synonymous sequence alterations that have 
been shown to be benign or disease causing through: presence in the general population (allele 
frequency >1%), or a high (≥0.95) or low (<0.05) probability of pathogenicity as determined by 
multifactorial likelihood analysis. Also, ensuring that variants classified using functional assay data 
or shown to cause aberrant splicing are excluded from the validation set. This assay has been 
chosen based on the feasibility of establishing its use in a clinical diagnostic setting. Furthermore, 
integration of splicing assay results into the model would require systematic validation of the 
commonly used assays in the diagnostic setting (i.e. RT-PCR and minigene).  
 
6.2.2 Future of the InSiGHT Variant Interpretation Committee 
The InSiGHT VIC continues to meet regularly (every few months) and actively promote 
submission of variants and associated data to the InSiGHT database. Members of the InSiGHT VIC 
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have been negotiating the merging of the French MMR network UMD databases into InSiGHT397 to 
consolidate the publically available MMR gene LSDBs. Additionally, the qualitative rules and 
model as they currently stand assume that a variant is a high-risk deleterious mutation or a neutral 
variant. Another major challenge will be incorporating the interpretation of intermediate risk 
variants into the classification scheme, and associated clinical recommendations. The guidelines 
will continue to evolve to accommodate additional kinds of evidence.  
 
Developing sequence variant classification criteria for use in other familial colorectal cancer genes, 
such as APC398 and MUTYH (both accounting for <1% of colorectal cancer399) is also on the 
agenda. This will require the recruitment of further expertise to the InSiGHT VIC. Importantly, 
microattribution has been set up for the MMR genes and will be easily transferrable to other genes 
on the LSDBs to promote and acknowledge data submission.  
 
6.3 Outcomes and significance of standardized sequence variant classification criteria 
Variants of uncertain clinical significance are a large problem in the clinical setting. Cases found to 
be carriers of these types of variants in a disease gene such as the MMR genes are faced with 
difficult decisions involving risk-reducing surgeries and clinical management of their whole family. 
I helped lead the first large-scale comprehensive classification effort demonstrating the value of 
evaluation by expert panel in the curation of an LSDB (of which I am now a recognized curator). 
Importantly, rationale and summary information used to assign variant pathogenicity are provided 
on the publically accessible database. The major outcome of this project is the availability of a 
standardized and normalized consensus sequence variant classification scheme for MMR genes that 
has accompanying recommendations for family management.  
 
The InSiGHT MMR gene variant database is now a more effective tool for interpreting the clinical 
significance of sequence variants that can be used by clinicians, genetic counsellors, and 
researchers. There are currently classifications available for 2,360 (and counting) MMR gene 
variants, consisting of 1,340 variants where full high-risk LS surveillance guidelines and predictive 
testing of at-risk relatives would be recommended. Thus, these classifications are immediately 
translational into the clinical setting for use in the counselling of suspected LS cases and their 
families. As a result of the push for unpublished data through the implementation of 
microattribution, there are 182 MMR gene sequence variants that need to be assigned classifications 
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by the InSiGHT VIC. This number is expected to grow as the database gets increasing exposure. 
Furthermore, the criteria and database classifications have been used to categorize the MMR gene 
sequence variants in the C-CFR, which will be used to inform future iterations of the multifactorial 
model. The InSiGHT initiative provides a model for transparent DNA variant interpretation for 
other diseases. 
 
6.4 Conclusion 
In summary, this study presents the successful development and application of quantitative 
(statistical) and qualitative approaches to interpreting the clinical significance of sequence variants 
identified in the MMR genes. Consensus classification criteria, which incorporate a working MMR 
gene multifactorial likelihood model, can now be used to classify variants of uncertain clinical 
significance. Furthermore, the flowchart assembled to assist in the functional assay interpretation, 
and the catalogue of naturally occurring alternative splicing transcripts, can provide important 
assistance in planning further experimentation to test the effects on protein function of variants.  
 
My role in this project was to pull together expertise from an international multidisciplinary 
committee to provide a comprehensive approach to MMR gene sequence variant classification. 
Furthermore, I played an integral role in the transformation of the InSiGHT database, of which I am 
now a co-curator. The InSiGHT initiative provides a key model of multi-disciplinary collaboration 
for the transparent interpretation of DNA variants, which is imperative with high-throughput DNA 
sequencing technologies accelerating the discovery of rare variants that require interpretation. 
Moreover, it is possible to transfer the underlying principles of these models to interpretation of 
variation in other cancer susceptibility genes. 
 
 259 
List of References 
1. Vasen, H.F. et al. Revised guidelines for the clinical management of Lynch syndrome 
(HNPCC): recommendations by a group of European experts. Gut (2013). 
2. Lynch, H.T. & de la Chapelle, A. Genetic susceptibility to non-polyposis colorectal cancer. 
J Med Genet 36, 801-18 (1999). 
3. Umar, A. et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer 
(Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96, 261-8 (2004). 
4. Steinke, V. et al. Evaluating the performance of clinical criteria for predicting mismatch 
repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families. Int J 
Cancer 135, 69-77 (2014). 
5. Warthin, A.S. Heredity with reference to carcinoma as shown by the study of the cases 
examined in the pathological laboratory of the University of Michigan, 1895-1913. Arch 
Intern Med 35, 348-359 (1913). 
6. Lynch, H.T., Shaw, M.W., Magnuson, C.W., Larsen, A.L. & Krush, A.J. Hereditary factors 
in cancer. Study of two large midwestern kindreds. Arch Intern Med 117, 206-12 (1966). 
7. Lynch, H.T. et al. Review of the Lynch syndrome: history, molecular genetics, screening, 
differential diagnosis, and medicolegal ramifications. Clin Genet 76, 1-18 (2009). 
8. Lynch, H.T. et al. Genetics, natural history, tumor spectrum, and pathology of hereditary 
nonpolyposis colorectal cancer: an updated review. Gastroenterology 104, 1535-49 (1993). 
9. Ryan, P. et al. Comparison of clinical schemas and morphologic features in predicting 
Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the 
context of familial gastrointestinal cancer registries. Cancer 118, 681-8 (2012). 
10. Viel, A. et al. Lack of PMS2 gene-truncating mutations in patients with hereditary colorectal 
cancer. Int J Oncol 13, 565-9 (1998). 
11. Wang, Q. et al. Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and 
hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer. Hum Genet 105, 
79-85 (1999). 
12. Lynch, H.T., Smyrk, T. & Lynch, J.F. Molecular genetics and clinical-pathology features of 
hereditary nonpolyposis colorectal carcinoma (Lynch syndrome): historical journey from 
pedigree anecdote to molecular genetic confirmation. Oncology 55, 103-8 (1998). 
13. Jass, J.R. Diagnosis of hereditary non-polyposis colorectal cancer. Histopathology 32, 491-7 
(1998). 
14. Moreira, L. et al. Identification of Lynch syndrome among patients with colorectal cancer. 
JAMA 308, 1555-65 (2012). 
15. Ward, R.L., Hicks, S. & Hawkins, N.J. Population-based molecular screening for Lynch 
syndrome: implications for personalized medicine. J Clin Oncol 31, 2554-62 (2013). 
16. Hampel, H. et al. Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis 
Colorectal Cancer) among Endometrial Cancer Patients. Cancer Res 67, 9603 (2007). 
17. Buchanan, D.D. et al. Tumor Mismatch Repair Immunohistochemistry and DNA MLH1 
Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 
60 Years Optimizes Triage for Population-Level Germline Mismatch Repair Gene Mutation 
Testing. J Clin Oncol 32, 90-100 (2014). 
18. Plaschke, J. et al. Lower incidence of colorectal cancer and later age of disease onset in 27 
families with pathogenic MSH6 germline mutations compared with families with MLH1 or 
MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J 
Clin Oncol 22, 4486-94 (2004). 
19. Bonadona, V. et al. Cancer risks associated with germline mutations in MLH1, MSH2, and 
MSH6 genes in Lynch syndrome. Jama 305, 2304-10 (2011). 
20. Barrow, E., Hill, J. & Evans, D.G. Cancer risk in Lynch Syndrome. Fam Cancer (2013). 
 260 
21. Alarcon, F. et al. Estimating cancer risk in HNPCC by the GRL method. Eur J Hum Genet 
15, 831-6 (2007). 
22. Dunlop, M.G. et al. Cancer risk associated with germline DNA mismatch repair gene 
mutations. Hum Mol Genet 6, 105-10 (1997). 
23. Jenkins, M.A. et al. Cancer risks for mismatch repair gene mutation carriers: a population-
based early onset case-family study. Clin Gastroenterol Hepatol 4, 489-98 (2006). 
24. Quehenberger, F., Vasen, H.F. & van Houwelingen, H.C. Risk of colorectal and endometrial 
cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for 
ascertainment. J Med Genet 42, 491-6 (2005). 
25. Stoffel, E. et al. Calculation of risk of colorectal and endometrial cancer among patients 
with Lynch syndrome. Gastroenterology 137, 1621-7 (2009). 
26. Wijnen, J.T. et al. Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk 
in Lynch syndrome. Gastroenterology 136, 131-7 (2009). 
27. Xicola, R.M. & Llor, X. Cancer risk assessment in Lynch syndrome: does the gene matter? 
Jama 305, 2351-2 (2011). 
28. van Vliet, C.M. et al. Dependence of colorectal cancer risk on the parent-of-origin of 
mutations in DNA mismatch repair genes. Hum Mutat 32, 207-12 (2011). 
29. Dowty, J.G. et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 34, 490-
7 (2013). 
30. Baglietto, L. et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl 
Cancer Inst 102, 193-201 (2010). 
31. Barrow, E. et al. Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and 
tumour distribution. A report of 121 families with proven mutations. Clin Genet 74, 233-42 
(2008). 
32. Senter, L. et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 
mutations. Gastroenterology 135, 419-28 (2008). 
33. Wijnen, J. et al. Familial endometrial cancer in female carriers of MSH6 germline 
mutations. Nat Genet 23, 142-4 (1999). 
34. Berends, M.J. et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 
25 index carriers of a germline variant. Am J Hum Genet 70, 26-37 (2002). 
35. Hendriks, Y.M. et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 
mutations: impact on counseling and surveillance. Gastroenterology 127, 17-25 (2004). 
36. Peterlongo, P. et al. MSH6 germline mutations are rare in colorectal cancer families. Int J 
Cancer 107, 571-9 (2003). 
37. Devlin, L.A., Graham, C.A., Price, J.H. & Morrison, P.J. Germline MSH6 mutations are 
more prevalent in endometrial cancer patient cohorts than hereditary non polyposis 
colorectal cancer cohorts. Ulster Med J 77, 25-30 (2008). 
38. Barrow, E. et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: 
a report of 121 families with proven mutations. Clin Genet 75, 141-9 (2009). 
39. Kastrinos, F. et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302, 
1790-5 (2009). 
40. Win, A.K. et al. Colorectal and other cancer risks for carriers and noncarriers from families 
with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 30, 
958-64 (2012). 
41. Azzouzi, A.R. et al. Clinically localised prostate cancer is microsatellite stable. BJU Int 99, 
1031-5 (2007). 
42. Burger, M. et al. Elevated microsatellite alterations at selected tetranucleotides (EMAST) 
and mismatch repair gene expression in prostate cancer. J Mol Med (Berl) 84, 833-41 
(2006). 
43. Lotsari, J.E. et al. Breast carcinoma and Lynch syndrome: molecular analysis of tumors 
arising in mutation carriers, non-carriers, and sporadic cases. Breast Cancer Res 14, R90 
(2012). 
 261 
44. Wen, Y.H. et al. DNA mismatch repair deficiency in breast carcinoma: a pilot study of 
triple-negative and non-triple-negative tumors. Am J Surg Pathol 36, 1700-8 (2012). 
45. Win, A.K., Lindor, N.M. & Jenkins, M.A. Risk of breast cancer in Lynch syndrome: a 
systematic review. Breast Cancer Res 15, R27 (2013). 
46. Ryan, S., Jenkins, M.A. & Win, A.K. Risk of prostate cancer in Lynch syndrome: a 
systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 23, 437-49 
(2014). 
47. Haraldsdottir, S. et al. Prostate cancer incidence in males with Lynch syndrome. Genet Med 
(2014). 
48. Raymond, V.M. et al. Elevated risk of prostate cancer among men with Lynch syndrome. J 
Clin Oncol 31, 1713-8 (2013). 
49. Suspiro, A. et al. The Muir-Torre syndrome: a rare variant of hereditary nonpolyposis 
colorectal cancer associated with hMSH2 mutation. Am J Gastroenterol 93, 1572-4 (1998). 
50. Turcot, J., Despres, J.P. & St Pierre, F. Malignant tumors of the central nervous system 
associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum 2, 
465-8 (1959). 
51. Hamilton, S.R. et al. The molecular basis of Turcot's syndrome. N Engl J Med 332, 839-47 
(1995). 
52. Lebrun, C. et al. Turcot syndrome confirmed with molecular analysis. Eur J Neurol 14, 470-
2 (2007). 
53. Holter, S. et al. Hepatic adenomas caused by somatic HNF1A mutations in children with 
biallelic mismatch repair gene mutations. Gastroenterology 140, 735-6 (2011). 
54. Medina-Arana, V. et al. Adrenocortical carcinoma, an unusual extracolonic tumor 
associated with Lynch II syndrome. Fam Cancer 10, 265-71 (2011). 
55. Medina Arana, V. et al. Highly aggressive leiomyosarcoma associated with Lynch II 
syndrome: increasing the range of extracolonic cancers related with hereditary non-
polyposis colonic cancer. Ann Oncol 13, 807-8 (2002). 
56. Sijmons, R. et al. Inclusion of malignant fibrous histiocytoma in the tumour spectrum 
associated with hereditary non-polyposis colorectal cancer. Genes Chromosomes Cancer 29, 
353-5 (2000). 
57. Aaltonen, L.A. et al. Clues to the pathogenesis of familial colorectal cancer. Science 260, 
812-6 (1993). 
58. Thibodeau, S.N., Bren, G. & Schaid, D. Microsatellite instability in cancer of the proximal 
colon. Science 260, 816-9 (1993). 
59. Risinger, J.I. et al. Genetic instability of microsatellites in endometrial carcinoma. Cancer 
Res 53, 5100-3 (1993). 
60. Ionov, Y., Peinado, M.A., Malkhosyan, S., Shibata, D. & Perucho, M. Ubiquitous somatic 
mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. 
Nature 363, 558-61 (1993). 
61. Geiersbach, K.B. & Samowitz, W.S. Microsatellite instability and colorectal cancer. Arch 
Pathol Lab Med 135, 1269-77 (2011). 
62. de la Chapelle, A. & Hampel, H. Clinical relevance of microsatellite instability in colorectal 
cancer. J Clin Oncol 28, 3380-7 (2010). 
63. Samowitz, W.S. et al. Microsatellite instability in sporadic colon cancer is associated with 
an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 10, 917-
23 (2001). 
64. Papadopoulos, N. et al. Mutation of a mutL homolog in hereditary colon cancer. Science 
263, 1625-9 (1994). 
65. Torlakovic, E., Skovlund, E., Snover, D.C., Torlakovic, G. & Nesland, J.M. Morphologic 
reappraisal of serrated colorectal polyps. Am J Surg Pathol 27, 65-81 (2003). 
66. Cunningham, J.M. et al. Hypermethylation of the hMLH1 promoter in colon cancer with 
microsatellite instability. Cancer Res 58, 3455-60 (1998). 
 262 
67. Herman, J.G. et al. Incidence and functional consequences of hMLH1 promoter 
hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95, 6870-5 (1998). 
68. Miyakura, Y. et al. Extensive methylation of hMLH1 promoter region predominates in 
proximal colon cancer with microsatellite instability. Gastroenterology 121, 1300-9 (2001). 
69. Toyota, M. et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci 
U S A 96, 8681-6 (1999). 
70. Hampel, H. et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) 
among endometrial cancer patients. Cancer Res 66, 7810-7 (2006). 
71. Metcalf, A.M. & Spurdle, A.B. Endometrial tumour BRAF mutations and MLH1 promoter 
methylation as predictors of germline mismatch repair gene mutation status: a literature 
review. Fam Cancer 13, 1-12 (2014). 
72. Geisler, J.P. et al. Mismatch repair gene expression defects contribute to microsatellite 
instability in ovarian carcinoma. Cancer 98, 2199-206 (2003). 
73. Furlan, D. et al. The high frequency of de novo promoter methylation in synchronous 
primary endometrial and ovarian carcinomas. Clin Cancer Res 12, 3329-36 (2006). 
74. Gylling, A. et al. Is gastric cancer part of the tumour spectrum of hereditary non-polyposis 
colorectal cancer? A molecular genetic study. Gut 56, 926-33 (2007). 
75. Furihata, M. et al. Genetic analysis of hMLH1 in transitional cell carcinoma of the urinary 
tract: promoter methylation or mutation. J Urol 165, 1760-4 (2001). 
76. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-54 (2002). 
77. Rajagopalan, H. et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 
Nature 418, 934 (2002). 
78. Deng, G. et al. BRAF mutation is frequently present in sporadic colorectal cancer with 
methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 
10, 191-5 (2004). 
79. Domingo, E. et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC 
in patients with functional MLH1 and MSH2 genes. Oncogene 24, 3995-8 (2005). 
80. Lubomierski, N. et al. BRAF mutations in colorectal carcinoma suggest two entities of 
microsatellite-unstable tumors. Cancer 104, 952-61 (2005). 
81. McGivern, A. et al. Promoter hypermethylation frequency and BRAF mutations distinguish 
hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 3, 
101-7 (2004). 
82. Wang, L. et al. BRAF mutations in colon cancer are not likely attributable to defective DNA 
mismatch repair. Cancer Res 63, 5209-12 (2003). 
83. Valeri, N. et al. Modulation of mismatch repair and genomic stability by miR-155. Proc 
Natl Acad Sci U S A 107, 6982-7 (2010). 
84. Markowitz, S. et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with 
microsatellite instability. Science 268, 1336-8 (1995). 
85. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 
330-7 (2012). 
86. Kim, T.M., Laird, P.W. & Park, P.J. The landscape of microsatellite instability in colorectal 
and endometrial cancer genomes. Cell 155, 858-68 (2013). 
87. Gylling, A.H. et al. Differential cancer predisposition in Lynch syndrome: insights from 
molecular analysis of brain and urinary tract tumors. Carcinogenesis 29, 1351-9 (2008). 
88. Kandoth, C. et al. Integrated genomic characterization of endometrial carcinoma. Nature 
497, 67-73 (2013). 
89. Edelstein, D.L. et al. Rapid development of colorectal neoplasia in patients with Lynch 
syndrome. Clin Gastroenterol Hepatol 9, 340-3 (2011). 
90. Vasen, H.F. et al. Guidelines for the clinical management of Lynch syndrome (hereditary 
non-polyposis cancer). J Med Genet 44, 353-62 (2007). 
91. Winawer, S.J. et al. Colorectal cancer screening: clinical guidelines and rationale. 
Gastroenterology 112, 594-642 (1997). 
 263 
92. Jass, J.R. HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological 
similarities and differences. Fam Cancer 3, 93-100 (2004). 
93. Jenkins, M.A. et al. Pathology features in Bethesda guidelines predict colorectal cancer 
microsatellite instability: a population-based study. Gastroenterology 133, 48-56 (2007). 
94. Ruemmele, P. et al. Histopathologic features and microsatellite instability of cancers of the 
papilla of vater and their precursor lesions. Am J Surg Pathol 33, 691-704 (2009). 
95. Agaram, N.P., Shia, J., Tang, L.H. & Klimstra, D.S. DNA mismatch repair deficiency in 
ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases. Am J 
Clin Pathol 133, 772-80 (2010). 
96. Schulmann, K. et al. HNPCC-associated small bowel cancer: clinical and molecular 
characteristics. Gastroenterology 128, 590-9 (2005). 
97. Wilentz, R.E. et al. Genetic, immunohistochemical, and clinical features of medullary 
carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol 156, 
1641-51 (2000). 
98. Broaddus, R.R. et al. Pathologic features of endometrial carcinoma associated with HNPCC: 
a comparison with sporadic endometrial carcinoma. Cancer 106, 87-94 (2006). 
99. van den Bos, M. et al. More differences between HNPCC-related and sporadic carcinomas 
from the endometrium as compared to the colon. Am J Surg Pathol 28, 706-11 (2004). 
100. Walsh, M.D. et al. Molecular, pathologic, and clinical features of early-onset endometrial 
cancer: identifying presumptive Lynch syndrome patients. Clin Cancer Res 14, 1692-700 
(2008). 
101. Shih, K.K. et al. Clinicopathologic significance of DNA mismatch repair protein defects and 
endometrial cancer in women 40years of age and younger. Gynecol Oncol 123, 88-94 
(2011). 
102. Garg, K. et al. Selection of endometrial carcinomas for DNA mismatch repair protein 
immunohistochemistry using patient age and tumor morphology enhances detection of 
mismatch repair abnormalities. Am J Surg Pathol 33, 925-33 (2009). 
103. Shia, J., Black, D., Hummer, A.J., Boyd, J. & Soslow, R.A. Routinely assessed 
morphological features correlate with microsatellite instability status in endometrial cancer. 
Hum Pathol 39, 116-25 (2008). 
104. Ketabi, Z. et al. Ovarian cancer linked to lynch syndrome typically presents as early-onset, 
non-serous epithelial tumors. Gynecol Oncol (2011). 
105. Segev, Y. et al. Risk factors for ovarian cancers with and without microsatellite instability. 
Int J Gynecol Cancer 24, 664-9 (2014). 
106. Aysal, A. et al. Ovarian Endometrioid Adenocarcinoma: Incidence and Clinical Significance 
of the Morphologic and Immunohistochemical Markers of Mismatch Repair Protein Defects 
and Tumor Microsatellite Instability. Am J Surg Pathol (2011). 
107. Huang, Y.Q. et al. Comparative features of colorectal and gastric cancers with microsatellite 
instability in Chinese patients. J Zhejiang Univ Sci B 11, 647-53 (2010). 
108. Chun, N. & Ford, J.M. Genetic testing by cancer site: stomach. Cancer J 18, 355-63 (2012). 
109. Leach, F.S. et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal 
cancer. Cell 75, 1215-25 (1993). 
110. Bronner, C.E. et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is 
associated with hereditary non-polyposis colon cancer. Nature 368, 258-61 (1994). 
111. Fishel, R. et al. The human mutator gene homolog MSH2 and its association with hereditary 
nonpolyposis colon cancer. Cell 75, 1027-38 (1993). 
112. Lindblom, A., Tannergard, P., Werelius, B. & Nordenskjold, M. Genetic mapping of a 
second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet 5, 279-82 
(1993). 
113. Peltomaki, P. et al. Microsatellite instability is associated with tumors that characterize the 
hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 53, 5853-5 (1993). 
 264 
114. Foulkes, W.D. et al. The founder mutation MSH2*1906G-->C is an important cause of 
hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum 
Genet 71, 1395-412 (2002). 
115. Nystrom-Lahti, M. et al. Founding mutations and Alu-mediated recombination in hereditary 
colon cancer. Nat Med 1, 1203-6 (1995). 
116. van Riel, E. et al. A novel pathogenic MLH1 missense mutation, c.112A > C, p.Asn38His, 
in six families with Lynch syndrome. Hered Cancer Clin Pract 8, 1-9 (2010). 
117. Palombo, F. et al. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in 
human cells. Science 268, 1912-4 (1995). 
118. Papadopoulos, N. et al. Mutations of GTBP in genetically unstable cells. Science 268, 1915-
7 (1995). 
119. Nicolaides, N.C. et al. Mutations of two PMS homologues in hereditary nonpolyposis colon 
cancer. Nature 371, 75-80 (1994). 
120. De Vos, M., Hayward, B.E., Picton, S., Sheridan, E. & Bonthron, D.T. Novel PMS2 
pseudogenes can conceal recessive mutations causing a distinctive childhood cancer 
syndrome. Am J Hum Genet 74, 954-64 (2004). 
121. Hayward, B.E. et al. Extensive gene conversion at the PMS2 DNA mismatch repair locus. 
Hum Mutat 28, 424-30 (2007). 
122. Kovacs, M.E., Papp, J., Szentirmay, Z., Otto, S. & Olah, E. Deletions removing the last 
exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. 
Hum Mutat 30, 197-203 (2009). 
123. Ligtenberg, M.J. et al. Heritable somatic methylation and inactivation of MSH2 in families 
with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 41, 112-7 
(2009). 
124. Mauillon, J.L. et al. Identification of novel germline hMLH1 mutations including a 22 kb 
Alu-mediated deletion in patients with familial colorectal cancer. Cancer Res 56, 5728-33 
(1996). 
125. Perez-Cabornero, L. et al. Characterization of new founder Alu-mediated rearrangements in 
MSH2 gene associated with a Lynch Syndrome phenotype. Cancer Prev Res (Phila) (2011). 
126. Eng, C. High frequency of large gene deletions and rearrangements in Lynch syndrome--
back to the future? Gastroenterology 129, 1124-6 (2005). 
127. Taylor, C.F., Charlton, R.S., Burn, J., Sheridan, E. & Taylor, G.R. Genomic deletions in 
MSH2 or MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: 
identification of novel and recurrent deletions by MLPA. Hum Mutat 22, 428-33 (2003). 
128. Hitchins, M.P. et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N 
Engl J Med 356, 697-705 (2007). 
129. Hitchins, M.P. et al. Dominantly Inherited Constitutional Epigenetic Silencing of MLH1 in 
a Cancer-Affected Family Is Linked to a Single Nucleotide Variant within the 5'UTR. 
Cancer Cell 20, 200-13 (2011). 
130. Boland, C.R. & Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology 
138, 2073-2087 e3 (2010). 
131. Andrew, E.R., Peplinska, B. & Kempka, M. Molecular dynamics in solid L-adrenaline by 
proton NMR. Solid State Nucl Magn Reson 10, 117-21 (1998). 
132. Borgdorff, V., Pauw, B., van Hees-Stuivenberg, S. & de Wind, N. DNA mismatch repair 
mediates protection from mutagenesis induced by short-wave ultraviolet light. DNA Repair 
(Amst) 5, 1364-72 (2006). 
133. Borgdorff, V., van Hees-Stuivenberg, S., Meijers, C.M. & de Wind, N. Spontaneous and 
mutagen-induced loss of DNA mismatch repair in Msh2-heterozygous mammalian cells. 
Mutat Res 574, 50-7 (2005). 
134. Sansom, O.J. et al. Apoptosis and mutation in the murine small intestine: loss of Mlh1- and 
Pms2-dependent apoptosis leads to increased mutation in vivo. DNA Repair (Amst) 2, 1029-
39 (2003). 
 265 
135. Smith-Roe, S.L., Hegan, D.C., Glazer, P.M. & Buermeyer, A.B. Mlh1-dependent 
suppression of specific mutations induced in vivo by the food-borne carcinogen 2-amino-1-
methyl-6-phenylimidazo [4,5-b] pyridine (PhIP). Mutat Res 594, 101-12 (2006). 
136. Hofstra, R.M. et al. Tumor characteristics as an analytic tool for classifying genetic variants 
of uncertain clinical significance. Hum Mutat 29, 1292-303 (2008). 
137. Liu, T. et al. The role of hPMS1 and hPMS2 in predisposing to colorectal cancer. Cancer 
Res 61, 7798-802 (2001). 
138. Wu, Y. et al. A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet 29, 
137-8 (2001). 
139. Liu, H.X. et al. The role of hMLH3 in familial colorectal cancer. Cancer Res 63, 1894-9 
(2003). 
140. Loukola, A., Vilkki, S., Singh, J., Launonen, V. & Aaltonen, L.A. Germline and somatic 
mutation analysis of MLH3 in MSI-positive colorectal cancer. Am J Pathol 157, 347-52 
(2000). 
141. Korhonen, M.K., Vuorenmaa, E. & Nystrom, M. The first functional study of MLH3 
mutations found in cancer patients. Genes Chromosomes Cancer 47, 803-9 (2008). 
142. Ou, J. et al. Biochemical characterization of MLH3 missense mutations does not reveal an 
apparent role of MLH3 in Lynch syndrome. Genes Chromosomes Cancer 48, 340-50 
(2009). 
143. Wu, Y. et al. Germline mutations of EXO1 gene in patients with hereditary nonpolyposis 
colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology 120, 1580-7 
(2001). 
144. Alam, N.A. et al. Germline deletions of EXO1 do not cause colorectal tumors and lesions 
which are null for EXO1 do not have microsatellite instability. Cancer Genet Cytogenet 
147, 121-7 (2003). 
145. Jagmohan-Changur, S. et al. EXO1 variants occur commonly in normal population: 
evidence against a role in hereditary nonpolyposis colorectal cancer. Cancer Res 63, 154-8 
(2003). 
146. Thompson, E. et al. Hereditary non-polyposis colorectal cancer and the role of hPMS2 and 
hEXO1 mutations. Clin Genet 65, 215-25 (2004). 
147. Morak, M. et al. Biallelic MUTYH mutations can mimic Lynch syndrome. Eur J Hum 
Genet (2014). 
148. Castillejo, A. et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome 
patients. Eur J Cancer (2014). 
149. Kunkel, T.A. & Erie, D.A. DNA mismatch repair. Annu Rev Biochem 74, 681-710 (2005). 
150. Li, G.M. Mechanisms and functions of DNA mismatch repair. Cell Res 18, 85-98 (2008). 
151. Sachadyn, P. Conservation and diversity of MutS proteins. Mutat Res 694, 20-30 (2010). 
152. Li, F. et al. The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair 
through Its Interaction with MutSalpha. Cell 153, 590-600 (2013). 
153. Pluciennik, A. & Modrich, P. Protein roadblocks and helix discontinuities are barriers to the 
initiation of mismatch repair. Proc Natl Acad Sci U S A 104, 12709-13 (2007). 
154. Sixma, T.K. DNA mismatch repair: MutS structures bound to mismatches. Curr Opin Struct 
Biol 11, 47-52 (2001). 
155. Fishel, R. The selection for mismatch repair defects in hereditary nonpolyposis colorectal 
cancer: revising the mutator hypothesis. Cancer Res 61, 7369-74 (2001). 
156. Harfe, B.D. & Jinks-Robertson, S. DNA mismatch repair and genetic instability. Annu Rev 
Genet 34, 359-399 (2000). 
157. Taschner, P.E. & den Dunnen, J.T. Describing structural changes by extending HGVS 
sequence variation nomenclature. Hum Mutat 32, 507-11 (2011). 
158. Ban, C., Junop, M. & Yang, W. Transformation of MutL by ATP binding and hydrolysis: a 
switch in DNA mismatch repair. Cell 97, 85-97 (1999). 
 266 
159. Tran, P.T. & Liskay, R.M. Functional studies on the candidate ATPase domains of 
Saccharomyces cerevisiae MutLalpha. Mol Cell Biol 20, 6390-8 (2000). 
160. Raschle, M., Dufner, P., Marra, G. & Jiricny, J. Mutations within the hMLH1 and hPMS2 
subunits of the human MutLalpha mismatch repair factor affect its ATPase activity, but not 
its ability to interact with hMutSalpha. J Biol Chem 277, 21810-20 (2002). 
161. Kondo, E., Suzuki, H., Horii, A. & Fukushige, S. A yeast two-hybrid assay provides a 
simple way to evaluate the vast majority of hMLH1 germ-line mutations. Cancer Res 63, 
3302-8 (2003). 
162. Plotz, G., Raedle, J., Brieger, A., Trojan, J. & Zeuzem, S. N-terminus of hMLH1 confers 
interaction of hMutLalpha and hMutLbeta with hMutSalpha. Nucleic Acids Res 31, 3217-26 
(2003). 
163. Hardt, K. et al. Missense variants in hMLH1 identified in patients from the German HNPCC 
consortium and functional studies. Fam Cancer (2011). 
164. Guarne, A., Junop, M.S. & Yang, W. Structure and function of the N-terminal 40 kDa 
fragment of human PMS2: a monomeric GHL ATPase. EMBO J 20, 5521-31 (2001). 
165. Lutzen, A., de Wind, N., Georgijevic, D., Nielsen, F.C. & Rasmussen, L.J. Functional 
analysis of HNPCC-related missense mutations in MSH2. Mutat Res 645, 44-55 (2008). 
166. Iaccarino, I., Marra, G., Palombo, F. & Jiricny, J. hMSH2 and hMSH6 play distinct roles in 
mismatch binding and contribute differently to the ATPase activity of hMutSalpha. EMBO J 
17, 2677-86 (1998). 
167. Schopf, B. et al. Interplay between mismatch repair and chromatin assembly. Proc Natl 
Acad Sci U S A (2012). 
168. Iaccarino, I., Marra, G., Dufner, P. & Jiricny, J. Mutation in the magnesium binding site of 
hMSH6 disables the hMutSalpha sliding clamp from translocating along DNA. J Biol Chem 
275, 2080-6 (2000). 
169. Plotz, G. et al. Mutations in the MutSalpha interaction interface of MLH1 can abolish DNA 
mismatch repair. Nucleic Acids Res 34, 6574-86 (2006). 
170. Schmutte, C., Sadoff, M.M., Shim, K.S., Acharya, S. & Fishel, R. The interaction of DNA 
mismatch repair proteins with human exonuclease I. J Biol Chem 276, 33011-8 (2001). 
171. Brieger, A. et al. Characterization of the nuclear import of human MutLalpha. Mol Carcinog 
43, 51-8 (2005). 
172. Leong, V., Lorenowicz, J., Kozij, N. & Guarne, A. Nuclear import of human MLH1, PMS2, 
and MutLalpha: redundancy is the key. Mol Carcinog 48, 742-50 (2009). 
173. Gassman, N.R. et al. Cooperative Nuclear Localization Sequences Lend a Novel Role to the 
N-Terminal Region of MSH6. PLoS One 6, e17907 (2011). 
174. Guerrette, S., Acharya, S. & Fishel, R. The interaction of the human MutL homologues in 
hereditary nonpolyposis colon cancer. J Biol Chem 274, 6336-41 (1999). 
175. Kondo, E., Horii, A. & Fukushige, S. The interacting domains of three MutL heterodimers 
in man: hMLH1 interacts with 36 homologous amino acid residues within hMLH3, hPMS1 
and hPMS2. Nucleic Acids Res 29, 1695-702 (2001). 
176. Lamers, M.H. et al. The crystal structure of DNA mismatch repair protein MutS binding to a 
G x T mismatch. Nature 407, 711-7 (2000). 
177. Clark, A.B., Deterding, L., Tomer, K.B. & Kunkel, T.A. Multiple functions for the N-
terminal region of Msh6. Nucleic Acids Res 35, 4114-23 (2007). 
178. Mendillo, M.L. et al. A conserved MutS homolog connector domain interface interacts with 
MutL homologs. Proc Natl Acad Sci U S A 106, 22223-8 (2009). 
179. Mukherjee, S. & Feig, M. Conformational change in MSH2-MSH6 upon binding DNA 
coupled to ATPase activity. Biophys J 96, L63-5 (2009). 
180. Guerrette, S., Wilson, T., Gradia, S. & Fishel, R. Interactions of human hMSH2 with 
hMSH3 and hMSH2 with hMSH6: examination of mutations found in hereditary 
nonpolyposis colorectal cancer. Mol Cell Biol 18, 6616-23 (1998). 
 267 
181. Kleczkowska, H.E., Marra, G., Lettieri, T. & Jiricny, J. hMSH3 and hMSH6 interact with 
PCNA and colocalize with it to replication foci. Genes Dev 15, 724-36 (2001). 
182. Laguri, C. et al. Human mismatch repair protein MSH6 contains a PWWP domain that 
targets double stranded DNA. Biochemistry 47, 6199-207 (2008). 
183. Jiricny, J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7, 335-46 
(2006). 
184. Marra, G. et al. Mismatch repair deficiency associated with overexpression of the MSH3 
gene. Proc Natl Acad Sci U S A 95, 8568-73 (1998). 
185. Nystrom-Lahti, M. et al. Functional analysis of MLH1 mutations linked to hereditary 
nonpolyposis colon cancer. Genes Chromosomes Cancer 33, 160-7 (2002). 
186. Sacho, E.J., Kadyrov, F.A., Modrich, P., Kunkel, T.A. & Erie, D.A. Direct visualization of 
asymmetric adenine-nucleotide-induced conformational changes in MutL alpha. Mol Cell 
29, 112-21 (2008). 
187. Schroering, A.G., Edelbrock, M.A., Richards, T.J. & Williams, K.J. The cell cycle and DNA 
mismatch repair. Exp Cell Res 313, 292-304 (2007). 
188. Stojic, L. et al. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 
type methylating agents requires the ATR kinase. Genes Dev 18, 1331-44 (2004). 
189. Stojic, L., Brun, R. & Jiricny, J. Mismatch repair and DNA damage signalling. DNA Repair 
(Amst) 3, 1091-101 (2004). 
190. Xie, J. et al. An MLH1 Mutation Links BACH1/FANCJ to Colon Cancer, Signaling, and 
Insight toward Directed Therapy. Cancer Prev Res (Phila) 3, 1409-1416 (2010). 
191. Pedrazzi, G. et al. Direct association of Bloom's syndrome gene product with the human 
mismatch repair protein MLH1. Nucleic Acids Res 29, 4378-86 (2001). 
192. Vo, A.T. et al. hMRE11 deficiency leads to microsatellite instability and defective DNA 
mismatch repair. EMBO Rep 6, 438-44 (2005). 
193. Chen, J. & Sadowski, I. Identification of the mismatch repair genes PMS2 and MLH1 as 
p53 target genes by using serial analysis of binding elements. Proc Natl Acad Sci U S A 102, 
4813-8 (2005). 
194. Win, A.K. et al. Risks of colorectal and other cancers after endometrial cancer for women 
with Lynch syndrome. J Natl Cancer Inst 105, 274-9 (2013). 
195. Win, A.K. et al. Risks of primary extracolonic cancers following colorectal cancer in lynch 
syndrome. J Natl Cancer Inst 104, 1363-72 (2012). 
196. Aaltonen, L.A. et al. Incidence of hereditary nonpolyposis colorectal cancer and the 
feasibility of molecular screening for the disease. N Engl J Med 338, 1481-7 (1998). 
197. Lindor, N.M. et al. Immunohistochemistry versus microsatellite instability testing in 
phenotyping colorectal tumors. J Clin Oncol 20, 1043-8 (2002). 
198. Salovaara, R. et al. Population-based molecular detection of hereditary nonpolyposis 
colorectal cancer. J Clin Oncol 18, 2193-200 (2000). 
199. Terdiman, J.P. et al. Efficient detection of hereditary nonpolyposis colorectal cancer gene 
carriers by screening for tumor microsatellite instability before germline genetic testing. 
Gastroenterology 120, 21-30 (2001). 
200. Hampel, H. et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal 
cancer). N Engl J Med 352, 1851-60 (2005). 
201. Gudgeon, J.M. et al. Lynch syndrome screening implementation: business analysis by a 
healthcare system. Am J Manag Care 17, e288-300 (2011). 
202. Newcomb, P.A. et al. Colon Cancer Family Registry: an international resource for studies of 
the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 16, 2331-43 
(2007). 
203. Schofield, L., Grieu, F., Goldblatt, J., Amanuel, B. & Iacopetta, B. A state-wide population-
based program for detection of lynch syndrome based upon immunohistochemical and 
molecular testing of colorectal tumours. Fam Cancer (2011). 
 268 
204. Vasen, H.F., Mecklin, J.P., Khan, P.M. & Lynch, H.T. The International Collaborative 
Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 
34, 424-5 (1991). 
205. Vasen, H.F., Watson, P., Mecklin, J.P. & Lynch, H.T. New clinical criteria for hereditary 
nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International 
Collaborative group on HNPCC. Gastroenterology 116, 1453-6 (1999). 
206. Ponz de Leon, M., Sassatelli, R., Benatti, P. & Roncucci, L. Identification of hereditary 
nonpolyposis colorectal cancer in the general population. The 6-year experience of a 
population-based registry. Cancer 71, 3493-501 (1993). 
207. Madlensky, L. et al. A preventive registry for hereditary nonpolyposis colorectal cancer. 
Can J Oncol 5, 355-60 (1995). 
208. Fujita, S., Moriya, Y., Sugihara, K., Akasu, T. & Ushio, K. Prognosis of hereditary 
nonpolyposis colorectal cancer (HNPCC) and the role of Japanese criteria for HNPCC. Jpn 
J Clin Oncol 26, 351-5 (1996). 
209. Han, H.J. et al. Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary 
nonpolyposis colorectal cancer. J Natl Cancer Inst 88, 1317-9 (1996). 
210. Shu, Z., Yanqin, H. & Ying, Y. Hereditary colorectal cancer in china. Hered Cancer Clin 
Pract 3, 155-64 (2005). 
211. Lancaster, J.M. et al. Society of Gynecologic Oncologists Education Committee statement 
on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107, 
159-62 (2007). 
212. Tan, Y.Y. et al. Improving identification of lynch syndrome patients: a comparison of 
research data with clinical records. Int J Cancer 132, 2876-83 (2013). 
213. Lindor, N.M. et al. Lower cancer incidence in Amsterdam-I criteria families without 
mismatch repair deficiency: familial colorectal cancer type X. JAMA 293, 1979-85 (2005). 
214. Woods, M.O. et al. The genetic basis of colorectal cancer in a population-based incident 
cohort with a high rate of familial disease. Gut 59, 1369-77 (2010). 
215. Rodriguez-Bigas, M.A. et al. A National Cancer Institute Workshop on Hereditary 
Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J 
Natl Cancer Inst 89, 1758-62 (1997). 
216. de Jong, A.E. et al. Microsatellite instability, immunohistochemistry, and additional PMS2 
staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10, 972-80 
(2004). 
217. Dinjens, W.N., van Leerdam, M.E. & Wagner, A. On the advent of MSI testing of all 
colorectal cancers and a substantial part of other Lynch syndrome-related neoplasms. Expert 
Rev Mol Diagn 10, 381-4 (2010). 
218. Hampel, H. Point: justification for Lynch syndrome screening among all patients with newly 
diagnosed colorectal cancer. J Natl Compr Canc Netw 8, 597-601 (2010). 
219. Hampel, H. et al. Feasibility of screening for Lynch syndrome among patients with 
colorectal cancer. J Clin Oncol 26, 5783-8 (2008). 
220. Southey, M.C. et al. Use of molecular tumor characteristics to prioritize mismatch repair 
gene testing in early-onset colorectal cancer. J Clin Oncol 23, 6524-32 (2005). 
221. Schofield, L., Grieu, F., Goldblatt, J., Amanuel, B. & Iacopetta, B. A state-wide population-
based program for detection of lynch syndrome based upon immunohistochemical and 
molecular testing of colorectal tumours. Fam Cancer 11, 1-6 (2012). 
222. Boland, C.R. & Shike, M. Report from the Jerusalem workshop on Lynch syndrome-
hereditary nonpolyposis colorectal cancer. Gastroenterology 138, 2197 e1-7 (2010). 
223. Wijnen, J.T. et al. Clinical findings with implications for genetic testing in families with 
clustering of colorectal cancer. N Engl J Med 339, 511-8 (1998). 
224. Lipton, L.R. et al. Refining the Amsterdam Criteria and Bethesda Guidelines: testing 
algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. 
J Clin Oncol 22, 4934-43 (2004). 
 269 
225. Marroni, F. et al. A genetic model for determining MSH2 and MLH1 carrier probabilities 
based on family history and tumor microsatellite instability. Clin Genet 69, 254-62 (2006). 
226. Chen, S. et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. 
JAMA 296, 1479-87 (2006). 
227. Barnetson, R.A. et al. Identification and survival of carriers of mutations in DNA mismatch-
repair genes in colon cancer. N Engl J Med 354, 2751-63 (2006). 
228. Balmana, J. et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 
296, 1469-78 (2006). 
229. Kastrinos, F. et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 
germline mutations based on cancer history. Gastroenterology 140, 73-81 (2011). 
230. Win, A.K., Macinnis, R.J., Dowty, J.G. & Jenkins, M.A. Criteria and prediction models for 
mismatch repair gene mutations: a review. J Med Genet 50, 785-93 (2013). 
231. Boland, C.R. et al. A National Cancer Institute Workshop on Microsatellite Instability for 
cancer detection and familial predisposition: development of international criteria for the 
determination of microsatellite instability in colorectal cancer. Cancer Res 58, 5248-57 
(1998). 
232. Dietmaier, W. et al. Diagnostic microsatellite instability: definition and correlation with 
mismatch repair protein expression. Cancer Res 57, 4749-56 (1997). 
233. Cicek, M.S. et al. Quality assessment and correlation of microsatellite instability and 
immunohistochemical markers among population- and clinic-based colorectal tumors results 
from the Colon Cancer Family Registry. J Mol Diagn 13, 271-81 (2011). 
234. Laiho, P. et al. Low-level microsatellite instability in most colorectal carcinomas. Cancer 
Res 62, 1166-70 (2002). 
235. Buhard, O., Suraweera, N., Lectard, A., Duval, A. & Hamelin, R. Quasimonomorphic 
mononucleotide repeats for high-level microsatellite instability analysis. Dis Markers 20, 
251-7 (2004). 
236. Ebinger, M. et al. Simplified detection of microsatellite instability in colorectal cancer 
without the need for corresponding germline DNA analysis. J Clin Pathol 59, 1114-5 
(2006). 
237. Nardon, E. et al. A multicenter study to validate the reproducibility of MSI testing with a 
panel of 5 quasimonomorphic mononucleotide repeats. Diagn Mol Pathol 19, 236-42 
(2010). 
238. Soreide, K. High-fidelity of five quasimonomorphic mononucleotide repeats to high-
frequency microsatellite instability distribution in early-stage adenocarcinoma of the colon. 
Anticancer Res 31, 967-71 (2011). 
239. Suraweera, N. et al. Evaluation of tumor microsatellite instability using five 
quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123, 
1804-11 (2002). 
240. Xicola, R.M. et al. Performance of different microsatellite marker panels for detection of 
mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 99, 244-52 (2007). 
241. Williams, A.S. & Huang, W.Y. The analysis of microsatellite instability in extracolonic 
gastrointestinal malignancy. Pathology 45, 540-52 (2013). 
242. de Leeuw, W.J. et al. Prediction of a mismatch repair gene defect by microsatellite 
instability and immunohistochemical analysis in endometrial tumours from HNPCC 
patients. J Pathol 192, 328-35 (2000). 
243. Acharya, S. et al. hMSH2 forms specific mispair-binding complexes with hMSH3 and 
hMSH6. Proc Natl Acad Sci U S A 93, 13629-34 (1996). 
244. You, J.F. et al. Tumours with loss of MSH6 expression are MSI-H when screened with a 
pentaplex of five mononucleotide repeats. Br J Cancer 103, 1840-5 (2010). 
245. Stoffel, E.M. & Syngal, S. Adenomas in young patients: what is the optimal evaluation? Am 
J Gastroenterol 100, 1150-3 (2005). 
 270 
246. Yurgelun, M.B. et al. Microsatellite instability and DNA mismatch repair protein deficiency 
in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012). 
247. Park, S.K. et al. Microsatellite instability in young patients with sporadic colorectal 
adenomas. Hepatogastroenterology 58, 1531-7 (2011). 
248. Pino, M.S. et al. Deficient DNA mismatch repair is common in Lynch syndrome-associated 
colorectal adenomas. J Mol Diagn 11, 238-47 (2009). 
249. Mangold, E. et al. Tumours from MSH2 mutation carriers show loss of MSH2 expression 
but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J 
Pathol 207, 385-95 (2005). 
250. Peltomaki, P. Lynch syndrome genes. Fam Cancer 4, 227-32 (2005). 
251. Palomaki, G.E., McClain, M.R., Melillo, S., Hampel, H.L. & Thibodeau, S.N. EGAPP 
supplementary evidence review: DNA testing strategies aimed at reducing morbidity and 
mortality from Lynch syndrome. Genet Med 11, 42-65 (2009). 
252. Boland, C.R., Koi, M., Chang, D.K. & Carethers, J.M. The biochemical basis of 
microsatellite instability and abnormal immunohistochemistry and clinical behavior in 
Lynch syndrome: from bench to bedside. Fam Cancer 7, 41-52 (2008). 
253. Christensen, M. et al. Antibody-based screening for hereditary nonpolyposis colorectal 
carcinoma compared with microsatellite analysis and sequencing. Cancer 95, 2422-30 
(2002). 
254. Shia, J. et al. Immunohistochemistry as first-line screening for detecting colorectal cancer 
patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel 
may be as predictive as a 4-antibody panel. Am J Surg Pathol 33, 1639-45 (2009). 
255. Domingo, E. et al. Activated BRAF targets proximal colon tumors with mismatch repair 
deficiency and MLH1 inactivation. Genes Chromosomes Cancer 39, 138-42 (2004). 
256. Loughrey, M.B. et al. Incorporation of somatic BRAF mutation testing into an algorithm for 
the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 6, 301-10 
(2007). 
257. Bouzourene, H., Hutter, P., Losi, L., Martin, P. & Benhattar, J. Selection of patients with 
germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and 
BRAF mutation. Fam Cancer 9, 167-72 (2010). 
258. Jensen, L.H., Lindebjerg, J., Byriel, L., Kolvraa, S. & Cruger, D.G. Strategy in clinical 
practice for classification of unselected colorectal tumours based on mismatch repair 
deficiency. Colorectal Dis 10, 490-7 (2008). 
259. Bessa, X. et al. A prospective, multicenter, population-based study of BRAF mutational 
analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 6, 206-14 (2008). 
260. Lagerstedt Robinson, K. et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) 
diagnostics. J Natl Cancer Inst 99, 291-9 (2007). 
261. Walsh, M.D. et al. Analysis of families with Lynch syndrome complicated by advanced 
serrated neoplasia: the importance of pathology review and pedigree analysis. Fam Cancer 
8, 313-23 (2009). 
262. Capel, E., Flejou, J.F. & Hamelin, R. Assessment of MLH1 promoter methylation in relation 
to gene expression requires specific analysis. Oncogene 26, 7596-600 (2007). 
263. Parsons, M.T., Buchanan, D.D., Thompson, B., Young, J.P. & Spurdle, A.B. Correlation of 
tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) 
gene mutation status: a literature review assessing utility of tumour features for MMR 
variant classification. Journal of Medical Genetics 49, 151-157 (2012). 
264. Kaz, A. et al. Evidence for the role of aberrant DNA methylation in the pathogenesis of 
Lynch syndrome adenomas. Int J Cancer 120, 1922-9 (2007). 
265. Crepin, M. et al. Evidence of constitutional MLH1 epimutation associated to 
transgenerational inheritance of cancer susceptibility. Hum Mutat (2011). 
266. Clendenning, M. et al. Long-range PCR facilitates the identification of PMS2-specific 
mutations. Hum Mutat 27, 490-5 (2006). 
 271 
267. van der Klift, H.M. et al. Quantification of sequence exchange events between PMS2 and 
PMS2CL provides a basis for improved mutation scanning of Lynch syndrome patients. 
Hum Mutat 31, 578-87 (2010). 
268. Vaughn, C.P., Hart, K.J., Samowitz, W.S. & Swensen, J.J. Avoidance of pseudogene 
interference in the detection of 3' deletions in PMS2. Hum Mutat 32, 1063-71 (2011). 
269. Lynch, H.T. et al. Lynch Syndrome-Associated Extracolonic Tumors Are Rare in Two 
Extended Families With the Same EPCAM Deletion. Am J Gastroenterol (2011). 
270. Clendenning, M. et al. Mutation deep within an intron of MSH2 causes Lynch syndrome. 
Fam Cancer 10, 297-301 (2011). 
271. Palma, L., Marcus, V., Gilbert, L., Chong, G. & Foulkes, W.D. Synchronous occult cancers 
of the endometrium and fallopian tube in an MSH2 mutation carrier at time of prophylactic 
surgery. Gynecol Oncol 111, 575-8 (2008). 
272. Rhees, J., Arnold, M. & Boland, C.R. Inversion of exons 1-7 of the MSH2 gene is a frequent 
cause of unexplained Lynch syndrome in one local population. Fam Cancer 13, 219-25 
(2014). 
273. Engel, C. et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary 
nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 8, 174-82 (2010). 
274. Burn, J. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal 
cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378, 2081-7 (2011). 
275. Schmeler, K.M. et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the 
Lynch syndrome. N Engl J Med 354, 261-9 (2006). 
276. Lindor, N.M. et al. Recommendations for the care of individuals with an inherited 
predisposition to Lynch syndrome: a systematic review. JAMA 296, 1507-17 (2006). 
277. Kauff, N.D. How should women with early-onset endometrial cancer be evaluated for lynch 
syndrome? J Clin Oncol 25, 5143-6 (2007). 
278. Lu, K.H. & Daniels, M. Endometrial and ovarian cancer in women with Lynch syndrome: 
update in screening and prevention. Fam Cancer 12, 273-7 (2013). 
279. Capelle, L.G. et al. Risk and epidemiological time trends of gastric cancer in Lynch 
syndrome carriers in the Netherlands. Gastroenterology 138, 487-92 (2010). 
280. Padgett, R.A. et al. Nonconsensus branch-site sequences in the in vitro splicing of 
transcripts of mutant rabbit beta-globin genes. Proc Natl Acad Sci U S A 82, 8349-53 
(1985). 
281. Shapiro, M.B. & Senapathy, P. RNA splice junctions of different classes of eukaryotes: 
sequence statistics and functional implications in gene expression. Nucleic Acids Res 15, 
7155-74 (1987). 
282. Fairbrother, W.G. & Chasin, L.A. Human genomic sequences that inhibit splicing. Mol Cell 
Biol 20, 6816-25 (2000). 
283. Liu, H.X., Zhang, M. & Krainer, A.R. Identification of functional exonic splicing enhancer 
motifs recognized by individual SR proteins. Genes Dev 12, 1998-2012 (1998). 
284. Baralle, D. & Baralle, M. Splicing in action: assessing disease causing sequence changes. J 
Med Genet 42, 737-48 (2005). 
285. Lastella, P., Surdo, N.C., Resta, N., Guanti, G. & Stella, A. In silico and in vivo splicing 
analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects. 
BMC Genomics 7, 243 (2006). 
286. Mangold, E. et al. Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 
1,721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer 
116, 692-702 (2005). 
287. Pagenstecher, C. et al. Aberrant splicing in MLH1 and MSH2 due to exonic and intronic 
variants. Hum Genet 119, 9-22 (2006). 
288. Etzler, J. et al. RNA-based mutation analysis identifies an unusual MSH6 splicing defect 
and circumvents PMS2 pseudogene interference. Hum Mutat 29, 299-305 (2008). 
 272 
289. Charbonnier, F. et al. Alternative splicing of MLH1 messenger RNA in human normal cells. 
Cancer Res 55, 1839-41 (1995). 
290. Genuardi, M. et al. Characterization of MLH1 and MSH2 alternative splicing and its 
relevance to molecular testing of colorectal cancer susceptibility. Hum Genet 102, 15-20 
(1998). 
291. Tournier, I. et al. A large fraction of unclassified variants of the mismatch repair genes 
MLH1 and MSH2 is associated with splicing defects. Hum Mutat (2008). 
292. Belvederesi, L. et al. MSH2 missense mutations and HNPCC syndrome: pathogenicity 
assessment in a human expression system. Hum Mutat 29, E296-309 (2008). 
293. Belvederesi, L. et al. Assessing the pathogenicity of MLH1 missense mutations in patients 
with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic 
and functional features. Eur J Hum Genet 14, 853-9 (2006). 
294. Christensen, L.L. et al. Functional characterization of rare missense mutations in MLH1 and 
MSH2 identified in Danish colorectal cancer patients. Fam Cancer 8, 489-500 (2009). 
295. Blasi, M.F. et al. A human cell-based assay to evaluate the effects of alterations in the 
MLH1 mismatch repair gene. Cancer Res 66, 9036-44 (2006). 
296. Mastrocola, A.S. & Heinen, C.D. Nuclear reorganization of DNA mismatch repair proteins 
in response to DNA damage. DNA Repair (Amst) 9, 120-33 (2010). 
297. Drost, M. et al. A cell-free assay for the functional analysis of variants of the mismatch 
repair protein MLH1. Hum Mutat 31, 247-53 (2010). 
298. Drost, M. et al. A rapid and cell-free assay to test the activity of lynch syndrome-associated 
MSH2 and MSH6 missense variants. Hum Mutat (2011). 
299. Drost, M., Koppejan, H. & de Wind, N. Inactivation of DNA mismatch repair by variants of 
uncertain significance in the PMS2 gene. Hum Mutat 34, 1477-80 (2013). 
300. Polaczek, P., Putzke, A.P., Leong, K. & Bitter, G.A. Functional genetic tests of DNA 
mismatch repair protein activity in Saccharomyces cerevisiae. Gene 213, 159-67 (1998). 
301. Shimodaira, H. et al. Functional analysis of human MLH1 mutations in Saccharomyces 
cerevisiae. Nat Genet 19, 384-9 (1998). 
302. Shcherbakova, P.V. & Kunkel, T.A. Mutator phenotypes conferred by MLH1 
overexpression and by heterozygosity for mlh1 mutations. Mol Cell Biol 19, 3177-83 
(1999). 
303. Wanat, J.J., Singh, N. & Alani, E. The effect of genetic background on the function of 
Saccharomyces cerevisiae mlh1 alleles that correspond to HNPCC missense mutations. Hum 
Mol Genet 16, 445-52 (2007). 
304. Clark, A.B., Valle, F., Drotschmann, K., Gary, R.K. & Kunkel, T.A. Functional interaction 
of proliferating cell nuclear antigen with MSH2-MSH6 and MSH2-MSH3 complexes. J Biol 
Chem 275, 36498-501 (2000). 
305. Takahashi, M. et al. Functional analysis of human MLH1 variants using yeast and in vitro 
mismatch repair assays. Cancer Res 67, 4595-604 (2007). 
306. Drotschmann, K., Clark, A.B. & Kunkel, T.A. Mutator phenotypes of common 
polymorphisms and missense mutations in MSH2. Curr Biol 9, 907-10 (1999). 
307. Tran, H.T., Keen, J.D., Kricker, M., Resnick, M.A. & Gordenin, D.A. Hypermutability of 
homonucleotide runs in mismatch repair and DNA polymerase proofreading yeast mutants. 
Mol Cell Biol 17, 2859-65 (1997). 
308. Heinen, C.D. et al. HNPCC mutations in hMSH2 result in reduced hMSH2-hMSH6 
molecular switch functions. Cancer Cell 1, 469-78 (2002). 
309. Perera, S. & Bapat, B. The MLH1 variants p.Arg265Cys and p.Lys618Ala affect protein 
stability while p.Leu749Gln affects heterodimer formation. Hum Mutat 29, 332 (2008). 
310. Jager, A.C. et al. HNPCC mutations in the human DNA mismatch repair gene hMLH1 
influence assembly of hMutLalpha and hMLH1-hEXO1 complexes. Oncogene 20, 3590-5 
(2001). 
 273 
311. Ollila, S. et al. Pathogenicity of MSH2 missense mutations is typically associated with 
impaired repair capability of the mutated protein. Gastroenterology 131, 1408-17 (2006). 
312. Raevaara, T.E. et al. Functional significance and clinical phenotype of nontruncating 
mismatch repair variants of MLH1. Gastroenterology 129, 537-49 (2005). 
313. Brieger, A., Trojan, J., Raedle, J., Plotz, G. & Zeuzem, S. Transient mismatch repair gene 
transfection for functional analysis of genetic hMLH1 and hMSH2 variants. Gut 51, 677-84 
(2002). 
314. Couch, F.J. et al. Assessment of functional effects of unclassified genetic variants. Hum 
Mutat 29, 1314-26 (2008). 
315. Kansikas, M., Kariola, R. & Nystrom, M. Verification of the three-step model in assessing 
the pathogenicity of mismatch repair gene variants. Hum Mutat 32, 107-15 (2011). 
316. Adzhubei, I.A. et al. A method and server for predicting damaging missense mutations. Nat 
Methods 7, 248-9 (2010). 
317. Kumar, P., Henikoff, S. & Ng, P.C. Predicting the effects of coding non-synonymous 
variants on protein function using the SIFT algorithm. Nat Protoc 4, 1073-81 (2009). 
318. Ng, P.C. & Henikoff, S. Accounting for human polymorphisms predicted to affect protein 
function. Genome Res 12, 436-46 (2002). 
319. Tavtigian, S.V., Byrnes, G.B., Goldgar, D.E. & Thomas, A. Classification of rare missense 
substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. 
Hum Mutat 29, 1342-54 (2008). 
320. Tavtigian, S.V. et al. Comprehensive statistical study of 452 BRCA1 missense substitutions 
with classification of eight recurrent substitutions as neutral. J Med Genet 43, 295-305 
(2006). 
321. Li, B. et al. Automated inference of molecular mechanisms of disease from amino acid 
substitutions. Bioinformatics 25, 2744-50 (2009). 
322. Reva, B., Antipin, Y. & Sander, C. Predicting the functional impact of protein mutations: 
application to cancer genomics. Nucleic Acids Res 39, e118 (2011). 
323. Chao, E.C. et al. Accurate classification of MLH1/MSH2 missense variants with 
multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Hum 
Mutat 29, 852-60 (2008). 
324. Ali, H., Olatubosun, A. & Vihinen, M. Classification of mismatch repair gene missense 
variants with PON-MMR. Hum Mutat 33, 642-50 (2012). 
325. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human 
genetic variants. Nat Genet 46, 310-5 (2014). 
326. Yeo, G. & Burge, C.B. Maximum entropy modeling of short sequence motifs with 
applications to RNA splicing signals. J Comput Biol 11, 377-94 (2004). 
327. Desmet, F.O. et al. Human Splicing Finder: an online bioinformatics tool to predict splicing 
signals. Nucleic Acids Res 37, e67 (2009). 
328. Fairbrother, W.G. et al. RESCUE-ESE identifies candidate exonic splicing enhancers in 
vertebrate exons. Nucleic Acids Res 32, W187-90 (2004). 
329. Cartegni, L., Wang, J., Zhu, Z., Zhang, M.Q. & Krainer, A.R. ESEfinder: A web resource to 
identify exonic splicing enhancers. Nucleic Acids Res 31, 3568-71 (2003). 
330. Houdayer, C. et al. Evaluation of in silico splice tools for decision-making in molecular 
diagnosis. Hum Mutat 29, 975-82 (2008). 
331. Buratti, E. et al. Aberrant 5' splice sites in human disease genes: mutation pattern, 
nucleotide structure and comparison of computational tools that predict their utilization. 
Nucleic Acids Res 35, 4250-63 (2007). 
332. Vorechovsky, I. Aberrant 3' splice sites in human disease genes: mutation pattern, 
nucleotide structure and comparison of computational tools that predict their utilization. 
Nucleic Acids Res 34, 4630-41 (2006). 
 274 
333. Wimmer, K. et al. Diagnostic criteria for constitutional mismatch repair deficiency 
syndrome: suggestions of the European consortium 'Care for CMMRD' (C4CMMRD). J 
Med Genet (2014). 
334. Trimbath, J.D. et al. Cafe-au-lait spots and early onset colorectal neoplasia: a variant of 
HNPCC? Fam Cancer 1, 101-5 (2001). 
335. Gallinger, S. et al. Gastrointestinal cancers and neurofibromatosis type 1 features in children 
with a germline homozygous MLH1 mutation. Gastroenterology 126, 576-85 (2004). 
336. Herkert, J.C. et al. Paediatric intestinal cancer and polyposis due to bi-allelic PMS2 
mutations: case series, review and follow-up guidelines. Eur J Cancer 47, 965-82 (2011). 
337. Bougeard, G. et al. Early onset brain tumor and lymphoma in MSH2-deficient children. Am 
J Hum Genet 72, 213-6 (2003). 
338. Poley, J.W. et al. Biallelic germline mutations of mismatch-repair genes: a possible cause 
for multiple pediatric malignancies. Cancer 109, 2349-56 (2007). 
339. Menko, F.H. et al. A homozygous MSH6 mutation in a child with cafe-au-lait spots, 
oligodendroglioma and rectal cancer. Fam Cancer 3, 123-7 (2004). 
340. Agostini, M. et al. Two PMS2 mutations in a Turcot syndrome family with small bowel 
cancers. Am J Gastroenterol 100, 1886-91 (2005). 
341. Leenen, C.H. et al. Pitfalls in molecular analysis for mismatch repair deficiency in a family 
with biallelic pms2 germline mutations. Clin Genet 80, 558-65 (2011). 
342. Johannesma, P.C. et al. Childhood brain tumours due to germline bi-allelic mismatch repair 
gene mutations. Clin Genet 80, 243-55 (2011). 
343. Gururangan, S. et al. Multifocal anaplastic astrocytoma in a patient with hereditary 
colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental 
retardation, and inherited PMS2 mutation. Neuro Oncol 10, 93-7 (2008). 
344. Okkels, H. et al. Polyposis and early cancer in a patient with low penetrant mutations in 
MSH6 and APC: hereditary colorectal cancer as a polygenic trait. Int J Colorectal Dis 21, 
847-50 (2006). 
345. Plaschke, J. et al. Compound heterozygosity for two MSH6 mutations in a patient with early 
onset of HNPCC-associated cancers, but without hematological malignancy and brain 
tumor. Eur J Hum Genet 14, 561-6 (2006). 
346. Rahner, N. et al. Compound heterozygosity for two MSH6 mutations in a patient with early 
onset colorectal cancer, vitiligo and systemic lupus erythematosus. Am J Med Genet A 
146A, 1314-9 (2008). 
347. Jasperson, K., Samowitz, W. & Burt, R. Constitutional mismatch repair-deficiency 
syndrome presenting as colonic adenomatous polyposis: clues from the skin. Clin Genet 
(2010). 
348. Chen, P.C. et al. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch 
repair and tumor suppression in the mouse. Cancer Res 65, 8662-70 (2005). 
349. de Wind, N., Dekker, M., Berns, A., Radman, M. & te Riele, H. Inactivation of the mouse 
Msh2 gene results in mismatch repair deficiency, methylation tolerance, 
hyperrecombination, and predisposition to cancer. Cell 82, 321-30 (1995). 
350. de Wind, N., Dekker, M., van Rossum, A., van der Valk, M. & te Riele, H. Mouse models 
for hereditary nonpolyposis colorectal cancer. Cancer Res 58, 248-55 (1998). 
351. Edelmann, W. et al. Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. Cancer Res 
59, 1301-7 (1999). 
352. Prolla, T.A. et al. Tumour susceptibility and spontaneous mutation in mice deficient in 
Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet 18, 276-9 (1998). 
353. Reitmair, A.H. et al. Spontaneous intestinal carcinomas and skin neoplasms in Msh2-
deficient mice. Cancer Res 56, 3842-9 (1996). 
354. Reitmair, A.H. et al. MSH2 deficient mice are viable and susceptible to lymphoid tumours. 
Nat Genet 11, 64-70 (1995). 
 275 
355. Baker, S.M. et al. Male mice defective in the DNA mismatch repair gene PMS2 exhibit 
abnormal chromosome synapsis in meiosis. Cell 82, 309-19 (1995). 
356. de Wind, N. et al. HNPCC-like cancer predisposition in mice through simultaneous loss of 
Msh3 and Msh6 mismatch-repair protein functions. Nat Genet 23, 359-62 (1999). 
357. Edelmann, W. et al. The DNA mismatch repair genes Msh3 and Msh6 cooperate in 
intestinal tumor suppression. Cancer Res 60, 803-7 (2000). 
358. Edelmann, W. et al. Mutation in the mismatch repair gene Msh6 causes cancer 
susceptibility. Cell 91, 467-77 (1997). 
359. Wei, K., Kucherlapati, R. & Edelmann, W. Mouse models for human DNA mismatch-repair 
gene defects. Trends Mol Med 8, 346-53 (2002). 
360. Feitsma, H., Kuiper, R.V., Korving, J., Nijman, I.J. & Cuppen, E. Zebrafish with mutations 
in mismatch repair genes develop neurofibromas and other tumors. Cancer Res 68, 5059-66 
(2008). 
361. Peltomaki, P. & Vasen, H. Mutations associated with HNPCC predisposition -- Update of 
ICG-HNPCC/INSiGHT mutation database. Dis Markers 20, 269-76 (2004). 
362. Woods, M.O. et al. A new variant database for mismatch repair genes associated with Lynch 
syndrome. Hum Mutat 28, 669-73 (2007). 
363. Tavtigian, S.V., Greenblatt, M.S., Lesueur, F. & Byrnes, G.B. In silico analysis of missense 
substitutions using sequence-alignment based methods. Hum Mutat 29, 1327-36 (2008). 
364. Hicks, S., Wheeler, D.A., Plon, S.E. & Kimmel, M. Prediction of missense mutation 
functionality depends on both the algorithm and sequence alignment employed. Hum Mutat 
(2011). 
365. Miller, P.J. et al. Classifying variants of CDKN2A using computational and laboratory 
studies. Hum Mutat 32, 900-11 (2011). 
366. Plon, S.E. et al. Sequence variant classification and reporting: recommendations for 
improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29, 
1282-91 (2008). 
367. Bell, J., Bodmer, D., Sistermans, E. & Ramsden, S.C. Practice guidelines for the 
Interpretation and Reproting of Unclassified Variants (UVs) in Clinical Molecular Genetics. 
(http://cmgsweb.shared.hosting.zen.co.uk/BPGs/Best_Practice_Guidelines.htm, 2007). 
368. Richards, C.S. et al. ACMG recommendations for standards for interpretation and reporting 
of sequence variations: Revisions 2007. Genet Med 10, 294-300 (2008). 
369. Eggington, J.M. et al. A comprehensive laboratory-based program for classification of 
variants of uncertain significance in hereditary cancer genes. Clin Genet (2013). 
370. Barnetson, R.A. et al. Classification of ambiguous mutations in DNA mismatch repair genes 
identified in a population-based study of colorectal cancer. Hum Mutat 29, 367-74 (2008). 
371. Lucci-Cordisco, E., Boccuto, L., Neri, G. & Genuardi, M. The use of microsatellite 
instability, immunohistochemistry and other variables in determining the clinical 
significance of MLH1 and MSH2 unclassified variants in Lynch syndrome. Cancer Biomark 
2, 11-27 (2006). 
372. Spurdle, A.B., Couch, F.J., Hogervorst, F.B., Radice, P. & Sinilnikova, O.M. Prediction and 
assessment of splicing alterations: implications for clinical testing. Hum Mutat 29, 1304-13 
(2008). 
373. Greenblatt, M.S. et al. Locus-specific databases and recommendations to strengthen their 
contribution to the classification of variants in cancer susceptibility genes. Hum Mutat 29, 
1273-81 (2008). 
374. Kaput, J. et al. Planning the human variome project: the Spain report. Hum Mutat 30, 496-
510 (2009). 
375. Peltomaki, P. & Vasen, H.F. Mutations predisposing to hereditary nonpolyposis colorectal 
cancer: database and results of a collaborative study. The International Collaborative Group 
on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 113, 1146-58 (1997). 
 276 
376. Ou, J. et al. A database to support the interpretation of human mismatch repair gene 
variants. Hum Mutat 29, 1337-41 (2008). 
377. Plazzer, J.P. et al. The InSiGHT database: utilizing 100 years of insights into Lynch 
syndrome. Fam Cancer 12, 175-80 (2013). 
378. Kohonen-Corish, M.R. et al. Deciphering the colon cancer genes--report of the InSiGHT-
Human Variome Project Workshop, UNESCO, Paris 2010. Hum Mutat 32, 491-4 (2011). 
379. Goldgar, D.E. et al. Integrated evaluation of DNA sequence variants of unknown clinical 
significance: application to BRCA1 and BRCA2. Am J Hum Genet 75, 535-44 (2004). 
380. Goldgar, D.E. et al. Genetic evidence and integration of various data sources for classifying 
uncertain variants into a single model. Hum Mutat 29, 1265-72 (2008). 
381. Arnold, S. et al. Classifying MLH1 and MSH2 variants using bioinformatic prediction, 
splicing assays, segregation, and tumor characteristics. Hum Mutat 30, 757-70 (2009). 
382. Spurdle, A.B. Clinical relevance of rare germline sequence variants in cancer genes: 
evolution and application of classification models. Curr Opin Genet Dev 20, 315-23 (2010). 
383. Pastrello, C. et al. Integrated analysis of unclassified variants in mismatch repair genes. 
Genet Med 13, 115-24 (2011). 
384. Easton, D.F. et al. A systematic genetic assessment of 1,433 sequence variants of unknown 
clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J 
Hum Genet 81, 873-83 (2007). 
385. Bruegl, A.S. et al. Evaluation of Clinical Criteria for the Identification of Lynch Syndrome 
among Unselected Endometrial Cancer Patients. Cancer Prev Res (Phila) (2014). 
386. Egoavil, C. et al. Prevalence of Lynch syndrome among patients with newly diagnosed 
endometrial cancers. PLoS One 8, e79737 (2013). 
387. Kidambi, T.D. et al. Selective Versus Universal Screening for Lynch Syndrome: A Six-Year 
Clinical Experience. Dig Dis Sci (2014). 
388. Perez-Carbonell, L. et al. Comparison between universal molecular screening for Lynch 
syndrome and revised Bethesda guidelines in a large population-based cohort of patients 
with colorectal cancer. Gut 61, 865-72 (2012). 
389. MacArthur, D.G. et al. Guidelines for investigating causality of sequence variants in human 
disease. Nature 508, 469-76 (2014). 
390. Parc, Y., Boisson, C., Thomas, G. & Olschwang, S. Cancer risk in 348 French MSH2 or 
MLH1 gene carriers. J Med Genet 40, 208-13 (2003). 
391. Kurzawski, G. et al. Germline MSH2 and MLH1 mutational spectrum including large 
rearrangements in HNPCC families from Poland (update study). Clin Genet 69, 40-7 (2006). 
392. Mensenkamp, A.R. et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of 
mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 146, 643-646 
e8 (2014). 
393. Haraldsdottir, S. et al. Colon and Endometrial Cancers with Mismatch Repair Deficiency 
can Arise from Somatic, Rather Than Germline, Mutations. Gastroenterology (2014). 
394. Wong, Y.F. et al. Detection of microsatellite instability in endometrial cancer: advantages of 
a panel of five mononucleotide repeats over the National Cancer Institute panel of markers. 
Carcinogenesis 27, 951-5 (2006). 
395. Zhao, H. et al. Mismatch repair deficiency endows tumors with a unique mutation signature 
and sensitivity to DNA double-strand breaks. Elife 3, e02725 (2014). 
396. Drost, M. et al. Genetic screens to identify pathogenic gene variants in the common cancer 
predisposition Lynch syndrome. Proc Natl Acad Sci U S A (2013). 
397. Grandval, P. et al. UMD-MLH1/MSH2/MSH6 databases: description and analysis of 
genetic variations in French Lynch syndrome families. Database (Oxford) 2013, bat036 
(2013). 
398. Groden, J. et al. Identification and characterization of the familial adenomatous polyposis 
coli gene. Cell 66, 589-600 (1991). 
 277 
399. Half, E., Bercovich, D. & Rozen, P. Familial adenomatous polyposis. Orphanet J Rare Dis 
4, 22 (2009). 
 278 
List of Appendices 
Appendix 1:  MMR protein multiple sequence alignments 
Appendix 2:  Colon Cancer Family Registry data use agreements 
Appendix 3:  InSiGHT data submission template 
Appendix 4:  InSiGHT VIC variant review template 
 
 
 
Appendix 1: MMR protein multiple sequence alignments 
The following hand-curated alignments were used in for analyses in Chapter 2. 
 
Abbreviations of species 
Hsap  Homo sapiens 
Caet  Cercopithecus aethiops (monkey) 
Mmul  Macaca mulatta (monkey) 
Mmus  Mus musculus (mouse) 
Btau  Bos Taurus (cow – laurasiatheria) 
Cfam  Canis lupus familiaris (dog) 
Mdom  Monodelphis domestica (grey short-tailed opossum – marsupialia) 
Ggal  Gallus gallus (chicken – aves) 
Xlae  Xenopus laevis (frog – amphibia) 
Xtro  Xenopus tropicalis (frog – amphibia) 
Drer  Danio rerio (zebrafish – teleostei) 
Pmar  Petromyzon marinus (lamprey eel – agnatha) 
Cint  Ciona intestinalis (sea squirt – tunicate) 
Bflo  Branchiostoma floridae (lancelet – cephalochordate) 
Spur  Strongylocentrotus purpuratus (purple sea urchin – echinodermata) 
Nvec  Nematostella vectensis (starlet anemone – cnidarian) 
Tadh  Trichoplax adhearens (placozoa) 
MLH1
Hsap 0 M S - F V A G V I R R L D E T V V N R I A A G E V I Q R P A N A I K E M I E N C L D A K S T S I Q V
Mmul 0 M S - F V A G V I R R L D E T V V N R I A A G E V I Q R P A N A I K E M I E N C L D A K S T S I Q V
Mmus 0 M A - F V A G V I R R L D E T V V N R I A A G E V I Q R P A N A I K E M I E N C L D A K S T N I Q V
Cfam 0 M S - L V A G V I R R L D E T V V N R I A A G E V I Q R P A N A I K E M I E N C L D A K S T S I Q V
Mdom 0 M S - L V A G V I R R L D E K V V N R I A A G E V I Q R P A N A I K E M I E N C L D A R A S A I Q V
Ggal 0 M A - L V A G V I R R L D E A V V N R I A A G E V I Q R P A N A I K E M I E N C L D A K S T S I Q V
Xlae 0 M - - - - A G V I R R L E E T V V N R I A A G E V I Q R P A N A I K E M I E N C L D A K S T S I Q V
Drer 0 M - - - - A G V I R R L D E T V V N R I A A G E I I Q R P A N A I K E M M E N C L D A K S T N I Q I
Pmar 0 M A - - A P C V I R R L D E A V V N R I A A G E V I Q R P A N A I K E M M E N C L D A K A T S I Q V
Cint 0 M A E S G V V V I K R L D E T V V N R I A A G E V I Q R P A N A V K E M I E N C L D A G S T T I T V
Bflo 0 M - - - - A G T I R R L E E T V V N R I A A G E V I V R P A N A V K E M L E N C L D A K S S S I Q V
Spur 0 M - - - - A G T I R K L D E T V V N R I A A G E V I Q R P A N A L K E M I E N C L D A K S T S I Q V
Nvec 0 M A D - - I P S I R K L D E T V V N R I A A G E V I Q R P A N A L K E M I E N C L D A K S T S I T V
Tadh 0 M - - - - E R K I Q K L D E K V V N R I A A G E V I Q R P A N A I K E M I E N S L D A K A T L I Q V
 
Hsap 49 I V K E G G L K L I Q I Q D N G T G I R K E D L D I V C E R F T T S K L Q S F E D L A S I S T Y G F
Mmul 49 I V K E G G L K L I Q I Q D N G T G I R K E D L D I V C E R F T T S K L Q S F E D L A S I S T Y G F
Mmus 49 V V K E G G L K L I Q I Q D N G T G I R K E D L D I V C E R F T T S K L Q T F E D L A S I S T Y G F
Cfam 49 V V K E G G L K L I Q I Q D N G T G I R K E D L D I V C E R F T T S K L Q S F E D L A S I S T Y G F
Mdom 49 T V R E G G L K L I Q V Q D N G S G I R R E D L D I V C E R F T T S K L R A F E D L A S I A T Y G F
Ggal 49 V V K E G G L K L I Q V Q D N G C G I R K E D L H I V C E R F T T S K L Q K F E D L A S I S T Y G F
Xlae 46 T V K D G G M K L I Q I Q D N G T G I R K E D L D I V C E R F T T S K L Q S F E D L S N I S T Y G F
Drer 46 T V K E G G L K L I L I Q D N G T G I R K D D M E I V C E R F T T S K L K S F D D L S S I A T Y G F
Pmar 48 T V K N G G L K L I Q I Q D N G T G I R K E D M E I V C E R F T T S K L E K F E D L S S I A T F G F
Cint 50 S L K S G G L K M L Q I S D N G H G I R R E D M E I V C E R F T T S K L K E F D D L K T I A T F G F
Bflo 46 V V K S G G L K L L Q I Q D N G T G I R R D D M G I V C E R F T T S K L Q K F E D L T S I A T Y G F
Spur 46 T V K S G G M K L L Q I Q D N G T G I R K D D M D I V C E R F T T S K L R E F N D L T S I S T Y G F
Nvec 48 T V K S G G L K L L Q I Q D N G C G I R K E D M H I V C E R F T T S K L S K F E D L S S I S T Y G F
Tadh 46 T V K S G G L K L I Q I Q D N G H G I K K E D L D I V C E R F T T S K L S R F E D L S S M V T Y G F
 
Hsap 99 R G E A L A S I S H V A H V T I T T K T A D G K C A Y R A S Y S D G K L K A P - - - - - - - P K P C
Mmul 99 R G E A L A S I S H V A H V T I T T K T A D G K C A Y R A S Y S D G K L K G P - - - - - - - P K P C
Mmus 99 R G E A L A S I S H V A H V T I T T K T A D G K C A Y R A S Y S D G K L Q A P - - - - - - - P K P C
Cfam 99 R G E A L A S I S H V A H V T I T T K T A E A K C A Y R A T Y S D G K L K A P - - - - - - - P K P C
Mdom 99 R G E A L A S I S H V A H V T V T S K T A E A K C A Y R A S Y S D G K L K A P - - - - - - - P K P C
Ggal 99 R G E A L A S I S H V A H V T V T T K T A D A K C A Y R A S Y S D G K I K A P - - - - - - - P K P C
Xlae 96 R G E A L A S V S H V A H V T I T T K T A D G K C A Y R A S Y A D G K L K A P - - - - - - - P K P C
Drer 96 R G E A L A S I S H V A H V T I T T K T A D A K C A Y R A N Y C D G K L K S P - - - - - - - P K P C
Pmar 98 R G E A L A S I S H V A H V T I T T K T A D S M C A Y R A M Y C D G K L K A P - - - - - - - P K P C
Cint 100 R G E A L A S I S H V A H L S I T S R T K D S K C G Y K A S Y L D G R I K G S - - - - - - - P R P T
Bflo 96 R G E A L A S I S H V A H V T I V T R T A D S K C A Y K A S Y S D G K P L A T - - - - - - - P K P C
Spur 96 R G E A L A S I S H V A H V T I V T R T E D S K C A Y K G N F S D G K L K A A - - - - - - - I K P C
Nvec 98 R G E A L A S I S H V A H V T I T T K T A H S S C A Y K A S Y S D G K L V P P R P G L P A E P K P C
Tadh 96 R G E A L A S I S H V A H V A I V T R T E D S K C A Y R A T Y A D G K M V P G Q P N A S A D P K P C
 
Hsap 142 A G N Q G T Q I T V E D L F Y N I A T R R K A L K N P S E E Y G K I L E V V G R Y S V H N A G I S F
Mmul 142 A G N Q G T Q I T V E D L F Y N I A T R R K A L K N P S E E Y G K I L E I V G R Y S I H N A G I S F
Mmus 142 A G N Q G T L I T V E D L F Y N I I T R R K A L K N P S E E Y G K I L E V V G R Y S I H N S G I S F
Cfam 142 A G N Q G T Q I T V E D L F Y N I S T R R K A L K N P S E E Y G K I L E V V G R Y S I H N S G I S F
Mdom 142 A G N Q G T Q I T V E D L F Y N V A T R R K A L K N P S E E Y G K I L D V V G R Y S V H N S G V S F
Ggal 142 A G N Q G T Q I M V E D L F Y N V N T R R K A L K N P S E E Y A K I L E V V G R Y A I H N S G I S F
Xlae 139 A G N Q G T Q I S V E D L F Y N V S T R R K A L K S P S E E H A R I V E V V S R Y A I H N S G I G F
Drer 139 A G N Q G T L I S V E D L F Y N V S T R R K A L K S P S E E Y S R I V E V V S R Y A I H N S G K S F
Pmar 141 A G N Q G T Q I T A E D L F Y N V A T R R K A L K S A S E E H G K I T E V V S R Y S I H Y S G V S F
Cint 143 A G N T G T Q I T V E D L F Y N V P T R R K A F K S P S E E H Q K I A D V M T R Y A L H N S G K S F
Bflo 139 A G N Q G T Q I T V E D L F Y N V P S R R K A M R S P G E E H A K V A E V M S R Y A I H N A G V G F
Spur 139 A G N R G T Q I T V E D L F Y N V A T R R K A L K S A S E E H N K I S E V V S R Y A I H N A G V A F
Nvec 148 A G N K G T Q I T V E D L F Y N V A T R R K A L K S P G E E Y S K V V D V V S K Y S I H N T G V A F
Tadh 146 A G N V G T Q I N V E D L F F N T P L R L K A L K N P N E E F N K I T E V I S R Y A V H Q E G V G F
 
Hsap 192 S V K K Q - G E T V - - - - A D V R T L P N A S T V D N I R S I F G N A V S R E L I E I G C E D K T
Mmul 192 S V K K Q - G E T V - - - - A D V R T L P N A S T V D N I R S I F G N A V S R E L I E I G C E D K T
Mmus 192 S V K K Q - G E T V - - - - S D V R T L P N A T T V D N I R S I F G N A V S R E L I E V G C E D K T
Cfam 192 S V K K Q - G E T V - - - - A D V R T L P N A T T V D N I R S I F G N A V S R E L I E V G C E D K T
Mdom 192 S V K K Q - G E T V - - - - P D I R T L T N A T V V D N I R S I F G N A V S R E L I E V G C D D P L
Ggal 192 S V K K Q - G D T V - - - - S D V R T L S N A T T V D N I R S I F G N A V S R E L I E V G C E D A N
Xlae 189 S V K K Q - G E T M - - - - A D V R T L S N A T T V D N I R T V F G N A V S R E L I G V G C E E D K
Drer 189 S V K K Q - G E M V - - - - A D V K T L P N A S V L D N I R V V F G V A V S R E L I E V E C E D Q K
Pmar 191 T L K K Q - G E S T - - - - A D V R T L P G A T T V D N I R A V Y G A P V A R E L I E V N Y E D K K
Cint 193 T L R K T D G D S G P S G G V S V R T Q L G S S F V T N I G T L F G S K V A K E V I E V K H Y D T Q
Bflo 189 T L K K Q - G E S M - - - - A E L R T S P T S S T I D N I R T V Y G P A V A R E L I E V K C D D S R
Spur 189 T L K K S - G E S T - - - - A D V R T S Q N A S T V D N I R S V F G P T V A R E L L E I N H E N S G
Nvec 198 T L K K Q - G E A T - - - - A D V R T T S T A S L H D N I R A I Y G T A V A R E L V D I D C D N S R
Tadh 196 I L K K Y - G D S N - - - - A T V R T - S G S S R L D N I R T I Y G A S T A R E L L E V S L E N K K
 
Hsap 237 L A F K M N G Y I S N A N Y S V K K C I F L L F I N H R L V E S T S L R K A I E T V Y A A Y L P K N
Mmul 237 L A F K M N G Y I S N A N Y S V K K C I F L L F I N H R L V E S T S L R K A I E T V Y A A Y L P K N
Mmus 237 L A F K M N G Y I S N A N Y S V K K C I F L L F I N H R L V E S A A L R K A I E T V Y A A Y L P K N
Cfam 237 L A F K M N G Y I S N A N Y S V K K C I F L L F I N H R L V E S T S L R K A I E T V Y A A Y L P K N
Mdom 237 L A F R M K G F I S N A N Y S V K K C I F L L F I N R R L V E S S A L R K A V E S V Y A A Y L P K N
Ggal 237 L A F K M K G Y I T N A N Y S V K K C I F L L F I N H R L V E S T A L R K A I E T V Y A A Y L P K S
Xlae 234 L A F K M K G Y V T N A N Y S M K K C I F L L F I N A R L V E S T A L K K A I E T V Y A A Y L P K N
Drer 234 F A F K V K G Y I S N A N Y S V K K C I L I L F I N H R L V E S S A L K K A I E T V Y T A Y L P K N
Pmar 236 L V L K M R G Y I S N A N Y S M K K C V F L L F I N H R L V D S T A L R K A I E M V Y A A Y L P K N
Cint 243 L Q L K T F G Y I S N A N C S M K K F V F L L F I N N R L V D C S V L K K S L D S V Y Q S Y L P K G
Bflo 234 L A F S M K G Y I S N A N Y S T K K F I F L L F I N H R L V D S T A L R K A L E A V Y S A Y L P K N
1
50
100
143
193
238
Spur 234 L G F K L S G Q I S N A N Y S V K R L I F L L F I N H R L V D S S S L R K A I E A V Y S T Y L P K N
Nvec 243 L G F Y M K G C I T N A N Y S V K K L I F L L F I N H R L V D S T A L R R S L E T V Y E A Y L P K G
Tadh 240 L G I G M N G L I S N A N Y S A K K C I F L L F I N H R L V E C S N L R K A I E N V Y A A Y L P K H
 
Hsap 287 T H P F L Y L S L E I S P Q N V D V N V H P T K H E V H F L H E E S I L E R V Q Q H I E S K L L G S
Mmul 287 T H P F L Y L S L E I S P Q N V D V N V H P T K H E V H F L H E E S I L E R V Q Q H I E S K L L G S
Mmus 287 T H P F L Y L S L E I S P Q N V D V N V H P T K H E V H F L H E E S I L Q R V Q Q H I E S K L L G S
Cfam 287 T H P F L Y L S L E I S P Q N V D V N V H P T K H E V H F L H E D S I L E R V Q Q H I E S K L L G S
Mdom 287 S H P F L Y L S L E I A P Q N V D V N V H P T K H E V H F L H E D S I L E R V Q Q H I E G R L L G A
Ggal 287 T H P F L Y L S L E I A P K N V D V N V H P T K H E V H F L H E D S I L E R V Q Q H V E S K L L G S
Xlae 284 T H P F L Y L S L D I A P Q N V D V N V H P T K H E V H F L H E D S I I E R V Q Q H I E S K L L G S
Drer 284 T H P F L Y L S L E I A P Q N I D V N V H P T K H E V H F L H E D S I I E S I Q K H I E N K L L G S
Pmar 286 S H P F L Y I S L E L A P Q N V D V N V H P T K H E V H F L H E D S I T E A V Q Q H V E S K L L G S
Cint 293 S H P F V Y L S L E M P T N N L D V N V H P T K H E V H F L H E D E V V T S V Q K Q V E A S L L S C
Bflo 284 M H P F V Y M S V E I M P S H V D V N V H P T K H E V H F L H E D V I I E A I Q K Q V E T S L L G C
Spur 284 A H P F I Y F S L E I A P H N V D V N V H P T K H E V H F L H E E A I I E D I Q K C L E Q K L L G C
Nvec 293 T H P F V Y M S L Q I T P S N V D V N V H P T K H E V H F L H E D A I V E A V Q K C V E M K L L G C
Tadh 290 T H P F L Y L S L Q I S P R N V D V N M H P T K H E V Q F L H E D K I I D A I Q N V I E N K L L G A
 
Hsap 337 N S S R M Y F T Q T L L P G L A G - P S G E M V K S T T S - - L T S S S T S G S S D K V Y A H Q M V
Mmul 337 N S S R M Y F T Q T L L P G L A G - P S G E M V K S T A S - - L T S S S T S G S S D K V Y A H Q M V
Mmus 337 N S S R M Y F T Q T L L P G L A G - P S G E A A R P T T G - - V A S S S T S G S G D K V Y A Y Q M V
Cfam 337 N S S R M Y F T Q T L L P G L A G - P S G E V V K S T T G - - - A T P S S T G S G D K V Y A H Q M V
Mdom 337 N S S R T Y F T Q T L L P G M A G - P V P E G A K S A V G - - - A S A P P P G P S D R V S A Q H M V
Ggal 337 N S S R M Y F T Q T L L P G A E C - S S S E V V K S A A S - - - S S T A A K G T S D K V Y A H Q M V
Xlae 334 N S S R M Y F T Q T L L P G H S V - C A S G F T K P L P - - - - A S S T S Q K S S E K V Y A H Q M V
Drer 334 N S S R T Y F T Q T L L P G L S A - S A S - V A K - - - - - - - A S S S S A D P Q E R V Y A H Q M V
Pmar 336 N S S R T Y F S Q A L L P N A P L - V G L E S T Q E G G S - - - T R P G P S A A S D R V Y A H Q L V
Cint 343 D S S R T F Y M Q K L L P T N T S K P T G E N T K E S T K D T T H P T K D K Q P P T R V Y D H Q L V
Bflo 334 N S S R T F F T Q A L L P G A I V - P V S E V T - - - - - - - - S S G T S S G T S S K T Y A H Q L V
Spur 334 N S S R T Y F T Q A L L P G S N L - S I A D D E D K - - - - - - S K G Q R S S S T D Q V Y A H H M V
Nvec 343 N T S R T F Y T Q A L L P G V A G - T K S S E S - - - - - - - - A D V A G K S S S A N V Y A H Q M V
Tadh 340 N S S R T F L A Q T F L P T T S G - P T T K T K V I Q D N A E V P I S S G S I S Q K K A Y A H Q L V
 
Hsap 384 R T D S R E Q K L D A F L Q P L S K P L S S Q P Q A I V T - - E D K T D I S S G R A R Q Q D E E M L
Mmul 384 R T D S R E Q K L D A F L Q P L S K P L S S Q T Q A I V P - - E D K T D I S S G R A R Q Q D E E M L
Mmus 384 R T D S R D Q K L D A F L Q P V S S L V P S Q P Q D P A P V R G A R T E G S P E R A T R E D E E M L
Cfam 383 R T D S R E Q K L D A F L Q P M S K A L S S Q L Q A V V P - - E D R T D V S S G R T G Q Q D E E M F
Mdom 383 R T D S R E Q K L D A F L Q P V S R S S V E R P E G - - - - - - - R T A - - - A G A G Q P D E E M E
Ggal 383 R T D S R E Q K L D A F L Q P V N N P L S A G P T E E T T - - G D K V G P P E G T V R P Q D A E M E
Xlae 379 R T D S R E Q K L D A F L Q P L N R Q Q L S F S G C Q T P - - E N A E G Q K H N R V P S E D T K V A
Drer 375 R T D S K A Q K L D A F L Q P S A S S S S S A A Q R K T - - - - - - E K T S S T S T A V Q D S V E L
Pmar 382 R K D A R D Q K I N I F L Q P Q A R A Q V G L P P A R Q X X X X X X X X X X X X X X X X X X X X X X
Cint 393 R T D S K L Q K L D S F L L K S K N K X X X X X X X - - - - - - - - X X X X X X X X X X X X X X X X
Bflo 375 R T D H R D Q K L E A F L K K P E D P I I S S P S V S - - - - - - - - - - A K T S V A E V D S A I P
Spur 377 R T D S K D Q K L D A F L Q V T P S G T K D K S S S - - - - - - - - - - - S S S S R Y Q R D V G V V
Nvec 384 R T D S R E Q T L H A F I K P D G K S V A N R N S S - - - - - G D D A P S I S P T N K R S N E G S G
Tadh 389 R T D H L S Q K L E I F L E P K N P T S N T S H - - - - - - - - - - - - - S S S C S H E L E K E R P
 
Hsap 432 E L P A P A E V A A K N Q - S L E G D T T K G T S E M S E K R G P T S - S - - N P R K R H R E D - -
Mmul 432 E L P S P A E V A A K N Q - S L E G D T T K G T S E M S E K R G P T S - S - - N P R K R H R E D - -
Mmus 434 A L P A P A E A A A E S E - N L E R E S L M E T S D A A Q K A A P T S - S P G S S R K R H R E D - -
Cfam 431 E L P E P D Q V A A T N Q - G M E E E T T E G T S E T S E K K G P P S - S P G N P R K R P R E S - -
Mdom 423 E L P E P A A G A P R P - - - - - - - - - P E G L E Q G E - R P P P - - E A A C P K K R P R E D - -
Ggal 431 D V S E L L E T A D L I E - M A D V Q Q D A V M P G G P S K S G H L S P E K A L P R K R P R E D - -
Xlae 427 E - P S D L E I L D V L E A T A N S E S Y V L K Q K K T D D S - - P N - N I E Q P R K R P R R V - -
Drer 419 D D A E L L T A A D V E - P C G G - - - - - - - E D P Q T D A Q P P G - D E A P P R K R P H V E - -
Pmar 432 X X X X X X X X X X X X X - X X X X X X X X X X X X X X X X X X X X X - X - - X X X K R P R T D A D
Cint 435 X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X - -
Bflo 415 S T S T T T D A - - - - - - - - - D A - T D V P M A T - - - - - - E - - E H K K Q K K R P R E E - -
Spur 416 E I L A P A E G M D T D D - G - - - Q T L P R Y L K K N R K T G P C F - - - F L C R K R P R S E - -
Nvec 429 T D P K V I D K E T F Q A - Q Y R K P N S V E P S I S - - - - - - - - - - - - - E N K R A K - - - -
Tadh 426 A I K E K L T E - S E V T N A P - - - - - E E V I I D - - - - - - - - - - - - - D N S V A E D I - -
 
Hsap 476 - - - - - - - - - - - - - S D V E - - - - - - - - - - M V E D - D S R K E M T A A C T P R R R I I N
Mmul 476 - - - - - - - - - - - - - S D V E - - - - - - - - - - M V E D - D S R K E M T A A C T P R R R I I N
Mmus 480 - - - - - - - - - - - - - S D V E - - - - - - - - - - M V E N - A S G K E M T A A C Y P R R R I I N
Cfam 477 - - - - - - - - - - - - - S D V E - - - - - - - - - - M V E D - D S R K D M T A A C T P R R R I I N
Mdom 459 - - - - - - - - - - - - - S D V E - - - - - - - - - - M R E D - - - - - E M T A A C C P R R R V V K
Ggal 478 - - - - - - - - - - - - - T D I Q - - - - - - - - - - M - E E - D N R K E M T A A C T P K R R I I N
Xlae 471 - - - - - - - - - - - - - S D V E - - - - - - - - - - M L E D V G S V K T L T A A S T P R R R I I N
Drer 458 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - E V K E D L T A A S L P R R R I V K
Pmar 478 G A M G C E A E A F A G G S R V E E A E A A A A A E E G M E E - E - Q E P L M A A A L P K R R V F S
Cint 483 - - - - - - - - - - - X X X X X X - - - - - P - - - - S T P D D I E S H D K T S A G L P R K R E I R
Bflo 445 - - - - - - - - - - - - - - - - - - - - - - - - - - - R I E E E S E - E A I I G N K S P Q R R P I T
Spur 457 - - - - - - - - - - - V S S D T E G P S S R P - - - - G P S D - E D Q E L V S R Q P K P K R K E I Q
Nvec 461 - - - - - - - - - - - - - - - - - - - - - - - - - - - L V E E - S N S F K R Q K L N Q F P R R E V Q
Tadh 455 - - - - - - - - - - - - - A - I - - - - - - - - - - - - - - - - - H S Q Q G E K R K L T K Q R E L K
 
Hsap 502 L T S V L S L Q E E I N E Q G H E V L R E M L H N H S F V G C V N P Q W A L A Q H Q T K L Y L L N T
Mmul 502 L T S V L S L Q E E I N E R G H E V L R E M L H N H S F V G C V N P Q W A L A Q H Q T K L Y L L N T
Mmus 506 L T S V L S L Q E E I S E R C H E T L R E I L R N H S F V G C V N P Q W A L A Q H Q T K L Y L L N T
Cfam 503 L T S V L S L Q E E I N E R G H E T L R E M L H N H S F V G C V N P Q W A L A Q H Q T K L Y L L N T
Mdom 481 L T S V L T L Q D E I S E R G H E A L R E M L R D H S F V G C V S P Q W A L A Q Y Q T R L Y L L N T
Ggal 503 L T S V L T L Q E E I S N Q S H E S L Q E M L R D H S F V G C V S P Q W A L V Q H R T K L Y L L N T
Xlae 498 L T S I L S L Q K E I E E C G H T S L Q D M L L N H S F V G C V N P Q W A L A Q F Q T K L Y L L N T
Drer 476 L T S I K G L R D Q I E L Q T H K G L Q E L L Q N H S F V G S V S P Q W T L V Q H Q T K L Y L L N T
477
288
503
338
385
433
Pmar 526 F V S I L A L Q S E I T S S K H D G L H E V M K N H T F V G C V D P T W A L L Q H Q T R L Y L V N T
Cint 513 L T S V L Q L Q D E V K Q K S N K D L C L V L H D H T F V G C V E P E L A L I Q H Q T K L H L V N T
Bflo 467 L T S V L T L H Q E I K D N M H T G L R E M V T Q L K F V G C V D P T R A L V Q H Q T K L Y L V S T
Spur 491 L T S V L E L Q K E I E D D A H E D L R D L L K Q H T F V G T V D A E Y A L I Q H K T K L Y L V N T
Nvec 483 L I S V Q K L R E K I D K A E H R G L K D L F E E H K F V G C V T P S Q A L V Q H N T K L Y L A N I
Tadh 474 L T S V Q N L R N A V E E N V A E E L Q A M V R G M Q F V G C V T E S H A A F Q F E T G L Y L G N T
 
Hsap 552 T K L S E E L F Y Q I L I Y D F A N F G V L R L S E P A P L F D L A M L A L D S P E S G W T E E D G
Mmul 552 T K L S E E L F Y Q I L I Y D F A N F G V L R L S E P A P L F D L A M L A L D S P E S G W T E E D G
Mmus 556 T K L S E E L F Y Q I L I Y D F A N F G V L R L S E P A P L F D L A M L A L D S P E S G W T E D D G
Cfam 553 T K L S E E L F Y Q I L I Y D F A N F G V L R L S E P A P L F E L A M L A L D S P E S G W T E E D G
Mdom 531 T C L S E E L F Y Q I L I C D F A N F G I L R L S E P A P L Y D L A M L A L D H P E S G W T E E D G
Ggal 553 T K L S Q E L F Y Q I L I Y D F A N F G V L R L S E P A P L Y E L A M L A L E D P E S G W T E E D G
Xlae 548 T K L S Q E L F Y Q I L I Y D F G N F G V M K L S E P A P L Y D L A M L A L D N K E S G W T E E D G
Drer 526 T K L S Q E L F Y Q I L I Y D F G N F G V L R L S N P A P L Y D L A M L A L D S E E S G W T E E D G
Pmar 576 T K L S Q E L F Y Q I L I Q D F G N F G V L R L S T P A P L Y Q I I M M A L E D P D S G W T E E D G
Cint 563 G R L S E Q L F Y Q I L L Q D F G N F A I F R L T E A A P I Y E L A M L G L N S E E S G W T P A D G
Bflo 517 R R L S Q E L F Y Q L A L F D F G N F G M L R L S E P A P I G E L A M L A L D S E E S G W T E E D G
Spur 541 L K L S Q E L F Y Q L T L Y D F G N F G L M K L S N P A P I F E L A M I A L D S A E S G W S E S D G
Nvec 533 H S L S R E L F Y Q I I M F Q F G D F G F L R L S E S A P L Y E L A L L A L E S P E S G W T P A D G
Tadh 524 T N L S K E L F Y Q S I I F N F G N F E K F R L S S P A S L Y D L A M L A L D S E D S G W T E E D G
 
Hsap 602 P K E G L A E Y I V E F L K K K A E M L A D Y F S L E I D E E G N L I G L P L L I D N Y V P P L E G
Mmul 602 P K E G L A E Y I V E F L K K K A E M L A D Y F S L E I D E E G N L I G L P L L I D N Y V P P L E G
Mmus 606 P K E G L A E Y I V E F L K K K A E M L A D Y F S V E I D E E G N L I G L P L L I D S Y V P P L E G
Cfam 603 P K E G L A E Y I V E F L K K K A E M L A D Y F S L E I D E E G N L I G L P L L I D N Y V P P L E G
Mdom 581 P K E G L A E Y I V E F L K R K A E M L A D Y F S L E I D E E G N V T G L P L L L D N Y V P Q L E G
Ggal 603 P K E G L A E Y I V E F L K K K T E M L K D Y F S L E I D E E G N L T G L P L L I D N Y I P L L E G
Xlae 598 P K E G L A E Y I V Q F L K K K T E M L A D Y Y S L E I D Q E G N L I G L P L L L D N Y I P P M E G
Drer 576 P K E G L A Q Y I V D F L K Q K A E M L E E Y F S L E I D A E G N L T G L P M L L D N Y T P A M E G
Pmar 626 P R E E L A E H A A A F L N Q R A E M L Q D Y F S L E I D Q D G N L S G L P L L L D N Y I P A M E G
Cint 613 S K E K L A K Y V V N F L V E K A E M L S D Y F C L D I T K D G M I S G I P M L L K Q Y N P P L H G
Bflo 567 S K E E L S Q Y I V T F L Q Q K A P M L L D Y F S L Q I D S D G N L C T L P L L L D N Y I P P L E G
Spur 591 P K D Q L A Q Y I V D F L K S K A D M L N D Y F S I V I D E E G N L C S I P L I L D K Y I P A M E G
Nvec 583 A K E D L A Q Y I K D F L M Q K A E M L L D Y F S L E I D G E G N L L S L P L L L E E Y V P N L N G
Tadh 574 S K E D L A Q H V S E F L Q M K G E M M T D Y F S L E I D K - G C I K T L P M L L D G Y E P D L L G
 
Hsap 652 L P I F I L R L A T E V N W D E E K E C F E S L S K E C A M F Y S I R K Q Y I S E E S T L S G Q Q S
Mmul 652 L P I F I L R L A T E V N W D E E K E C F E S L S K E C A M F Y S I R K Q Y I S E E S T L S G Q Q S
Mmus 656 L P I F I L R L A T E V N W D E E K E C F E S L S K E C A M F Y S I R K Q Y I L E E S T L S G Q Q S
Cfam 653 L P I F I L R L A T E V N W D E E K E C F E S L S K E C A M F Y S I R K Q Y I S E E S T L S G Q Q S
Mdom 631 L P M F V L R L A T E V N W D E E K E C F Q S L S K E C A R F Y A I R K Q Y V A E E D H E V S D Q K
Ggal 653 L P M F I L R L A T E V N W D E E K E C F E T L S K E L S M F Y S I R K Q Y I I D E T N L T R S Q N
Xlae 648 L P L F I L R L A T E V N W D D E K E C F A S F S K E C S N F Y S I R K Q Y I L D E S S N N A D N K
Drer 626 L P M F I L R L A T E V N W D K E K E C F R E F S V E C S H F Y S I R K S Y T L E A D A D E P Q D -
Pmar 676 L P L F M L R L T T E V N W E E E K E C F E S F S R E C S A F Y S V R K E F T L E E T T A E T E P S
Cint 663 L P T F V M R L A T E V D W E S E K S C F D T V C K E I A R F Y A V K N N F T D S D I F S E E P V V
Bflo 617 L P M F V L R L A T E V D W D N E K E C F Q S F A R E C G L F Y A I R - - - - - - - S S L A S T S E
Spur 641 L P M F I L R L A T E V D W D S E R D C F Q T F A K E C S L F Y R I Q K N S K L T D T R G E N D A A
Nvec 633 L P M F V L R L A T E V E W D S E L E C F D T F A K E C S R F F S F K P D V N P D D D L D Q N E A S
Tadh 623 L P M F A L R L A T E V N W D H E E S C F K T F A I E C S R F Y A M R K G H D L L L Q C S E K N Q V
 
Hsap 702 E V P - - - - - G S I P N S - W K W T V E H I V Y K A L R S H I L P P K H F T E D G N I L Q L A N L
Mmul 702 E V P - - - - - G S I P N S - W K W T V E H I V Y K A L R S H I L P P K H F T E D G N I L Q L A N L
Mmus 706 D M P - - - - - G S T S K P - W K W T V E H I I Y K A F R S H L L P P K H F T E D G N V L Q L A N L
Cfam 703 E V C - - - - - G S S A N P - W K W T V E H I V Y K A F R S H L L P P K H F T E D G N I L Q L A N L
Mdom 681 E E C - - - - - E S S P V S - W K W T V E H I L Y K A F R S H L F P P T H F S E D G N I L Q L A N L
Ggal 703 E D S - - - - - D S G P P P - W K W T V E H V V Y K A F R T H L L P P K H F T D D G N I L Q L A N L
Xlae 698 S L - - - - - - - T G S S S - W R W T T E H I L Y K A F R T H L L P P K P F T E D G S I L Q I A N L
Drer 675 - - - - - - - - - - A E M S - W Q W K V E H V L F K A L R S L F S P A K H L S E D G S V L Q I A S L
Pmar 726 Q E P - - - - - S S T G S P H W K W T V E H C V F K A L R S V L L P P R Q F A E D G T L L Q I A N L
Cint 713 V E T - - - - - D S E W S P - W K Q M V E H V V F R A L R D V I V - P M T M G E D G T F L Q L A N L
Bflo 660 D - - - - - - - - - - S K S - W K W T V E H A L F P A F R A S L L P P K M F A E D R S V L Q I A N L
Spur 691 S G A - - - - - D M P S Y N - W K W T I E F V I F P A L K S T L L P P K R F A G D A S I L Q V A N L
Nvec 683 S S D C K R P G T S P D V P - W K W S V E H V L F P A F R S G L V P P T R F A E D G T L L Q I A N L
Tadh 673 F Q - - - - - - V D K R K M - W K W K V E H L L Y P A F K S S L F L P K R F Q D D G T I L K I A D L
 
Hsap 746 P D L Y K V F E R C
Mmul 746 P D L Y K V F E R C
Mmus 750 P D L Y K V F E R C
Cfam 747 P D L Y K V F E R C
Mdom 725 P D L Y K V F E R C
Ggal 747 P D L Y K V F E R C
Xlae 740 P D L Y K V F E R C
Drer 714 P D L Y K V F E R C
Pmar 771 T D L Y R V F E R C
Cint 756 P D L Y K V F E R C
Bflo 699 P D L Y K V F E R C
Spur 735 P D L Y K V F E R C
Nvec 732 T E L Y K V F E R C
Tadh 716 K E L Y K V F E R C
747
553
603
653
703
MSH2
Hsap 0 M A - V Q - P K E T L Q L E S A - A E V G F V R F F Q G M P E K P T T T V R L F D R G D F Y T A H G
Caet 0 M A - V Q - P K E T L Q L E S A - A E V G F V R F F Q S M P E K P T T T V R L F D R G D F Y T A H G
Mmus 0 M A - V Q - P K E T L Q L E G A - A E A G F V R F F E G M P E K P S T T V R L F D R G D F Y T A H G
Btau 0 M A - V Q - P K D T L Q L D S A - A E V G F V R F F Q G M P E K P T T T V R L F D R G D F Y T A H R
Mdom 0 M A - V Q - P K E V L A M D S Q - A E C S F V R F F Q A L P A K P L T T V R L F D R G D Y Y T A H G
Ggal 0 M A - A E A P R E A V W P E G A G A E A G F V R A V L S L L E K P D T T V R F F E R G D Y Y S V H G
Xlae 0 M A - V Q - P K E K L S M D S G - A E N G F L H F Y Q S M P E K P D T T V R V F D R N D Y Y T V H G
Drer 0 M A - V Q - P K Q N L S M D S A - S E H G F L N F Y F S M S D K P D T T V R V F D R N D Y Y T V H G
Pmar 0 M A A V Q - A K E Q L S L E P A - Q E N G F V S F F A S M S E K A E A T V R L F D R A D F Y T V H G
Cint 0 M A N L Q - A K A K W S I D - - - D Q V G F F K F R D S L P E R A D A T Y R V F D H G E F Y S S H S
Bflo 0 M A - V T - P N Q Q L Q L D N A - Q E L G F L N F V R T M P E K P A T T F R A F D R T E Y Y T A H G
Spur 0 X X - X X - X X X X X X X X X X - X X X X X X X X X X X X X X X X X X X X X X X X X X D Y Y T V H G
Nvec 0 X X - X X - X X X X X X X X X X - X X X X X X X X X X X X X X X X X X X X X X X X X X D Y Y T V H G
Tadh 0 M A - S S - S T Q Q L T L D G T - N Q N G F R R F L D S L P E K L E T T I R I F D R S D W F T V H G
 
Hsap 47 E D A L L A A R E V F K T Q G V I K Y M - G P A G A K N L Q S V V L S K M N F E S F V K D L L L V R
Caet 47 E D A L L A A R E V F K T Q G V I K Y M - G P A G A K N L Q S V V L S K M N F E S F V K D L L L V R
Mmus 47 E D A L L A A R E V F K T Q G V I K Y M - G P A G S K T L Q S V V L S K M N F E S F V K D L L L V R
Btau 47 E D A L L A A R E V F K T Q G V V K Y M - G P A G A K T L E S V V L S K M N F E S F V K D L L L V R
Mdom 47 E D A L L A A R E V F K T Q A V I K Y I - G L T G S K K L E S V V L S K M N F E S F S K D L L L V R
Ggal 49 A D A R L A A R E L F R T R A V I R Q L A G A P G N Q K L E S V V L S K M N F E S F V R D L L L V R
Xlae 47 G D A L F A A K E V F K T N G V I K Y L - G - S G N K K L E S V V L S K M N F E S V V K D L L L V R
Drer 47 K D A I F A A K E V F K T N G V I K N L - G - S G N R R L E S V V L S K M N F E S F V R D L L L V R
Pmar 48 R D A L L V S R D V F K T T A V V K M L - G - T G S R K L E S V V L S K M N F E S V V R D L L L V R
Cint 46 K D A D L A A K H T F K S S T A V K E L - G - K K D A K V P T V F L S Q L N F E S L A R D L L L V M
Bflo 47 P D A I F A A K E I F K T M G I T G V F L P - V G P N K M E Y V N L S K M N F E S L V R E L L L V R
Spur 47 Q D A V F A A R E V F K T L G V I K H L - G - S G A N K T E S V V L S K M N F E S V V R D L L L V R
Nvec 47 P D A L F A A K E V F K T S S V V K Y L - G - T G D H K V P S V V L S K M N F E S T C R D L L L I R
Tadh 47 S D A I F V A N N I F R S K S V I R Y Y - R - N G N E K L E Y V V L N N A N Y E K V L R D L L L V R
 
Hsap 96 Q Y R V E V Y K N R A G N K A S K E N D W Y L A Y K A S P G N L S Q F E D I L F G N N D M - - S A S
Caet 96 Q Y R V E V Y K N R A G N K A S K E N D W Y L A Y K A S P G N L S Q F E D I L F G N N D M - - S A S
Mmus 96 Q Y R V E V Y K N K A G N K A S K E N E W Y L A F K A S P G N L S Q F E D I L F G N N D M - - S A S
Btau 96 Q Y R V E V Y K N R A G N K A S K E N D W Y L A F K A S P G N L S Q F E D I L F G N N D M - - S A S
Mdom 96 Q Y R V E V Y K N K A G N K A T K E N D W H V A F K A S P G N L S Q F E E I L F G N N D M - - S C S
Ggal 99 H Y R V E V Y K N K A G S K S V K E N D W Y L A Y K G S P G N L A Q F E E V L F A N N D M - - S M A
Xlae 95 Q Y R V E V Y K N K S G G K Y S K E N D W Q L A F K A S P G N L T Q F E E I L F G N N D M - - S T A
Drer 95 Q Y R V E V Y K N - A S - K S S K E H D W Q I A F K A S P G N L T Q F E E I L F G S G G G P A E G A
Pmar 96 Q Y R V E V Y R N R A G - K A S R D N D W Q L A Y K A S P G N L A Q F E D I L F G N V D M - - S A S
Cint 94 Q Y R L E V Y R Q S S N R K - - - - - - W E L A Y K A S P G N L N E V E D I L F K N V D I G D Q T S
Bflo 96 Q Y R L E V Y K N K G T A K - - - N N D W E L D I K A S P G N L T Q V E D F I F G S S G - - A V T S
Spur 95 Q Y R V E V Y S N Q A T G K A - - - N N W T L A Y K A S P G N L T Q F E E I L F G N N D M - - S S S
Nvec 95 Q Y R I E M Y R S K G G - K N S - - S A W E L V A K G S P G N L Q Q F E D I L F G N S E M - - S A S
Tadh 95 Q Y R I E L Y K N K G T - K T - - N Q Q W Y L A E K A T P G N L R C F E E I I F G N N E M - - S E S
 
Hsap 144 I G V V G V K M S A - - - - - - - - - - - - - - - - - - V D G Q R Q V G V G Y V D S I Q R K L G L C
Caet 144 I G V V G V K M S T - - - - - - - - - - - - - - - - - - V D G Q R Q V G V G Y V D S T Q R K L G L C
Mmus 144 V G V M G I K M A V - - - - - - - - - - - - - - - - - - V D G Q R H V G V G Y V D S T Q R K L G L C
Btau 144 I G V V G V K M S T - - - - - - - - - - - - - - - - - - V D G Q R Q V G V G Y V D S T Q R K L G L C
Mdom 144 I G G V G V K L S I - - - - - - - - - - - - - - - - - - V D G Q R L V G V G Y V D S I Q R K L G L C
Ggal 147 I G V V G V K L S S - - - - - - - - - - - - - - - - - - A D G Q R V I G V G Y V D T T L R K L S V C
Xlae 143 V G V V G I K L V S - - - - - - - - - - - - - - - - - - S E G Q R L V G V G Y V D S T L R K L G V C
Drer 143 V G V V G V R L G T - - - - - - - - - - - - - - - - - G T D G Q R V V G V G Y V D S T L R K L G V C
Pmar 143 A G V V A I K L G L A C G V G P G G T A A A A G G S G G A D A Q R V V G V G F A D T T L R R L C V C
Cint 138 S A V I S V K Y T L - - - - - - - - - - - - - - - - - A A G G Q S T V G L A Y V D T R S C E V M Y A
Bflo 141 S G V L A V K L S G - - - - - - - - - - - - - - - - - - E G N N K V V G A G Y A D A T M R K L G V C
Spur 140 A S V M A V K V T G - - - - - - - - - - - - - - - - - - E S G Q R L V G V G Y A D A T L R E L G V S
Nvec 140 A V V M A I K L G T - - - - - - - - - - - - - - - - - - V T G Q R V V G V A Y A D V A S R K L G V C
Tadh 140 A P V I A I R L V V - - - - - - - - - - - - - - - - - - E N G Q R I I G V A Y A D A T L Y N L G I S
 
Hsap 176 E F P D N D Q F S N L E A L L I Q I G P K E C V L P - G G E - T A G D M G K L R Q I I Q R G G I L I
Caet 176 E F P D N D Q F S N L E A L L I Q I G P K E C V L P - G G E - T A G D M G K L R Q I I Q R G G I L I
Mmus 176 E F P E N D Q F S N L E A L L I Q I G P K E C V L P - G G E - T T G D M G K L R Q V I Q R G G I L I
Btau 176 E F P D N D Q F S N L E A L L I Q I G P K E C V M P - G G E - T A G D M G K L R Q V I Q R G G I L I
Mdom 176 E F P D N D Q F S N L E A L L I Q I G P K E C V L P - G G E - T A G D M G K L R Q V I E R G G I L I
Ggal 179 E F P D N D Q F S N L E A L L V Q L G P K E C V L P - G G D - T A G E M G K L R Q V V Q R G G I L I
Xlae 175 E F P D N D Q F S N L E A L L V Q I G P K E C V M P - G G E - T A G D M G K L R Q I V K R G G I L I
Drer 176 E F P D N D Q F S N L E A L L V Q I G P K E C V L P - A G D - S G G D Q G K L K Q V V Q R G G I L L
Pmar 193 E F P D N D Q F S N L E A L L V Q L G P K E C V L P - A G E - V Q A D A G K L R Q X X X X X X X X X
Cint 171 E F S D N D H F S N L E S A I I Q L G P K E C I V P - K L D - T S H E A S K L S E V I K R S G L L I
Bflo 173 E F V D N D Q F S N L E A L V I Q T G P K E C L I P - A G E - N T P D M G R L R M V L E R N G L L I
Spur 172 E F A D N D Q F S N L E A L M V Q L G P R E C L L P S G G D P N N P E F S K L R Q V V Q R G G V L I
Nvec 172 E F A D N D Q F S N L E A L I V Q L G P K E C L M A - S T D - S S G D A A K T H E V V K R S N I L V
Tadh 172 Q F E D N D L M T N L E A L M V Q I G P K E C I L V - S G E - T S V D A V K L R Q V I N K T G V L V
 
Hsap 224 T E R K K A D F S T K D I Y Q D L N R L L K G K K - - - - G E Q M N S A V L P E M E N Q V A V S S L
Caet 224 T E R K K A D F S T K D I Y Q D L N R L L K G K K - - - - G E Q M N S A V L P E M E N Q V A V S S L
Mmus 224 T E R K R A D F S T K D I Y Q D L N R L L K G K K - - - - G E Q I N S A A L P E M E N Q V A V S S L
Btau 224 T E R K R A D F S T K D I Y Q D L N R L L K G K K - - - - G E Q V N S A V L P E M E N Q V A V S S L
Mdom 224 T E R K K V D F A A K D I V Q D L N R L L K S K K - - - - G D Q V N S A V L P E M E N Q V A I S S L
Ggal 227 T D R K K A D F T T K D I V Q D L N R L L K S R K - - - - G E Q M N S A A L P E M E K Q V A V S S L
Xlae 223 T D R K R A E F S T K D S V Q D L N R L L K A K K - - - - G E Q V T S A A L P E M E K Q V A M S A L
Drer 224 T D R K K S E F T T K D I V Q D L N R L L K A R K - - - - G E T V S S A A L P E M E K K I A M S C L
Pmar 241 X X X X X X X X X X X X X X X X X X X X X X X X X - - - - X X X X X X X X X X X X X X X V A M S S L
Cint 219 T E R P K S N F S T K D L A Q D L K R L I K T K K K Q S D Q D E V P V G A S W T S D H P L A S S S L
Bflo 221 T E R R K A E Y S T K D N V Q D L N R L L K P K T K - - - G E Q V N S A A L P E I E K T A A M A S V
177
225
1
48
97
145
Spur 222 T D R K K V D F T T K D I I Q D L N R L L K V G R N - - - V E Q V N S A A L P E M E K T N A M G S V
Nvec 220 T E R K K V E F S N K D I V Q D L N R L L K L T A - - - - G - - G N S A T L P E M D M I H A T A A L
Tadh 220 T E R K K S D F N D K D I V Q D L N R L L R I K S - - - - G - - - N A A T L A E I D Q Q V A M S C V
 
Hsap 270 S A V I K F L E L L S D D S N F G Q F E L T T F D F S Q Y M K L D I A A V R A L N L F Q - - - - - G
Caet 270 S A V I K F L E L L S D D S N F G Q F E L T T F D F S Q Y M K L D I A A V R A L N L F Q - - - - - G
Mmus 270 S A V I K F L E L L S D D S N F G Q F E L A T F D F S Q Y M K L D M A A V R A L N L F Q - - - - - G
Btau 270 S A V I K F L E L L S D D S N F G Q F E L T T F D F S Q Y M K L D I A A V R A L N L F Q - - - - - G
Mdom 270 S A V I K Y L E L L S D D S N F G Q F E L T T F D L S Q Y M K L D N A A V R A L N L F Q - - - - - G
Ggal 273 S A V I K F L E L L S D D S N F G Q Y E L T T F D L S Q Y M V L D N A A V Q A L N L F Q - - - - - S
Xlae 269 A A V M K Y L E L L S D E S N F G Q F V M T N F D L S Q Y M K L D N A A V G A L N L F P - - - - - G
Drer 270 E A V I K Y L E L L A D E A N F G S F K M T T F D L N Q Y M R L D N A A V Q A L N L F Q - - - - - G
Pmar 287 A A L V K Y L E L T S D E S G F G Q F E L S T F D L G Q Y V R L D S A A V R A L N L F Q - - - - - G
Cint 269 S S L I R Y L E L M S K E E N F G E F R I R K F E L S Q Y M K L D S A A Y S A L N L F P E R T A Q G
Bflo 268 S A L I K Y L E L L G D E T N F G Q F K L E T F D L N Q Y M R L D A A A V R A L N L L P - - - - - T
Spur 269 S A L I K Y M E L L G D E T N F G Q F K L T T F D L S Q Y M K L D A A A V R A L N L T S T - - - - G
Nvec 264 A A V I K Y L E L L S D E S N F S Q F K L S S F D L S Q Y M K L D A A A V R A L N L L P - - - - - N
Tadh 263 T A L I K Y L E L L S N V S N F N Q F D L V T F D L S Q F M K L D S A A V R A L N L F P - - - - - S
 
Hsap 315 S V E D T T G S Q S L A A L L N K C K T P Q G Q R L V N Q W I K Q P L M D K N R I E E R L N L V E A
Caet 315 S V E D T T G S Q S L A A L L N K C K T P Q G Q R L V N Q W I K Q P L M D K N R I E E R L N L V E A
Mmus 315 S V E D T T G S Q S L A A L L N K C K T A Q G Q R L V N Q W I K Q P L M D R N R I E E R L N L V E A
Btau 315 S V E D T S G S Q S L A A L L N K C K T P Q G Q R L V N Q W I K Q P L M D K N R I E E R L N L V E A
Mdom 315 S A E D K S G T Q S L A A L L N K C K T P Q G Q R L L N Q W I K Q P L L D K N R I E E R L N L V E A
Ggal 318 S V E N A N N T Q S L A G L L N K C R T P Q G Q R L V N Q W I K Q P L M D K N R I E E R L N L V E A
Xlae 314 S A E D T S G T Q S L A G L L N K C K T P Q G Q R L V N Q W I K Q P L M D K N R V E E R L N L V E A
Drer 315 S S D D A T G T H S L A G L L N K C R T P Q G Q R L V N Q W I K Q P L I D K N K I E E R L D L V E T
Pmar 332 S S D E G G R T Q S L F G L L N R C R T A Q G Q R L L A Q W I K Q P L L D Q N R I E E X X X X X X X
Cint 319 V A Q N S K P V D S L Y G L L N Y C Q T V Q G Q R L L S R W I K Q P L I D V N I L E E R L S I V E A
Bflo 313 S L D G G N R F Q S V A G L L T H C R T S Q G H R L L T Q W V K Q P L M D K N R I E E R L N V V E A
Spur 315 P E K D I N G G M S L T S L L N K C K T A Q G Q R L L G Q W V K Q P L L D K - - I E E R L D M V E T
Nvec 309 P M D G G N K S M C L T G L L N K C K T P Q G Q R L V A Q W I K Q P L M D K N K I E E R L N I V E A
Tadh 308 P S D A G N K L R C L M G V L N Y C K T A P G Q R L L A Q W L K Q P L M D I A K I E E R L N L V D V
 
Hsap 365 F V E D A E L R Q T L Q E D L L R R F P D L N R L A K K F Q R Q A A N L Q - D C Y R L Y Q G I N Q L
Caet 365 F V E D A E L R Q T L Q E D L L R R F P D L N R L A K K F Q R Q A A N L Q - D C Y R L Y Q G I N Q L
Mmus 365 F V E D S E L R Q S L Q E D L L R R F P D L N R L A K K F Q R Q A A N L Q - D C Y R L Y Q G I N Q L
Btau 365 F V E D A E L R Q N L Q E D L L R R F P D L N R L A K K F Q R Q A A N L Q - D C Y R L Y Q G I N Q L
Mdom 365 F V V D A E L R Q S L Q E D L L R R F P D L H R F A K K F Q R H A A N L Q - D C Y R M Y Q A I N Q L
Ggal 368 F V V D T E L R Q G L Q E D L L R R F P D L N R L A K K F Q R Q A A T L Q - D C Y R M Y Q A I N Q L
Xlae 364 F V M D V E L R Q C L Q E D L L R R F P D L N R L A K K F Q R Q T A N L Q - D C Y R L Y Q A V N H L
Drer 365 F V E D S E L R K S C Q E D L L R R F P D L N R M A K K F Q R Q S S N L Q - D C Y R V Y Q S V G Q L
Pmar 382 X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X - X X X X X X X X X X X X
Cint 369 F V D C S E L R R S L V D E H L K K L P D F D R L S K K F H R K K A T L Q - D S Y R V Y Q A I K Q M
Bflo 363 L V E D A E L R Q T L Q E E Q L R K V P D F H R L A K K F Q R K R A N L Q Q D C Y R V Y Q A L N I I
Spur 363 F F N D L E L R Q T L Q E E P L K R V P D F Q R L A K K F Q R K R A T L Q - D C Y K V Y Q A V D Y L
Nvec 359 F V E D T E L R Q T L Q D E - M K K F P D F S R L A K K F Q R Q K A T L Q - D C V R V Y Q S V Q R L
Tadh 358 F V D D T E L R Q S V Q E D H L K R F P D L Q R L A K K F Q R S R A N L Q - D C V R V Y Q S I N R V
 
Hsap 414 P N V I Q A L E K H E G K - - - H Q K L L L A V F V T P L T D L R S D F S K F Q E M I E T T L D M D
Caet 414 P N V I Q A L E K H E G K - - - H Q K L L L A V F V T P L T D L R S D F S K F Q E M I E T T L D M D
Mmus 414 P S V I Q A L E K Y E G R - - - H Q A L L L A V F V T P L I D L R S D F S K F Q E M I E T T L D M D
Btau 414 P N V I Q A L E K Y E G K - - - H Q A L F L A V F V T P L I D L R S D F S K F Q E M I E T T L D M D
Mdom 414 P N V I Q A L E K H E G K - - - H Q M L L L A I F V T P L T D L H S D F S K F Q E M I E T T L D M N
Ggal 417 P N V V Q A L E K H E G A - - - H Q M L L L A G F I T P L N D I H S D F S K F L E M I E T T V D M D
Xlae 413 P T V V Q A I E K Y E G T - - - H Q M L L L A V F A T P L S D L S S D F S K F Q E M I E T T L D M D
Drer 414 P N V V L A L E R Y S G K - - - H Q V L L H A A F I S P L N D L I S D F S K F Q E M I E T T L D M N
Pmar 431 X X X X X X X X X X X X P - - - R Q A L L E E L F V Q P L L E L E N D F S K F Q E M I E T T L D M E
Cint 418 P Y V C E S I D R H A E A L E N N Y N L L R E T F L N P I H Q L S L D F E K F T E M L E T T L D F K
Bflo 413 P H L T E A L E K H A G S - - - H R S L L M E L F S N P I K E L L Y D F R K F Q E M V E T T M D M D
Spur 412 P N L I E I L E K H E G D - - - K A H L L R E H F S N P L T E M L M D F S K F Q E M V E T T L D L Q
Nvec 407 E P F A D V L E R Y H G D - - - H R K L L V E C F R D P L M E L V A D F A K F C D L V E T T I D L E
Tadh 407 N C L I K A L V G Y D S A - - - Y K D L I R N M Y S N P L S D L T T D F Q K Y Q E L I E T T V D L D
 
Hsap 461 Q V E N H E F L V K P S F D P N L S E L R E I M N D L E K K M Q S T L I S A A R D L G L D P G K Q I
Caet 461 Q V E N H E F L V K P S F D P N L S E L R E I M N D L E K K M Q S T L I S A A R D L G L D P G K Q I
Mmus 461 Q V E N H E F L V K P S F D P N L S E L R E V M D G L E K K M Q S T L I N A A R G L G L D P G K Q I
Btau 461 Q V E N H E F L V K P S F D P N L S E L R E I M D D L E K K M Q S T L V S A A R D L G L D P G K Q I
Mdom 461 Q V E N H E F L V K A S F D P H L T Q L R E S I D N L E K K M Q S S L T S A A R E L G I E A G K H I
Ggal 464 K V E N H E F L V K A S F D P N L T E L R E K M N E L E E S M Q T L L K S A A K E L G L E A G K S I
Xlae 460 Q V E N H E F L V K A S F D P N L T E L R E K M D E L E K N M Q G A L G G A A R E L G L D A G K S I
Drer 461 Q V E H H E F L V K P S F D P T L S D L R E N M D R L E K A M Q A A L S S A A R E L G L E A A K T V
Pmar 478 Q V E N H E F L V K S T F D P N L E E L R S R M D E L E R D M D K A L S S T A R D L X X X X X X X X
Cint 468 L I E K H E F M V K C D F D P E L K R L R V K M D D I E E E M N E S F T Q A A D Q L G L E K G K T I
Bflo 460 R V D K H E F V I K P D F D D N L K E L R E K M N K L D E D I K S H L N E A A R E L K L E P N K V L
Spur 459 Q V E N H E F L I K P D F D E N L M V L R T K M D E L E D D L K T Q I N R A A R D L G L E A N K T V
Nvec 454 Q V E N H E Y L I K A T F D E G L Q E C R E H M D E I L E K F P V E L N K A G R D L S L E P S K T I
Tadh 454 S V A N H E F V I K P S I D P D L Q G Y R N Q M D D L I E Q I S R L L S L A A R D L G L E A N K S I
 
Hsap 511 K L D S S A Q F G Y Y F R V T C K E E K V L R N N K N F S T V D I Q K N G V K F T N S K L T S L N E
Caet 511 K L D S S T Q F G Y Y F R V T C K E E K V L R N N K N F S T V D I Q K N G V K F T N S K L T S L N E
Mmus 511 K L D S S A Q F G Y Y F R V T C K E E K V L R N N K N F S T V D I Q K N G V K F T N S E L S S L N E
Btau 511 K L D S S T Q F G Y Y F R V T C K E E K V L R N N K N F S T V D I Q K N G V K F T N S K L T S L N E
Mdom 511 K L D S N A Q L G Y Y F R V T C K E E K V L R S N K N F N T L D V Q K N G V K F T N S K L A A F N D
Ggal 514 K L E S N S Q F G H H F R I T C K E E K V L R N N T K F K I T D T Q K N G V K F T N S K L S A I N E
Xlae 510 K L E S N S Q I G H Y F R V T C K E E K A L R N N K K F T T I D I Q K N G V R F T N S K L S S L S E
Drer 511 K L E S N A Q I G Y F F R V T C K E E K S L R N N K K F T T L D V Q K N G V R F T N S K L S S L N E
462
512
271
316
366
415
Pmar 528 X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X S K L S A L N E
Cint 518 K L E L A P Q F G Y V F R V T C K E E K S L R Q N K K F T T L D T N K A G V R F V N T Q L Q Q L S D
Bflo 510 K L E T S T Q L G Y H F R V T L K E E K A L R G N K K Y R T L E T S K N G V K F T D S D L Q R M N E
Spur 509 K L E S N N M L G Y F F R V T R K E E K A L R N N S K Y S T I D T N K N G V R F T N S K L R G L N D
Nvec 504 K L E S N N Q L G Y F F R I T R K E E K V L R N N K R Y S T I E T R K D G V R F T N S A L S Q L N D
Tadh 504 K L E S N S Q F G Y Y F R V T L K E E K A L R S N K R F M M I D T N K H G V R F T N N N L E S L N K
 
Hsap 561 E Y T K N K T E Y E E A Q D A I V K E I V N I S S G Y V E P M Q T L N D V L A Q L D A V V S F A H V
Caet 561 E Y T K N K T E Y E E A Q D A I V K E I V N I S S G Y V E P M Q T L N D V L A Q L D A V V S F A H V
Mmus 561 E Y T K N K G E Y E E A Q D A I V K E I V N I S S G Y V E P M Q T L N D V L A H L D A I V S F A H V
Btau 561 E Y T K N K T E Y E E A Q N A I V K E I V N I S S G Y V E P M Q T L N D V L A Q L D A V V S F A H V
Mdom 561 E Y L K I R D E Y E E A Q D A I V K E I I N I S S G Y V E P M Q T L N D V L A Q L D A V V S F A N V
Ggal 564 E Y I K N R E E Y E E A Q D A I V K E I I N I A S G Y A E P I Q T M N D V I A Q L D A I V S F A H V
Xlae 560 E Y M R N R E E Y E E A Q N A I V K E I I T I S A G Y V D P I Q T L N D V I A Q L D A V V S F A H V
Drer 561 E Y T K S R E E Y E E A Q N A I V K E I I S I A A G Y V D P V Q T L N E V I A Q L D A V L S F A V V
Pmar 578 E Y V R C R D D Y Q E T Q K A I V V E I I N I S A G Y T E P M Q L L S D V V A R L D V L T S L A L V
Cint 568 D Y Q D C R A A Y E A Q Q D A V V M E I M T I A C G Y A E P M R S L G D V I A K L D V L L S F A Q A
Bflo 560 E Y L K S K E A Y A D T Q K A V V D E I L G I A A G Y V E P M G S L S D V I A Q L D A L V S F A C A
Spur 559 E H M A A K E E Y N E T Q K A V V D E I I G I A S G Y V E P M L S M N D I T A Q L D V L V S F A H V
Nvec 554 E F R G Y K D T Y N D V Q G K L A A E V L K I A G G Y S E P M Q G L S D V I A Q I D A L V S F A H V
Tadh 554 S L Q E I K S M Y D G K Q E D F A V E V I N I A S G Y Y E P L Q S L S R I I A H L D V I V S F A H A
 
Hsap 611 S N G A P V P Y V R P A I L E K G - Q G - - R I I L K A S R H A C V E V Q D E I A F I P N D V Y F E
Caet 611 S N G A P V P Y V R P A I L E K G - Q G - - R I I L K A S R H A C V E V Q D E I T F I P N D I Y F E
Mmus 611 S N A A P V P Y V R P V I L E K G - K G - - R I I L K A S R H A C V E V Q D E V A F I P N D V H F E
Btau 611 S D A A P V P Y V R P V I L E K G - R G - - R I T L K A S R H A C V E V Q D E V A F I P N D V H F E
Mdom 611 A N G A P I P Y V R P V I L E K G - Q G - - R I I L K G S R H A C V E V Q D E V A F I P N D I N F E
Ggal 614 S N G A P V P Y V R P V V L E K G - Q G - - R I V L K G A R H P C I E V Q D E V A F I P N D V T F E
Xlae 610 S N S A P V P Y V R P V I L E K G - Q G - - R I V L H S A R H P C I E M Q D D V A F I P N D I T F E
Drer 611 S H A A P V P F I R P K I L E K G - S G - - R L V L K A A R H P C V E A Q D E V A F I P N D V T F I
Pmar 628 S H S A P V A Y V R P R L S P P G - - G - - D L V L K G A R H P C L E A Q D D V A F I P N D V A F H
Cint 618 A V T A P T P Y V R P V L Q P L G - T G S N L I K L D Q C R H P C V E R Q D D V S F I P N D L L L K
Bflo 610 S A N A P I P Y V R P K L T E K G - R G - - G I K L V N A R H P C L E L Q D D V Q F I P N D A S F D
Spur 609 S A G A P I S Y V R P T L H A Q G - E G - - L L H L V Q S R H P C L E M L D D V A F I P N N V T F D
Nvec 604 S A N A P I P Y V R P T I T P K G S E G - - D I I L T G S R H P C L E I Q D N V A F I A N D V T L S
Tadh 604 S T N A P V P Y V R P T I L D T S - D R - - I I E L T E A R H P C L E M Q D D V A F I P N D V K F A
 
Hsap 658 K D K Q M F H I I T G P N M G G K S T Y I R Q T G V I V L M A Q I G C F V P C E S A E V S I V D C I
Caet 658 K D K Q M F H I I T G P N M G G K S T Y I R Q T G V I V L M A Q I G C F V P C E S A E V S I V D C I
Mmus 658 K D K Q M F H I I T G P N M G G K S T Y I R Q T G V I V L M A Q I G C F V P C E S A E V S I V D C I
Btau 658 K D K Q M F H I I T G P N M G G K S T Y I R Q T G V V V L M A Q I G C F V P C E W A E V S I V D C I
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Nvec 136 K A L A L S S T E R - E G L I C C I P S D E E S E A E M E R N A S Q E N D S G D G S T D D E V N T A
Tadh 154 E V M K T P A D Q R - E K Y L A T - W S E D F A D S D S D - - A E C L M A M D - - - - - - - - - - -
 
Hsap 230 V Q P K T Q G S R R S S - - - - - - R Q I K K - R R V I S - D S E S D I G G S D V E F K P D T K E E
Mmul 230 V Q P K T Q G S R R S S - - - - - - R Q I K K - R R V I S - D S E S D I G G S D V E F K P D T K E E
Mmus 230 A Q P S V Q G P R R S S - - - - - - R Q V K K - R R V I S - D S E S D I G G S D V E F K P D T K Q E
Btau 229 V R P K V Q G S R R S S - - - - - - R Q I K K - R R V I S - D S E S D V G G S D V E F K P D T K E E
Mdom 236 V R P K R H L A K R S T - - - - - - A R N K K - R R V V S - D S E S D I G G S D V E F K P D T K E E
Ggal 200 V K G N K R V P N R G S - - - - - - A I K A K - R R R V L - D S D S D R D G S D V E F K P D V K - E
Xlae 215 - - V K K R Q P V R E S K - - - K N G K P K R - R R I T I - E S D S D N E G S D D E F K P E - - D S
Drer 225 T K P S R R P P R A A A E - - - K S Q K S K R - R R I V V - A S D S D D S G E - - E F D P N K - A G
Pmar 215 X X X X X X X X X X X G - - - - - - R K N K R - R R I V V - P S D T D D S - - D A E F K P D T - V D
Cint 188 - A G G S D D A R H - K S - - - - - R D K K R - R R I M E - E S D F S D E D G D F K P P P D V E - G
Bflo 198 V A T K K R P S K L R R K - - - - - K G S K R I R L A V D S G S E S G K Y - S I L Y F K P D S E - D
181
231
1
44
86
132
Spur 200 I T I R R R K P R A A A K N A M S T Q K K K R - R R I R V - A S D S E S S - - G D E F K P D S D - D
Nvec 185 M R P R R K A A V - - - - - - - G - G M K K R K - R V M I - E S D S D G S - - D - D F K P E S E - E
Tadh 189 - - I D E P - - - - - - - - - - - - - Q T A H R - D N N N - D A D S D - N D E D - D - - - - I - - N
 
Hsap 272 G S S D E - - - - - - - I S S G V G - - - - - - - D S E S E G - L N S P V K V A R K R K R M - - V T
Mmul 272 G S S D E - - - - - - - I S S G V G - - - - - - - D S E S E G - P N S P V K V A R K R K R V - - V T
Mmus 272 G S S D D - - - - - - - A S S G V G - - - - - - - D S D S E D - L G T F G K G A P K R K R A - - M V
Btau 271 A S S D E - - - - - - - I S S G V G - - - - - - - D S D S E G - L D T P V K V A P K R K R M - - V T
Mdom 278 G S S D E - - - - - - - A S S G M G - - - - - - - E S D S D - - T D S P V K A P K R R R - - - - - -
Ggal 241 A S S E E - - - - - - - A S S G V D E N E A T D V E T D E E S I E E S P I K V P S K R K R G - - N V
Xlae 256 A S S D E - - - - - - - A S S G V D E A K L S - - E P D S E T E E D S P V K V P L K R K R G - - N P
Drer 267 G S S D E D K E E E E G V N S G A E E E - - - - - E S E P E T E P D S P V K - P I K R K R P - - - T
Pmar 254 A S S D E - - - - - - - A S S G V D E K E A S - - E P E S A S D P E S P V K - - - K R K R T - - T T
Cint 228 D E E D D - - - - - - - E S S G V D E S T L S - - - - - - D Q E E E E P V E I G K K R K R S P L P V
Bflo 241 D D S D - - - - - - - - V S S G V D E K D I S - - E P E T E S E P E S P I K P T R K R K R E - - P A
Spur 245 E S E G A - - - - - - - V S S G L D E D E I S - - A S E T E S D P E T P K K A - K K R K R G - - S T
Nvec 221 S D D S - - - - - - - - V S S G A E E E E P S - S D N N S E D E E E E E T K N T K K R K R G - - S T
Tadh 214 A T E E D - - - - - - - V N I P L K K R - - - - - N T K L S Q S Q S K Q S K S P A N R S K V - - I D
 
Hsap 305 G N G S - - - L K R K S S - - - - - - - - - R K E T P S A T K Q A T S I - - - - S S E T K N - T L R
Mmul 305 G N G S - - - L K R K S S - - - - - - - - - R K E M P S A T K R A T G I - - - - S S E T K N - T L S
Mmus 305 A Q G G - - - L R R K S L - - - - - - - - - K K E T G S A - K R A T P I - - - - L S E T K S - T L S
Btau 304 G N G S - - - L K R K S S - - - - - - - - - R K E M P S A T K R A T G I - - - - S S E T K N - T L S
Mdom 306 G N S T - - - L K K K S L - - - - - - - - - G G Y T P N V S K R V V G V - - - - S S E T K I - T L N
Ggal 282 S K P S - - - - K R S S L - - - - - - - - - E N E H S E A P K R A A P V - - - - S L E A K S - K L T
Xlae 295 D K P T - - - G P K K R L - - - - - - - - - Q D E L S E T P K R A S N V - - - - S A E A K L - K L S
Drer 308 E K P T - - - - K S K S K - - - - - - - - - P E T P K R A P A A L P S V - - - - S T D A K S - R L S
Pmar 290 K A P A - - - L T P S R Q P L M L G L S S V A S S G K A A T P K Q A Q T - - - - G S N A K A - K L S
Cint 265 K T P S T P L T P R T P M - - - - - - - - - T P R N P M T P R T P A S V - - - - S K E T K S - K L S
Bflo 279 K T P S - - - R G K A K P D L S - - - - - - S F S T P S S R L G T P S - - - - - S T A T P G G T V R
Spur 283 S T V T - - - P S T N K - - - - - - - - - - S A K K P R S T F G T P S V - - - - S S T T K S - R L S
Nvec 260 S T P S - - - S K K G K L A P N - - - - - - M T S N P T S N T P K P A K - L S S S L A T K I - T N S
Tadh 250 - - - - - - - - A E N F E - - - - - - - - - Y Q G S S N K S A S S T N T A T T A - - N - - R - N N S
 
Hsap 338 A F S A P Q N - - - S E S Q A H V S G - G - G D D S S R P T V W Y H E T L E W L K E E K R R D E H R
Mmul 338 A F S A P Q N - - - P E S Q A H V S G - G - G D D S S R P T V W Y H E T L E W L K E E K R R D E H R
Mmus 337 A F S A P Q N - - - S E S Q T H V S G - G - G N D S S G P T V W Y H E T L E W L K P E K R R D E H R
Btau 337 A F S V P Q N - - - S E P Q A H I S G - G - C D D S N R P T V W Y H E T L E W L K E E K R R D V H R
Mdom 339 A F S A P Q N - - - F E S Q A H V S G - G - G D G S H G S T Q W Y H E T L E W L K E G K R K D A C R
Ggal 314 L F A A P E N - - - F E S Q A N A C S - G - G T N G F - - A A W E H E K L E W L Q E G K K K D A H R
Xlae 328 S F S A P E S - - - F E S Q T N A G G - - - T - G S V - - S V W D H E K F D W L Q D G R R K D L K R
Drer 340 A F S A P D N - - - F D S Q S S A N G - - - T E G G S - - T V W D H E K L E W L Q D G K R K D A Q R
Pmar 332 A F S S - D T - - - L E S Q N G G G Q - D - G G K E G - - G G W D H E K L D W L R D G K R R D G K R
Cint 301 L F Q A D P D - - - S S V - - - - - - M - - - - - - E E K Q K Y L H E T L D F L H P S K I K D T Q G
Bflo 315 T P G A H Q N - - - T K N K L A M F S - - A P E G S E E K A K F D H E T Y E F L Q E G N I R D A K K
Spur 315 A F Q S P - - - - - - - A P S S P S P - - S P A A D S E E T R F P H Q R Q E W L K P G K R K D I K G
Nvec 299 A S K A A T S L A R F Q M T S S P A P V T E P D E N G N T G V Y L H E K L D W L K E G K R K D K H G
Tadh 278 S P K S S S P - - - P A - N R N - - - V - - N A V N D G N D N Y I H Q G L K W M Q D G F R K D S K G
 
Hsap 383 R R P D H P D F D A S T L Y V P E D F L N - - S C T P G M R K W W Q I K S Q N F D L V I C Y K V G K
Mmul 383 R R P D H P D F N A S T L Y V P E D F L N - - S C T P G M R K W W Q I K S Q N F D L V I C Y K V G K
Mmus 382 R R P D H P E F N P T T L Y V P E E F L N - - S C T P G M R K W W Q L K S Q N F D L V I F Y K V G K
Btau 382 R R P D H P D F D A S T L Y V P E D F L N - - S C T P G M R K W W Q I K S Q N F D L V I F Y K V G K
Mdom 384 R R P D H S D Y D P N T V H V P E D F L N - - T C T P G M R R W W Q I K S Q N F D L V I F Y K V G K
Ggal 357 R R Q N H P D Y D P C T L Y V P E D Y L N - - K C T P G M R R W W Q L K S Q N F D A V I C Y K V G K
Xlae 369 K K Q N D A D Y D P S T L Y V P D D F L N - - K C T P G M R K W W Q L K S Q N F D T V I F Y K V G K
Drer 382 K R Q S D E N Y D P T T L Y V P E D F L N - - R T T P G M R R W W Q L K S E M F D T V L F Y K V G K
Pmar 374 R L Q S D P E Y D P S S I Y V P D S F L S - - A C T P G M R R W W E I K S T L F D T V L F F K V G K
Cint 336 R K P D D P L Y D K S S L K I P N D F M T - - K L T P A M H Q W W K L K S T N F N V V L F F K V G K
Bflo 360 R L P T D E D Y D P R T L Y V P D S F L M - K N T T P L M R K W W E V K S Q L Y D T V L F F K V G K
Spur 356 R P E Q D P E Y D S S T L F V P K S F M - - D K T T P A M R Q W W E M K S K Y Y N A V L F F K M G K
Nvec 349 R P M L H P D Y D P K T L L V P Q S Y L T S K D V T P A M R Q W W Q L K S E H F D T V L F F K V G K
Tadh 319 R L Q S D P E Y D S R T L W L P S G F L K - - E Q T P L M R Q W W Q I K S E N F D S V L C F K V G K
 
Hsap 431 F Y E L Y H M D A L I G V S E L G L V F M K G N W A H S G F P E I A F G R Y S D S L V Q K G Y K V A
Mmul 431 F Y E L Y H M D A L I G V S E L G L V F M K G N W A H S G F P E I A F G R Y S D S L V Q K G Y K V A
Mmus 430 F Y E L Y H M D A V I G V S E L G L I F M K G N W A H S G F P E I A F G R F S D S L V Q K G Y K V A
Btau 430 F Y E M Y H M D A L I G V S E L G L V F M K G N W A H S G F P E I A F G R Y S D S L V Q K G Y K V A
Mdom 432 F Y E L Y H M D A V I G V N E L G L V F M K G N W A H S G F P E I A F G R Y S D S L V Q K G Y K V A
Ggal 405 F Y E L Y H M D A V T G V N E L G L I F M K G S W A H S G F P E T A F G R F S A I L V Q K G Y K I A
Xlae 417 F Y E L Y H M D A V I G V N E L G L T F M K G A W A H S G F P E I A F G R F S D V L V Q K G Y K V A
Drer 430 F Y E L Y H M D A V I G V N E L N L T F M K G T W A H S G F P E I G F G R F S D V L V Q K G Y K V A
Pmar 422 F Y E L Y H M D A L T G V S E L G L L F M K G T W A H S G F P E T S F A R F S D G L V Q K G Y K V A
Cint 384 F Y E L Y H M D A V V G V K E L G L T Y M K G N F A H S G F P E V A F G R Y A D T L V Q K G Y T V A
Bflo 409 F Y E L Y H M D A I T G V N E L G L I F M K G S Q A H C G F P E I A Y G R Y S D T L V Q K G Y R V A
Spur 404 F Y E L Y H M D A E V A V K E L G L I F M K G E N A H C G F P E I A F S R Y S E T L I Q K G Y R I A
Nvec 399 F Y E L Y H M D A T T G V K E L N L I Y M K G N F A H A G F P E I A F G R Y S D T L I Q K G Y K I A
Tadh 367 F Y E M Y H M D A L I G I S E L G L I L M R V - - T H C G F P E I A F S R Y A E T L A Q R G Y R V V
 
Hsap 481 R V E Q T E T P E M M E A R C R K M A H I - S K Y D R V V R R E I C R I I T K G T Q T Y S V L E G D
Mmul 481 R V E Q T E T P E M M E A R C R K M V H I - S K Y D R V V R R E I C R I I T K G T Q T Y S V L E G D
Mmus 480 R V E Q T E T P E M M E A R C R K M A H V - S K F D R V V R R E I C R I I T K G T Q T Y S V L D G D
Btau 480 R V E Q T E T P E M M E A R C R K M A H I - S K Y D R V V R R E I C R I I T K G T Q T Y S V L E G D
Mdom 482 R V E Q T E T P E M M E A R C R K L S H I - S R F D R V V R R E I C R I I T K G T Q T Y S V L D G E
Ggal 455 R V E Q T E T P E M M E A R C K A T A H T - T K F D K V V R R E I C R I I T K G T Q T Y S I I D C D
Xlae 467 R V E Q T E T P E M M E V R C K S M S H P - S K F D R V V R R E I C R I I T K G T Q T Y S V L D G N
Drer 480 R V E Q T E T P N M M E A R C K K L A R P - T K F D K V V K R E V C R I I T R G T Q T Y S V L D G A
339
384
432
482
273
306
Pmar 472 R V E Q T E T P D M M E A R C R A M A R P A T K L D K V V K R E V C R I I T K G T Q T Y S I L D G D
Cint 434 R V E Q T E T P E Q N Q Q R I R G K S L P - - K H E K T L R R E I C R V T T K G T Q V H N M W Q G G
Bflo 459 R I E Q T E T V P Q S E E R Y R K L A K P - T K F D K V V R R E V C R I T T K G T K T Y S F L E G D
Spur 454 R V E Q T E T P D M M Q E R V K H C K A V - T K F D K V V K R E I C R I S T Q A T R T F S F I D G D
Nvec 449 R V E Q T E T P E M M K E R C K K N R T N - S K F D Q V V K R E I C A V T T K G T K M Y S F R D G D
Tadh 415 R V E Q T E T P Q M M E E R V K S S T R P - T K F D K V V N R E V C G R I T K A T R T F S V Q N Y E
 
Hsap 530 P S E N Y S K Y L L S L K E K - - - E E - - - - - - - - - - - - D S S G - H T R A Y G V C F V D T S
Mmul 530 P S E N Y S K Y L L S L K E K - - - E E - - - - - - - - - - - - D S S G - H T R A Y G V C F V D T S
Mmus 529 P S E N Y S R Y L L S L K E K - - - E E - - - - - - - - - - - - E T S G - H T R V Y G V C F V D T S
Btau 529 P S E N Y S K Y L L S L K E K - - - E E - - - - - - - - - - - - E S S G - H T R V Y G V C F V D T S
Mdom 531 P S E S S N K Y L L C V K E K - - - E E - - - - - - - - - - - - E A S G - H T R L Y G V C F I D T S
Ggal 504 P T E N H N K Y L L C V K E K - - - E - - - - - - - - - - - - - D S S G - Q - R V Y G V C F V D T S
Xlae 516 P S E S H S K Y L L C F K E K - - - M D - - - - - - - - - - - - D S S G - Q R R I Y G V S F V D T S
Drer 529 P S E T Q S K Y L L S I K E K - - S E E - - - - - - - - - - - - D S T G - H G H I Y G V C F I D T S
Pmar 522 P S D A Q N K F L L A V R E R - - - E G P P G G S G N N S G A N E T G A - S V R T Y G V C F V D T S
Cint 482 S K H H E S D F L L S I S E R V V N R N - - - - - - - - - - - - E S S G S V C R E F G V C F V D T T
Bflo 508 T G E A A N S Y L L A I A E K - - A N E - - - - - - - - - - - - D I A G - D Q S V Y G V C F V D T S
Spur 503 T C E A Q S S Y L L A V T E R - - P C E - - - - - - - - - - - - G S S G - G E S V Y G V C I V E T S
Nvec 498 C T E S E A A Y L L A V A E K - - E L S - - - - - - - - - - - - D C G G - - E S M Y G V C F L D T S
Tadh 464 D P N S E N A F L L A I I E R - - E R D - - - - - - - - - - - - D L A V - G H S L L G V C F L D T T
 
Hsap 564 L G K F F I G Q F S D D R H C S R F R T L V A H Y P P V Q V L F E K G N L S K E T K T I L K S S L S
Mmul 564 L G K F F I G Q F S D D R H C S R F R T L V A H Y P P V Q V L F E K G N L S K E T K T I L K S S L S
Mmus 563 L G K F F I G Q F S D D R H C S R F R T L V A H Y P P V Q I L F E K G N L S T E T K T V L K G S L S
Btau 563 L G R F F I G Q F S D D R H C S R F R T L V A H Y P P V Q V L F E K G N L S M D T K M I L K S S L S
Mdom 565 V G K F Y M G Q F S D D R H C S R F R T L V A H Y T P A Q I L F E K G N L S V E T R K V L K G S L S
Ggal 536 V G K F Y V G Q F S D D R H C S R F R T L V A H Y T P V Q V L F E K G N L T V D T Q K I L K G S L I
Xlae 550 V G K F H V G Q F E D D R H C S R F R T L V A H F P P I Q I L F E K G N P S S D T K K V L K S C L S
Drer 564 V G R F H I G Q F Q D D R H C S R L R T L V A H Y S P A Q V I F E K G N P S I E T L K I F K A I V A
Pmar 568 V G V F H L G Q F T D D R H C S R F R T L V A H H A P A Q V L Y E R G G L S A E T Q K I V R V T L A
Cint 520 V G V F H L G Q F T D D R H C S R L C T M L A H H S P S Q V L F E R G K L S N E L N K I L R T G L S
Bflo 543 I G K F H I G Q F Q D D R H S S R L R T L I A Q Y T P S Q V L F E R G K L S S K T Q S I L N S N L S
Spur 538 I G K F Y I G Q F Q D D R H S S R F R T L I A H Y P P A Q V L F E R G K L L P K T Q Q L L S N N L V
Nvec 532 I G K F H I G Q F K D D R Q A S R L R T L I A H H P P V Q V L T C R G S Y T S K T Q H I L S H E L M
Tadh 499 I G K F H L G Q F T D D R Q C S R L R T L V T H F Q P V Q I L Y E R G K V S S K L Q H I F Q H D L L
 
Hsap 614 C S L Q E G L I P G S Q F W D A S K T L R T L L E E E Y F R E K - - - - - - - - L S - D G I G V M L
Mmul 614 S S L Q E G L I P G S Q F W D A S K T L R T L L E E G Y F R E K - - - - - - - - L S - D D I G V M L
Mmus 613 S C L Q E G L I P G S Q F W D A T K T L R T L L E G G Y F T G - - - - - - - - - - N - G D S S T V L
Btau 613 S S L Q E G L I P G S Q F W D A A K T L R T L L E E G Y F I D K - - - - - - - - L N - E D G G V M L
Mdom 615 S S I Q E G L T P G S Q F W D A A K T L K T L L E E G Y F K E K - - - - - - - - L N - - - - V A E L
Ggal 586 S C I Q E G L I S G S Q F W S A S K T L K V L L E E E Y F K E N - - - - - - - - Q N - T E S G C V L
Xlae 600 T S I Q E S L Q P T S Q F W D A F K T L K T L A E E A Y F E K D - - - - - - - - F Q - P G S - G N L
Drer 614 S S L Q E G L N A G S Q F W D A Q K T L K V L A E E D Y F K E S - - - - - - - - K D D N K K A S V L
Pmar 618 S A L Q D A L T P S T Q F W D A T K T L K V L A E E G Y F K V E D E R - - G G S G G G G G S S G A L
Cint 570 S I L Q N P L V P G S Q F W D A P K T L K T L L N E K Y F V K E - - - - - - - - - - - - - N D N V W
Bflo 593 T A L R E A L - S S S E F W D A P K T L K F L A E K S Y F S E T G T - - - - - E D E E E T G D S C W
Spur 588 S V L K D S L L P G S E F W D A S K T L K A L M E K G Y F E D S E R D K D G Q E N G G K G G L S C W
Nvec 582 S S L T E H L A P G S E F W D A S K T L K F L A E G N Y F K N D - - - - - - - - K D G A D E S V N W
Tadh 549 S A M K D A L A P G S E F W D S N N T L K I L S E K S Y F T K D G N - - - - - E - A D D A S L D T W
 
Hsap 655 P Q V L K G M T S E S D S I G L T P G E K S E L A L S A L G G C V F Y L K K C L I D Q E L L S M A N
Mmul 655 P Q V L K G M T S E S D S I G L T P G E K S E L A L S A L G G C I F Y L K K C L I D Q E L L S M A N
Mmus 652 P L V L K G M T S E S D S V G L T P G E E S E L A L S A L G G I V F Y L K K C L I D Q E L L S M A N
Btau 654 P Q V L K G M T S E S D S I G L T P G E K S E L A L S A L G G C V F Y L K K C L I D Q E L L S M A N
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Mdom 296 D P A K I S R I V N E V Y H L Y N R H Q Y P F V V L N I S V D S E C V D I N V T P D K R Q I L L Q E
Ggal 296 D P A K V V K L V N E V Y H L Y N K H Q Y P F I V L N I C V D S E C V D I N V T P D K R Q I L L Q E
Xtro 296 D P A K V S K I V N E V Y H L Y N R H Q Y P F V V L N I C V S S E C V D I N V T P D K R Q I L L Q E
Drer 294 D P V K V S K L V N E V Y H M Y N R H Q Y P F V A L N I A V A S D C V D V N V T P D K R Q I L L Q E
Pmar 293 D L A K V S K L V N E V Y H S Y N R H Q Y P F L V L N I V S S T D L V D V N V T P D K R L V L L Q E
Cint 285 T L P R L S K I V N E V Y H R F N R H Q F P F I A I N I A T R H D L V D V N V T P D K R K V F F Q N
Bflo 285 D L P K V S K V V N E V Y H M Y N R H Q Y P F V V L D I S L A R D S V D V N V T P D K R Q V W L Q E
Spur 289 D F P K V C S L I N E V F H M Y N R H Q Y P F V V M D I S L A K D A V D V N V T P D K R K V L V Q E
Nvec 298 D L P K V S R V V S E V Y H M Y N R H Q F P F V M L D I S L K R D A V D V N V T P D K R Q V F L Q Q
Tadh 290 D L I K A S R V I N E T Y H M Y N R H Q Y P F F A L D I S L R K G T V D V N V T P D K R Q I L M Q N
 
Hsap 347 E K L L L A V L K T S L I G M F D S D V N K L N V S Q Q P L L D V E G N L I K M H A A D L E K P M V
Mmul 346 E K L L L A V L K T S L I G M F D S D V N K L N V S Q Q P L L D I E G N L V K M H A A D L E K P L V
Mmus 347 E K L L L A V L K T S L I G M F D S D A N K L N V N Q Q P L L D V E G N L V K L H T A E L E K P V P
Btau 347 E K L L L A V L K T S L I G M F E S D V N K L Q V S Q Q P L L D V E G H L I K R P S A E M E K P E P
Mdom 346 E K F L L A V L K T S L I G M F D S G V N K L S V N Q K P L L D S G G N L L K M Y S T E M E K T L P
Ggal 346 E K L L L A I L K T S L I E M F G S D V N K L N V N Q N - L L D I V G N - V K A P P G D A E K P W V
Xtro 346 E K L L L A L L K T S L N A V F S S T V N K L G M N Q T - L V D A A G T S R K L N L Q A L A S P - -
Drer 344 E K L L L A I L K S S L I A M F E T G V N K I S L N H I - S P A F T S M S R P T G - T S A C S D D Q
Pmar 343 E R L L L A V V K A T L T S I Y E P T L N Q L P I N T T P R A G R P A S - - - - - - - S A P R S T G
Cint 335 E N L L F A I M T S S M T Q L Y S L D G - C H E V G S T E C S I S L P - - - - - - - - - - - C R S P
Bflo 335 E R T L L A I I K T S L M Q M Y E P T A S V Y A V N Q A V L P N T Q S L T C T I G H V S L K K E L P
Spur 339 E K T L L A I L K A S L K T M F E P R S S C Y D V N Q K P L S A V T P S S L A L S N M F S R S - - P
Nvec 348 E K L L L A T L R T S L I K M F D P G T S T Y E V N Q K V F T Q I K L S P S P T Q A S H F - S L A P
Tadh 340 E K A L L T V I K A S L V R M Y D P I A S S Y E I S R G I T T - G A T T - - S T Q S A A A D Q H D N
 
Hsap 397 E K Q D Q S P S L R - - T - G E E K K D V S I S R L R E A F S L R - H T T E N K P H S P K T P E P R
Mmul 396 E K Q D H S P S L R - - T - R E E K R D V S I S R L R E A F S L R - H R T E N K P H S P K T P E A R
Mmus 397 G K Q D N S P S L K - - S T A D E K R V A S I S R L R E A F S L H - P T K E I K S R G P E T A E L T
Btau 397 E K K D D P A P L R - - T R G E E K R V V T I S R L R E T F S L R - H S T E N K S R G P K A T D P R
Mdom 396 E K K N - L I S L Q - - N K G E E K R T L T I S R L R E A F S L Q - H T T E Q S F Q T L K T H K - -
Ggal 394 E M S H H S E T E N - - P S S E G K R V M T L S R L R E S F S L - - H Q T E S Y F Q S P K K V K Q R
Xtro 393 - - - - - - - P S - - - D H T D A K S S L A V S R L K E A F S H H - Q T A P A S S P L T K P I K A Q
Drer 392 E M G S V S E T L T - - Y D G P P K T S I N L A G L K E A F S N H - Q - A P G I G S K Q S S H K A A
Pmar 386 G G P D R - P P K A - - L D A - - G K A R A F S G L G R A F G F R - P S L G F G R G S S D A A Q P S
Cint 373 S V T E T S Q T F S - - P L S S F R R T M G D D V I N S D I T K P - R K R S A S F A T K V A - - - -
Bflo 385 G I K E N P P S G K - - Q E - A C S E A T S V S L L D K E E T L E - H K A E G K P D D P L H C T L S
Spur 387 S S S Q G S S L G S S Q A S T G S P S T G Q V S S P T S S L G C S Q F S S S Q G S P C F R - - - - -
Nvec 397 G - - D N - P S G N - N - - - A Y A - A T S G G F H S N S L - N - S L H G N N N V S G L S V G K Y E
Tadh 387 E N N D E - - - I Q - - I - - - - - - - I S E K D I N - N K K H - L T N D E C E L S E V S N N S L R
 
Hsap 443 R S P L G Q K R G M - L S S S T S - G A I S D K G V L R P - - - - - - - - - - - - - - - - - - - - -
Mmul 442 R S P P G Q K R G T - P S S S T S - D A V S D R G F L R P - - - - - - - - - - - - - - - - - - - - -
Mmus 444 R S F P S E K R G V - L S S Y P S - D V I S Y R G L R G S - - - - - - - - - - - - - - - - - - - - -
Btau 444 R V S P K Q K S S A Q F P R A L G - P P C S Q K H I S E P - - - - - - - - - - - - - - - - - - - - -
Mdom 440 Q D S P R Q R N P W S F C S T S S - L V N S S K P I S G K E - - - - - C - G - - - - - - - - - - - -
Ggal 440 H S S S K Q L S - - - L D T I L S - T V R T Q K A V L S E D - - - - - S E S - - - - - - - - - - - -
Xtro 432 Q P S P N Q R K L V S F F S M N P - K E C V A S R P S G R I - - - - - H - - - - - - - - - - - - - -
Drer 438 C A G P S Q K K M L S F V S C S K - K V T D F L P P L K S P - - - - - T - - - - - - - - - - - - - -
Pmar 430 P T S P E D C G S F - S Q E D C G K E A P G D S S Q S D A G - - - - - A - - - - - - - - - - - - - -
Cint 416 - - - - K Q P R L D K F V M T Q H - K V T S Q C W P V L P D - - - - - - - - - - - - - - - - - - - -
Bflo 431 M T D Q M S K D N R I E T A T N I - I S T K S A P E L E S W - - - - - T P V - - - - - - - - - - - -
Spur 432 P S S Q R E A K R A G T L N L G N - L K R S F A H A S H Q - - - - - - - - - - - - - - - - - - - - -
Nvec 437 K S C V R Q K N F L N S L S N F K - R K F S E L S P C G E K K Q N E P V A K Q A R L T E I F C K N E
Tadh 423 Q C R I H G F N L A Y K I H F L Y - N V K P T E V N S K P - - - - - - - - - - - - - - - - - - - - -
 
Hsap 470 Q K E A V S S S H G P S D - - - P T D R - - A E V - E K D S G H G S T S V - D S E - G F - S I P D T
Mmul 469 Q K E A T S S G Q G P R D - - - P T D G - - A E V - E K D S G H G S T S V - D S E - G F - S I P D T
Mmus 471 Q D K L V S P T D S P G D - - - C M D R - - E K I - E K D S G L S S T S A - G S E E G F - S T P E V
Btau 472 G E E G R T S A Q G P H D - - - L M S R - - V E M - E E D S G H G S A S A - G S E E A S - S T P E T
Mdom 471 S Q E M V E P T P C I H S - S M S P K P - - V D T - D K D S G H S G T F T - Q S D E G S - S T P E K
Ggal 469 C H E M K S K M P V P R K - Y - - L R K - - - V D - D I D S G F C S T S - - E S D A G Y - N T P E A
Xtro 462 S E S E I K N E H G N S L T L G A D D K - - L E S - D C D S G K G S S S V P D S E V G C - T T P E L
Drer 468 T F T A V S S I K L S T V - C S V K Y K - - S - - - T F D S D A D G S G A A S L K S A E - D Y P E I
Pmar 460 Q E E E E S T A E G S V D - - - N G S A - - P L L - R C D S P H V G - - - - - - G C G E V G G A A R
Cint 441 Q N N E R S V L P D Q S - N G - - Q Q - - - - V L - P D Q N N E R P V L P D Q S N G Q P - V L P D Q
Bflo 463 H D H D R L Q T D E C L - A V - - L S D - - - E S - N K E Q Q K Q T V P I A C I E S P Q - K H G S S
Spur 460 D D E E E E K Q P K R S - K T - - G E S - - - H K - V E D C L S P A V A L L R S D G E S - G F C E S
Nvec 486 D K E I I C S E F S E N - S G - - S E I S G I I T - E G D D E I G L S S A G Q H E E Q M - E R V H R
Tadh 451 C V E I V T E G K S T L - A S - F G W R - - K I S S E Y V T K I V Y N L S K S T E S S N - N M E V T
 
Hsap 511 G S H C S S E Y A A S S P G D R G - - S Q E - - - - - - - - H V D S Q E K A P - - - E T D D S F - S
Mmul 510 G S H C S S E C A A S S P E D R G - - S Q E - - - - - - - - H A D S Q E K A P - - - E T D D S F - S
Mmus 513 A S S F S S D Y N V S S P E D R P - - S Q E - - - - - - - - T I N C G D - - - - - - - L D C R P - P
Btau 514 S S H P S T D R V A S S P E D K F - - S Q E - - - - - - - - N M E S R E K L P - - - E T D H R L - S
Mdom 515 G A G R E C I T S S P R E D Y T F - - S K E - - - - - - - - N V D I F K K S P - - - G I D S Q F - S
Ggal 509 G S C V I S E S V N N P I E E E F C S S E E Q H Q N E Y L K T V G H S E K S L - - - E C D I Q V - L
Xtro 508 S S H Q S G E S E T G S P E T L H - - T A E - - - - - - - - N K C A V E H S R - - - A I L - - - - -
Drer 511 K Q E N H S E S F L - - - - - - H - - H G I - - - - - - - - N - - K T D V K A - - - E I V D K P - -
471
512
298
348
398
444
Pmar 498 G E D - - - Q C L E A V S V E K V - - - - - - - - - - - - - E K E V R G G S P - - - R I L S V L - A
Cint 482 N N G R P V L P D Q S N R Q P V L - - P D Q - - - - - - - - N N E - R - - - - - - - P V L P D Q S N
Bflo 505 I N T S T S D K D L H E - - - - - - - G - - - - - - - - - - - - - S E I T V Q - - - V K E V K I - Q
Spur 502 S T G G S S G I R S S E E S Q T - - N S S - - - - - - - - - - Q E P S Q E T P - - - E H R L H C - T
Nvec 531 G N Q P T K V K E I L L L K E D N - - K N D - - - - - - - - S L A L D S S S I - - - F P V M Q S - D
Tadh 496 E S K S E I N E I L S K P - - - - - - - - - - - - - - - - - Y T S T A K K A K I E L A P N Y K V - L
 
Hsap 547 D V D C H S N Q E D T G - C K F R V L P Q P T N L A T P N T K R F K K - E E I L S S S D I C Q K L V
Mmul 546 D M D C H P N Q E D T A - C K F R V S P Q P T N L A S P N T K R F K K - E E I L S N S D I R Q K L V
Mmus 545 G T G Q S L K P E D H G - Y Q C K A L P - L A R L S P T N A K R F K T - E E R P S N V N I S Q R L P
Btau 550 G T K C H L N Q E E S S - S T S G V L P Q P T K L S S P N A K R F T K - E G I P L N P S V L A E S V
Mdom 551 I T E S C L E E K S I E - N V F I N L S - P P S N S S P Q G K R F K K - E V S S L N F S V P P K V M
Ggal 555 G T E H K L N R V N D C - N N Q T N L P Q E A T N S L P R V R R F K N - E A D D F K A G I H P K V E
Xtro 540 G Q E D E P Y P E E L A Q I D I A L K P S Y C D D T I P T C K R A K V - E D D A L P S A - - - - - -
Drer 538 - M D E N L W S Y E T L - P E T K S E Q H Q N R I F S P E A K R A R R - E D E P P A Q N C L V D F K
Pmar 528 S T S V G L G V L D R F - H R X X X X X X X X X X X X X X X X X X X X - X X X X X X X X X X X X X X
Cint 514 G Q P V - L P D Q N N G - R P V L P D K S N G Q P V L P D Q N N G R - P - - - - - - - - - - - - V L
Bflo 531 N S R I P L A R S D F E - N Q - Q N T L S Q E E D A K - - - - - - - - - - - - - - - - - - - S E K V
Spur 536 S T D V G - S A I E D G - E T H R I L I H R M D D S T - - - - - - - - - - - - - - - - - - - - - - -
Nvec 567 L K E E S F H A G Q N - I Q E T S E - - - V T K L A D R K T S S H K K A E D I T K T P S I G - - - -
Tadh 528 E A V D P I V Q N I - - - - - - - - - - - N G N F F - - I L Q S N K K - E N V D E N S D D I P N D D
 
Hsap 595 N T Q D M - S A S Q V D V A V K I N K K V V P L D F S M S S L A K R I K Q L H H E A Q Q - S E G E Q
Mmul 594 N T Q N V - S A S Q V D V A V K I N K K V V A L D F S M S S L A K R I K Q L H R E T Q Q - S E G E Q
Mmus 592 G P Q S T - S A A E V D V A I K M N K R I V L L E F S L S S L A K R M K Q L Q H L K A Q - N K H E L
Btau 598 K A Q S A - S A T - V D V A V K I N K K I V P L D F S M S S L A K R I K Q L C Q Q E Q Q - Q E S Q Q
Mdom 598 N A E E L - S A S Q V D I A I K V T K K E V P L D F S M I S L T K R I Q Q L Q Q Q E Q Q - R V K A Q
Ggal 603 N T R N Y - M P C - V D V L V E V K K K T V P L E F S M K A L A E R V R K I V Q Q Q Q K - C T E T Q
Xtro 583 - - C T V - Q P D T V D A P M N I Q R R T K P L P F S M A N L T K G M E R I K Q Q Q R I - K E E T E
Drer 585 - S R N A - S L K - F D A P V N I K K K T V L L P F S Q Q E L S K R M Q R L Q A Q R T K S N E Q E P
Pmar 576 X X X X X - X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X - X X X X X
Cint 549 - P D H N - N G Q - - P V L P - - - - - - - D Q N N G Q P V L P D A K H - - - P S N I E P S Q P P T
Bflo 560 S G A K L - S L L S F D Q A T D I H R K E V K L A F S M D S L R Q K L K R - - H A E H K - E R T E M
Spur 561 - - - - - - - P - - - S S S D S G Q R R E V T V P L S L A G L R R A R E Q - - R E T Q E - R E E G I
Nvec 609 - - E T F P D D H E D L K V I F S R R K T V E V E F S M E K L R S R S H S L N T S I T Q N - A - E V
Tadh 564 G E E N - S E - D - I S L P I N T K S S N N L L Q F D F E E I R K I - K - - - - T D Q N - S E N T N
 
Hsap 643 N Y R K F R A K I C P G E N Q A A E D E L R K E I S K T M F A E M E I I G Q F N L G F I I T K L N E
Mmul 642 N Y R K F R A K I C P G E N Q A A E D E L R K E I S K T M F A E M E I I G Q F N L G F I I T K L N E
Mmus 640 S Y R K F R A K I C P G E N Q A A E D E L R K E I S K S M F A E M E I L G Q F N L G F I V T K L K E
Btau 645 N Y R K F R A K I C P G E N Q A A E D E L R K E I S K T M F A E M E I I G Q F N L G F I I T K L N A
Mdom 646 N Y R R F R A K I S P G E N Q A A E D E L R K E I S K D M F A E M E I I G Q F N L G F I I T K L N E
Ggal 650 N Y R R F R A K I S P G E N K V A E D E L R K E I S K E M F A K M E I I G Q F N L G F I I A K L N S
Xtro 629 R Y R R F R A K I N P G D N Q A A E D E L R K E I S K E M F A K M E I I G Q F N L G F I I T K L D S
Drer 632 K Y R R F R A K I N P G E N Q T A E D E L K K E I S K D M F K E M E I I G Q F N L G F I I T K I K S
Pmar 624 X X X X X X X X X X X X X X X X X X X X X X X X X X K H M F A H M E V V G Q F N L G F V V A R L G P
Cint 585 E Y S L F R A N L - - A D T T T A E A E L T K N L D K S S F Q Q M A P V G Q F N L G F V I G R H G N
Bflo 606 M G R S F R A K I S P S D N Q A A E D E L R R E I S K D K F T Q M E I L G Q F N L G F I I A R L G G
Spur 598 A G R T F R A K I A P S D N A S A E E E L S R E I S K D M F S K M E I L G Q F N L G F I I A K L G Q
Nvec 655 - - R I F R A K I S P E N N S A A E E E L T K N I E K G S F A R M E I V G Q F N L G F I L A K L D N
Tadh 605 I G S S F H A T I A P D N N T A A E N E L R R E I S K D M F Q E M E I I G Q F N L G F I I A R H N Q
 
Hsap 693 D I F I V D Q H A T D E K Y N F E M L Q Q H T - V L Q G Q R L I A P Q T L N L T A V N E A V L I E N
Mmul 692 X X X X X X X X X X X X X X X X X X X X X X X - X X X X X X X X X P Q T L N L T A V N E A V L I E N
Mmus 690 D L F L V D Q H A A D E K Y N F E M L Q Q H T - V L Q A Q R L I T P Q T L N L T A V N E A V L I E N
Btau 695 D I F I V D Q H A T D E K Y N F E M L Q Q H T - V L Q G Q R L I A P Q T L S L T A V N E A I L I E N
Mdom 696 D L F I I D Q H A T D E K Y N F E M L Q L H T - V L Q G Q R L I M P Q T L N L T A V N E A I L I E N
Ggal 700 D L F I I D Q H A T D E K Y N F E M L Q Q H T - V L Q G Q K L I A P Q N L N L T A V N E T V L I E N
Xtro 679 D L F M I D Q H A T D E K Y N F E M L Q Q E T - V L Q G Q R L I A P Q K L H L T A V N E T V L I D N
Drer 682 D L F I I D Q H A T D E K Y N F E M L Q Q N T - V L K G Q R L I V P Q S L H L P A I S E T V L M E N
Pmar 674 D L F I V D Q H A S D E K Y N Y E T L R R D S A T L H G Q R L I A P L K L P L T A V G E L V L M E N
Cint 633 D L F I I D Q H A S D E I Y N Y E T L Q A T Q - T L Q T Q N L V V P L K L Q L T P A G K I V L I E N
Bflo 656 D L F I I D Q H A T D E K Y N F E M L Q R N T - V L Q G Q R L I Q P Q S L H L T A A N E S I L M D N
Spur 648 D L F I I D Q H A T D E K Y N F E T L Q K H T - V L Q G Q R L I Q P L P L E L T A V N E S I L M D D
Nvec 703 D L F I I D Q H A S D E K Y N F E M Q Q R N T - V L R N Q R L I I P R K L E L T A V N E S I L L D N
Tadh 655 D L F I I D Q H A S D E K Y N Y E Y L Q L N T - N L K G Q Q L I Q P K H L F L T P T E E E V L M D N
 
Hsap 742 L E I F R K N G F D F V I D E N A P V T E R A K L I S L P T S K N W T F G P Q D V D E L I F M L S D
Mmul 741 L E I F R K N G F D F V I D E N A P V T E R A K L I S L P T S K N W T F G P Q D I D E L I F L L S D
Mmus 739 L E I F R K N G F D F V I D E D A P V T E R A K L I S L P T S K N W T F G P Q D I D E L I F M L S D
Btau 744 L E I F R K N G F D F V I D E H A P V T E R A K L I S L P T S K N W T F G P Q D I D E L L F M L S D
Mdom 745 L E I F R K N G F D F I I D E H A P V T E R V K L I S L P T S K N W T F G P Q D I D E M I F M L S D
Ggal 749 L E I F R K N G F D F V I N E N A P V T Q R V K L I S L P T S K N W T F G P Q D I D E L I F M L S D
Xtro 728 L D I F K K N G F D F I F D E E A P I T E R V K L I S L P T S K N W T F G Q Q D I E E L I F M L S D
Drer 731 L E I F R K N G F D F L I D E D A Q V M D R V K L V S L P T S K N W T F G P N D I E E L I F M L S D
Pmar 724 L D I F R K N G F D F I I D E Q A P A T Q R V R L T T L P V Q R G W M F G V S D V E E L V F L L S D
Cint 682 L E I F R K N G F G F K I S S D E A - T - - I H L T T I P T H N P H P L G P P D I D E M I F M L S D
Bflo 705 M D I F R K N G F E F T I Q E D A P C T E R V K L V S M P V S K N W T F G K E D I E E L I F M L S D
Spur 697 V E I F K K N G F D F I I N E D G R P T E R V K L V S Q P F S K N W T F G K D D I D E L I F M L S D
Nvec 752 L E I F R K N G F E F Q I D D D A P A T Q K V K L V S V P T S K N W T F G V E D V E E L I F M L S D
Tadh 704 V N I F E K N G F S F S I D P D A P P T K R I K M T S V P Y G R G C I F N E E D V Q E M I M M L T D
 
Hsap 792 S P G V M C R P S R V K Q M F A S R A C R K S V M I G T A L N T S E M K K L I T H M G E M D H P W N
Mmul 791 S P G V M C R P S R V K Q M F A S R A C R K S V M I G T A L N T S E M K K L I T H M G E M D H P W N
Mmus 789 S P G V M C R P S R V R Q M F A S R A C R K S V M I G T A L N A S E M K K L I T H M G E M D H P W N
Btau 794 S P G V M C R P S R V R Q M F A S R A C R K S V M I G T P L N T S E M K K L I T H M G E M D H P W N
Mdom 795 C P G V M C R P S R V R Q M F A S R A C R K S V M I G T A L N K N E M K K L I T H M G E I E H P W N
793
596
644
694
743
548
Ggal 799 C P G V M C R P S R V R Q M F A S R A C R K S V M I G T A L N V Q E M K K L V T H M G E I E H P W N
Xtro 778 S P G V M C R P S R V R Q M F A S R A C R K S V M I G T A L N V H E M K K L V T H M G E I E H P W N
Drer 781 S P G I M C R P S R V R Q M F A S R A C R K S V M V G T A L N T S E M K K L V L H M G E I E Q P W N
Pmar 774 R P G V M C R P S R V Q Q M L A S K A C R K S V M I G T A L N A T E M R R L L L H M G E M E Q P W S
Cint 729 A P G V M C R P T R V R R I F A T R A C R M S T M I G T S L T K R Q M L R L I R H M S E I V H P W N
Bflo 755 A P G V M C R P S R V R Q M F A S R A C R K S V M I G T A L N R G E M Q Q L L T H M G E I E Q P W N
Spur 747 A P G V H C R P T K V R Q M F A S R S C R K S I M I G T A L N K A E M K K L V C H M G E L E Q P W N
Nvec 802 A P G I L C R P T R V R K M F A S R A C R M S I M V G T A L S H A H M Q G I V G H M G Q M E H P W N
Tadh 754 M P G V M C R P T T V S R M F A T R S C R R S I M I G T A L N T S Q M K K I L K H M G E I E H P W N
 
Hsap 842 C P H G R P T M R H I A N L G V I S Q N
Mmul 841 C P H G R P T M R H I A N L G V I S Q N
Mmus 839 C P H G R P T M R H V A N L D V I S Q N
Btau 844 C P H G R P T M R H I A N L D V I S Q S
Mdom 845 C P H G R P T M R H I A S L N I I S Q D
Ggal 849 C P H G R P T M R H I A S L D L I A S E
Xtro 828 C P H G R P T M R H I A N L D M I S Q D
Drer 831 C P H G R P T M R H L A N L D M I S Q D
Pmar 824 C P H G R P T M R H L V N L D L L T G P G G R D G P Q L Q Q Q R R H Q H A A A S A V G P S D G Q E N
Cint 779 C P H G R P T M R H L I D I G K L R - Q
Bflo 805 C P H G R P T M R H L F N L N M L P - D
Spur 797 C P H G R P T M R H L F N L N M M P - D
Nvec 852 C P H G R P T M R H V V N L A M L P - S L S E
Tadh 804 C P H G R P T M R H L F N L N V A T V S L K E D S A N K
843



















Instructions InSiGHT.Submission.template.v.1.0.xlsx Page.1
InSiGHT.Data.Submission.Template
Please.submit.all.variants.=.truncating,.missense,.polymorphism.and.other.types
There.are.3.data.formats.to.chose.to.use.as.a.guide.for.submission:
1).Clinical.data
2).Pedigree.data
3).In.Vitro=Functional.data
Note:.each.template.has.example.data.
There.is.also.a."custom.template".where.you.can.decide.which.columns.to.include.based.on.your.available.data
If.you.have.difficulty.conforming.to.a.template,.then.submit.in.a.format.that.suits.you.
Send%data%to%John+Paul%Plazzer:
johnpaul@variome.org
InSiGHT.Database.Curator
The.Royal.Melbourne.Hospital
Victoria,.Australia
Optional: Custom%Template%+%make%it%easier%to%transfer%your%data
Column.Number.(Please.
specify) Data.field
Family%ID
1 Patient%ID Enter.numbers.(1=26).which.correspond.to.your.column.order,.leave.blank.for.columns.that.are.not.in.your.system...
Sex This%will%update%the%"custom%template"%worksheet.
2 Family%History
Selection%Criteria%for%proband%testing
6 Detection%Technique%
7 Testing%Coverage%
11 %Testing%stopped%when%variant%detected%(Yes,No)
Year%test%performed
3 Gene
4 Variant(s)%
5 Protein
10 Classification
ICD+10
Type%of%Neoplasm%
Age%of%onset/diagnosis
Last%known%age%if%healthy/unknown%disease
Additional%Phenotype
MSI
8 MLH1%protein%expression
9 MSH2%protein%expression
MSH6%protein%expression
PMS2%protein%expression
BRAF%V600E%mutation%status%
BRAF%V600E%mutation%testing%method
MLH1%methylation
MLH1%methylation%testing%methods
1)#Clinical InSiGHT#Submission#template#v.1.0.xlsx Page#2
Family'ID Patient'ID Sex Family'History
Selection'Criteria'for'
proband'testing
Detection'Technique#>#
refer#to#list#in#Detection#
Technique#worksheet
Testing'Coverage#>#gene(s)#or#
exon(s)#or#region(s)#
tested/screened
'Testing'stopped'when'variant'
detected'A'Yes#='stopped'
when'variant'found
Year'test'
performed Gene
Variant(s)'>#if#a#person#has#more#than#one#
variant,#they#can#be#listed#in#the#same#cell#or#
create#another#row#>#your#choice.##Same#cell#
means#you#don't#have#to#duplicate#the#
disease/tumour#info. Protein
Example_1 person_123 Male Bethesda Family#History SEQ# MLH1,MSH2,#MSH6,PMS2 2008 MSH2 c.1046C>T p.Pro349Arg
Example_2 person_124 Male Bethesda IHC SEQ# MLH1,MSH2,MSH6 2008 MSH2 c.1046C>T p.Pro349Arg
Example_3 person_125 Male Bethesda Family#History SEQ# 7,8 2006 MSH2 c.1046C>T p.Pro349Arg
Example_4 person_126 Female Bethesda MSI SEQ# MLH1 Yes 2006 MLH1 c.2027T>G p.Leu676Arg
Example_5 person_127 Male Bethesda Family#History SEQ# MLH1,MSH2,MSH6 2006 MLH1 c.203T>A p.Ile68Asn
Example_6 person_128 Male AM#I MSI SEQ# MLH1,MSH2,MSH6,PMS2 2009 MLH1:c.1046C>T#+#MSH2:c.123A>G MLH1:p.Pro349Arg#+#MSH2:p.Val41Pro
Example_6 person_128 Male AM#I MSI SEQ# MLH1,MSH2,MSH6,PMS2 2009 MLH1:c.1046C>T#+#MSH2:c.123A>G MLH1:p.Pro349Arg#+#MSH2:p.Val41Pro
Example_6 person_128 Male AM#I MSI SEQ# MLH1,MSH2,MSH6,PMS2 2009 MLH1:c.1046C>T#+#MSH2:c.123A>G MLH1:p.Pro349Arg#+#MSH2:p.Val41Pro
Example_7 person_129 Male Bethesda Family#History SEQ# 2 2011 MSH2 c.1046C>T p.Pro349Arg
Example_8 person_130 Female None IHC PTT# MLH1 2010 MLH1 c.74T>C p.Ile25Thr
Example_9 person_131 Male Bethesda Family#History SEQ# MLH1,MSH2,MSH6 2010 MSH2 c.1004C>T p.Thr335Ile
Example_10 person_132 Female Am#II Family#History SEQ# MLH1,MSH2,MSH6,PMS2 2008 MSH2 c.222delA p.Arg74Glufsx7
Example_10 person_132 Female Am#II Family#History SEQ# MLH1,MSH2,MSH6,PMS2 2008 MSH2 c.123A>G p.Val41Pro#
Example_10 person_132 Female Am#II Family#History SEQ# MLH1,MSH2,MSH6,PMS2 2008 MSH2 c.222delA p.Arg74Glufsx7
Example_10 person_132 Female Am#II Family#History SEQ# MLH1,MSH2,MSH6,PMS2 2008 MSH2 c.123A>G p.Val41Pro#
1)#Clinical InSiGHT#Submission#template#v.1.0.xlsx Page#3
ICDA10
Type'of'Neoplasm'>#Try#to#list#one#disease#
per#row#(especially#if#each#tumour#has#
MSI/IHC#results).#If#a#patient#has#multiple#
diseases,#add#a#new#row Age'of'onset/diagnosis
Last'known'age'
if'
healthy/unkno
wn'disease Additional'Phenotype MSI
MLH1'protein'
expression
MSH2'protein'
expression
MSH6'
protein'
expression
PMS2'
protein'
expression
BRAF'V600E'
mutation'
status'
BRAF'V600E'
mutation'testing'
method
MLH1)
methylation
MLH1)methylation'
testing'methods
D12.6# Adenoma unknown
C18.4 Malignant#neoplasm#of#transverse#colon 35,6 MSI>H Negative
C18.4 Malignant#neoplasm#of#transverse#colon 30,2 MSI>H
C18.2 Malignant#neoplasm#of#transverse#colon 27 MSI>H 0%
C18.2 Malignant#neoplasm#of#ascending#colon 38 MSI>H >10%/positive
C18.6 Malignant#neoplasm#of#descending#colon 44,6 >0>1% >0>1%
C18.0 Malignant#neoplasm#of#caecum 52,3 MSI>H
C18.4 Malignant#neoplasm#of#transverse#colon 56,8 >0>1%
C20 Malignant#neoplasm#of#rectum 35,5 MSS
D12.6# Adenoma unknown >10%/positive >10%/positive
C18.2 Malignant#neoplasm#of#ascending#colon 45 MSI>H
CRC 20 #café>au>lait#spots
Endometrial 30 #café>au>lait#spots
CRC 20 #café>au>lait#spots
Endometrial 30 #café>au>lait#spots
2)#Pedigree InSiGHT#Submission#template#v.1.0.xlsx Page#4
Family'ID Patient'ID Father'ID Mother'ID
sex
#1#=#male,
#2#=#female,
#0#=#unknown
age'
age/age#at#death/age#at#
prophylactic#surgery;#
0=unknown Cancer1 agedx1 Cancer2 agedx2
Example#Family#12 person123 person125 person124 2 65 C541 40 C499 40
Example#Family#12 person124 person126 person127 2 87 C449 65 C421 75
Example#Family#12 person125 person129 person128 1 52 C182 44 C259 51
Example#Family#12 person126 0 0 2 77
Example#Family#12 person127 0 0 1 59
Example#Family#12 person128 0 0 2 77 C509 73
Example#Family#12 person129 person133 person132 1 26
Example#Family#12 person130 person125 person124 2 60 C259 55
Example#Family#12 person131 person125 person124 2 62 C449 54
Example#Family#12 person132 0 0 2 0
Example#Family#12 person133 0 0 1 62 C189 47
2)#Pedigree InSiGHT#Submission#template#v.1.0.xlsx Page#5
Cancer3 agedx3 Cancer4 agedx4 Cancer5 agedx5 Cancer6 agedx6
Proband
proband#for#
variant:#1=yes;#
0=no variant'name
carrier'status
genotyping#
status#for#
variant:
0=untested
1=negative
2=positive
C189 53 C679 59 C259 60 C449 62 1 MSH2#c.1046C>T#p.Pro349Arg 2
0 MSH2#c.1046C>T#p.Pro349Arg 1
0 MSH2#c.1046C>T#p.Pro349Arg 2
0 MSH2#c.1046C>T#p.Pro349Arg 0
0 MSH2#c.1046C>T#p.Pro349Arg 0
0 MSH2#c.1046C>T#p.Pro349Arg 0
0 MSH2#c.1046C>T#p.Pro349Arg 0
0 MSH2#c.1046C>T#p.Pro349Arg 2
0 MSH2#c.1046C>T#p.Pro349Arg 1
0 MSH2#c.1046C>T#p.Pro349Arg 0
0 MSH2#c.1046C>T#p.Pro349Arg 0
3)#In#Vitro+Functional#data InSiGHT#Submission#template#v.1.0.xlsx Page#6
Gene DNA Protein Type#+#Category#of#test Description Method#+#Specific#method#used#for#test
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# in#vitro#MMR#assay
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# protein#interaction pull#down#assay#(in#vitro)
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# in#vivo#repair#in#yeast instability#of#GT#tract#in#reporter#gene
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# splicing#assay pSPL3#minigene
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# reporter#assays#in#yeast dominant#negative#effect
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# protein#interaction pull#down#assay
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# protein#interaction
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# MMR#activity mutant#MLH1#(+hPMS2)#transfected#in#HCT116#(colon#cancer#cell#line,#MLH1#deficient),#cell#extracts#were#added#to#heteroduplex#DNA#containing#a#GT#mismatch.#repair#measured.MMR#activity#assay#in#MLH1 deficient#cell#line
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# functional#assays#using#yeast assay#based#on#the#mutation#frequency#in#a#reporter#gene
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# protein#abundancy Western#blotting
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# protein#abundancy protein#expression#in#yeast#cells
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# protein#abundancy expression#in#human#cells#%#of#wt
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# mRNA
EXAMPLE#GENE#EXMPL1 c.123A>C p.Q41P# splicing details,#primers
3)#In#Vitro+Functional#data InSiGHT#Submission#template#v.1.0.xlsx Page#7
Year6test6performed Measured#+#What#is#being#measured
Result6+#Variant#result#versus#wildtype#result
Number#of#reps?
%#function
Expressed#as#numerical#measure Reference
2007 repair#efficiency#(G.T#heteroduplex) #46.5%#versus#42%
2007 interaction#with#hPMS2 low
2006 loss#of#MMR >67%
2008 decrease#in#exon#inclusion#in#HeLa,#COS+7#and#Hep+3B#cells#respectively no#change,#70%#decrease#and#28%#decrease
2007 DNE 0#out#of#3#tests
2007 interaction#with#hPMS2#compared#to#WT 90,6%#versus#100%
%#interaction#with#PMS2#in#Yeast 4
2009 #MMR#activity 81.7%#versus#0%
2007 mutation#frequency 4.60E+05
2005 MSH2#protein#levels 0.85 Thompson#et#al.,#2012
2007 protein#expression#in#yeast#cells reduced Thompson#et#al.,#2012
2007 expression#in#human#cells#%#of#wt 17 Thompson#et#al.,#2012
2008 RNA#Defect#Observed? #Skipping#of#exon#8#(r.589_677del)
2011
Detection(Technique(List InSiGHT(Submission(template(v.1.0.xlsx Page(8
arrayCGH( (array(for(Comparative(Genomic(Hybridisation
arraySEQ( (array(for(resequencing
arraySNP( (array(for(SNP(typing
arrayCNV( (array(for(Copy(Number(Variation((SNP(and(CNV(probes)
BESS( (Base(Excision(Sequence(Scanning
cDNA(SEQ cDNA(SEQ
CMC( (Chemical(Mismatch(Cleavage
CSCE( (Conformation(Sensitive(Capillary(Electrophoresis
ddF( (dideoxy(Fingerprinting
DGGE( (DenaturingOGradient(GelOElectrophoresis
DHPLC( (Denaturing(HighOPerformance(Liquid(Chromatography
DOVAM( (Detection(Of(Virtually(All(Mutations((SSCA(variant)
DSCA( (DoubleOStrand(DNA(Conformation(Analysis
EMC( (Enzymatic(Mismatch(Cleavage
HD( (HeteroDuplex(analysis
IHC( (ImmunoOHistoOChemistry
mPCR( (multiplex(PCR
MAPH( (Multiplex(Amplifiable(Probe(Hybridisation
MCA( (highOresolution(Melting(Curve(Analysis((hrMCA)
MLPA( (Multiplex(LigationOdependent(Probe(Amplification
Northern( (Northern(blotting
PAGE( (PolyOAcrylamide(GelOElectrophoresis
PCR( (Polymerase(Chain(Reaction
PCRdig( (PCR(+(restriction(enzyme(digestion
PFGE( (PulsedOField(GelOElectrophoresis((+Southern)
PTT( (Protein(Truncation(Test
RTOPCR( (Reverse(Transcription(and(PCR
SEQ( (SEQuencing
Southern( (Southern(blotting
SSCA( (SingleOStrand(DNA(Conformation(polymorphism(Analysis((SSCP)
SSCAf( (fluorescent(SSCA((SSCP)
TaqMan( (TaqMan(assay
Western( (Western(Blotting
Variant'review'template_InSIGHT'VIC.xlsx Page'1
In vitro (mammalian) In vivo (yeast)
MSH2 c.1786_1788delAAT p.Asn596del
Normal'(cDNA'RTJPCR'J'Liu'et'al'1996;'
cDNA'RTJPCR'&'minigene'J'Auclair'et'al'
2006;'minigene'J'Tournier'et'al'2008)
Reduced'molecular'switch'
function'MSH2JMSH6'(DNA'
binding;'ATPase;'ATPγS'
binding;'sliding'clamp'
dissociation'J'Heinen'et'al'
2002)
Gene Variant Protein
Probability'of'
Pathogenicity:'Class'5'
>0.99;'Class'4'0.95J0.99;'
Class'3'0.05J0.949;'Class'
2'0.001J0.049;'Class'1'
<0.001
Sequence'
variation'
resulting'in'a'
stop'codon'
Large'genomic'
rearrangement'
(deletion'or'
duplication)
mRNA expression: stability, allelic 
expression levels, in vitro/ex vivo 
splicing (assay description) or 
variant location in splicing 
donor/acceptor site
Sub-cellular 
localization (assay 
description)
MMR'function'(assay'description)'
Variant'review'template_InSIGHT'VIC.xlsx Page'2
In vitro (mammalian) In vivo (yeast) In vitro (mammalian) In vivo (yeast) MLH1 MSH2 MSH6 PMS2
Normal'MSH3/MSH6'
interaction'(GSTJfusion'
protein'interaction'assay'J'
Guerrette'et'al'1998)
MSI$H'(9'tumours:'1'J'
Christensen'et'al'2002;'4'J'
Katballe'et'al'2002;'1'J'
Wahlberg'et'al'2002;'1'J'
Losi'et'al'2005;'1'J'
Barnetson'et'al'2006;'1'J'
Pedroni'et'al'2007);'MSI$L'
(1'J'Barnetson'et'al'2006)
no'loss'(8'
tumours:'5'J'
Stormorken'et'al'
2003;'1'J'Losi'et'
al'2005;'1'J'
Barnetson'et'al'
2006;'1'J'Pedroni'
et'al'2007)
loss'(15'tumours:'5'
J'Stormorken'et'al'
2003;'1'J'Losi'et'al'
2005;'2'J'Barnetson'
et'al'2006;'1'J'
Pedroni'et'al'2007;'
6'J'Sjursen'et'al'
2011)/no'loss'(1'J'
Wahlberg'et'al'
2002)
loss'(12'tumours:'3'J'
Stormorken'et'al'
2003;'1'J'Losi'et'al'
2005;'2'J'Barnetson'
et'al'2006;'6'J'
Sjursen'et'al'2011)
Revised'AMS'(7'affected'nonJ
proband'carriers,'LOD'5.7'J'
Stormorken'et'al'2003;'LR'
75.6,'4'families'J'Ripa'et'al'
2005)
Segregates:'fulfils'
class'5'criteria
Family'
History/(Segregation):'
FH=revised'Ams,'or'other,'
specify;'(variant'
segregation='LR,'#'affected'
nonJproband'carriers,'no'
further'information)
Summary'
segregation:'highest'
class'for'which'
segregation'criteria'
are'fulfilled
MMR'subunit'interaction'(subunits'tested,'assay'
description)
Protein'expression'and'stability'(assay'
description) MSI Status - using a standard panel of 5-10 
markers (# tumours)
IHC'(#'tumours)'J'use'only'if'no'MSI'data'for'same'patient
Variant'review'template_InSIGHT'VIC.xlsx Page'3
0/50'(Denmark'J'Ripa'2005) Not'reported
Class'4'$'likely'pathogenic:'variant'demonstrates'deficient'protein'
function'in'MMR'functional'assays'and'≥2'MSIJH'tumours'(fulfils'all'
class'5'criteria'except'for'control'frequency)
Mary'et'al.;'Hum.'Mol.'Genet.'3:'2067(1994);'Borresen'et'al.;'1995;'
Buerstedde'et'al.;'1995;'Liu'et'al.;'Nature'Med.'2:'169'(1996);'Moslein'et'
al.;'1996;'Wijnen'et'al.;'1997;'Guerrette'et'al;'1998;'Lin'et'al.;'1999;'
Heinimann'et'al.;'1999;'Syngal'et'al.;'1999;'Wang'et'al.;'1999;'Otway'et'al.;'
2000;'Peel'et'al.;'2000;'Bisgaard'et'al.;'2002;'Christensen'et'al.;'2002;'
Heinen'et'al;'2002;'Katballe'et'al.;'2002;'Wahlberg'et'al.;'2002;'Stormorken'
et'al.;'2003;'Losi'et'al.;'2005;'Ripa'et'al.;'2005;'Stormorken'et'al.;'2005;'
Auclair'et'al.;'2006;'Barnetson'et'al.;'2006;'Irmejs'et'al.;'2007;'Ou'2007;'
Pedroni'et'al.;'2007;'Ponz'de'Leon'et'al.;'2007;'Grindedal'et'al.;'2008;'
Nilbert'2008;'Tournier'et'al.;'2008;'Sjursen'2010;'Limburg'2011
CoJoccurrence/coJobservation'(variant'
J'in#trans/in#cis,'patient'phenotype'
and'age'at'diagnosis)
References
Control'frequency:'#'carriers/total'#'
assayed'(geographical'
origin/ethinicity)'or'estimated'risk'in'
caseJcontrol'study'(95%'confidence'
interval)''
Classification
